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ABSTRACT
Cyclic adenosine 5’: 3’ monophosphate (cAMP) is a ubiquitous second messenger 
in cells which transduces the action of a wide variety of hormones and neurotransmitters. 
cAMP phosphodiesterase (PDE) enzymes provide the sole route for the degradation of 
cAMP and ai*e thus placed in a key position for regulating cAMP-dependent processes. The 
cAMP-specific PDE4 enzyme family are encoded by four genes (PDE4A, -B, -C and -D) 
which each generate a number of isoenzymes by alternative 5’ mRNA splicing. This 
process gives rise to PDE4 isoenzymes with unique extreme NHi-terminal splice regions, 
one or two upstream conserved regions (UCR1/UCR2) and a central to COOH-terminal 
catalytic miit. The extreme NHa-terrainal splice domains confer distinct modes of 
regulation and intracellulai’ targeting on the PDE4 isoenzymes. Understanding the distinct 
physiological roles of individual PDE4 isoenzymes may aid the development of more 
specific PDE4 inhibitor-based drugs for therapeutic use in a number of disease states.
I have assessed the involvement of PDE4 isoenzymes in the cAMP-dependent 
effect of growth hormone (GH) on the differentiation of mouse 3T3 F442A preadipocyte 
cells (Chapter 3). The PDE4-specific inhibitor rolipram had previously been shown to 
potentiate the GH-promoted differentiation of these cells to adipocytes. Using the reverse 
transcription-polymerase chain reaction (RT-PCR) with isoenzyme-specific primer pairs, I 
determined the PDE4 mRNA transcripts expressed in 3T3-F442A preadipocytes, which 
were PDE4A1, -A5, -B2, -C2, -D3 and -D5.1 cloned and sequenced the PCR fragments for 
mui'ine PDE4A5, -B2 and -05 to verify their identities. Stimulation with GH caused an 
increase in the activity o f PDE4A. Having identified PDE4A5 as the sole PDE4A splice 
variant expressed in these cells, I showed that the level of the PDE4A transcript is not 
affected by GH treatment. This result combined with other studies suggests that challenge 
with GH results in the specific activation of PDE4A5 via a post-translational modification, 
rather than an effect on transcription. The GH-dependent activation of PDE4A5 is 
proposed to serve as a brake on the process of 3T3 F442A differentiation.
In Chapter 4 of this thesis I have analysed the intracellular targeting of the rat 
PDE4A isoenzymes RNPDE4A1 (RDI) and RNPDE4A5 (rpde6). I have used chimeric 
constructs to show that the unique NHi-terminal regions of RDI (amino acids 1-100) and 
rpde6 (amino acids 1-256) can confer membrane association on the normally soluble 
protein glutathione-5'-transferase (GST). Furtliermore, the region between amino acids 103 
and 256 on rpde6, which is shared with the other long PDE4A splice variant rpde39
(RNPDE4A6), is sufficient for membrane binding. The NHi-terminal regions of RDI and 
rpde6 bind to components o f the P2-membrane fraction that have different thermal 
stabilities suggesting that they interact with distinct lipid or protein anchoring molecules.
I have further investigated the protein-protein Interactions of rpde6 (Chapter 5). 
Evidence was obtained from yeast-2-hybrid studies that rpde6 might interact with a novel 
immimophilin-like protein, RB3. I confirmed this interaction in vitro^ by showing that a 
purified GST-fusion of RB3 (but not GST) could pull down rpde6 from the cytosolic 
fraction of transfected COS-7 cells. Subcellular distribution analysis of transfected COS-7 
cells showed that RJB3 was distributed between the PI low-speed pellet fraction (-16%) 
and the cytosolic S fraction and was absent from the high speed P2-membrane fraction, in 
contrast to rpdc6 which was present in all tlnee fractions. This suggests that the in vivo 
interaction between RB3 and rpde6 may be limited to particular subcellular compartments.
The association of GST-RB3 had a marked inhibitoiy effect on the catalytic activity 
of cytosolic rpde6 (IC50 ~0.2pM), which was also seen with a maltose binding protein 
(MBP)-tagged RB3, but not with GST or MBP alone. This inhibitoiy effect was also seen 
with a GST fusion of the FK506 binding protein FKBP52, the closest homologue of RB3. 
In contrast to cytosolic rpde6, particulate (PI and P2) fraction rpde6 was resistant to 
inhibition by RB3.
I have shown that the COOH-terminal half of RB3 (amino acids 170-330) which 
contains a 34-amino acid tetratricopeptide repeat (TPR) motif in its COOH-terminal region 
mediates both the binding and inliibition of cytosolic rpde6.1 have mapped the RB3 
binding site on rpde6 to amino acids 218-259, which corresponds to the NHz-terminal half 
of UCR2. The NH2-terminal region of rpde6 has previously been shown to interact with the 
SH3 domains of Src-family tyrosyl kinases such as Lyn. I have shown that that Lyn SH3 
does compete with RB3 for interaction with rpde6.
The above studies suggest that the association of RB3 or a similar TPR-containing 
protein may represent a new mechanism for the regulation and/or intracellular targeting of 
rpde6 in vivo. Alternatively, this interaction may provide a means for the specific 
regulation of RB3 function by rpde6.
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CHAPTER 1
Introduction
1.Introduction
1.1 The cAWIP signalling pathway
Cyclic adenosine 5’: 3’ monophosphate (cAMP) is a ubiquitous second messenger 
involved in a wide range of physiological processes such as lipolysis, glycogenolysis 
(Manganiello et al., 1996), cytoskeletal function, regulation of gene transcription (Daniel et 
al., 1998), cell growth, proliferation (Dugan et al., 1999), differentiation (Yarwood et al.,
1998), neurotransmission, learning and memory (Byers et al., 1981). The cAMP signalling 
pathway is illustrated in Figur e 1.1. cAMP is generated from ATP by the action of the 
membrane-bound enzyme adenylyl cyclase (AC). The activity of this enzyme is regulated 
by external stimuli (e.g. hormones or neurotransmitters) via the concerted action of G 
protein coupled receptors (GPCRs) and heterotrimeric G proteins. The latter consists of 
guanine nucleotide binding aG s subunit and a tightly associated G|3y dimer (Hamm and 
Gilchr ist, 1996). The binding of a ligand to a GPCR causes the intracellular- domain of this 
receptor- to interact with the aGs subunit. This causes a conformational change in the aGs 
subunit that results in the release of GDP and its replacement with GTP. aGs-GTP is then 
released from Gpy and diffuses within the membrane to activate adenylyl cyclase. In 
contrast to this, aG i subunits have inhibitory effects on adenylyl cyclase. The GPy dimer is 
also involved in the regulation of adenylyl cyclase activity. For example, GPy can have 
inliibitory effects on the adenylyl cyclase isoform AC-I, but synergises with aG s in the 
activation of the AC-II and AC-IV isoforms (Taussig and Gilman, 1995). It should be 
noted that adenylyl cyclase can also be activated by the direct binding of the diterpene 
agent forskolin (Houslay and Milligan, 1997) and by cholera toxin, which ADP-ribosylates 
and activates a stimulatory G protein.
The activation o f adenylyl cyclase results in an elevation in the intracellular 
concentration of cAMP. This in turn results in the activation of cAMP-dependent protein 
kinase (PKA). The PKA holoenzyme is a heterotetramer consisting of two regulatoi-y (R) 
subunits and two catalytic (C) subunits. Each of the R subunits binds to one molecule of 
cAMP and this results in the release and activation of the two C subunits. The C subunits 
phosphorylate and thereby regulate a large number of proteins including ion channels, 
cytoskeletal elements and metabolic enzymes. The activated C subunits may also 
translocate to the nucleus where they can phosphoi-ylate and regulate transcription factors 
such as CREB (cAMP-response element binding protein). PKA-phosphorylated CREB
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binds to the co-activator CBP (CREB binding protein) and activates the expression of 
number o f genes by binding to cAMP response elements (CRE) in their promoter regions 
(Frank and Greenberg, 1994; Lalli and Sassone-Corsl, 1994; Roesler et al., 1988).
The phosphodiesterase (PDE) enzymes represent a crucial component of the 
cAMP-signalling pathway. PDEs catalyse the hydrolysis of cAMP to 5’AMP (see Figure 
1.1) and thus provide the sole route for the degradation of cellular cAMP. The activity of 
PKA in cells therefore lai'gely depends on the relative activities of adenylyl cyclase and 
PDEs. The regulation o f these two opposing enzyme activities is equally important in the 
control o f cAMP-dependent processes.
PKA enzymes are only activated above a certain threshold cAMP level. Therefore, 
cells that express adenylyl cyclase isoforms with a high basal level of activity will be more 
responsive to signals that elevate cAMP by inhibiting PDE activity. Several physiological 
processes such as lipolysis in adipocytes (Manganiello et al., 1996) and the production of 
insulin by pancreatic (3-cells appear to be regulated by signals that act via PDE isoenzymes 
(Zhao et a l, 1997).
--isBy lowering the local intracellular concentration of cAMP, PDEs provide one 
mechanism for the desensitisation of cAMP signalling pathways. Other mechanisms for 
desensitisation exist, including those that involve the uncoupling of adenylyl cyclase from 
the GPCR. Once such mechanism is the phosphorylation of the GPCR by G-protein 
coupled receptor kinases (GRK) or by PKA. This is followed by the binding of an arrestin 
protein to the intracellular domain of GPCR, which then sterically blocks the binding of 
heterotrimeric G proteins (Luttrel et al., 1999). Other proteins that may be involved in | |
desensitisation are PKIs (PKA-inhibitor proteins) which binds to and inhibit the C subunit 
o f PKA (Daniel et al., 1998).
Figure 1.1 depicts the classical cAMP signalling pathway in which PKA acts as the -
cAMP sensor protein. Recently a new tai-get protein for cAMP has been cloned, called
i
EPAC (Exchange protein directly activated by cAMP) (De Rooij et a l, 1998). EPACs 
function as cAMP-activated guanine nucleotide exchange factor (cAMP-GEF) (Kawasaki 
et a l, 1998). The EPAC protein contains a cAMP binding domain fused to a GEF domain. 
These proteins are responsible for the cAMP-dependent activation of the small G protein 
Rapl, a close relative of Ras. In a similar maimer to heterotrimeric G proteins, small G 
proteins such as Rapl and Ras are activated by the exchange o f a bound GDP molecule for 
GTP. With small G proteins this process is catalysed by guanine nucleotide exchange
I
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factors (GEFs). The binding of cAMP to EPAC results in the allosteric activation of its 
GEF domain, which promotes the GDP/GTP exchange on Rapl. Activated Rapl can 
phosphorylate a number of proteins including Raf-B, which results in the activation of the 
Raf-MEK-ERK kinase cascade (Vossler et al., 1997). PKA is not involved in the cAMP- 
dependent aetivation of R ap l. Therefore, EPACs represent a new family of cAMP sensors 
and a new point of cross talk between cAMP signalling and the Raf-MEK-ERK kinase 
pathways. EPAC may also be negatively regulated by PDEs. The activation of PDEs will 
result in a decrease in the local concentration of cAMP, which would lead to a decrease in 
the activity of EPACs. This may be a new mechanism for the down-regulation of the Raf- 
MEK-ERK pathway.
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Figure 1.1 cAMP signalling pathway
cAMP is generated by the membrane-bound adenylyl cyclase (AC). The activity o f this 
enzyme is regulated by external stimuli (e.g. hormones or neurotransmitters) which bind to 
G protein coupled receptors (GPCRs) which are seven-pass transmembrane proteins. The 
ligand/receptor complexes bind to and activate the aGs subunit o f the heterotrimeric G 
protein Gs. aGs diffuses along the membrane and activates adenylyl cyclase (AC) which 
catalyses the formation o f cAMP from ATP. Adenylyl cyclase is also activated by the 
direct binding o f forskolin. cAMP binds to the R subunits o f PKA which results in the 
release and activation o f the C subunits which phosphorylate a broad range o f substrate 
proteins, including transcription factors such as CREB. The breakdown o f cAMP to 
5’AMP is catalysed by phosphodiesterase (PDE) enzymes.
GRK= G protein coupled receptor kinase, CREB = cAMP response element binding 
protein, PK1= PKA-inhibitor protein.
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1.1.1 The cGMP signalling pathway
Another second messenger with many physiological roles is cyclic guanosine 3’: 5’ 
monophosphate (cGMP). These roles include smooth muscle relaxation, inhibition of 
platelet aggregation, neutrophil degranulation and visual signal transduction (Corbin and 
Francis, 1999). The cAMP-pathway is analogous to the cGMP-signalling pathway.
However, there are several key differences. Firstly, both soluble and transmembrane forms 
of guanylate cyclase exist, in contrast to adenylyl cyclase isoforms, which aie all 
membrane-associated. The soluble guanylate cyclase exists as a heterodimer and is 
activated by nitric oxide. The up-regulation of cGMP via this route is involved in processes 
such as the relaxation of arteriolar smooth muscle (Moreland et a l, 1999). In 
transmembrane guanylate cyclases the binding of a ligand to their extracellulai' domains
■results in an activation of their intracellular catalytic domains and the production of cGMP. 
Examples of this type of guanylate cyclase are the GC-D odorant receptors that are specific 
to olfactory neurones (Juilfs et a l , 1997) and the atrial natriuretic peptide receptor. In 
contrast to the tetrameric PKA enzyme, its counterpart in the cGMP pathway, PKG 
(cGMP-dependent protein kinase) is a single polypeptide that contains a regulatory domain 
for binding cGMP and a catalytic domain. As discussed below (see section 1.3) certain 
PDE families catalyse the breakdown of cGMP to 5’GMP. One such family, PDE6, is a 
central component of the visual signalling pathway (Korschen et a l, 1999).
<î
1.2 Isoform multiplicity and Intracellular targeting of the components of the 
cAMP signalling pathway
Isoform multiplicity occurs at all levels of the cAMP signalling pathway. The 
multitude of physiological responses that can be elicited by the activation of the cAMP 
signalling pathway in different cells is based on the selective expression of these isoforms. 
This is firstly seen at the level of the G-protein coupled receptors (GPCRs) o f which there 
are many isoforms including those for amines, peptides, eicosanoids, light and odorants. 
Secondly, a considerable variety of heterotrimeric G protein complexes are possible from a 
choice of at least 20 a  isoforms, 5 p isoforms and 12 y isoforms (Clapliam, 1996; Hamm
and Gilclirist, 1996). The a  subunits from different G proteins have a variety of effects, 
which include the stimulation (aGs) or inhibition (aGi) of adenylyl cyclase, or association 
with specific GPCRs, such as the odorant receptors (Golf) (Juilfs et a l, 1997).
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At least nine adenylyl cyclase (AC) isoenzymes exist, which show different patterns 
of regulation. For example AC-I, -III and -VIII are stimulated by Ca^Vcalmodulin 
(Ca^^/CaM), whereas AC-Y and AC-VI are inliibited by Ca^'^/CaM. The diversity of 
adenylyl cyclase isoenzymes is increased fuither by alternative mRNA splicmg. For 
instance, AC-VIII produces tlnee splice variants with different Ca^VCaM sensitivities. 
Certain adenylyl cyclase isoenzymes ai*e also phosphorylated by PKA (AC-V) and 
phosphorylation by PKC can activate the AC-I/II/III isoforms (Houslay et ah, 1997). 
Therefore, the adenylyl cyclase isoenzymes expressed by a cell will affect the integration of 
intracellular Ca^^ and cAMP signals. Although all adenylyl cyclase isoenzymes are 
activated by the aGs subunit o f stimulatory G proteins, the other aGs subunits, (including 
aGp and aGi), have different effects on different adenylyl cyclase isoenzymes. In addition, 
certain adenylyl cyclase isoenzymes appear to have distinct patterns o f intracellular 
localisation. For example, ACIII is exclusively found in the cilia of olfactory neurones 
(Juilfs et ah, 1997) and other work has suggested the co-localisation o f the Ca^^-sensitive 
isoenzymes ACI and ACVIII with plasma membrane Ca^^ chaimels (Fagan et ah, 1996).
Isoform multiplicity also occurs at the level of the PKA holoenzyme. Two forms of 
R subunit were originally identified, with RI being mostly cytoplasmic and RII being 
associated with the particulate fraction o f cells. Four separate gene products, RIa, Rip,
R lla  and RIIp have now been identified, with additional isoforms of RIa arising through 
alternative mRNA splicing (Daniel et ah, 1998). Three forms exist for the C subunit as 
well, namely Ca, Cp and Cy and mRNA splice variants have been reported for the C a and 
Cp genes. These subunits can give rise to a considerable number of R2C2 combinations that 
display different cAMP sensitivities (Daniel et ah, 1998).
The intracellular localisation of PKA is determined by the association of their R 
subunit dimers with A-kinase anchoring proteins (AKAPs). The AKAPs are an 
increasingly large family of proteins that are responsible for targeting PICA to a diverse 
range o f intracellular locations such as the nucleus (AKAP350), mitochondria (AKAP84), 
microtubules (MAP2) and the plasma membrane (AKAP79) (Edwards and Scott, 2000). 
The association of R subunits with AKAPs restricts the action o f PKA to specific regions 
o f the cell and limits its access to substrates. In this way, the AKAPs confer specificity on a 
multi-functional kinase that has a very broad range of substrate proteins (Cheley et ah, 
1994). The first AKAP proteins to be identified all associated with the RII subclass o f 
proteins. These associations were high affinity, in the nanomolar range (Carr et ah, 1992).
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More recently, novel AKAPs have been discovered that can associate with the both RI and 
RII subunits (Huang et al., 1997). The association with RI is of a lower affinity, in the 
micromolar range. This interaction is likely to be physiologically relevant when RII 
concentrations are limiting (Burton et al., 1997). Targeting domains have been identified 
on a number of AKAPs including a mitochondrial membrane targeting sequence in 
AKAP 8 4 and spectrin-like repeats in mAKAP that direct it to the perinuclear region 
(Colledge and Scott, 1999).
different intracellular pools of cAMP (Hohl and Li, 1991). The components of cAMP 
signalling pathway that are involved in the generation of cAMP (i.e. the GPCRs and 
adenylyl cyclase) are localised to specific regions of plasma membrane. In addition, both 
PKA (which detects cAMP) and PDE (which degrades cAMP) are targeted to specific 
regions within the 3-D matrix of the cell. Therefore, a system is in place whereby the 
activation of certain GPCRs can result in an increase the concentration of cAMP within 
discrete compartments within the cell. This results in the activation of specific sub-
The isoform diversity seen for the above proteins is also clearly seen in the
phosphodiesterase (PDE) family, which is the main subject o f this thesis. At least 10 PDE 1■families have been identified to date containing over 30 isoenzymes in total. As discussed 
below in section 1.3 the different PDE isoenzymes show distinct patterns of regulation and 
intracellular tai’geting. The PDE isoenzymes expressed by a cell will profoundly effect the 
response to stimuli that act via cAMP or cGMP.
1.2.1 The compartmentalisation of cAMP
As discussed in the previous section, multiple isofbrms with different patterns of
yregulation and intracellular targeting exist at each level of the cAMP signalling pathway. i j
The combination of isofbrms expressed by a cell will affect the duration and the magnitude 
of the cAMP response. However, this does not explain how the cAMP signalling pathway L
can be used by two different signals to produce two different effects in the same cell. An 
early example of this was the effect o f isoproterenol and prostaglandin Ei on cardiac 
myocytes (Hayes et al., 1982). Both these agents caused an increase in intracellular cAMP, 
which led to the activation of PKA. However, stimulation with isoproterenol resulted in the 
increased phosphorylation o f -16  proteins that were not phosphorylated upon stimulation %
with prostaglandin E i.
An hypothesis put forward to explain tliis was that the different hormones affect
1 Introduction 8
■fi
1
populations of PKA enzymes that are targeted to these compartments by their association
flwith AKAP anchoring proteins. These targeted PKAs will only phosphorylate substrates in 
their vicinity. Different stimuli affect distinct cAMP compartments and thereby cause 
unique physiological responses. The cAMP levels in these various compartments could be 
differentially regulated by specifically targeted PDEs which breakdown cAMP.
Several studies have identified a role for PDE isoenzymes in the 
compartmentalisation of cAMP. For example, Jurevicius and Fischmeister have studied the 
cAMP-dependent activation of Ca^ '^ chaimels by p2-adrenoceptor agonists in frog cardiac 
myocytes (Jurevicius and Fischmeister, 1996). In this system, the p2-adrenoceptor agonist, 
isoprenaline causes an elevation in cAMP and the activation of PKA (as described in 
section 1.1), which phosphorylates and activates the L-type Ca^”^ chamiels in the plasma 
membrane (Hartzell et ah, 1991). Jurevicius and Fischmeister showed that the 'local' 
stimulation of Ca^^ chaimels in the half of the cell exposed to the agonist was 40-fold 
greater than tlie 'distant' stimulation in the other half o f the cell that had not been exposed 
to agonist. The prevalence of the local effect of the agonist over its distant effect was 
significantly diminished by the presence of the PDE inliibitor, IBMX (Jurevicius and 
Fischmeister, 1996). Further analysis with PDE family-specific inhibitors (see section 1.3 
below) suggested that the localised activation of the Ca^ "^  channels was due, at least in part, 
to the compartmentalisation of cAMP by PDE3 and PDE4 (Jurevicius et al., 1997).
Several groups have uncovered evidence for the existence of two distinct pools of 
cAMP in the same cell tliat are regulated by different PDE isoenzymes. For instance,
Dousa and coworkers have studied two cAMP-regulated processes in the mesangial cells of 
the kidney glomeruli. One of these processes is the generation of superoxide during the 
respiratory bm'st, which is a factor in the pathogenesis of glomerulonephritis (Dousa,
1999). This process was inhibited by PDE4-specific inhibitors, such as rolipram, but not 
by the PDE3-specific inhibitor, cilostamide (Chini et al., 1994; Chini et al., 1997). Another 
c AMP-dependent process in mesangial cells is the mitogenic stimulation of DNA 
synthesis, which was inhibited by PDE3 inhibitors, but unaffected by PDE4 inhibitors.
This implied that two different PDE isoenzymes compartmentalise two separate pools of 
cAMP that regulate DNA synthesis or superoxide generation. The specific involvement of 
PDE4 in the regulation of the respiratory burst suggests that PDE4 inliibitors might be 
developed for use in treating inflammatory glomerulopathies without affecting DNA 
synthesis (Dousa, 1999).
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The above studies have demonstrated that PDE isoenzymes play a crucial role in 
the compartmentalisation of cAMP. A greater understanding o f this process will be gained 
from identifying the specific PDE isoenzymes that are involved. Information on the 
intracellular localisation, protein-proteiii interactions and regulation of these PDE 
isoenzymes may aid the design of drugs that target specific pools of cAMP within cells. 
These drugs may have more effective therapeutic actions with fewer side effects.
1.3 The phosphodiesterase superfamily
The PDE superfamily is large and complex (Beavo et al., 1994). At the present time 
it consists of at least 11 families that catalyse the hydrolysis of cAMP, cGMF or both. 
These PDE families can be luither distinguished according to their primaiy struetures, their 
modes o f regulation and their inhibition by specific inhibitors. Each o f the PDE families 
contains one to four genes and many of these genes generate several isoenzymes by 
alternative 5’ mRNA splicing and the use of different transcription initiation sites. This 
results in PDE isoenzymes with common central and COOH-terminal regions and variable 
NH2“terminal regions. In addition, alternative 3’ mRNA splicing has been observed for 
members of the PDEl family. The isoenzymes within each of these PDEs families show 
distinct patterns of expression in different tissues and have different characteristics. A 
summaiy of the general characteristics of each o f the 11 families is given Table 1.1.
The focus of this thesis will be the PDE4 cAMP-specific family. A major theme 
will be the intracellulai- targeting, proteins-protein interactions and regulation of certain 
isoenzymes within this gene family. In order to understand the properties and functions of 
the PDE4 isoenzymes, it is necessaiy to review the PDE superfamily as a whole.
1.3.1 PDE nomenclature
A system of nomenclature has been developed to cope with the complexity o f the 
PDE superfamily (Beavo et al., 1994). This can be explained with the following example 
of HSPDE4A5 where ‘HS’ refers to the species of origin (in this case Homo sapiens), 
‘PDE4’ refers to the gene family, ‘A ’ refers to the gene and ‘5’ refers to the splice variant. 
A letter sometimes given after the splice valiant number refers to the specific GenBank 
report for a splice variant that has been cloned separately by two or more groups.
1.3.2 Structure and regulation of PDE isoenzymes
All PDE isoenzymes have the same general structure, which is shown in the first 
column of Table 1.1. The catalytic imits of PDEs generally occupy the central to COOH- 
terminal region of these enzymes. This region is conseiwed between members of the same 
gene family. However, the NHi-terminal regions of PDEs are variable and contain 
sequence motifs involved in the regulation of PDE catalytic activity. For instance, the 
PDEl isoenzymes have two putative Ca^^/calmodulin (Ca^^/CaM) binding domains in their 
NH2-terminal regions. The binding of Ca^VCaM causes the activation of these isoenzymes, 
which can hydrolyse both cAMP and cGMP. The PDEl family contains 3 genes and the 
diversity of this family is fluther increased by 5’ and 3’ alternative mRNA splicing which 
results in isoenzymes which differ at the NH2- and COOH-termini. One consequence of the 
5’ alternative mRNA splicing is the generation of splice variants with different Ca^VCaM 
binding affinities. For instance, the NH2-terminal regions of PDEl C2 and the other PDE 1C 
splice variants diverge at a point midway between the two Ca^'^/CaM binding domains. As 
a result, PDE1C2 has a significantly greater sensitivity to Ca^ "^  when compared with 
PDEl C l, "3, -4 and -5 (Yan et al., 1996). The NH2-terminal regions of PDE 1C 
isoenzymes also contain sites for regulation by phosphoiylation. PKA-phosphoiylation of 
PD ElA l and 1A2 reduces the affinity of these isoenzymes for Ca^VCaM (Beavo, 1995). 
Therefore PDEl isoenzymes provide a means of cross talk between the cAMP and Ca^^ 
signalling systems.
The PDE2, PDE5, PDE6, PDE 10 and most recently identified PDEl 1 families all 
contain two GAF domains within their NH2-terminal regions (see Table 1.1) (Fawcett et 
al., 2000; Soderling et al., 1999; Soderling and Beavo, 2000). GAF domains have been 
identified in a diverse range of proteins, including those from plants, bacteria and 
vertebrates (Aravind and Pouting, 1997). The name GAF stands for thine proteins that 
contain these conserved domains: cGMP-specific phosphodiesterases, cyanobacterial 
Anabaena adenylyl cyclase and the Escherichia coli transcriptional regulator fhlA. In 
PDE5 and 6, these GAF domains have been shown to bind cGMP (Granovsky et al., 1998). 
The cAMP and cGMP hydmlysing activities of the GAF-containing PDE2 isoenzymes are 
activated by the allosteric binding of cGMP (Beavo, 1995). Therefore, PDE2 may mediate 
cross talk between cAMP and cGMP signalling pathways. For instance, in a certain subset 
o f olfactory neurones activation of transmembrane guanylate cyclase may result in the
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activation of PDE2 which may result in a down-regulation of the cAMP signalling pathway 
activated by odorant receptors (Juilfs et ah, 1997).
The cGMP-specific PDE6 has a very specialised function in the visual signal 
transduction pathway and is exclusively expressed in the rod and cone photoreceptors of 
the retina. PDE6 differs from the other PDEs in that it is a multi-subunit protein. In bovine 
rod photoreceptors the PDE6 holoenzyme consists of the catalytic subunits (a  and p) in 
association with two inlnbitory y subunits (Stryer, 1991). The a  and p subunits correspond 
to PDE6A and PDE6B,respeetively (see Table 1.1). The visual signalling pathway in rod 
photoreceptors is initiated by a photon-induced change in the conformation o f the 
rhodopsin receptor in the internal disc membranes. This results in the activation of the 
heterotrimeric G protein transducin. The a  subunit of transducin interacts with the PDE6 
holoenzyme and causes the release of the a  and p catalytic subunits from the inliibitory y 
subunit. The activation of these catalytic subunits results in a drop in the levels of cGMP. 
This in turn results in the closure of cGMP-gated ion chamiels in the rod photoreceptor 
plasma membrane, membrane hyperpolarisation and a decrease in neurotransmitter release 
(Chabre and Deterre, 1989; Yarfitz and Hurley, 1994). PDE6A and PDE6B may be 
regulated by the association of cGMP with their NHg-terminal GAF domains (Granovsky 
et al., 1998). The binding of cGMP to rod photoreceptor PDE was increased in the 
presence of the y subunit, whereas activated rod PDE had a reduced affinity o f cGMP 
(Yamazaki et al., 1982).
The cGMP-specific PDE5 shares certain structural similarities with PDE6. The 
binding of cGMP to the NHi-terminal GAF domains of PDE5 results in a conformational 
change that allows phosphorylation and activation by PKG and PKA (Turko et al., 1998). 
The exact physiological role of this phosphorylation is unclear. However, Loclihead et al 
have provided evidence that two binding proteins form a regulatoiy complex with PDE5 in 
airway smooth muscle cells (Lochhead et al., 1997). Interestingly, these proteins, which run 
at 14 and 18kDa on SDS-PAGE, can be detected in the membranes of these cells using an 
antibody raised against the 24-46 region o f the inhibitory y subunit of PDE6. A peptide 
corresponding to this 24-46 region and full-length recombinant y both prevented the PKA- 
induced activation of PDE5. This suggests that an epitope common to the 14 and 18kDa 
proteins and the y subunit interacts with PDE5 and prevents its activation by PKA. 
Therefore, regulation by both protein-protein interactions and phosphorylation are common 
characteristics of members of the PDE superfamily.
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As discussed in section 1 A, the PDE4 isoenzymes also have two conserved regions 
(UCRl and UCR2) at their extreme NHi-termini that appear to be involved in the 
regulation of enzyme activity. These aie similarly placed to the paired GAF domains in 
PDE2, “5, “6 and -10 and the paired Ca^VCaM binding domains in PDEl. Therefore, a 
general theme of PDE regulation is that conformational changes in the NH2-terminal, 
caused by phosphorylation, protein- or cyclic nucleotide-interaction, can affect the function 
of the catalytic unit.
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Table 1.1 Phosphodiesterase superfamily
PDE family
C«**/CaM Calalytic 
binding
PDE2
Genes Substrate Inhibitors 
________specificity____________
Examples of 
regulation
binding 
GAF domain
Catalytic
PDEIA cGMP and 
PDEIB cAMP 
PDEIC
cGMP and 
cAMP
Nicardipine,
Methoxymethyl-
IBMX
Vinpocetine,
KS-505a
EHNA
Stimulated by 
Ca^Vcalmodulin 
Phosphorylated by 
PKA/PKG
Stimulated by 
cGMP
PDE3 PDE3A cAMP specific Cilostamide, Competitively
H M PDE3B milrinone, Inhibited by cGMP.
transmembrane Catalytic enoximone Activated by Insulindomain Siguazodan in adipocytes
PDE4 PDE4A cAMP specific Rolipram, Ro-20- Phosphorylated by
PDE4B 1724, CDP840, PKA,
UCRl UCR2 Catalytic PDE4C RP 73401, Phosphorylated by
PDE4D CP80633 ERK2
PDES
C T Z H :
cGMP binding Catalytic 
GAF domain
PDE6
cGMP binding Catalytic 
GAF domain
PDE5 cGMP specific Zaprinast
Sildenafil
PDE6A cGMP specific Zaprinast, 
PDE6B dipyridamole
PDE6C
cGMP binding 
results in 
phosphorylation 
by PKA/PKG 
Stimulated by photons, 
via rhodopsin and 
transducin. Inhibited 
by Y subunit.
PDE7
Catalytio
PDE8
i — n - c
PAS
domain
Catalytic
PDE7A cAMP specific
PDE8A cAMP specific Dipyridamole 
PDE8B (Ki=4.5pM)
PDE9
Catalytic
PDE10
■c z x z h :
cGMP binding Catalytic 
GAF domain
PDE9A cGMP specific SCH 518666
Zaprinast
PDEIOA cAMPand g# # ' 
tcGMP
PDE11 PDEl 1A cAMPand 
F ' cGMP
cGMP binding Catalytic] 
GAF domain
Zaprinast,
dipyridamole
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1.3.3 Intracellular targeting of PDEs
As discussed in the previous section, numerous mechanisms exist for the regulation 
of PDE isoenzymes. Different PDE isoenzymes also show distinct patterns of intracellular 
localisation. In many cases these differences have been attributed to the unique NH2- 
terminal regions of PDE isoenzymes. The targeting of PDE isoenzymes in the cell is likely 
to be a crucial aspect of their function, particularly in the compartmentalisation of cAMP. 
For instance, in olfactory neurones the splice variant PDE1C2 co-localises with the 
adenylyl cyclase isoform ACIII in the cilia that extend from the dendrites into the nasal 
epithelium (Juilfs et al., 1997). ACIII and PDE1C2 are believed to be responsible for the 
rapid, transient cAMP response to odorants that bind to the G-protein coupled receptors in 
the cilial plasma membrane. PDE1C2 and ACIII ai’e not found in other parts of the 
neurone, such as the axons and the cell body. However, olfactory neurones express an 
undefined PDE4A isoenzyme that is found only in the axons and the cell body. This 
PDE4A splice variant may be involved in the transmission of signal tlirough the neurone to 
the olfactory bulb. The presence of two uniquely targeted PDE isoenzymes in one cell 
strongly suggests the existence of two separately regulated pools of cAMP in olfactory 
neurones.
PDE3 provides an example of the way in which the NH2-terminal regions of PDE 
isoenzymes can determine their intracellular localisation. So far, two PDE3 genes have 
been identified, A and B. These genes have been shown to generate at least tlnee 
isoenzymes: PDE3A1, PDB3A2 and PDE3B (Kasuya et al., 1995; Meacci et al., 1992; 
Taira et al., 1993). PDE3A1 and PDE3B may correspond to the 130-135kDa species 
observed in the sarcoplasmic reticulum fraction of cardiac myocytes and the endoplasmic 
reticulum fraction o f adipocytes (Degerman et al., 1990; Smith et al., 1993). These two 
isoenzymes contain a hydrophobic segment in their NH2-terminal regions that is predicted 
to form six transmembrane helices (Degerman et al., 1997). This may explain why these 
isoenzymes are targeted to the membrane fractions of adipocytes and cardiac myocytes 
(Degerman et al., 1990; Smith et al., 1993). Recombinant PDE3A1 and 3B are both 
associated with the particulate fractions of Sf9 cells (Kasuya et al., 1995; Leroy et al.,
1996). However, trimcated species that lacked the NHi-terminal hydrophobic domain were 
cytosolic (Degerman et al., 1997). Similarly, the PDE3A2 isoenzyme has a veiy short NH2- 
terminal splice domain that lacks the hydrophobic region. As expected, recombinant
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PDE3A2 was found in the cytosolic fraction of Sf9 cells (Kasuya et a l ,  1995). Therefore, it 
has been hypothesised that the NHz-terminal hydrophobic region targets PDE3A1 and 3B 
to the membrane fraction of cells (Degerman et al., 1997). This could be tested by 
expressing the hydrophobic region as a fusion to a normally soluble protein and then 
assessing the ability of this fusion to bind to membrane preparations. This teclmique was 
used to characterise the membrane-association region of PDE4A1 as described in section
PDE3B results in a drop in the level of cAMP and a reduction in the activity of PKA. This 
results in net dephosphorylation and inactivation of hormone-sensitive lipase (HSL) and a
1.8.1 below.
The targeting of PDE3B to intracellular membranes or the plasma membrane may 
play an important role in the compartmentalisation of cAMP pools in lipolysis. PDB3B 
mediates the inhibitoiy effects of insulin on lipolysis in adipocytes (Manganiello et al.,
1996). Insulin acts via a pathway that involves IRS-1, PI3-kinase and an unidentified PDE3 
kinase (PDE3IK) which activates PDE3B by phosphoiylation at Ser302. Activation of
decrease in the hydrolysis of stored triglyceride (Degerman et al., 1997). It is possible that
membrane-associated PDE3B is targeted to a region within the cell where it is in close 
proximity to an AKAP-anchored PKA and HSL. In this way, PDE3B could control a pool 
of cAMP that specifically regulates lipolysis via PKA and HSL. This would explain why 
PDE3 inhibitors and not PDE4 inhibitors prevent the inliibitoiy effects of insulin on 
lipolysis in adipocytes.
The effect of alternatively spliced NH2-terminal regions on the intracellular 
targeting of PDE isoenzymes is also seen for members of the cAMP-specific PDE7 family. 
Two splice variants have been cloned for this family: PDE7A1, which is found in multiple 
tissues and PDE7A2, which is expressed mainly in skeletal muscle and cardiac myocytes 
(Han et al., 1997). The NH2-terminal region of PDE7A2 contains hydrophobic sequences. 
As a result, PDE7A2 is predominately found in the particulate subcellular fraction of 
tissues. In contrast, the NHz-terminus of PDE7A1 contains a large number of polar and 
positively charged residues. The intracellulai* localisation of PDE7A1 is more complex. For 
example, in foetal skeletal muscle PDE7A1 is mainly soluble, whereas in brain it is 
distributed between the soluble and the particulate fiactions (Han et al., 1997). One 
explanation for these differences is that PDE7A1 interacts with one or more targeting 
proteins with tissue-specific patterns o f expression.
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A recent study has suggested that PDE6A and B (a  and P) may associate with a 
signalling complex in the outer segments of rod photoreceptor cells. The formation of this 
complex is mediated by glutamic-acid-rich proteins (GARPs) (Korschen et al., 1999). The 
GARP proteins GARPl and GARP2 bind tightly to the membrane fraction of rod outer 
segments and provide a scaffold for the binding of PDE6, guanylate cyclas^he ATP- 
binding cassette transporter (ABCR). In many ways GARP proteins are similar to the
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scaffold proteins described in section 1.10.2, which bind to a number of proteins in the
same signalling pathway and thereby increase the efficiency of signal transduction.
However, the association o f light-activated PDE6 with GARP results in an inhibition of 
.PDE activity. This led to the suggestion that the association of guanylate cyclase and PDE6 
prevents the unnecessary cycling of cGMP in rod photoreceptors that have been saturated 
by high light conditions (Korschen et al., 1999). The association of PDE isoenzymes with 
scaffold proteins may thus turn out to be recurrent theme in the PDE superfamily.
So far, not much information has been obtained on the regulation and targeting of 
the newly discovered families PDE8, -9,-10 and -11 (see Table 1.1). All four of these 
families show broad but unique patterns of tissue expression. The isoenzymes generated by 
PDE8 genes are cAMP-specific and are expressed in a number of tissues including testis, 
ovary and intestine (Soderling et al., 1998). Interestingly, these isoenzymes contain Per- 
ARNT-Sim (PAS) homology domains in their NHi-terminal regions (Soderling and Beavo, 
2000). These domains have been shown to mediate the homo- and hetero-dimerisation of a 
number of proteins including the Drosophila proteins Per and Sim (Huang et al., 1995; 
Huang et al., 1993). The association of the aiyl hydrocarbon receptor (AhR) with the Ah 
receptor nuclear translocator (ARNT) is mediated by their PAS domains (Fukunaga et al., 
1995; Schmidt and Bradfield, 1996). In addition, PAS domains are also believed to 
mediate the hetero-dimerisation of White collar 1 and 2 which ai’c involved in blue-light 
signal transduction in the fungus Neurospora crassa (Linden and Macino, 1997).
Therefore, PAS domains may be involved in the protein-protein interactions or intracellular 
targeting o f PDE8 isoenzymes. The PDE 10 and PDEl 1 isoenzymes have dual 
cAMP/cGMP hydrolysing activity and contain GAF domains in their NHi-terminal regions 
(Fawcett et al., 2000; Soderling et al., 1999). These are potential allosteric binding sites for 
cGMP, which may be involved in the regulation of these isoenzymes.
The above two sections have given an overview of the diverse mechanisms of 
regulation and intracellular targeting in the PDE superfamily as a whole. The following
I
sections focus on the cAMP-specific PDE4 family. Studies using specific inhibitors have 
identified PDE4 as a potential tai get in the treatment of a number of conditions, including 
inflammatory diseases such as astlima and atopic dermatitis (see section 1.9). The multiple 
isoenzymes in this family again show diverse patterns of tissue expression, regulation and 
intracellular targeting. A major research aim is to determine the in vivo fimctions o f these 
isoenzymes, which may aid the development of novel therapeutic agents.
1.4 PDE4 cAMP-specific phosphodiesterases: structure and alternative 5’ 
mRNA splicing
The mammalian PDE4 cAMP-specific phosphodiesterases are a complex family of 
at least 16 isoenzymes that are specifically inhibited by the anti-depressant drug rolipram 
(Henkel-Tigges and Davis, 1989). The PDE4 isoenzymes show considerable homology to 
the dunce family of phosphodiesterases o f Drosophila melanogaster (Chen et al., 1986) 
which are essential for learning and memory in this organism (Dudai et al., 1976). The first 
member o f the mammalian PDE4 family to be cloned (PDE4A1) was isolated in a screen 
of a rat brain cDNA library using dunce cDNA as a probe (Davis et al., 1989). Other PDE4 
isoenzymes have been cloned by low-stringency cDNA library screening, using as probes 
the cDNA clones isolated in previous screens (Bolger et al., 1993; Livi et al., 1990; 
McLaughlin et al., 1993).
The PDE4 isoenzymes aie derived from four genes A, B, C and D in rats, humans 
and mice. These genes are highly conserved between species. Indeed, each of the four 
human PDE4 genes are more related to their rat counterparts than they are to each other 
(Bolger et al., 1994; Bolger, 1994). The human clrromosomal loci o f these genes have been 
defined by screening somatic cell hybrids and by fluorescence in situ hybridisation. PDE4A 
and PDE4C are both located on chromosome 19, at positions p i 3.2 and p i3.1, respectively 
(Horton et al., 1995; Milatovich et al., 1994; Sullivan et al., 1999). PDE4B is found on 
chromosome 1, region p31 and PDE4D maps to chromosome 5, region q l2  (Szpirer et al.,
1995).
The diversity of PDE4 isoenzymes comes from the use of alternative promoters for 
the initiation of transcription and the process o f alternative 5’ mRNA splicing (Chabot, 
1996; Lopez, 1998). In the latter process the 3’ exons that encode the core region are 
spliced to a range of alternative 5’ exons (Bolger, 1994; Obernolte et al., 1993). This 
generates for each gene a number of isoenzymes that have shai*ed central and COOH-
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terminal core regions and unique NH2-terminal regions (Figure 1.2). As discussed below, 
these unique NH2“terminal domains appear to confer distinct modes of targeting and 
regulation on the PDE4 isoenzymes. A number of screening studies have shown that 
different tissues and cell lines express different combinations o f PDE4 isoenzymes (Bolger, 
1994; Erdogan and Houslay, 1997; MacKenzie and Houslay, 2000; Muller et al., 1996; 
Torphy et al., 1995). The complement of PDE4 isoenzymes expressed in a cell will clearly 
affect the spatial and temporal nature of the cAMP signal.
In PDE4 genes A, B and D there are two major splice junctions, (labelled 1 and 2 in 
Figure 1.2). Alternative splicing at the first junction (1) gives rise to Tong forms’ whereas 
splicing at the downstream junction (2) gives rise to the ‘short forms’. The relative 
positions of these splice junctions are conserved in PDE4B and PDE4D (Figure 1.3) 
(Monaco et al., 1994; Sullivan et al., 1998). However, the PDE4A gene is different in that 
the splice junction for the short splice variant, PDE4AI (RDI) is shifted slightly 
downstream relative to the splice junctions for the short splice variants of PDE4B and 
PDE4D (see Figure 1.3). In addition, the alternative splicing o f the PDE4C gene differs 
from the other 3 genes and short PDE4C forms comparable to the 4A, B and D short forms 
have not been identified (Obernolte et al., 1997; Sullivan et al., 1999). The general pattern 
o f alternative 5’ mRNA splicing shown by the mammalian PDE4 genes is conserved 
between species. For example, the primary transcript of the Drosophila dunce gene is 
alternatively spliced at the same relative positions as the mammalian PDE4A, B and D 
transcripts (Bolger et al., 1993; Davis et al., 1989; Henkel-Tigges and Davis, 1989; Qui et 
a l , 1991; Swimien et a l, 1989).
Three regions show striking sequence conservation within the PDE4 family. These 
are the catalytic unit in the core region and two Upstream Conserved Regions (UCRs) 
found towards the NH2-terminal ends of the PDE4 isoenzymes (Bolger et a l, 1994; Bolger,
1994) (see Figure 1.2). These regions are very highly conserved between species and >80% 
amino acid identity is observed between the corresponding regions o f rat PDE4 and 
Drosophila dunce isoenzymes (Davis et a l, 1989; Houslay et a l, 1998). The positions of 
the two splice junctions shown in Figure 1.2 and Figure 1.3 mean that all long PDE4 forms 
contain both UCRl and UCR2 whereas the short forms of PDE4A, 4B and 4D lack UCRl. 
An exception is PDE4A1, which also lacks the NH2-terminal half of UCR2.
It should be noted that these three conserved regions are flanked by variable 
regions, shown as heavy black bars in Figure 1.2 and Figure 1.3. The variable region
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between UCRl and UCR2 is referred to as LRl (Linker Region 1) whereas the region 
between UCR2 and the catalytic imit has been named LR2. The extreme COOH-terminal 
regions of PDE4 isoenzymes are also variable. This feature o f the PDE4 isoenzyme family 
has been exploited to produce antibodies that are specific for the splice variants derived 
from a single PDE4 gene (Erdogan and Houslay, 1997) (Houslay et ah, 1998). Antibodies 
raised against these extreme COOH-terminal regions can therefore be used as probes in 
western blotting experiments to identify the presence of the PDE4 splice variants of a 
particular gene, by comparison of their observed molecular weights with recombinant 
protein standards (MacKenzie and Houslay, 2000).
Various attempts have been made to clearly define the catalytic imit in PDE4 
isoenzymes. A definition based on sequence similarity suggests that it is around 360-390 
amino acids in length (Houslay et al., 1998). Within this region the amino acid residues 
that are essential for catalytic function are His433, His437, His473, His474, His477,
His505 and Thi'544 (numbering based on HSPDE4A4B) (Jacobitz et al., 1997; Jin et al., 
1992). 3D structural analysis of the PDE4 enzyme will be needed for a full understanding 
of the catalytic mechanism. Although the COOH-terminal catalytic unit is highly conserved 
throughout the PDE4 family, some sequence differences do occur between genes in the 
core region. These differences have allowed the generation of gene- and isoenzyme- 
specific primers for RT-PCR analyses of the isoenzymes expressed in different cell lines 
(Erdogan and Houslay, 1997; Kostic et al., 1997) (see Chapter 3).
The two upstream conserved regions UCRl and UCR2 have very different primary 
structures. The ~55 amino acids of UCRl can be divided into two subdomains. The NH2- 
terminal half of UCRl is polar and contains a high proportion of charged residues whereas 
the COOH-terminal half is hydrophobic. In contrast, UCR2 is entirely polar. Secondary 
structure predictions on this ~76 amino region suggest that it can be divided into three 
helical subdomains. The NPI2- and COOH-terminal subdomains are negatively charged, 
whereas the central domain has an overall positive charge (Houslay et ah, 1998).
The very high conservation of the UCRs between species suggests that these 
regions are functionally significant. The function of these regions has recently been 
investigated. Studies on HSPDE4D3, using yeast two-hybrid and ‘pull-down’ constructs 
expressing various portions of UCRl and UCR2, have shown that an interaction occurs 
between these regions (Beard et al., 2000). The fact that this interaction was obseiwed using 
a number o f different fusion constructs for both UCRl and UCR2 suggests that these
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regions are self-folding protein domains. The UCR1:UCR2 interaction was blocked by the 
alanine substitution of the acidic residues Glul46, Glul47 and Asp 149 within the NIT2- 
terminal half of UCR2. This interaction was also blocked by the alanine substitution of 
positively charged amino acids, (Arg98 and ArglOl in PDE4D3), found towards the 
COOH-terminal end of UCRl. It was therefore proposed that an intramolecular interaction 
occurs between UCRl and UCR2 that is mediated by oppositely charged residues.
Significantly, the phosphorylation of Ser54 (in PDE4D3) at the NH2-terminal end 
o f UCRl also disrupted the interaction with UCR2 (Beard et al., 2000). The mutation of 
Ser54 to Asp, which mimics phosphorylation, had a similar effect. Interestingly, the 
phosphorylation of PDE4D3 at Ser54 by PKA is known to cause both enzyme activation 
and an alteration in the sensitivity of this isoenzyme to rolipram inliibition (Hoffmami et 
al., 1998). Therefore, the UCR domains may form an intramolecular module that regulates 
the function of the catalytic unit (discussed further in section 1.7.2).
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Scale: 100 amino acid residues
Figure 1.2 PDE4 general structure
The general domain structure of a long PDE4 splice variant is shown. Grey bars mark the 
positions of the upstream conserved regions (UCRl and UCR2). The catalytic unit is 
shown by a white bar. The thick black line represents the unique NH2-terminal splice 
domain and grey circles mark the splice junctions. The region downstream of the second 
splice jmiction is shared by all the isoenzymes from one gene and is thus referred to as the 
core region. The NH2-terminal regions of long PDE4 isoenzymes contain an extreme NIT2- 
terminal splice domain that is unique to each isoenzyme and a region between the first (‘ U) 
and second (‘2’) splice junctions that is common to all the long forms within a single gene 
subfamily.
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Figure 1.3 Structure of mRNA transcripts of PDE4 splice variants
This figure shows a schematic diagram o f the mRNA transcripts that encode the PDE4 
splice variants in rats and humans. The positions o f the ATG initiator methionine codons 
are marked with white squares, whereas the termination codons are marked with black 
squares. Grey and white bars mark the positions o f the upstream conserved regions (UCRl 
and UCR2) and the catalytic unit, respectively. Black lines represent the unique NH2- 
terminal splice domains and grey circles, numbered 1 and 2, mark the splice junctions. It 
should be noted that the rat homologues o f the human splice variants PDE4A6, PDE4A8, 
PDE4C2, PDE4C3, PDE4C4 and PDE4D5 have not yet been cloned. The inactive, 
truncated splice variant HSPDE4A8 (2el) has been shown separately.
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1.5 Tissue distribution of PDE4 isoenzymes
PDE4 isoenzymes show distinct patterns of expression in tissues, which suggest 
that they have specific roles in cells (Muller et a l , 1996). There are several methods for 
assessing the expression of PDE4 isoenzymes in different tissues. The first method is the 
reverse-transcription polymerase chain reaction (RT-PCR) using specific 
oligodeoxynucleotide primer pairs for the detection of the transcripts of PDE4 isoenzymes 
(this method is discussed in detail in chapter 3). A second method is RNase protection 
analysis, in which the presence of PDE4 isoenzyme transcripts are detected by their ability 
to hybridise with specific antisense probes, to form RNA:RNA duplexes that are resistant 
to RNase-degradation. The third strategy that is employed for the detection of PDE4 
isoenzymes is western blotting using antibodies that are specific for the isoenzymes 
derived from a single PDE4 gene (see section 1.4 above). The advantage of the latter 
method is that is detects the PDE4 isoenzymes that aie actually expressed, as opposed to 
those that are merely transcribed.
A number of studies have examined the expression of the PDE4 genes (A, B, C and
D) in various cell lines and tissues. Most o f the tissues studied expressed PDE4A, PDE4B
and PDE4D (Engels et a l, 1994; Muller et a l, 1996). However, PDE4C expression was
restricted to only adipocytes, lung and brain, which suggests that PDE4C isoenzymes have 
.specialised functions. The range of tissues that have been screened for the individual PDE4 
isoenzymes is more limited. A particularly good source of PDE4 isoenzymes is rat brain 
which expresses PDE4A1, 4A5,4A6, 4B1, 4B2, 4C2, 4D1, 4D2, 4D3, 4D4 and 4D5 
(Beard et a l, 1999; Bolger et a l, 1997; Houslay et a l, 1998). However, these isoenzymes 
are differentially expressed in the various brain regions (Lobban, 1994; McPhee et a l,
1995). A few cell lines such as U937 monocytes (MacKenzie and Houslay, 2000) and 
Jurkat T-cells (Erdogan and Houslay, 1997) have also been screened for individual PDE4 
isoenzymes. A comparison of these two cell lines illustrates the fact that different cell types 
express very unique combinations of PDE4 isoenzymes, which define the cell’s response to 
signals mediated via cAMP.
1.6 Regulation of PDE4 expression
The chi'onic stimulation of certain cells with hormones has been shown to alter the 
expression pattern of PDE4 isoenzymes. A prime example of this is the induction of the
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short forms PDE4D1 and PDE4D2 which has been observed in a number of cell lines 
(Conti and Jin, 2000). The transcription of these isoenzymes is controlled from one intronic 
promoter (Vicini and Conti, 1997). As shown in Figure 1.3, PDE4D2 differs from PDE4D1 
by the deletion of an 86 nucleotide section downstream of the PDE4D1 start codon. This 
results in a frame shift, which shifts the stait of translation to a methionine in the middle of 
UCR2 (Monaco et al., 1994).
The induction of these isoenzymes was first demonstrated in rat Sertoli cells treated 
with follicle stimulating hormone (FSH). The increase in the mRNA levels and 
transcription rates for PDE4D1/PDE4D2 in the Sertoli cells was observed after Ih and 
reached a maximum after 3h (Conti et al., 1995; Swimien et al., 1989; Swinnen et al.,
1991). A similai’ effect was observed with the non-hydrolysable cAMP analogue C^,- 
dibutyiyl cAMP (BtzcAMP) and the adenylyl cyclase activator forskolin indicating that the 
induction was a cAMP-dependent process. Therefore, chi’onic (> lh) elevation o f cAMP in 
Sertoli cells switches on transcription of both PDE4D1 and PDE4D2 from an intronic
t|:.promoter (Verghese et al., 1995). 41
The induction of PDE4D1 and PDE4D2 expression by an increase in intracellular 
cAMP has been observed in a number of other cell lines, including FRTL-5 thyroid cells 
(Jin et al., 1998; Sette et al., 1994), Jurkat T-cells (Erdogan and Houslay, 1997), Mono f
Mac 6 monocytic cells (Verghese et al., 1995) and rat skeletal myoblasts (Kovala, 1994). In 
FRTL-5 thyroid cells the induction of PDE4D1 and PDE4D2 expression occurred after
chronic (24h) stimulation of these cells with thyroid stimulating hormone (TSH). This |
î=;induction followed the acute activation of the constitutively expressed PDE4D3 
isoenzyme, which was seen after a 15min incubation with TSH (Sette et al., 1994). As 
discussed in section 1.7.1, this activation is a result o f phosphorylation by PKA. Unlike 
PDE4D1 and PDE4D2, the expression level of PDE4D3 was not affected by elevated 
levels of cAMP in these cells. This demonstrates the fact that separate promoters control 
the expression of different isoenzymes derived from a single PDE4 gene. Four putative 
promoter regions have been identified in the RNPDE4D (Conti and Jin, 2000). The 
existence of such multiple promoters allows different combinations of PDE4 isoenzymes to 
be expressed under different conditions.
In contrast to the long PDE4D isofbrms 4D3, 4D4 and 4D5 which are found in the 
particulate and soluble fractions of cells, the short forms 4D1 and 4D2 are found entirely 
within the soluble, cytosolic fraction (see section 1.8 below). From this one would infer
■Ï
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that the long and short PDE4D isoenzymes occupy distinct compartments within the cell 
and they may therefore regulate different cellular functions. Therefore, the long-term 
hormonal induction of PDE4D1 and PDE4D2 may result in a profound change in the 
control of intracellular compai’tmentalised pools of cAMP.
Changes in intracellular cAMP levels can regulate the expression of other 
transcripts apart from PDE4D1 and PDE4D2. The c AMP-dependent induction of the short 
PDE4B form PDE4B2 has been observed in a number of cells, including U937 cells 
(Torphy et al., 1995) and monocytes (Verghese et al., 1995). In Jurkat T-cells, the cAMP- 
dependent increase the transcription o f short PDE4D isoenzyme was accompanied by a 
drop in the level of a novel, as yet imidentified PDE4A transcript (Erdogan and Houslay,
1997). Therefore, the hormonal treatment of cells has dichotomous effects on the 
expression of PDE4 isoenzymes.
1.7 Regulation of PDE4 activity
As discussed in section 1.4 most of the structural diversity within the PDE4 family 
occui's at extreme NHi-terminal ends of the isoenzymes, as a result o f alternative 5’mRNA 
splicing. It has been hypothesised that the extreme NHi-terminal regions confer distinct 
modes of intracellular targeting and regulation on PDE4 isoenzymes in vivo (Houslay,
1995; Houslay et al., 1995). The effect of these NH2-terminal splice domains on the acute 
regulation of PDE4 activity is discussed in the following sections.
1.7.1 Phosphorylation of PDE4D3 by PKA and ERK2
The activity of the PDE4 isoenzymes can be regulated in a rapid and transient 
fashion by phosphorylation at certain key sites. This mode of regulation has been most 
extensively studied in the PDE4D3 isoenzyme. As mentioned in section 1.6, Conti and co­
workers originally showed that this isoenzyme was phosphoiylated and activated by PKA
in rat thyroid FRTL-5 cells in response to an acute (15min) stimulation with TSH (Sette
ofand Conti, 1996; Sette et al., 1994). This preceded the inductioivPDE4Dl and PDE4D2 
observed after a 24h treatment with TSH (Sette et al., 1994). Therefore, TSH produces both 
an acute and a long-term effect on PDE4D activity in thyroid cells. Both forms of 
regulation must be taken into consideration in assessing the effect o f hormones on PDE4 
activity in cells.
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There are two sites o f PKA phosphorylation in PDE4D3, Seri 3 and Ser54 (see 
Figure 1.4). However, the phosphorylation of Ser54 at the beginning of UCRl was 
concui’i'ent with enzyme activation (Sette and Conti, 1996). This was confirmed by the 
replacement of Ser54 with an aspartate residue which mimicked phosphoiylation at this 
site and led to a 3-fold increase in catalytic activity (Hoffmann et al., 1998). In addition, the 
activated, phosphorylated form of wild-type PDE4D3 and the Ser54-> Asp mutant both 
showed an increased affinity for the PDE4-specific inhibitor, rolipram. This increase in 
rolipram affinity was just one aspect of an overall change in the kinetics of rolipram 
inliibition, which implied a conformational change in the catalytic unit. The phosphorylated
form of PDE4D3 showed the chaiacteristics of paitial competitive inhibition, whereas the 
non-activated form displayed simple competitive inhibition with rolipram (Hoffmann et al.,
1998).
In addition to being activated by PKA phosphorylation in its NTU-terminal region, 
PDE4D3 is inhibited by an ERK2-dependent phosphorylation at the COOH-terminal end 
of the catalytic unit (see Figure 1.4). Epidermal growth factor (EOF), which activates the 
RajflMEK-ERK signalling pathway (Blumer and Johnson, 1994), resulted in a rapid (within 
5mill) drop in the activity of recombinant PDE4D3 expressed in COS-1 cells (Hoffmann et 
al., 1999) which was accompanied by an elevation of intracellular cAMP. This effect of 
EOF treatment was also seen in 3T3 F442A and HEK293 cells where PDE4D3 is 
expressed endogenously. The inhibition o f PDE4D3 was the result of phosphoiylation by 
the MAP kinase ERK2 at Ser579. Closer examination of the sequence surrounding this 
phosphorylation site in the COOH-terminal region of the catalytic unit revealed the 
presence o f ‘KIM’ and ‘FQF’ docking sites for the association of ERK2 (MacKenzie et al.,
2000) (see Figure 1.4). Mutational analysis confirmed that these sites mediated association 
with ERK2. As discussed in section 1.8, PDE4D3 associates with the particulate fraction of a 
cells, which suggests that it may be specifically targeted. Therefore, PDE4D3 represents a 
means by which the Raf-MEK-ERK2 pathway can modulate discrete pools of cAMP
within cells.
The inhibitory effect of EOF treatment on PDE4D3 activity was reversed within 
20min. This recoveiy was due to the feedback activation of PKA, which activates PDE4D3 
by phosphoiylation at Ser54. Therefore PKA and ERK2 have opposing effects of PDE4D3
activity. Therefore, PDE4D3, which is expressed in a broad range of cells, represents a
'■ 'fepoint of cross talk between the Raf-MEK-ERK pathway and cAMP pathway.
i :
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Figure 1.4 PKA and ERK2 phosphorylation sites and ERK2 docking sites in FDE4D3
PDE4D3 has two phosphorylation sites for PKA (Seri 3 and Ser54) and one 
phosphorylation site for the MAP kinase ERK2 (Ser579). PKA phosphorylation at Ser54 
results in the activation of the enzyme, whereas ERK2 phosphoiylation at Ser579 results in 
inhibition. The positions of the ‘KIM’ and ‘FQF’ docking sequences for the association of 
ERK2 and the conserved residues with these motifs are also shown. X represents any 
amino acid.
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1.7.2 Phosphorylation of other PDE4D isoenzymes
The short forms PDE4D1 and PDE4D2 lack the UCRl region that contains the site 
for phosphorylation and activation by PKA. This again suggests that the expression of 
PDE4D1 and PDE4D2 in cells may have a profound effect on the response to signals that 
act via the cAMP pathway. The ERK2 phosphorylation site (PXSP) at the COOH-terminal 
end of the catalytic unit is present in all PDE4D isoenzymes and is conserved in PDE4B 
and PDE4C. However, PDE4A isoenzymes contain the slightly different sequence (RXSP) 
which does not appear to be a substrate for ERK2 action (Hoffmann et al., 1999). 
Intriguingly, ERK2 phosphorylation had different effects on the activities of the short and 
long PDE4D isoenzymes (MacKenzie et al., 2000). As shown in Figure 1.5, these 
isoenzymes contained different portions of the upstream conserved regions UCRl and 
UCR2. The different responses of these isoenzymes to ERK2 phosphorylation suggested 
that the UCR domains had a regulatory role. The long isoenzymes, PDE4D3 and PDE4D5, 
which contained both UCRl and UCR2, were both inliibited by ERK2 phosphoiylation. In 
contrast, the species that lacked UCRl but contained an intact UCR2 (i.e. PDE4D1 and the 
UCR2 + CAT NH2~terminal truncate) were stimulated upon ERK2 phosphoiylation. 
However, PDE4D2, which lacks all o f UCRl and the first 32 amino acid residues of 
UCR2, was inliibited by ERK2 phosphoiylation, but to a lesser degree than that observed 
with the long forms (MacKenzie et a l, 2000).
Therefore, it would appear that ERK2 phosphorylation has an intrinsic inhibitory 
effect on the core catalytic unit. This inliibitoiy effect is amplified in long isoenzymes that 
contain both UCRl and UCR2. However, in the absence of U CRl, UCR2 directs the 
stimulation of catalytic activity in response to ERK2 phosphorylation. This is abolished by 
the removal of the NH2-terminal half of UCR2. It has therefore been proposed that the 
UCRl and UCR2 domains form an intramolecular module that regulates the response o f the 
catalytic unit to phosphorylation by ERK2 (MacKenzie et a l ,  2000).
The above analysis of PDE4D3 phosphorylation has touched on several important 
aspects of PDE4 regulation that will be explored later in this thesis. Firstly, the above study 
has shown that alterations to the structure of the NH2-terminal ends o f PDE4 isoenzymes, 
such as phosphorylation at Ser54, can severely affect the activity of catalytic unit and its 
conformational state, shown by a change in rolipram affinity. Secondly, the activation or 
inhibition of various PDE4D isoenzymes by ERK-phosphorylation has shown that the
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UCRl and UCR2 regions affect the regulation of the catalytic unit. The different effects of 
ERK2 and PKA on different PDE4D isoenzymes also implied that the selective expression 
of different isoenzymes in cells could potentially be used to tailor cAMP responsiveness.
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Figure 1.5 Effect of ERK2 phosphoi'ylation on a range of PDE4D substrates
This figure summarises the effect o f ERX2 phosphorylation on the activity long and short 
PDE4D isoenzymes and NHz-termlnal deletion mutants (MacKenzie et al., 2000). These 
species contain various portions of the UCRl and UCR2. The positions of the ERK2 and 
PKA phosphoi'ylation sites aie indicated. The key to this schematic diagram is the same as 
that used in Figure 1.2 with thinner black lines representing the unique NHi-terminal splice 
domains of the PDE4D splice variants. Grey circles represent the splice junctions.
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1.7.3 Effect of phosphatidic acid on PDE4 activity
Another mechanism for the acute regulation o f PDE4 via their NHg-terminal 
regions is activation by phosphatidic acid (PA). PA is a phospholipid that accumulates in a 
number of cells in response to mitogenic or hormonal stimulation. PA can be produced by 
a number of biosynthetic routes (Athenstaedt and Damn, 1999). For example, PA can be 
produced the action of diacylglycerol kinase on diacylglycerol (DAG) which is a product of 
the hydrolysis of phospholipids by phospholipase C (PLC). Alternatively, PA can be 
produced by the direct action of phospholipase D (PLD) on various phospholipids. PA has 
been suggested to act as an intracellular second messenger and can modulate a number of 
signalling proteins including Raf-1 kinase and PKC (ElBawab et al., 1997).
The mitogenic stimulation of rat thymocytes with concanavalin A led to an
accumulation of PA and the activation of PDE4 and a resultant drop in the level of
intracellular cAMP (ElBawab et al., 1997). As discussed later in section 1.9.1, elevated
cAMP levels have an inhibitory effect on the immune response of a number of cells.
Therefore, the PA-induced drop in cAMP levels may be a mechanism for the activation of
certain immune responses such as the proliferation of T lymphocytes (Savany et al., 1996).
Studies with a range of PA-like molecules showed that the negatively char ged phosphate
group was essential for maximal PDE4 inhibition. Studies of the effect of PA on various
recombinant PDE4 isoenzymes showed that PA specifically activated the long forms, while
having no affect on the short forms (Nernoz et a l, 1997). A distinguishing featme of the
long PDE4 forms is the presence of UCRl in their NHz-terminal regions. As mentioned in
section 1.4, the NH2-terrninal half of UCRl is highly polar with an overall positive charge,
whereas the COOH-terminal half of this region is hydrophobic. This may present an ideal
binding surface for interaction with the amphipathic PA molecules, with the negatively
charged phosphate group of PA interacting with UCRl. By affecting the intramolecular 
« •interactions of UCRl, the binding of PA may cause a conformational change that results in 
the activation of the PDE4 catalytic unit. This would be compatible with the mechanism 
proposed for the activation of PDE4D3 by phosphorylation at Ser54 and the theoiy that 
UCRl and UCR2 form an intramolecular module that regulates the activity of the catalytic 
unit (see section 1.7.2 above).
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1.8 Intracellular targeting of PDE4 isoenzymes
A crucial step in understanding the function of signalling enzymes, including 
PDE4, is to determine their intracellular localisation. A common method used in the initial
isoenzymes are predominantly determined by their unique NH2-terminal alternatively 
spliced regions.
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characterisation of new PDE4 isoenzymes is transient expression in COS cells (Shakur et 
al., 1993; Sullivan et al., 1994). These cells allow high expression of transfected proteins
and have very low levels o f endogenous PDE4 activity (Scotland et ah, 1998).
Information on the intracellular localisation of PDE4 isoenzymes can at first be 
obtained from their distribution between particulate and soluble fractions of these cells. A 
low speed (lOOOg) PI-pellet fraction, a high-speed (100,000g) P2-pellet fraction and a 
high-speed supernatant S fraction are usually prepared for this purpose. The PI-pellet 
fraction is generally composed of nuclear and cytoskeletal components, the P2-pellet 
fraction contains plasma membranes, endoplasmic reticulum, Golgi stacks, endosomes and 
lysosomes and cytoskeletal components (Seotland et al., 1998) and the S fraction contains 
‘soluble’ cytosolic proteins. Table 1.2 shows that the distribution of PDE4 isoenzymes 
between these fractions varies considerably in transiently transfected COS-7 cells. In this 
table, the presence of a PDE4 isoenzyme within a particular fraction is indicated with a 
tick. Quantitative analyses of the distribution of the certain PDE4 isoenzyme have also
-s::been presented.
Variation is seen not only in the relative association of PDE4 isoenzymes with the
particulate fractions but also in the susceptibility of these associations to the detergent
Triton X-100 and high salt concentrations, which disrupt hydrophobic and electrostatic
interactions, respectively. Susceptibility to either salt or detergent might indicate an
interaction with an integral membrane protein, a membrane-associated protein or a
phospholipid. Resistance to solubilisation with detergent often indicates an association
with the cytoskeletal fraction (El Benna et al., 1999; Jung and Moroi, 1988; Slusarewicz et
al., 1994; Yan et al., 1995). As shown in Table 1.2, subtle differences are observed
between the PDE4 isoenzymes derived from the same gene, in terms of the effects these
agents have on their association with the particulate fractions, which suggests that they
interact with distinct anchoring components. The PDE4 isoenzymes derived from a single
gene differ only in their extreme NH2-terminal splice domains (see Figure 1.3). This further 
. .suggests that the distinct patterns of intracellular targeting shown by the different PDE4
it
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Table 1.2 Subcellular distribution data for PDE4 isoenzymes in transfected COS-7 
cells
This table summarises the distribution o f PDE4A, 4B, and 4D isoenzymes between the 
low-speed pellet (PI), high-speed pellet (P2) and S fractions o f transfected COS-7 cells. 
No data has been obtained for PDE4C isoenzymes. In some cases quantitative analyses 
were carried out and the percentage values are given. Pellet-associated PDE4 isoenzymes 
are either resistant (R)  or susceptible ( ^  to solubilisation with IM NaCl or 5% Triton X- 
100. The particulate isoenzymes that can only be solubilised with a combination o f  both 
Triton and NaCl are indicated as (Triton + NaCl) S
PDE4
isoenzyme
RNPDE4A1
short
(also known as  
RD1)__________
RNPDE4A5
long
(also known as  
rpde6)
HSPDE4A5B
long
(also known as  
pde46)_________
RNPDE4A6
long
(also known as  
rpde39)
HSPDE4B1
long
HSPDE4B2
short
HSPDE4B3
long
Subcellular distribution in transfected COS-7 
cells isoenzyme present isoenzyme absent
PI
21 % 
Triton R 
NaCIR
yf as-----
V 19%
Triton R
17% 
Triton R 
NaCl#"I kill
26% 
Triton S
m a
^  23% 
Triton S
m m s
y
Triton S 
NaCl R
^  28% 
Triton R 
NaCl R
26% 
Triton R 
NaCIR
Triton R 
NaCIR
^  11% 
Triton S 
NaCIR
^  12% 
Triton S 
NaCIR
^  17% 
Triton R 
NaCl R
51%
y 55%
y 71%
y 61%
y 58%
Refs
(Pooley et al., 
1997; Shakur et 
al., 1995)
(McPhee et al.,
1999)
(Huston et al.,
2000 )________
(McPhee et al.,
1999) (Huston et 
al., 1996)
(Bolger et al., 
1996)
(Huston et al., 
1997)
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Table 1.2 continued
PDE4
isoenzyme
Subcellular distribution in transfected COS-7 
cells isoenzyme present isoenzyme absent
Refs
HSPDE4D1
short
(Bolger et al., 
1997)
HSPDE4D2
short
HSPDE4D3
long
HSPDE4D4
long
HSPDE4D5
long
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1.8.1 Membrane targeting of RNPDE4A1 (RDI)
The short splice variant RNPDE4A1 (RDI) provides a clear example of the 
profound influence the unique NHi-terminal splice domains have on the targeting of PDE4 
isoenzymes. RNPDE4A1 has only been detected in rat brain, which suggests that it may 
have a specific neuional role (Bolger et ah, 1996). This isoenzyme is found entirely within 
the high-speed pellet (P2) fraction in both brain and transiently transfected COS-7 cells 
(McPhee et ah, 1995; Shakur et al., 1993), It can be solubilised from this fraction by low 
(<0.1 %) concentrations o f the detergent Triton X-100 (see Table 1.2). Analysis by confocal 
immunofluorescence microscopy showed that RNPDE4A1 was associated with the plasma 
membrane, the Golgi apparatus and punctate vesicle-like structures adjacent to the plasma 
membrane in COS-7 cells (Shakur et al., 1995). Interestingly, the distribution of 
RNPDE4A1 in the stably transfected FTC thyroid carcinoma cells was slightly different in 
that it associated almost exclusively with the Golgi apparatus. These observations in COS 
cells and FTC cells suggested that RNPDE4A1 might have a role in the intracellular 
trafficking of vesicles between the Golgi apparatus and the plasma membrane (Houslay, 
1996). Vesicular traffic along the exocytotic route has been shown to be a cAMP- 
dependent process (Muniz et al., 1996).
A major step in understanding the intracellular targeting o f RNPDE4A1 came from 
the finding that the removal of the 25 amino acid NH2-terminal splice domain of 
RNPDE4A1 completely abolishes its association with the P2-membrane fraction. The 
truncated species Met^’^ RDl, which conesponds to the core region of PDE4A beginning at 
the second splice junction, was foimd entirely within the cytosolic S fraction o f transfected 
COS cells. Confocal immunofluorescence microscopy showed that Met^^RDl had a diffuse 
cytosolic distribution (Shakur et al., 1995). This suggested that the imique NH2-terminus of 
RNPDE4A1 contained a motif for interaction with the P2 (membrane) fraction. This was 
confirmed by Scotland and Houslay who showed that the fusion of this domain to 
chloramphenicol acetyl transferase (CAT) conferred membrane association on this 
normally soluble bacterial protein (Scotland and Houslay, 1995; Scotland and Houslay,
1998). The NH2-terminal splice domain of RNPDE4A1 is therefore crucial to any function 
of tills isoenzyme that would require its precise localisation in cells, such as the 
compartmentalisation of cAMP.
1 Introduction 36
The mechanism of taigeting of the RNPDE4A1 NH2-terminal splice domain has 
not yet been established. The unique NH2-terminal splice domain bears no homology to 
any other Icnown protein. Its solubilisation from the P2 fraction with detergent suggests that 
it may interact with a lipid component. However, RNPDE4A1 appears to only associate 
with certain cellular membranes. Therefore, the interacting component must also be 
specifically localised within the cell.
In order to assess the feasibility of a lipid interaction, the 3-D structure of the 
RNPDE4A1 splice domain was determined by ^H-NMR (Smith et al., 1996). This 
identified the presence of two helical regions separ ated by a hinge. The first helical region, 
Leu3-Cysl 1, is amphipathic in nature, and contains the polar residues Asp5, Cys8, Glu9, 
ThrlO, and Cysl 1. The second o f these helical regions, Prol4-Lys24 contains a compact 
unit o f hydrophobic residues, Prol4-Trp20. The bulky side chains o f the tluee tryptophans 
at positions 15, 19 and 20, and the leucine at position 16 interact to form a hydrophobic 
cluster. Interesting, deletion of region 14-20 abolished membrane association, in contrast 
to the deletion of regions 2-7, 8-13 and 21-25. Therefore, it is possible the region 14-20 
provides a hydrophobic surface for interaction with membrane lipids, or alternatively a 
membrane-associated protein. The nature of the interacting component is investigated later 
in this thesis (Chapter 4).
1.8.2 interaction of RNPDE4A5 (rpde6) with SH3 domains
The targeting of PDE4 isoenzymes by their extreme NH2-tenninal regions is further 
illustrated by a comparison of the intracellular localisation o f the short PDE4A isoenzyme 
RNPDE4A1 with that of the long isoenzyme RNPDE4A5 (rpde6). This isoenzyme has 
been detected in a number of specific regions of the rat brain and in a range of cell lines 
including thymocytes (ElBawab et al., 1997; Nemoz et al., 1997), Jurkat T-cells (Seybold 
et al., 1998), pheochromocytoma (PC 12) cells and U937 human monocytes (MacKenzie 
and Houslay, 2000). It is found in all fractions (PI, P2 and S) of transfected COS-7 cells 
and brain. In contrast to RNPDE4A1, RNPDE4A5 could not be solubilised from rat brain 
membranes with Triton X-100. This suggested that RNPDE4A5 interacted with the 
detergent insoluble cytoskeletal fraction (Yan et al., 1995). This was supported by 
immunofluorescence analysis in COS-7 cells that showed RNPDE4A5 to associate with a 
network extending tlnoughout the cell with a concentration in the perinuclear region 
(Huston et al., 2000).
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Analysis of the sequence o f the unique NHz-terminal splice domain of RNPDE4A5 
revealed the presence of three proline-rich motifs (see Figure 1.6). These were reminiscent 
of the sites for high-affinity binding of Src homology 3 (SH3) domains. SH3 domains are 
self-folding globular* protein modules of around 50 amino acids that mediate protein- 
protein interactions in signalling networks (Pawson, 1995). These domains bind to left- 
handed polyproline type II structures with the core motif PXXP (Alexandropoulos, 1995; 
Mayer and Eck, 1995). These motifs are also characterised by the presence of adjacent 
arginine residues. SH3 domains found in a wide variety of proteins including the 
cytoskeletal elements myosin and fodrin (Mayer, 1993), adaptor proteins such as Grb2, Crk 
and SHC (Buday, 1999) and the Src family of cytoplasmic tyrosyl kinases (Cooper and 
Howell, 1993; Sicheri et al., 1997). The latter are involved in a large number of signalling 
pathways including those downstream of growth factor and cytokine receptors (Abram and 
Courtneidge, 2000; Erpel and Courtneidge, 1995; Tatosyan and Mizenina, 2000).
Pull down experiments using a panel of SH3 domains fused to GST did indeed 
show an interaction between RNPDE4A5 and certain SH3 domains (O' Connell et al.,
1996). The best binders were the SH3 domains o f Src family tyrosyl kinases Lyn, Fyn and 
Src. Only very weak association was observed with the SH3 domains of the adaptor 
proteins Grb2 and Crk. The binding o f RNPDE4A5 to the Src family tyrosyl kinase SH3 
domains was resistant to dissociation witli Triton X-100. Interaction with SH3 domains 
was not seen with the other PDE4A splice variants RNPDE4A6 (rpde39) and RNPDE4A1 
indicating that binding was determined by motifs in the 103 amino acid unique NH2- 
terminal domain of RNPDE4A5 (O' Connell et al., 1996).
The interaction of RNPDE4A5 with SH3 domains may target RNPDE4A5 to the 
cytoskeleton. A number of cytoskeletal proteins, such as fodrin or cortactin contain SH3 
domains. Association with SH3 domain proteins may bring RNPDE4A5 into close 
proximity with a regulatoiy kinase or phosphatase. Alternatively, interaction of 
RNPDE4A5 with Src tyrosyl kinase domains may allow signal transduction pathways 
activated through Src, such as the Ras pathway and the MAP kinase cascade, to 'cross-talk' 
with the cAMP signalling pathways.
The observed interaction of RNPDE4A5 with SH3 domains also opens up new 
possibilities for the involvement of PDE4 in the regulation of superoxide generation by 
NADPH oxidase in a number of cell types. The assembly and activation of the NADPFI- 
oxidase complex requires the interaction the p47-phox and p67-phox (McPhail, 1994)
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which contain SH3 domains. Inliibition of PDE4 inliibits the respiratory burst in 
eosinophils, neutrophils (Spina et al., 1998) and kidney glomeruli cells (Chini et al., 1994) 
(see section 1.2.1) and PDE4 isoenzymes have recently been shown to be targeted to the 
forming phagosome, the site o f superoxide generation in neutrophils and macrophages 
(Pryzwansky et al., 1998). Therefore, the interaction between RNPDE4A5 and SH3 
domains illustrates the importance of finding protein interaction partners for PDE4 
isoenzymes in order to identify their possible roles in signalling cross-talk or the 
compartmentalisation of cAMP.
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Figure 1.6 The putative SH3 domain-binding motifs in RNPDE4A5 (rpde6) and its 
human homologue HSPDE4A4B (pde46)
The domain structure of RNPDE4A5 and its human homologue HSFDE4A4B is shown. 
The position o f the start of HSPDE4A4C (h6.1) is indicated with an arrow. This species is 
essentially a truncated version of HSPDE4A4B with a unique nine-residue section at its 
NH2“terminus. The sequences of the thr ee putative SH3 domain-binding motifs in the 
unique NHi-terminal splice domains o f RNPDE4A5 and HSPDE4A4B are shown above 
the structure. The positions the two key proline residues of the PXXP motif and adjacent 
proline and arginine residues in these sequences are indicated in bold. Sequence differences 
in HSPDE4A4B are shown above the RNPDE4A5 sequences. The HSPDE4A4B 
homologue contains an additional proline-rich insertion in its LR2 region that constitutes a 
further putative SH3 domain-binding site.
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1.8.3 Interaction of HSPDE4A4B (pde46) with SH3 domains
The SH3 binding motifs observed in the unique NHi-terminal splice domain of 
RNPDE4A5 are conserved in the human homologue of this splice variant, HSPDE4A4B 
(pde46) (see Figure 1.6). Like RNPDE4A5, HSPDE4A4B also interacts ’with the SH3 
domains o f Src family tyrosyl kinases, with a preference for Lyn SH3 (McPhee et al.,
1999). HSPDE4A4B is also found in both the cytosolic and particulate fractions o f COS-7 
cells and its immunofluorescence pattern suggests that it associates with the cytoskeleton in 
the perinuclear region and also at distinct cortical regions near the cell periphery (Huston et 
al., 1996). Furthermore, immunofluorescence analysis showed that HSPDE4A4B and Lyn 
co-localised to the same subcellular structures.
The aligmiient of the sequences of HSPDE4A4B and RNPDE4A5 has identifled the 
presence of a proline-rich insert in the variable LR2 region of HSPDE4A4B that contains 
an additional SH3-domain binding motif (see Figure 1.6). When expressed as a GST 
fusion, this LR2 insert could be co-immunoprecipitated with Lyn SH3, indicating a direct 
interaction. This region also mediated the association of a truncated species, HSPDE4A4C 
(h6.1) with Lyn SH3, in contrast with the rat PDE4A NHz-terminal truncate Met^^RDl, 
which does not bind to SH3 domains.
Differences were observed between the particulate and soluble forms of 
HSPDE4A4B in COS-7 cells, in terms of their kinetics of inhibition by the PDE4-specific 
inhibitor rolipram. Particulate HSPDE4A4B showed complex partial competitive 
inhibition by rolipram with an increased affinity for this inhibitor in comparison to 
cytosolic HSPDE4A4B, which displayed simple competitive inliibition (Huston et ah,
1996). These results suggested that the par ticulate and soluble forms of HSPDE4A4B had 
different conformational states. In contrast, the cytosolic and particulate forms of the rat 
homologue RNPDE4A5 both displayed simple competitive inliibition, suggesting they had 
the same conformation.
Ill order to explain this fundamental difference between HSPDE4A4B and 
RNPDE4A5, it was hypothesised that the altered conformation o f HSPDE4A4B observed 
in the particulate fraction was induced by the association o f an SH3-domain containing 
protein with the LR2 insert region. Therefore, the effect of Lyn SH3-association on the 
kinetics of rolipram inhibition was assessed. The binding of Lyn SH3 to cytosolic 
HSPDE4A4B did indeed switch the kinetics of rolipram inhibition from simple
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competitive to partial competitive, with a concomitant increase in rolipram affinity. A 
similar switch was observed for HSPDE4A4C (h6.1) after association with Lyn SH3. 
Deletion mutants that lacked all or par t o f the proline-rich insert region also associated 
with Lyn SH3, presumably via the putative SH3 domain binding sites within the unique 
NH2-terminal splice domain. However, these mutants did not show the aberrant kinetics of 
rolipram inhibition on binding to Lyn SH3, indicating that it was the specific interaction of 
Lyn SH3 with the LR2 region that induced the conformational change. Therefore, the 
interaction of HSPDE4A4B with SH3 domains causes the same conformational switch as 
that observed for HSPDE4A4B in the particulate fraction of transfected COS-7 cells.
This SH3 domain-induced conformational switch is in HSPDE4A4B similar to the 
switch observed when PDE4D3 is phosphorylated and activated by PKA. However, the 
binding of an SH3 domain to HSPDE4A4B does not result in the activation of catalytic 
unit. The above study highlights a potential mode of regulation in which the interaction of 
a protein with a specific PDE4 isoenzyme can induce a conformational change in the PDE 
catalytic unit. Understanding the mechanisms involved in these interactions may aid the 
design of drugs that inliibit the targeting o f PDE4 isoenzymes to specific subcellular 
compartments and the attainment of one or other conformational state.
1.8.4 Interaction of HSPDE4D4 with SH3 domains
The long HSPDE4D4 splice variant also interacts with SH3 domains (Beard et ah, 
1999). Like RNPDE4A5 and HSPDE4A4B, this isoenzyme shows a preference for 
association with the SH3 domains o f Src-tyrosyl kinases. These interactions are again 
directed by the unique NH2-terminal splice domain of HSPDE4D4, which contains proline- 
rich sequences. In contrast to the PXXP motifs seen in the NHz-terminal domains of 
RNPDE4A5 and HSPDE4A5, the NH2-terminal region of HSPDE4D4 contains several 
polyproline stretches, 6-7 residues in length. These differences may explain the slightly 
different pattern of SH3-domain interactions shown by HSPDE4D4. For instance, 
HSPDE4D4 associates with Lyn-, Src- and Fyn-SH3 domains with roughly equal 
efficiency, whereas RNPDE4A5 and HSPDE4A4B show a distinct preference for Lyn SH3 
(Beard et al., 1999).
These SH3-domain interacting isoenzymes are all expressed in brain (Bolger et ah,
1997). This suggests that the association of PDE4 isoenzymes with SH3 domains may have 
an important function in neurones. The associations of HSPDE4D4 with SH3 domains
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does not alter its catalytic activity or rolipram affinity. Therefore, the functional importance 
o f this interaction may simply be the targeting of HSPDE4D4 to a specific compartment 
within the cell,
1.8.5 Intracellular targeting of HSPDE4D5: interaction with the anchoring 
protein RACK1
.The PDE4D5 isoenzyme is expressed in numerous mammalian cell lines and also
the brain (Bolger et a l, 1997; MacKenzie and Houslay, 2000). Like the other long PDE4D
isoenzymes, PDE4D5 is distributed between the particulate and soluble fraction o f
transfected COS-7 cells (see section 1.8). The yeast-2-hybrid technique has been used to 
.successfully identify a protein binding partner for the HSPDE4D5 isoenzyme. The
Receptor for Activated C Kinase (RACKl) was identified in a screen of a HeLa cell two
hybrid cDNA library using HSPDE4D5 as bait (Yarwood et al., 1999). Subsequently it was
.shown that these two proteins have a very similar subcellular distribution patterns in 
transfected COS-7 cells and their interaction was confirmed by their co- 
immunoprecipitation from a number o f cell lines. Binding studies with purified 
recombinant RACKl and PDE4D5 indicated the interaction was high affinity and did not 
require intermediary proteins. The residues Asn22, Pro23, Trp24 and Asn26 within the 
unique NHi-terminal splice domain of PDE4D5 were found to be essential for interaction 
with RACKl.
RACKl (36kDa) is a member o f the WD40-repeat family o f proteins, which 
perform a wide range of functions (Neer et a l, 1994). RACKl is homologous to the p 
subunit of the stimulatoiy heterotrimeric G protein (Ron et a l, 1994). The p subunit has a 
‘propeller-like’ structure that consists of seven ‘blades’ that are believed to mediate 
interaction with proteins such as P-adrenergic receptor kinase (pARK) (Lambright et a l,
1996; Wall et a l, 1995). It is probable that RACKl has a similar tlnee-dimensional 
structure and PDE4D5 may indeed associate with one of its propeller blades.
RACKl was originally discovered as a protein binding partner for protein kinase C 
(PKC) (Mochly-Rosen et a l, 1991). RACKl is necessary for the translocation of PKC 
from the cytosol to the particulate fraction of cells upon activation with Ca^^ and PMA 
(phorbol 12-myristate 13-acetate). Other proteins have been shown to interact with 
RACKl, including phospholipase Cy, (Disatnik et a l, 1994), Src tyrosyl kinase (Chang et 
a l ,  1998) and p-integrin (Liliental and Chang, 1998).
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The binding region for RACKl on PKC is contained the within the C2 domain of 
the ‘conventional’ subfamily of PKCs which is exposed upon activation with Ca^^ and 
PMA (Mochly-Rosen, 1995). The unique NHi-terminal splice domain of PDE4D5 does not 
contain any regions with homology to the C2 region and no PMA-induced conformational 
change was necessary for the association of PDE4D5 with RACKl. Furthermore, the 
association with RACKl does not affect the catalytic activity or rolipram affinity of 
PDE4D5. Rather than regulating PDE4D5, RACKl may be acting as an anchor protein.
The simultaneous association of RACKl with PDE4D5 and other signalling proteins such 
as PKC and PLCy may allow more efficient cross talk between signalling pathways. 
Alternatively, the association with RACKl may localise PDE4D5 within the cell so that it 
can modulate a specific pool of cAMP. In this way PDE4A5 may regulate the activity of 
PKA and substrates of PKA in the vicinity of the RACKl complex.
1.9 Pharmacological importance of PDE4
As mentioned previously, PDE4 isoenzymes have been identified as potential 
targets in a number of diseases. The PDE4-specific inhibitor rolipram was originally 
discovered in the search for novel treatments for depression. Although early phase clinical 
trials indicated that rolipram was an effective anti-depressant, they also showed a number 
o f side effects, including nausea and vomiting. These side effects are a recurring problem 
in the use of PDE4 inhibitors as therapeutic agents, PDE4 inhibitors have also been shown 
to have anti-inflammatory effects. The potential use of PDE4 inliibitors in a number of 
disease states and possible approaches to developing more specific PDE4 inhibitor-based 
drugs are discussed in the following sections.
1.9.1 inflammatory diseases: asthma and atopic dermatitis
A potential use for the anti-inflammatoiy property of PDE4 inhibitors is in the 
treatment of asthma. This disease is characterised by an inflammatory response to inhaled 
allergenic or irritative substances, that results in bronchoconstriction, bronchial oedema 
and increased tone of airway smooth muscle (Spina et al., 1998). Astlima is a complex 
multifactorial condition. The inflammatory response involves the recruitment and 
activation of inflammatoiy cells to the airway. These include eosinophils, neutrophils, 
mast cells and T lymphocytes (Torphy, 1998). Once activated these cells generate of large 
number of different pro-inflammatory substances including cytokines, leukotrienes, and
1 Introduction 44
cytotoxic superoxide (generated in the respiratory burst by activated NADPH oxidase). The 
infiltration and activation of all of these cells are suppressed by an increase in the 
intracellular levels of cAMP (Spina et al., 1998).
p-adrenoceptor agonists (e.g. salbutamol), which cause bronchodilation by the 
relaxation o f airway smooth muscle, are commonly used in the treatment of asthma. This 
effect is mediated, at least in part, by the activation of PKA via the cAMP signalling 
pathway (Giembycz, 1996; Torphy et al., 1995). Another commonly used drug is the non­
specific PDE inhibitor theophylline. The mechanism of action of theophylline is unclear as 
it has other actions apart from PDE inhibition, such as the activation of adenosine receptors 
(Essayan, 1999).
Studies have shown that a major component of the PDE activity in the pro- 
inflammatory cells mentioned above is PDE4 (Spina et al., 1998; Torphy, 1998). This 
provides a rationale for developing PDE4 inhibitors as anti-astlima drugs. PDE4 inliibitors, 
such as rolipram and Ro 201724, are effective at suppressing the activity of many 
inflammatory cells. For instance, they suppress superoxide generation and leukotriene 
production by neutrophils and eosinophils and they suppress IgE induced degranulation in 
mast cells (Essayan, 1999). PDE4 inhibitors also reduce the infiltration of inflammatory 
cells to the airway epithelium, by reducing the production of chemotactic mediators and by
inhibitoiy effects on cell trafficking (Toiphy, 1998).
7PDE4 enzymes are expressed in airway smooth muscle and selective PDE4 f
inhibitors appear to have a relaxant effect on these smooth muscle cells (Poison and Strada,
1996). These effects o f PDE4 inliibits are potentiated by the presence of PDE3 inhibitors. 
Therefore, both PDE3 and PDE4 isoenzymes appear to be involved in the regulation of 1
airway smooth muscle tone.
A major disadvantage of the use of PDE4 inhibitors in the treatment of asthma and 
other diseases is their side effects of nausea and vomiting. This highlights the importance 
o f developing PDE4 inliibitors with greater specificity. Studies on the function o f PDE4 in 
inflammatory cells have suggested that PDE4 isoenzymes can adopt one of two 
conformational states, which can be distinguished by their relative affinities for the 
inhibitor rolipram. These states have been noted for the isoenzymes PDE4D3 (see section 
1.7.1) and HSPDE4A4B (see section 1.8.3). The balance between these two states varies 
from cell to cell. The major functional PDE4 in eosinophils was in the high-affinity state 
(Souness and Scott, 1993). However, the PDE4 isoenzymes that regulated TNFa
I
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production in human monocytes were in the low-affmity state. Compounds that 
preferentially inhibit the catalytic activity of one these two PDE4 conformational states 
may have more specific therapeutic actions with fewer side effects. The PDE4-selective 
inhibitor CDP840 preferentially inhibits the low rolipram affinity conformational state.
This drug appeal's to have an anti-inflammatory action that ablates the astlimatic late-phase 
response to allergen, without any side-effects (Harbinson et al., 1997). An understanding of 
this conformational switch may aid the development of compoimds that favour the 
adoption of one or other state and these may be of therapeutic value.
The high- and low-affinity PDE4 conformational states are believed to be
interconvertible. In the case of HSPDE4A4B, interaction with the SH3 domains of Src
tyrosyl kinases with the LR2 region of this isoenzyme caused the catalytic region to switch
.from the low- to the high-affinity state (see section 1.8.3). Other protein-protein 
interactions may govern the switch between PDE4 conformational states. Identifying these 
binding proteins and their mechanisms of interaction may be an important step in drug 
development.
Another approach to developing drugs with better tissue specificity is the search for 
compounds that specifically inhibit the isoenzymes derived from a single PDE4 gene (A,
B, C or D). This is based on the fact that different tissues show distinct patterns of 
expression for each of the four' genes. In this regard, the identification of the precise PDE4 
isoenzymes expressed in inflammatory cells and airway smooth muscle is imperative.
Interestingly, the inliibitor SB207499 shows selectivity for the PDE4D subfamily. 
SB207499 lacks the side effects o f nausea and vomiting seen with rolipram (Barnette et al.,
1998).
Another inflammatory disease where PDE4 inliibitors may be of therapeutic 
importance is atopic dermatitis (Spina et ah, 1998). This condition is characterised by 
emergence of skin lesions after exposui’e to various allergens. As in asthma, the
development of atopic dermatitis involves the infiltration of T-lymphocytes and other 
leukocytes to the sites of inflammation. The molecular basis of atopic dermatitis is unclear 
although it appears to involve aberrant levels of cAMP PDE activity in pro-inflammatory 
cells. Early clinical trials suggest that PDE4 inhibitors may be effective treatments for this 
disease. The PDE4-specific inhibitor CP-80633 appeared to have a therapeutic effect on 
this condition and inhibited many aspects of the inflammatory response, including 
superoxide production, eosinophil cheniotaxis and TNFa release (Cohan et ah, 1996).
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i1.9.2 Other conditions: Parkinson’s disease and diabetes insipidus
Another condition where PDE4 inliibitors could be exploited is in Parkinson’s 
disease. This condition is characterised by loss of dopaminergic neurones in the substantia 
nigra region within the brain. PDE4 inhibitors protected dopaminergic neurones from the 
pro-apoptotic effects of l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP) both in 
culture and in the substantia nigra of mice (Hulley et al., 1995). This highlights the 
potential use of PDE4-inliibiting drugs in the treatment of a major neurodegenerative 
disease.
PDE4 enzymes have also been implicated in the rare disease neplirogenic diabetes 
insipidus. In mouse models o f this condition the cells of the medullaiy collecting duct in 
the kidney show a poor response to the antidiuietic hormone vasopressin, which activates 
the cAMP pathway. Although the ability of vasopressin to stimulate adenylyl cyclase was 
unaffected, the cells from diseased state mice failed to accumulate sufficient cAMP 
(Takeda et al., 1991). This condition was ameliorated with the PDE4-specific inhibitor 
rolipram, which suggested that the abnormal response to vasopressin might be due to the 
over-expression of certain PDE4 isoenzymes in the collecting duct cells. Identifying the 
precise PDE4 isoenzymes involved is again crucial for our understanding of the molecular 
basis of this condition and for the development o f novel drugs (Houslay et ah, 1998).
1.10 Anchoring and scaffold proteins
As mentioned above, the identification of the protein-binding partners for PDE4
isoenzymes may be an important step in drug development. Although potential protein
binding partners have been found for PDE4A4/5, PDE4D4 and PDE4D5 there are many
other PDE4 isoenzymes for which protein interaction partners need to be defined. The 
.association of PDE4 isoenzymes with protein complexes may turn out to be a common 
theme o f this family. In these complexes the PDE4 isoenzymes may associate with more 
than one protein. Two overlapping classes of protein that serve as ‘molecular glue’ for 
signalling complexes have been defined by Faux and Scott (Faux and Scott, 1996). These 
are the scaffold proteins and anchoring proteins. The possibility that these proteins are 
intracellular targets for PDE4 isoenzymes is discussed below.
■■il'.
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their function. For example, a peptide corresponding to the RACKl binding site on sFKC 
blocked the translocation of sPKC to specific subcellular sites in cardiac myocytes and
peptides that blocked the interaction of PKC(3 with RACKl in pancreatic p cells blocked 
the glucose-induced translocation of PKCp to the cell peripheiy and reduced the 
production of insulin by these cells in response to glucose (Yedovitzky et a l, 1997). In a
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1.10.1 Anchoring proteins
Anchoring proteins target one or more signalling proteins to specific locations
within the cell. A prime example is RACKl, which has been shown to associate with PKC,
'PLCy, integrin p-subunit, Src tyrosyl kinase and PDE4D5. A number o f experiments have 
shown that the correct intracellulai* targeting of PKC isoforms via RACKl is essential for
.prevented the regulation of contraction by noradrenaline (Johnson et al., 1996). Similarly,
.similar manner, the precise intracellular localisation of PDE4D5 is probably essential for 
its function in vivo.
Other examples of anchoring proteins are the AKAPs, which were described in 
section 1.2. AKAPs are a growing family o f proteins that target PKA to various subcellular 
compartments. In addition to associating with the R subunits of PKA, AKAP79 has been 
shown to bind to PKC and protein phosphatase 2B (calcineurin) (Coghlan et al., 1995; 
Klauck et al., 1996). These three proteins bind to separate sites on AKAP79 and can
associate simultaneously in any combination (Klauck et al., 1996). In neurones, AKAP79 
is targeted to the postsynaptic density. Multivalent complexes such as this may allow the
.7efficient co-ordination o f signalling events at the synapse. The opposing actions of kinases
and phosphatases may be tightly integrated through their association with AKAPs. For
instance, an AKAP called Yotaio binds to PKA, protein phosphatase 1 (PPl) and the N-
methyl-D-aspartate (NMDA) receptor (Westphal et al., 1999). Under basal conditions, this
complex is believed to maintain the NMDA receptor in an inactive, dephosphoiylated state.
However, this situation is rapidly reversed by treatments that activate PKA (Westphal et
ah, 1999). Therefore, AKAPs conform to the ‘targeting hypothesis’ in which it proposed
that phosphorylation events are partly regulated by ‘targeting subunits’ which bring kinases
and phosphatases into close proximity with their substrates (Hubbard and Cohen, 1993).
In a similar manner to the association of PKC with RACKl, several studies have
shown that the correct association of PKA with AKAPs is essential for certain 
.physiological functions. Intracellular perfusion of a peptide corresponding to the conserved 
RII subunit binding region (Ht31) of AKAP79 into hippocampal neurones prevented the
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association of PKA with AKAP79 and abolished the PKA-dependent modulation of 
AMPA/kainate chamiels (Rosenniund et al., 1994). In another example disruption of the 
interaction of RII with AKAPs (Lester et al., 1997) blocked insulin secretion in pancreatic 
(3 islet cells.
Other anchoring proteins may exist that target PDE4 isoenzymes to specific 
intracellular locations. Identifying these anchoring species is a major research aim as 
compounds that block these interactions may be an effective way of inhibiting the function 
of specific PDE4 isoenzymes and these may be of pharmacological importance.
1.10.2 Scaffold proteins
Examples have been shown of proteins that provide a scaffold for the binding and 
spatial organisation o f proteins that occupy sequential positions in a single signal 
transduction pathway. A prime example of this in mammals is the organisation of the 
cytokine/stress activated JNK/SAPK pathway. The components o f this cascade MKK7, 
MLK3 and HPKl and JNK bind to the multivalent scaffold protein, JIPl (Pawson and 
Nash, 2000; Schillace and Scott, 1999). These components bind to separate sites on JIPl 
and the over-expression of JIPl increases the efficiency of the signal transduction process.
Scaffold proteins may be a widespread phenomenon for the organisation of signal- 
transduction pathways. One function of these scaffold proteins may be to segregate 
separate signal transduction processes (Faux and Scott, 1996). The association of PDE4 
isoenzymes with these scaffold proteins might provide a mechanism for controlling the 
levels o f cAMP in the vicinity o f the components of a signal transduction pathway. In this 
way, PDE4 isoenzymes could affect the regulation of signal transduction pathways by 
PKA.
1.11 Protein-protein interaction modules
As discussed in section 1.8 PDE4A4/5 and PDE4D4 both associate with the SH3 
domains of Src-family tyrosyl kinases. The SH3 domains are just one example of a number 
o f conserved protein modules that have been defined, including SH2, PDZ, PH, PTB and 
TPR domains. These are all independently folding, globular domains that are found in a 
range of proteins in various different combinations. These modules mediate protein-protein 
interactions and play an important role in the intracellular localisation of signalling 
molecules. The intracellular targeting of many other PDE4 isoenzymes, in addition to
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1.11.1 SH2 and SH3 domains
The Src homology domains SH2 and SH3 are self-folding modules of around 100
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PDE4A4/5, may be determined by these modules. The main characteristics of these 
modules are discussed below.
and 50 amino acids, respectively. SH3 domains specifically recognise proline-rich motifs 
with the core sequence PXXP that adopt left-handed polyproline type II helices. The 
implications of the association of SH3 domains with PDE4A4/5 and PDE4D4 were 
discussed in section 1.8. The SH2 domains specifically recognise short peptide motifs 
containing phosphotyrosine (pTyr). The 3-5 residues on the COOH-terminal side of the 
phosphotyrosine confer specificity for different SH2 domains (Pawson and Gish, 1992). 
The SH2 domains mediate the interaction of the protein components of tyrosine kinase 
signalling pathways. This is seen for the signalling pathways downstream of 
transmembrane receptor tyrosine kinases (RTKs) for peptide growth factors such as EGF 
and PDGF. The binding of ligands results in the oligomerisation of these receptors, which 
causes the autophosphoiylation of a number of tyrosine residues in their intracellular 
domains. This causes the recruitment of SH2 domain-containing signalling proteins 
including PLCy, adaptor proteins and the p85 subunit of PI3-kinase (Mayer, 1993).
The SH2 and SH3 domains are often found together in proteins that act as 
integrators of signalling pathways (Pawson, 1995). The adaptor proteins such as Grb2 and 
Crk consist almost entirely of SH2 and SH3 domains. These proteins function as co­
ordinators of signalling complexes. For instance, the SH2 domain of Grb2 associates with
'IpTyr sites on activated receptor tyrosine kinases. Simultaneously, the SH3 domain of Grb2 
associates with proline-rich sites on Sos (Mayer and Gupta, 1998). The later activates Ras, 
which in turn leads to the activation o f the Raf-MEK-ERK pathway. Other SH2 and SH3 |  
domain-containing proteins are involved in processes such as the organisation of the 
cytoskeleton and the control the cell movement. For example. Nek is an adaptor protein 
that co-ordinates the components of signalling pathways downstream of Eph receptors 
which control axon guidance during the development of the mammalian CNS (Pawson and 
Nash, 2000).
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1.11.2 PTB and WW domains
Another protein module that binds to pTyr motifs in addition to SH2 is the PTB 
(pTyr binding) domain (FormanKay and Pawson, 1999). These domains preferentially 
interact with the NPXY motif and in contrast to SH2 not all PTB domains require the 
phosphorylation of the tyrosine in this motif for high-affinity binding. PTB domains are 
often found in ‘docking proteins’ such as IRSl and She. These proteins associate with 
receptor tyrosine kinases that lack binding sites for SH2 domains. The RTKs 
phosphorylate the docking proteins at key tyrosine residues that provide binding sites for 
the SH2 domains of proteins such as Grb2 and PI3-kinase. The functions of many PTB - 
containing docking proteins overlap those o f the adaptor proteins described above in that 
they physically bring together proteins that occupy successive positions in signalling 
pathways.
WW domains are analogous to SFI3 domains in that they associate with proline-rich 
sites. These are relatively small domains of 35 to 40 amino acid residues and associate with 
PPXY or PPLP motifs (Pawson and Scott, 1997). The WW domains of the ubiquitin 
protein ligase Nedd4 mediate its association with epithelial Na"*" chamiels in the kidney. No 
association was seen between the WW domain of Nedd4 and PDE4A4/5 or PDE4D4 
(Beard et al., 1999). However, this does not exclude the possibility that other PDE4 splice 
variants interact with WW domains.
1.11.3 PDZ domains
Another recently identified protein module is the PDZ domain. These modules 
recognise E(S/T)DV motifs which are often found at the COOH-terminal ends of 
transmembrane ion channels subunits and receptors (Pawson and Scott, 1997). PDZ 
domains play an important role in the spatial organisation ion channels and receptors at the 
synapse. For instance, a major organiser protein of the post-synaptic density, PSD-95, 
contains tliree PDZ domains that bind to the NMDA channel receptor subunit NR2B and 
the Kv4.1 potassium chamiel. In this way, PSD-95 mediates the clustering of these ion 
chamiels in the postsynaptic membrane. Other PDZ proteins, such as GRIP and Homer act 
as adaptor proteins and mediate the clustering of certain receptors and their association 
with signalling proteins and cytoskeletal components (Schillace and Scott, 1999). A 
considerable number of PDE4 isoenzymes are expressed in the brain (section 1.5). Some of 
these isoenzymes, including PDE4A4/5 and PDE4A6, are found to associate with the
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cytoskeletal fraction of cells. PDZ proteins may be involved in the organisation of PDE4 
isoenzymes at the synapse.
As mentioned in section 1.1 many ion chamiel receptors are regulated by PKA- 
phosphorylation both in neurones and other cells. Several studies have shown that PKA is 
targeted to these ion chamiels by its association with AKAP anchoring proteins, such as 
AKAP79, which regulates AMPA/kainate receptors in hippocampal neurones (Rosenmund 
et ah, 1994). In airway epithelial cells the cystic fibrosis transmembrane conductance 
regulator (CFTR) Cl" channel is regulated by PKA phosphorylation (Schillace and Scott,
1999). A PDZ protein EBP50/NHERF binds to both the CFTR Cl" channel and the AKAP 
protein ezrin (Short et ah, 1998). This example shows that PDZ domains appear to be 
involved in both the spatial organisation of receptor ion channels and the regulation of 
these channels by PKA. The PKA enzymes that are targeted to these ion channels may be 
regulated by distinct pools of intracellular cAMP. Furthermore, the compartmentalisation 
o f these cAMP pools may require the co-localisation of cAMP-specific PDEs such as 
PDE4. Protein modules such as PDZ proteins may directly mediate the targeting of PDE4 
isoenzymes to these compartments.
4
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1.11.4 TPR domains
Another module that is involved in protein-protein interactions is the 
tetratricopeptide repeat (TPR). The TPR motif is a 34 amino acid m otif found in proteins 
involved in a wide range of cellular processes. These include cell cycle regulation (Lamb et 
al., 1995), peroxisomal and mitochondrial membrane transport (Terlecky et ah, 1995; Yano 
et ah, 1998), the organisation of the cytoskeleton and the generation o f superoxide during 
the respiratory burst in phagocytes (Pouting, 1996). Some TPR proteins, such as the 
anaphase promoting complex subunit cdc27 (Ollendorff and Donoghue, 1997) and the 
postsynaptic cytoskeletal protein rapsyn (Pouting and Phillips, 1996) interact with multiple 
proteins.
The ciystal structure o f the TPR domain of protein phosphatase 5 (PP5) has been
determined (Das et ah, 1998). PP5 contains 3 TPRs ananged in tandem. The individual
TPRs essentially fold into two antiparallel alpha helices (A and B). The tandem
arrangement of TPR motifs in PP5 results in the formation of a concertina-like
.arrangement o f A and B helices. This appears to form a right-handed helical superstructure,
■■i
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In proteins with several TPRs in tandem such a rapsyn (Pouting and Phillips, 1996), this 
would be extended to provide an ideal scaffold for the association o f a number of proteins.
The amino acid sequences of TPRs ar e highly degenerate with weak conservation 
between species. However, there are a number o f conserved positions which appear to help 
maintain the 3D structure of the TPR (Das et ah, 1998). A pro line residue is commonly 
observed at position 32 at the end of helix B. Small hydrophobic residues often occur at 
positions 8 and 20, which are the closest points of contact being helix A and helix B. Large 
hydrophobic residues are frequently seen at positions that form the interface between the 
two helices. The TPR domains of a number o f proteins including PP5 and the 
immunophilins Cyp40 and FKBP52 mediate their association with the molecular 
chaperone heat shock protein 90 (hsp90). Site directed mutagenesis studies showed that the 
basic residues (Lys97 and ArglOl) at the NHz-terminal end of TPR domain 3 in PP5 were 
essential for interaction with hsp90 (Russell et al., 1999). Further analysis by Russell et al 
indicated that the replacement of thiee acidic residues in the EEVD motif at the COOH- 
terminal end of hsp90 reduced the association with PP5. This suggested that the association 
o f a TPR-containing protein with hsp90 was mediated by electrostatic interactions between 
oppositely chai'ged residues.
Certain TPR proteins may be involved in the intracellular targeting of proteins. For 
example, the Immunophilin proteins Cyp40 and FKBP52 form complexes with the 
molecular chaperone hsp90 and steroid hormone receptors such as the glucocorticoid 
receptor (GR). Pratt and co-workers have a proposed a model where a chaperoned protein, 
such GR, is targeted to a specific region of the cell by a TPR protein that binds to hsp90 
(Owens-Grillo et al., 1996). Different TPR proteins, such as Cyp40 and FKBP52 have been 
shown to compete for interaction with the TPR acceptor site. The various TPR proteins 
confer different patterns of intracellular targeting on the resultant complexes (Owens-Grillo 
et al., 1996).
1.11.5 PH domains
Not all protein modules associate with peptide targets. For instance, pleckstrin 
homology (PH) domains are targeted to the membrane lipid bilayer by their association 
with the charged head groups o f specific polyphosphoinositides PI-4,5-Pz and PI-3,4,5-P3. 
The latter are generated by the action of phosphatidylinositol kinases. PH domains are 
found in a large number of proteins including the kinases Akt/PKB and PDKl, PLC
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isoforms, cytoskeletal proteins and the regulators of small G proteins. One function of PH- 
domain proteins may be to link the action of phosphatidyl inositol kinases with 
downstream signalling pathways. For instance, PI-3,4,5-p3, which is generated by PI3- 
kinase, binds to the PH domain of G rp l, The latter acts as a GEF for the small G protein 
A rf which controls vesicle trafficking. In this way, the activation of PI3-kinase by receptor 
tyrosine kinases (RTKs) is linked with the regulation of vesicle trafficking by Arf.
Several other protein modules have been shown to exist in addition to the ones 
described above (Pawson and Nash, 2000). These modules occnr in many different 
combinations in proteins, which allows the integration of a number o f signalling pathways. 
A common feature of these protein-protein interaction modules described above is their 
association with short sequence motifs on the target proteins. Peptide mimetic compounds 
could potentially block these interactions. Therefore, the identification of the protein 
modules that interact with PDE4 isoenzymes may lead the way to novel pharmacological 
agents that block the function of specific PDE4 isoenzymes.
1.12 Summary
Considerable isoform diversity occurs at all levels of the cAMP signalling pathway. 
The selective expression of these isoforms allows cells to tailor their responsiveness to 
stimuli that act via cAMP. This isoform diversity is particularly apparent in the cAMP- 
specific PDE4 family. This is partly the result of alternative 5’ mRNA splicing, which 
generates isoenzymes with shared catalytic core regions and unique NH2-terminal splice 
domains. One effect of these NH2-terminal regions is to confer distinct patterns of 
regulation on the individual isoenzymes. An example of this is shown by the different 
effects of ERK2 phosphorylation on the activity on the long and short PDE4D splice 
variants (see section 1.7.1).
An important goal in PDE4 research is the elucidation of the roles of individual 
PDE4 isoenzymes In cAMP-dependent processes. This will allow us to make predictions 
on the cAMP-responsiveness o f cells, based on the PDE4 isoenzymes that they express. It 
may also help in the identification o f the appropriate targets for the design of drugs to treat 
diseases where PDE4 has been implicated, such as asthma and atopic dermatitis. One 
approach is to use a model cell system where we can analyse a measurable cAMP- 
dependent process that is regulated by PDE4. One such system is the positive effect of
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growth hormone (GH) on the differentiation of 3T3 F442A preadipocytes, which is 
potentiated by the PDE4 specific inliibitor rolipram. In Chapter 3 I have determined the 
PDE4 isoenzymes expressed in these cells by RT~PCR and sequencing. Further analysis 
showed that GH specifically activated the PDE4A5 isoenzyme via PI3-kinase and p70S6 
kinase and this activation was suggested to act as a break on the process of differentiation. 
Therefore, an initial screen of PDE4 isoenzymes expressed by a cell is a key step in 
elucidating the physiological role of individual isoenzymes.
Studies have suggested that PDE4 isoenzymes may be involved in the regulation of 
compartmentalised pools of cAMP. The precise localisation o f these isoenzymes within the 
3D matrix o f the cell is likely to be a crucial aspect of this function. The distinct patterns of 
intracellular localisation shown by PDE4 isoenzymes may be due to targeting motifs within 
their unique NHz-terminal splice domains. In Chapter 4 I test this hypothesis by expressing 
the NH2“terminal domains of PDE4A1 and PDE4A5 as fusions to GST, These NHz- 
terminal domains do indeed confer particulate fraction association on the normally soluble 
GST. Further analyses using these constructs suggested that PDE4A1 and PDE4A5 interact 
with distinct components of the pai ticulate fraction.
A number of signalling proteins are targeted to specific regions of the cell by their 
association with scaffold and anchoring proteins. Recently, PDE4D5 has been shown to 
associate with the RACKl anchoring protein, which also associates with PKC and PLCy. 
This complex may thus allow the co-ordination of Ca^^ and cAMP signalling pathways. 
Subcellular distribution analyses suggest that many other PDE4 isoenzymes may be 
specifically targeted by anchoring proteins or lipids.
The formation of signalling complexes is often mediated by protein-protein 
interaction modules, including SH2, SH3, PDZ and TPR domains. The majority of these 
modules recognise short sequence motifs in their target proteins. The PDE4A4/5 and 
PDE4D4 isoenzymes can both bind to the SH3 domains from Src family tyiosyl kinases. 
Modules such as these may localise PDE4 isoenzymes to signalling proteins or complexes 
where they can modulate the local activity of PKA. PDE4 isoenzymes may well associate 
with two or more proteins, either sepaiately or as complexes. In Chapter 5 I show that 
RNPDE4A5 associates with a novel immunophilin-like protein RB3. This interaction 
appears to be mediated by the COOH-terminal half of RB3, which contains a TPR domain. 
Intriguingly, this interaction inhibits the catalytic activity of RNPDE4A5, which suggests 
that RB3 may modulate PDE4 function in vivo.
m
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2.Materials and Methods
Throughout the following methods the names of the companies used for the 
purchase of specific reagents or materials are given in parentheses. Where no company is 
mentioned, the reagent was purchase from Sigma-Aldrich. All reagents were of analytical 
grade.
CELL CULTURE TECHNIQUES
2.1 Cell culture
All cells were routinely cultured in 75cm^ flasks at 37°C in 95% air/5% CO2 in a 
humidified incubator. The media and sera used to culture these cells were obtained from 
Gibco BRL (UK).
t
2.1.1 Adherent cells
2.1.1.1 COS cells and HEK293 cells
The COS cells lines, including COS-1 and COS-7 are derived from the CV-1 cell 
line, which was originally established from simian kidney (African Green Monkey, 
Cercopithecus aethiops) (Gluzman, 1981; Scotland et al., 1998). These cells were 
transformed with an origin-defective mutant of SV40 DNA, which encoded the T antigen. 
The presence of the T-antigen allows vector plasmids, such as pcDNA3 and pSV-SPORT, 
which contain the SV40 origin of replication, to evade the normal block on DNA re­
replication. Therefore, COS cells aie able to support the expression of high copy numbers 
o f these vectors and thus high levels o f expression from cDNA carried by these vectors.
COS-1 and COS-7 cells were cultured as monolayers in DMEM with 0,2mM 
glutamine, 10% PCS, 200units/ml penicillin and 200pg/ml streptomycin. The adherent 
cells used in these studies were passaged when they were -90%  confluent (once eveiy 2-4 
days) and were split 1:3 to 1:6.
2.1.1.2 3T3 F442A preadipocytes and HEK293
The preadipocyte mouse fibroblast cell line 3T3 F442A (MacKenzie et al., 1998) 
and the human embryonic kidney cells (HEK293) (Brunn et al., 1997; Von Manteuffel et 
al., 1996) were cultured in an identical manner to COS cells (see previous subsection).
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%However, 3T3 F442A preadipocytes were cultured using DMEM containing 0.2mM 
glutamine, 10% NBCS, 200units/ml penicillin and 200pg/ml streptomycin
2.1.2 Suspension ceil lines
2.1.3 IVIOLT3, Jurkat T, B, and U937
The suspension cell lines used were as follows: Daudi B-cells (Hewitt et ah, 1997),
Jurkat T-cells (Erdogan and Houslay, 1997; Seybold et ah, 1998), U937 human monocytes 
(Torphy et ah, 1995) and murine M0LT3 T-lymphoblastic cells (Hayon et ah, 1999). These 
lines were all cultured in RPMI-1640 medium containing 0.2mM glutamine, 10% FCS, 
200units/ml penicillin and 200pg/ml streptomycin and were passaged every 2-4 days. The 
cells were harvested by centrifugation (5min, 1 OOOg at room temperature) when their 
density reached 2x 10  ^cells/ml. .1I
■
2.1.4 Stimulation of cell lines with biochemical agents
All treatments were carried out under normal growth conditions (37°C, 5% CO2 
humidified incubator). The stock solutions of PMA, GH and IBMX were prepared in 100% |
DMSO. To treat the cells, these effectors were diluted in the appropriate cell growth media 
to yield the final concentrations given below. The final concentration of DMSO in the K
growth medium was always < 0.1%, which has been shown to have no effect on cell PDE 
activity or expression (Erdogan and Houslay, 1997).
2.1.4.1 Stimulation of 3T3 F442A preadipocytes with GH, PMA and wortmannin
At -90%  confluence, 3T3 F442A mouse preadipocytes were serum starved for 16h.
These cells were then left untreated (control) or incubated for 30min with 25nM GH, 25nM 
PMA or 2nM wortmannin. These treatments were terminated by washing the cells with ice- 
cold PBS (ICN Biomedicals, see section 2.7.1 for composition) and proceeding with RNA 
extraction as described in section 2 .6.1.
2.1.4.2 Stimulation of C0S7 cells with IBMX, forskolin and PMA
In order to effect an increase in the total intracellular concentration of cAMP, and 
thus bring about an activation of PKA, cells at -90%  confluence were treated with a 
combination of forskolin, which activates adenylyl cyclase (Houslay and Milligan, 1997)
and IBMX, which prevents the breakdown of cAMP by inliibiting PDEs. COS-7 cells were "s.
I
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treated for 20min with 1 OOjiiM IBMX prior to the addition o f 1 OOpM forskolin and a 
further 20min incubation.
In order to activate both PKC, and ERK (activated downstream of PKC 
(MacKenzie et al., 1997)) in COS-7 cells, they were stimulated with lOOpM PMA for 
5mins. This treatment is known to produce an optimal ERK2-dependent stimulation of 
PDE4D3 activity (MacKenzie et al., 2000).
2.2 Transfection of COS ceils with plasmid DNA
I
Table 2.1 Buffers used for transfection of COS cells with DNA ITE buffer 10 mM Tris-HCl, pH8.0 
O.lmM EDTA
DEAE-dextran 1 Omg/ml DEAE-dextran in PBS
COS cells (COS-1 or COS-7) were seeded at a density o f approximately 50%
100mm plate a DNA solution was prepared by diluting lOpg of the plasmid to a final 
volume of 250pl in TE buffer and adding 200pl of a lOmg/ml DEAE-dextran solution.
This mixture was incubated at room temperature for 15min prior to the addition to the COS 
cell culture. Cultures were incubated for 3-4h at 37®C in a humidified incubator before the
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confluency onto 100mm diameter plates 18h before transfection. Immediately before 
transfection the culture medium was replaced with DMEM containing 10% (v/v) NBCS 
and 0.1 mM chloroquine to minimise DNA degradation (Sambrook et al., 1989). For each i
%
medium was aspirated and the cells shocked for 2min with 10% DMSO in PBS. The 
cultures were then rinsed once in PBS before the addition DMEM containing 10% FCS. 
The cultures were incubated in a hmnidified incubator for 72h before analysis by SDS-
PAGE/western blotting or PDE assay.
MOLECULAR TECHNIQUES
2.3 Agarose gel electrophoresis of DNA
Table 2.2 Buffers used for the separation of DNA by agarose gel electrophoresis
TAB running buffer 40 mM Tris-HCl, pH8.0 
20mM Acetic acid 
ImM EDTA
Agarose gel (0.7-2%) in 
TAB buffer
0.7-2% (w/v) Agarose 
0.5pg/ml Ethidium bromide 
TAB buffer
DNA was separated and visualised by electrophoresis on 0.7-2% agarose gels in the 
presence of ethidium bromide. The agarose gel mix was prepared as described above. The 
concentration of agarose was selected according to the size range of the DNA fragments to 
be sepamted (see Table 2.3 below). Appropriate volumes o f 6x blue/orange loading dye 
(Promega, UK) were added to the DNA samples to give a final concentration of Ix. These 
samples were applied to the gel and separated by electrophoresis in TAB runmiing buffer at 
lOOV. The presence of the intercalating dye, ethidium bromide, allowed the visualisation of 
the separated DNA bands under UV transillumination. The DNA fragments were sized by 
comparison to the 0X 174 HaelW molecular weight standard (Boehiinger Mannheim, UK), 
which contained fragments of the following sizes: 1353, 1078, 872, 603, 310, 281, 271,
234, 194, 118, and 72bp. These standards were used to generate a plot o f distance migrated 
versus Log [MW (bp)]. The resultant curve was used to determine the molecular weights of 
the PCR standards from their distances of migration on the agarose gel.
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Table 2,3 Relationship between the range of separation and agarose gel 
concentration.
Based on table 6.1 in (Sambrook et al., 1989).
Agarose concentration (%[w/v]) Efficient size range of separation o f  
DNA molecules (kbp)
0.7 0.8-10
1.2 0.4
2 0.1-2
2.4 Preparation of plasmid DNA
Plasmid DNA was prepared from transformed E. coli cultures using the Qiagen or 
Promega (Wizard™) DNA purification systems. Miniprep and maxiprep kits from both 
companies were used for small-scale and large-scale preparations of plasmid DNA, 
respectively. DNA purifications were carried out according to the instructions provided by 
the manufacturers.
2.6 Transformation of Escherichia co//with plasmid DNA
2.5.1 Preparation of heat-shock competent E. coli
Table 2.4 Media and buffers used for the preparation o f heat-shock competent E, co li
SOB liquid media 20g/l Bacto-tryptone
5g/l Bacto-yeast
lOmM NaCl
2.5mM KCl
RFl (pH adjusted to 5.8 lOOmM RbCl
with 0.2M acetic acid) 50mM MnCl2
30mM Potassium acetate
lOmM CaCl2
15% (w/v) Glycerol
RF2 (pH adjusted to 6.8 lOmM RbCl
with 0.2M NaOH) lOmM MOPS
75mM CaCl2
15% (w/v) Glycerol
I
To prepare ‘heat-shock’ transformation-competent Escherichia coli, a colony of the 
desired strain, (either JM109 or BL21) grown on LB-agar plates, was picked and used to 
inoculate a SOB culture. This culture was grown at 37°C until its absorbance at 550nm 
( O D 5 5 0 )  was 0.5-0.55. The cultiue was cooled on ice (30min) and pelleted by centrifugation 
at 600g for 15min. The cells were then resuspended in ice-cold buffer R Fl, and
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incubated for 15min on ice prior to centrifugation at 2500rpm for 9min at 4°C. The 
supernatant was removed and the pelleted cells were resuspended in ice-cold buffer RF2 
and incubated on ice for 15min. The cells were then aliquoted, snap frozen in a diy 
ice/ethanol bath and stored at -80°C.
2.5.2 Heat-shock transformation of competent E. co//.
Table 2.5 Media and buffers used for the transformation o f competent E . co li
SOC liquid media 2% (w/v) 
0.5% (w/v) 
lOmM 
2.5mM
Bacto-tiyptone
Bacto-yeast
NaCl
KCl
LB agar plates 2% (w/v) Bacto-tryptone
(containing ampicillin) 0.5% (w/v) Bacto-yeast
170mM NaCl
2% (w/v) Agar
Ampicillin 50pg/ml
J
45 
'1
Competent E. coli were transformed with plasmid DNA using the heat shock 
method described in (Sambrook et al., 1989). A sample o f the plasmid DNA (Ipl) was 
gently mixed with an aliquot (20pl) of the heat-shock competent cells prepared as 
described in the previous section. This mixtuie was incubated on ice for 30min. It was then 
heat-shocked at 42°C for 40s and returned to ice for a further 2min. SOC buffer (80ml) was 
then added to the cells and they were shaken at 225rpm for Ih at 37°C. The cells were then 
spread onto an LB agar plate containing 50pg/ml ampicillin and incubated overnight at 
37°C in order to obtain ampicillin resistant colonies (NB all the plasmids used in this study 
contained an ampicillin resistance gene for selection).
2.6 Reverse-transcription polymerase chain reaction (RT-PCR)
2.6.1 RNA extraction and purification from 3T3 F442A cells
Total RNA was extracted using the Tri reagent method. The medium was removed 
from confluent 3T3 F442A mouse preadipocytes and the cells were washed once with 
sterile PBS. The cells were scraped into 1ml of Tri reagent and homogenised by passing 
through a 0.45mm syringe needle 10 times.
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The homogenate was centrifuged at 12000g for lOmin at 4°C to remove cell debris.
The supernatant was transferred to a fresh tube and 0.2 volume chloroform was added. This 
mixture was vortexed for 15s, stored at room temperatme for 3min and then centrifuged at 
12000g for 15min at 4°C. The aqueous phase was transferred to a new eppendorf tube and 
0.5ml of propan-2-ol was added for every 1ml of Tri reagent used initially. This was stored 
at room temperature for 5-lOmin. The precipitated RNA was pelleted by centrifugation at 
12000g at 4°C for lOmin. The supernatant was removed and the RNA was washed by 
resuspending the pellet in 75% ethanol (containing 0,025% DEPC) followed by 
centrifugation at 7500g for 5min at 4°C. The supernatant was removed and the pellet was 
dried and then resuspended in 0.1% DEPC-treated water.
2.6.2 RNA extraction and purification from mouse brain
The brain of a mature male Balb-c mouse was removed, frozen in liquid nitrogen 
and weighed. The brain was then ground to a sluriy in liquid nitrogen using a pestle and 
mortar. Tri reagent was added to the slurry (1ml per 150mg of organ). The mixture was 
vortexed and then homogenised by 10 strokes on a rotary homogeniser. Total RNA was 
extracted from this homogenate using the Tri reagent method described above. i
2.6.3 DNase treatment of RNA
To eliminate contamination by genomic DNA, the aqueous suspension of RNA was 
treated with RNase-free DNase (10 units/20ug RNA) for 15min at 37°C. The DNase 
treated RNA was then pmified by phenol: chloroform extraction and ethanol precipitation 
as follows. One volume of acid (pH 4.5) 25:24:1 phenol: chloroform:isoamylalcohol was 
added to the aqueous suspension of RNA and the mixture was vortexed for Imin and then 
centrifuged at 12,000g at 4°C for 2min. The aqueous (upper) phase containing the RNA 
was transferred to anew  tube. One volume of 24:1 chloroformlisoamylalcohol was added 
and the mixture was vortexed for Imin and then centrifuged at 12,000g at 4°C for 2min. 
The aqueous phase was transferred to a new tube. RNA was precipitated by incubating 
with 0.5 volume of 7.5M ammonium acetate and 2.5 volumes of 100% ethanol at -80°C 
overnight. The precipitated RNA was pelleted by centrifugation at 12000g at 4°C for 5min. 
The pellet was washed with 70% ethanol and the RNA was resuspended in 0.1% DEPC- 
treated water. RNA solutions o f an acceptable purity gave a 260nm/280nm ratio of 1.7 to 2. Î
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2.6.4 First strand cDNA synthesis
First strand cDNA synthesis was caiiied out according to the instructions supplied 
with the First strand cDNA-kit (Amersham Pharmacia Biotech, Amersham, UK) using a 
total reaction volume of 33 pi. DNase treated RNA (5pg) was denatured at 65°C for lOmin 
and then incubated with reverse transcriptase, 6mM dithiothreitol, 6mM of each dNTP and
0.2pg of poly (dT) primer [Not l-d(T)ig] for 60min at 37°C. The cDNA was stored at - 
80°C until it was required.
2.6.5 Polymerase chain reaction
All components o f the PCR reaction, except for the primers, were obtained from 
Promega. Amplification was performed in 1 x PCR buffer (50mM KCl, 20 mM Tris-HCl 
pH 9.0, 0.1% Triton X-100) containing 200pM of each dNTP, 500nM of each primer and 
1.5mM MgClz. 2.5 units of Taq DNA polymerase were added to each 25pi reaction just 
before the start o f cycling. Amplification was performed on 0.5pl o f template cDNA 
prepared as described above (see section 2.6.4). The sequences of the oligodeoxynucleotide 
(ODN) primers used are given in the appropriate sections. As a positive control for the 
PCR amplifications to detect splice variants PDE4B2, PDE4D1 and PDE4D2, where no 
expression plasmid was available, 0.5pl of mouse brain cDNA was used as template. For 
all other splice variants, 0.5ng of a plasmid containing the appropriate clone was used as a 
template. After the indicated cycles of dénaturation and extension, a 9pl aliquot from each 
of the PCR reactions was resolved by electrophoresis on a 2% agarose gel. The 0X174 
HaeUl molecular weight standards (Boeliringer Mamiheim, Lewes, UK) were used to 
determine the size of the PCR fragments as described in section 2.3.
2.6.6 TA cloning of PCR fragments
The cloning and sequencing o f amplified PCR fragments is aided by the single-base
.A overhangs left by Taq polymerase at their 3’ ends. This allows their direct insertion into 
a pCR2.1 vector (Invitrogen), which in its linearized form has overhanging Ts at the 3’ 
ends of each of its DNA strands. The principles of TA cloning are described in Figure 2.1.
The system exploits the ability of the enzyme p-galactosidase to metabolise the colourless 
substrate X-gal to form a blue product. E.coli bacteria that contain a plasmid that expresses 
a functional p-galactosidase will form blue colonies on LB-agar plates that contain X-gal.
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However, E. coli that carry a plasmid containing an insert that disrupts the p-galactosidase 
coding region, will form white colonies. Once the PCR products have been cloned into 
pCR2.1 the inserts can then be sequenced using primers that anneal to sites on pCR2.1 that 
flank the insertion site.
RT-PCR products were cloned into the vector pCR2.1 using the Original TA 
Cloning™ Kit (Invitrogen). Ligations were performed by incubating 1 pi of the PCR product
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in a 1 Opl reaction mix containing 50ng of linearized pCR2.1, 1 x Ligation buffer
(Invitrogen) and 4 units T4 DNA ligase. The ligation reactions were incubated overnight at 
14°C.
The E. coli strain INVaF', provided with the kit, was used for the transformation ;1
and propagation of insert-containing pCR2.1 plasmids. Transformation was caiTied out as 
described in the manufacturer’s instruction. In brief, 5Opl aliquots of the INVaF’ cells 
were incubated with 2pl samples of the above ligation reaction in the presence o f 20mM P- 
mercaptoethanol for 30min on ice. The cells were then heat-shocked at 42°C and incubated 
with SOC medium as described in section 2.5.2. They were then plated on LB-agar plates 
containing 50pg/ml ampicillin and spread with 40mg/ml X-gal dissolved in N,N 
dimethylformamide (40ml per 100mm plate). These plates were then incubated overnight 
at 37°C in order to obtain, white, ampicillin resistant colonies oïE . coli transformed with 
insert-containing pCR2.1 plasmids.
I:
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Figure 2.1 Principles of the Invitrogen^" TA method for cloning PCR amplified 
fragments.
One feature of Taq DNA polymerase is that it appends an A-base overhang to the 3’ end of 
each strand of the PCR product. This allows the direct insertion of PCR products into the 
pCR2.1 vector (Invitrogen), which is supplied in a linearized form, with overhanging Ts at 
the 3’ ends of each of its DNA strands. The PCR products aie inserted within the a-peptide 
coding region (LacZa) of the enzyme p-galactosidase. Therefore, upon transformation into 
E. coli INV-aF’ cells, recircularised pCR2.1 vectors that lack an insert express P- 
galactosidase and produce blue ampicillin-resistant colonies on plates containing X-gal. 
However, insert-containing pCR2.1 vectors will be imable to express functional p- 
galactosidase and will therefore produce white ampicillin-resistant colonies on X-gal 
plates. In this way vectors containing the PCR product can be isolated and used for 
sequencing. The inserts are sequenced using ODN primers that amieal to either side of the 
insertion point.
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2.6.7 Sequencing of PCR fragments
Plasmid DNA was purified as described in section 2.4. The inserts were sequenced 
using the M l 3 forwai'd and reverse primers, provided by Invitrogen that anneal to either 
side of the insert site in pCR2.1. Sequencing was carried out using the ABI PRISM Dye 
Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, UK). Sequencing 
reactions were set up in a total volume of 20pl, with 0.16pM primer, 20ng/pl plasmid and 
8pi of terminator ready reaction mix. The following cycle conditions were used for the 
sequencing reaction (25 cycles): dénaturation, 96°C for 10s; annealing, 50°C for 15s; 
extension, 50°C for 4min. The extension products were precipitated by the addition o f 0.1 
volume of 3M sodium acetate (pH4.3) and 2 volumes of ethanol. The precipitated products 
were pelleted by eentrifugation and washed with 70% ethanol. Analysis of the sequencing 
products was performed on a model 373 automated sequencer (Applied Biosystems, UK).
2.7 Over-expression and purification of GST and MBP fusion proteins
2.7.1 Over-expression of GST and MBP fusion proteins
Table 2.6 Media and buffers used for the over-expressiou of GST and MBP-fusiou 
proteins
Luria Bertani (LB) 
mediiun
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract
1 % (w/v) Bacto-Tryptone
IPTG O.IM stock solution (stored at -20°C)
Complete PBS 
(PBS +protease 
inhibitors and DTT)
137mM NaCl
2.7mM KCl
4mM Na2HP04
0.15mM NaH2P04 (pH 7.4)
Ix Complete'^^ EDTA-free protease inliibitor 
cocktail (Boerhinger mannheim, UK) 
ImM DTT
E. coli (BL21 or JM109 strain) was transformed with either pGEX-2T (for the 
production of GST), pMAL-C2, (for the production of MBP), a recombinant pGEX vector 
containing species engineered to form in-frame fusions with GST, or recombinant pMALN 
containing species engineered to form in-frame fusions with MBP. These transformed
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bacteria were grown overnight at 37°C, with agitation, in LB medium containing 50|ag/ml 
ampicillin. Overnight cultures were diluted 1:30 in the same medium (2g/l glucose was 
included for MBP fusions) and these were grown at 37°C, with agitation, until the CD at 
600nm reached 0.6 - 1.0. Expression of the fusion protein was then induced by adding 
IPTG to a final concentration of 0.5mM (O.lmM for MBP-fusions) and growth was 
continued for a further 3-4h at 37°C (or 3h at 30°C for MBP-fusions) with agitation. The 
bacteria were harvested by centrifugation at 4000g for lOmin in a refrigerated centrifuge 
and then resuspended in 20ml phosphate buffered saline (PBS) containing ImM- 
dithiotlu'eitol (DTT) and Complete™ protease inliibitor cocktail (Boehringer Mannheim 
(UK), Ltd., Lewes, UK). Resuspended bacteria were stored, as 4ml aliquots, at ~20°C. 
Freezing at this stage assists the lysis o f the bacteria.
2.7.2 Purification of GST and MBP fusion proteins expressed in E. co//
Table 2.7 Buffers and materials used in the purification o f GST- and MBP-fusion  
proteins expressed in E. co li
Elution buffer: GST-fusion proteins lOmM Glutathione 
50mM Tris-HCl, pH 8.0
Elution buffer: MBP-fusion proteins lOmM Maltose in PBS
PBS and complete PBS See Table 2.6
Glutathione Sepharose 4B 
Amylose resin
(Amersham pharmacia biotech, 
UK)
(New England Biolabs)
Dialysis buffer 20mM Tris pH 8.0
2.7.2.1 Procedure 1: Batch purification
Purification of GST- or MBP-fusion proteins was carried out as described in (Smith 
and Johnson, 1988). Frozen aliquots of bacteria expressing GST- or MBP- fusion proteins 
(see above) were thawed at room temperatuie then held on ice and sonicated for 100s in 
20s pulses, separated by 20s intervals. Bacterial debris was then pelleted by centrifugation 
for 30min at 9000g in a refrigerated centrifuge and the supernatant was transferred to a 
fresh tube. Glutathione Sepharose beads (for GST-fusions) or amylose resin (for MBP- 
fusions) were equilibrated by washing twice with 20 bed volumes o f ice cold PBS and once 
with 10 bed volumes of complete PBS (containing IniM DTT and protease inliibitor
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cocktail). The equilibrated beads were added to the above sonicated bacterial supernatant 
(200pi bed volume Sepharose beads per 4ml supernatant) and incubated end over end at 
4°C for 2h. Following incubation, the beads were collected by centrifugation for 5min at 
2000g in a Jouan C312 ‘swing-out’ centrifuge and the supernatant was discarded. The 
beads were washed 4 times with 10 bed volumes of ice cold complete PBS per wash. Each 
wash step was carried out end over end for 30min at 4°C. Purified fusion protein was 
eluted by incubating the beads with one bed volume of elution buffer (see above table) 3 
times at 4°C for 15min.
2.7.2.2 Procedure 2: column purification
Certain GST-fusion proteins (GST-rpdeô*'^^*^ and GST“R D L ‘*^ °) were purified 
using a modification of the above procedure, carried out at 4°C. An equivalent amount of 
glutathione Sepharose beads were placed in a 20ml column supported on glass wool. The 
beads were equilibrated with 10 bed volumes of complete PBS. The bacterial sonicated 
supernatant (see above) was passed through this column twice. The beads were washed 
with 30 bed volumes of complete PBS. Bound protein was eluted by three separate lOmin 
incubations with 1 bed volume of glutathione elution buffer (Table 2.7).
2.7.2.3 Dialysis of eluates
The glutathione eluates of purified GST-fusions for use in PDE4 activity studies 
were dialysed against 20mM Tris-HCl pH8.0. This was necessary as glutathione may affect 
PDE activity (Souness and Scott, 1993). The eluates were combined and dialysed twice 
against 1 litre of 20mM Tris-HCl pH8.0 for 2h and once against 1 litre of the same buffer 
overnight. All dialysis steps were cai'ried out at 4°C. The dialysed protein was protein 
assayed (section 2.8), aliquoted, snap frozen in liquid N2 and stored at -80°C until required.
■Ï
■i.
2.7.3 Measures taken to increase the yield of soluble protein expressed in E, 
coli strains
A number of factors can prevent successful purification of GST- or MBP- fusion 
proteins. Using the system described in sections 2.7.1 and 2.7.2, the peptides fused to the 
GST or MBP affinity tags can undergo proteolytic degradation by bacterial proteases. 
Alternatively, certain fusion proteins may be insoluble (Shi et al., 1997). This is more 
likely for large or hydrophobic proteins (Harris, 1998). One way o f avoiding this is to
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reduce the temperature at which the bacteria are grown (Hengen, 1996) from 37°C to 30°C 
or room temperature. This modification was used successfully by Nair et al and Chen et al 
to express soluble forms of FKBP52 and protein phosphatase 5 (PP5) respectively (Chen 
and Cohen, 1997; Nair et ah, 1997). Leverson and Ness also used this strategy to purify 
GST-Cyp40 (Leverson and Ness, 1998).
In order to purify the large GST fusion proteins, e.g. GST-FKBP52 (see section 
5.13) with minimal proteolytic degradation problems, I used the following modifications to 
the methods set out in sections 2.7.1 and 2.7.2. The plasmids encoding the GST-fusion 
proteins were transformed into E. coli strain BL21 rather the JM109. This BL21 strain is 
recommended for use as it lacks a number of endogenous proteases that exist in other 
strains. The cultures were grown up at 30°C and induced when they were in late log phase,
i.e. when the ODeoo was close to 1. The cultures were then induced with O.lmM IPTG for 
the minimum time of 3h at room temperature. The lower growth temperature and shorter 
induction time were used to reduce the effect of proteases (Hengen, 1996) and to decrease 
the problem of insolubility. To reduce proteolytic degradation during the binding of the 
GST-fusion proteins to the glutathione Sepharose, the incubation time here was reduced 
from 2h to Ih.
BIOCHEMICAL TECHNIQUES
2.8 Protein assay
Protein was routinely measui'ed by the method of Bradford (Bradford, 1976). 
Protein assay dye concentrate (Bio-Rad) was diluted 1:4 with water to produce the protein 
assay dye solution. Samples were diluted with water and 1 volume of diluted sample was 
incubated with 4 volumes of protein assay dye solution for 5min at room temperature. The 
absorbance was then measured at 595nm (A595). Bovine serum albumin (BSA) was used as 
a standard to construct a cmwe of A595 versus protein concentration. This curve was linear 
between protein concentrations of 20pg/ml and 120pg/ml.
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2.9 SDS polyacrylamide gel electrophoresis (SDS-PAGE) of proteins
Table 2.8 Buffers and solutions for SDS-PAGE
Resolving gel 10-12% 29:1 acrylamide :N,N'-methylenebisacrylamide*
(10-12%) (w/v)
0.375M Tris-HCl, pHS.S
0.1% SDS
0.1% Ammonium persulphate
0.04% TEMED
Stacking gel (5%) 5% (w/v) 29:1 acrylamide:N,N'-methylenebisacrylamide
0.125M Tris-HCl (pH6.8)
0.1% SDS
0.1% Ammonium persulphate
0.1% TEMED
Tris-glycine 0.2M Glycine
running buffer 25mM Tris
1% (w/v) SDS
5X SDS loading 0.26M Tris-HCl (pH6.7)
buffer 55.5% Glycerol
(Laemmli buffer) 8.8% SDS
11.1% (3 -mercaptoethanol
0.007% Bromophenol blue
Coomassie blue 5% (v/v) Glacial acetic acid
stain 45% (v/v) Methanol
1 % (w/v) Coomassie brilliant blue
Destain As above, but no Coomassie
* Referred to as acrylamide in the text.
Proteins were separated according to their size by Tris-glycine SDS PAGE, 
following the method of Laemmli (Laemmli, 1970). The samples to be sepamted were 
diluted with Laemmli buffer (5x) to give a final concentration of Ix. These samples were 
boiled for 5min prior to storage and/or separation. Samples were separated by downward 
migration through a vertical two-phase gel consisting of a stacking gel (top) and a resolving 
gel (bottom). The gel apparatus was obtained from Bio-Rad. The gel was suspended 
between two separate reservoirs o f Tris-glycine rumiing buffer. A cathode and anode were 
placed in the top and bottom reservoirs respectively. Proteins were separated at 40mA
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constant current for 4-5h (30ml resolving gel) or Hi (5ml resolving gel). A 10% (w/v) 
aciylamide resolving gel was used for the separation of 21-lOOkDa proteins, whereas a 
12% (w/v) acrylamide resolving gel was used for the separation of 10-40kDa proteins 
(Sambrook et al., 1989). The prestained, broad range protein molecular weight markers 
used were obtained from New England Biolabs or Bio-Rad. Separated proteins were 
visualised by Coomassie blue staining (20min stain followed by Ih destain) or were 
transferred onto nitrocellose membrane for analysis by western blotting.
2.10 Western blotting
Table 2.9 Buffers for western blotting
Transfer buffer 0.2M Glycine
25mM Tris
1% SDS
20% Methanol
TBS-Tween 137mM NaCl
20mM Tris-HCl pH 7.6
0.1% Tween-20
Proteins were transferred from SDS-PAGE gels to nitrocellulose membranes 
(Protean) by electroblotting in transfer buffer at 1A constant current for 90min. The 
nitrocellulose membranes were blocked by incubation with 5% skimmed milk in TBS- 
Tween for Ih  shaking at room temperature. They were then incubated with primary 
antibody, diluted in 1% skimmed milk in TBS-Tween, either shaking at room temperature 
for 2h or at 4°C overnight. The antibody dilutions that were used are shown in Table 2.10 
below. After three lOmin washes in TBS-Tween, the nitrocellulose membranes were 
incubated with horseradish peroxidase (HRP) conjugated secondary antibody, diluted in 
1% skimmed milk in TBS-Tween, for 111 shaking at room temperature. The membranes 
were washed in TBS-Tween as before, rinsed with Milli-Q pure water and developed using 
the enhanced chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, UK) following 
the manufacturer’s instructions. Immediately after treating the membranes with ECL 
reagent, they were exposed to Kodak X-ray film for various lengths of time (10sec-30min).
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Table 2.10 Table of antibodies and the dilutions used for western blotting
Specific for: Name Primary or M onoclonal/ Dilution ■1secondary Polyclonal for western 
blotting 1
GST 83 Primary Polyclonal 1:1000
RNPDE4A
(generic)
651 Primary Polyclonal 1:1000 -1
V5-tagged’*' Anti V5 Primary Monoclonal 1:30,000 Jproteins
RB3 574 Primary Polyclonal 1:1000 ?
Mouse IgG
(whole
molecule)
Anti mouse IgG Secondary
(HRP-
conjugated)
Monoclonal 1:10,000 j
Rabbit IgG
(whole
molecule)
Anti rabbit IgG Secondary 
(HRP- 
conj ligated)
Monoclonal 1:10,000 1Î
* The anti"V5 antibody (Invitrogen) recognised the epitope GKPIPNPLLGl.DST 1
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2.11 Homogenisation and fractionation of ceils 
Table 2.11 Buffer used for the homogenisation of cells
KHEM buffer 50 mM KCl
50 mM HEPES-KOH, pH7.2
lOmM EGTA
1.92 mM MgClz i .
2.11.1 Preparation of cell lysates for analysis by SDS-PAGE/western blotting
Confluent adherent cells (COS-7, COS-1 and HEK293 cells) were washed twice 
with ice cold incomplete KHEM buffer and then scraped into complete KHEM buffer (+ 
ImM DTT and protease inhibitors) containing 0.5% Triton-X-100. Suspended cells (e.g. 
M0LT3 monocytes, U937 and B-cells) were centrifuged and washed twice with ice-cold 
KHEM buffer before being resuspended in ice-cold complete KHEM buffer containing 
0.5% Triton-X-100. All cell lines were homogenised using 10 strokes thi’ough a 26G 
needle (Microlanee). The homogenates were assayed for protein (section 2.8) and then 
mixed with 5x Laemmli buffer to give a final concentration of Ix (Table 2.8). The 
homogenates were then boiled for 3min.
2.11.2 Subcellular fractionation of cells
Confluent, adherent cells were washed twice with ice-cold KHEM buffer. The cells 
were then incubated on ice with complete KHEM buffer (KHEM buffer plus Ix 
Complete'*'" protease inhibitors [Boeluinger Mannlieim] and ImM DTT) for 15min. The 
majority of complete KHEM buffer was removed by aspiration and the cells were scraped 
into the residual complete KHEM buffer. The harvested cell suspension was disrupted by 
50 strokes of a pestle in a glass Whatman homogeniser.
The PI-pellet fraction, which is composed of nuclear and cytoskeletal components 
(Scotland et al., 1998), was generated by centrifuging the cell homogenate at 4°C for 
lOmin at lOOOg. The supernatant was retained and centrifuged at high speed (Ih at 
100,000g at 4“C) to obtain a second high-speed pellet fraction (P2) and a high-speed 
supernatant fraction (S). The P2-pellet fraction contains plasma membranes, endoplasmic 
reticulum, Golgi stacks, endosomes and lysosomes and cytoskeletal components (Scotland 
et al., 1998) whereas the S fraction contains ‘soluble’ cytosolic proteins. The PI and P2 
pellets were washed twice in complete KHEM buffer, by resuspension using 10 passes 
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tlirough a 26G needle. The volumes of the PI and P2 fractions were then equalised to the 
volume of the S fraction with complete KHEM buffer. The fractions (PI, P2 and S) were 
then aliquoted, snap frozen in liquid N2 and stored at -80°C.
2.12 Subcellular distribution analysis by western blotting
The distribution of a specific proteins of interest, (e.g. RB3), between the PI, P2 
and S subcellular fractions was determined by western blotting (Bolger et al., 1997; Huston 
et a l, 1997). A range of sample volumes (e.g. 5, 10, 15, 20 and 25pl) for each of the 
fractions were separated by SDS-PAGE (section 2.9) and transferred onto nitrocellulose. 
The nitrocellulose membranes were immunoblotted using a primary antibody specific for 
the protein of interest. The membranes were then developed by ECL and exposed to X-ray 
film (section 2.10). The net intensities of the bands corresponding to the protein of interest 
were determined by densiometry using the Kodak ID image analysis software. For each 
fraction, the net intensity values were plotted against the fraction volume originally loaded 
on the SDS-PAGE gel to yield linear graphs (see Figure 2.2). The gradients of these graphs 
gave values for the intensity units per pi of sample. As the P I, P2 and S fractions had been 
normalised the same volume (see previous section), these gradients were directly 
proportional to the relative amoimts o f the protein of interest in the tln*ee fractions. 
Therefore, for each of the fractions, the relative levels of the protein of interest (in Intensity 
Units/pl) were expressed as a percentage of the total amount in the cell homogenate (which 
is equivalent to the P I, P2 and S fractions combined). This method is illustrated in Figure 
2.2.
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Figure 2.2 Determination o f the percentage distribution of a specific protein between 
the P I, P2 and S subcellular fractions
The example given here is the determination o f the percentage distribution o f RB3 between 
the PI, P2 and S fractions o f transfected COS-7 cells. Samples o f  these fractions were 
separated by SDS-PAGE and immunoblotted using anti-RB3 specific antisera. For each o f  
the fractions, the intensity values o f  the bands obtained were plotted against sample 
volume. The gradients o f the resulting graphs gave the relative amounts o f RB3 in the three 
fractions (in Intensity Units/pl). These amounts were expressed as a percentage o f the total 
amount o f protein in the cell homogenate (PI+P2+ S).
2 M ateria ls and M ethods 77
2.13 Membrane association of GST-PDE4 NHa-termini fusion proteins
GST-PDE4 NH2-termini fusion proteins (e.g. GST-RDL'^^^ and GST-rpde6 '^^ ^^ ) 
were purified and eluted with glutathione buffer as described in section 2.7.2. Samples of 
the resuspended P2-‘membrane’ fraction of COS-7 cells (see section 2.11.2) were 
centrifuged at 4°C for 30min at 100,000g. The P2 pellets were resuspended to a final 
concentration o f 1 mg/ml protein in complete KHEM buffer (Table 2.11) containing 
purified GST-PDE4 NH2-termini fusion protein (50pg/ml). After incubation on ice for Ih 
this mixture was then centrifuged again as before. The pellets were washed 3 times in ice- 
cold complete KHEM buffer. They were then resuspended in complete KHEM buffer, 
transferred to a fresh tube and boiled in Laemmli buffer (final conc. = Ix) for 5min. The 
samples were separated on a 10% (w/v) acrylamide SDS-PAGE gel (see section 2.9). After 
separation, the proteins were transferred onto nitrocellulose membranes and 
immunoblotted using GST-specific antisera (see antibody Table 2.10, section 2.10) to 
determine the percentage binding of the fusion protein to the P2 membranes.
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2.13.1 Effect of Triton X-100 and NaCl on the membrane association of GST- 
PDE4 NH2 -termini fusion proteins
Samples of the P2 pellet fraction were incubated with purified GST-PDE4 NH2- 
termini fusion protein and washed 3 times with complete KHEM buffer as described 
above. The P2-pellets were then resuspended in 2M NaCl or 5% Triton X-100 in complete 
KHEM buffer and incubated on ice for 30min. Afterwards the P2-pellet was recovered by 
centrifugation (100,OOOg, 30min, 4°C), separated by SDS-PAGE and immunoblotted using 
anti-GST antisera as primary reagent as described in the previous section.
2.13.2 Membrane association assay for binding of PDE4 NH2 -terminus-GST 
fusion proteins to thermally denatured P2 fraction
Samples of the COS-7 cell P2-membrane fraction were incubated at 50°C for the 
time periods indicated in the appropriate figures. The samples were then incubated with 
pmified GST-PDE4 NH2-termini fusion protein and washed 3 times with complete KHEM 
as described in section 2.13 above. The P2 pellets were then separated by SDS-PAGE and |
transferred onto nitrocellulose. The relative amounts of GST-fusion protein associated with
the membrane samples were analysed by immunoblottlng with anti-GST antisera as 
primary reagent as described above.
2.14 Generation of a polyclonal antiserum to the GST-RBS^ '^ *^^  fusion protein
A fusion of full-length RB3 to the COOH-terminus of GST (GST-RB3^"^^®) was 
used to raise antisera against RB3 in rabbits, GST-RB3*'^^^ was over-expressed and 
purified on glutathione Sepharose beads as described in section 2.7. The purified protein 
was eluted with lOmM glutathione, 50mM Tris-HCl pH8.0, aliquoted, snap frozen and 
stored at -80°C. Two New Zealand White rabbits (No.s 574 and 575) were immunised by 
subcutaneous injection at two sepaiate sites with 50pg of GST-RB3^"^^° in complete 
Freud’s adjuvant. The rabbits were given an initial booster injection with the same amount 
of fusion protein in incomplete Freud’s adjuvant after 9 days and another identical boost 
after a further 12 days. Sample bleeds were talcen 11 days after each booster injection. The 
final bleed was taken 15 days after the second boost. The serum was aliquoted at stored at - 
80°C.
2.16 Phosphodiesterase (PDE) assay 
Table 2,12 Buffers used in PDE assay
PDE assay 20mM Tris-HCl (pH7.4)
buffer lOmM MgClz
Cyclic AMP ImM cAMP (prepared in PDE assay buffer)
Stock solution
Snake venom 1 Omg/ml Snake venom (Ophiophagus hannah)
stock solution
Dowex Ix 8- (prepai'ed as described below)
400
2.15.1 Principle of the PDE assay
Cyclic AMP-specific PDE activity was assessed by a modification o f the radioassay 
procedure of Thompson and Appleman (Thompson and Appleman, 1971) and Rutten et al 
(Rutten et al., 1973) as described previously (Marchmont and Houslay, 1980). The 
principles of this two-step assay are illustrated in Figure 2.3, In the first step, the samples to 
be assayed were incubated with IpM  8-[^H]-labelled cAMP substrate. In the second step
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the [^H]-labelled product of cAMP hydrolysis, 5’AMP, was dephosphorylated to adenosine 
by incubation with 0.2mg/ml snake venom. The negatively charged unliydrolysed cAMP 
was then sepaiated from the unchai'ged adenosine by incubation with Dowex ion exchange 
resin. The amount of unbound [^H]-adenosine in the supernatant was determined by 
scintillation counting in order to calculate the rate of cAMP hydrolysis.
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Figure 2.3 Two step PDF assay
In the first stage, the samples to be assayed were incubated with 8-[^H]-labelled cAMP at 
30°C for lOmin. In the second stage the -labelled product o f cAMP hydrolysis,
5’AMP, was dephosphorylated to adenosine by incubation with snake venom at 30°C for 
lOmin. The negatively charged unhydrolysed cAMP was separated from the uncharged 
adenosine by incubation with Dowex ion exchange resin. The amount of [^H]-labelled 
adenosine product in the supernatant was measured in a scintillation counter.
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2.15.2 Preparation of reagents
2.15.2.1 8-[^H]“labelled cAMP substrate
A 2pM solution of unlabelled cAMP was prepared by dilution of a ImM stock in 
PDE assay buffer. Immediately prior to use, 8-[^H]-labelled cAMP (Amersham Pharmacia 
Biotech) was added to this solution to a final concentration of SpCi/ml.
2.15.2.2 Snake venom
A 1 mg/ml solution o f snake venom {Ophiophagus hannah) was prepared by 
dilution of a stock solution with Milli-Q pure water.
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2.15.2.3 Dowex
Dowex Ix 8-400 was prepared by washing the resin once in IM NaOH for 15min, 
followed by extensive washing with Milli-Q pure water until the pH of the eluate fell to 7. 
The resin was then washed with IM HCl for 15min and rinsed several times with water 
until the pH rose to 3. The Dowex resin was then resuspended in 1 volume of water and 
stored at 4°C. Immediately prior to use ethanol was added to a (Dowex :H2O : ethanol) ratio 
o f ( l : l : l ) .
2.15.3 Procedure in detail
The first step of the PDE assay was carried out in a total reaction volume of lOOpl 
and at a final concentration of IpM  8-[^H] cAMP (O.lSpCi). The samples to be assayed 
were incubated with IpM  cAMP for lOmin at 30°C. The sample sizes were chosen to give 
initial reaction rates that were within the linear range for assay. The sample sizes were 
assumed to be within the linear range if <10% of the cAMP substrate had been consumed 
during the lOmin assay. The assay was commenced by the addition of 50pl of 2pM 8- 
[^H]-labelled cAMP to 25pl of appropriately diluted sample plus 25pl PDE assay buffer. 
Incubation was terminated by boiling for 2min.
In the second step the [^H]-labelled product of cAMP hydrolysis, 5’AMP, was 
dephosphorylated to adenosine by the addition of 25pi of 1 mg/ml snake venom to each - #
lOOpl reaction and incubation at 30°C for lOmin. The negatively charged, unhydrolysed 
cAMP was separated from the uncharged adenosine by the addition of 400pi
amylose resin, eluted with the appropriate elution buffer and dialysed into 20mM Tris-HCl 
pH8.0 as described in section 2.7. These proteins were diluted with 20mM Tris-HCl pH8.0 
as 4x stocks. Sample of the high-speed supernatant (S) fractions of COS-7 cells transfected 
with the plasmid expressing the appropriate PDE4 species were diluted in complete KHEM 
buffer. The assay was carried out in a final volume (after the addition of 8-[^H-cAMP]) of 
lOOpl as described in section 2.15. In the first stage 25pi of the diluted S fraction 
(containing a PDE activity of approx. lEU [=pmol/min/mg]) was mixed with 25pi of a 4x 
stock o f the purified fusion protein and incubated for Ih on ice. The PDE assay was 
commenced by the addition of 50pl of a 2pM solution of 8-[^H]-labelled cAMP and 
incubation for lOmin at 30°C as described in section 2.15.
Dose-effect studies were carried out using a range of concentrations (usually 0.01-1 
pM) of fusion protein. The molar concentrations referred to here are the final 
concentrations in the lOOpl reaction mixtures after the addition of 8-[^H]-eAMP. The 
molar concentrations of the fusion proteins used were determined from their predicted 
molecular weights (see Table 2.13). All recombinant GST-fusion constructs were prepared 
using the vector pGEX5X-3 and the DNA encoding the recombinant peptide was inserted
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Dowex:ethanol:water (1:1:1) and incubation at 4°C for 15min. The samples were vortexed 
at 5min intervals during this incubation to keep the Dowex in suspension. The samples 
were then centrifuged (13000g, 3min) and samples of the supernatant (150pl) were added 
to 1ml of Optiflow Safe 1 liquid scintillation cocktail (Fisons Chemicals Ltd). The [^H]- 
adenosine in these samples was then counted for Imin in a Wallac scintillation counter.
The cpms for each sample were corrected for a background using a blank reaction = |
(containing no PDE). The corrected counts were used to determine the initial rate of |
reaction (pmol cAMP hydrolysed/min). Determination of the protein content of the samples 
(section 2.8) allowed the results to be expressed in units of pmol cAMP/min/mg protein 
(=EU).
2.16 Effect of GST- or MBP-RB3 fusion proteins on the activity of PDE 
isoenzymes in vitro
The effect of the presence of GST- or MBP-fusions of the immunophilin RJB3 on 
the activity of a variety of PDE species was determined by assaying equal amounts of the 
PDE4 species in question in the presence of increasing concentrations of purified fusion Iprotein. The GST- or MBP-fusion proteins were purified on glutathione Sepharose or
§
at the Noi l site. Therefore, the predicted molecular weights of the fusion proteins were the 
sum of the predicted molecular weights o f GST-5X-3 (up to the N atl site) and the peptide 
to be fused.
Table 2.13 Actual molecular weights of GST- and MBP-fusion protein
Protein Molecular weight (g/mol = Daltons)
GST (2T) 26884
GST (5X-3) up to Notl site 27441
GST-FKBP52 . 78921
GST-PP5^^-‘“^ 46728
GST^RB3^‘^^ ^ 46568
GST-ÏRB3^‘^ ^^ 65638
GST-RB3*^^'^^^ 45940
GST-RDl^'^"" 39034
GST-rpde6^^^-^^^ 44038
GST-rpde6^-^^^ 55410
Lyn SH3-GST 34562
MBP (C2) 50848
MBP-RB3^"^^^ 88457
Data from dose-effect studies were analysed using the KaleidaGraph software 
package (Synergy software). Using these data I determined the values of IC50 for the 
inhibition of PDE isoenzymes by GST- and MBP-fusion proteins. The IC50 value is the 
concentration of the inhibitory fusion protein that produces 50% of the maximum 
inhibition attainable. The IC50 values were calculated by fitting the data to an equation of 
the form
v = V-{(V[I])/([I]+IC5o)} 
where v = PDE activity, V = PDE activity in the absence of an inhibitory GST or 
MBP-fusion protein, [I] -  micromolar concentration of inliibitory fusion protein.
2.16.1 The effect of Lyn SH3-GST on the inhibition of RB3 by GST-RB3 '^®^“
The effect o f Lyn SH3-GST on the inliibition of rpded (RNPDE4A5) by GST- 
RB3 '^^^® was determined using a modification of the protocol described in section 2.16 
above. Lyn SH3-GST was expressed in E  coli and affinity puiified on glutathione 
Sepharose beads (see section 2.7.2). Cytosolic rpde6 was bound to Lyn SH3-GST using the 
pull down method described in section 2.17. A sample (400pg) of the purified Lyn SH3- 
GST bound to glutathione beads was incubated with a sample (240 EU) of cytosolic rpde6
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from transfected COS-7 cells. The beads were washed three times with ice-cold complete 
KHEM buffer and complexes of rpde6 bound to Lyn SH3-GST were eluted into a total 
volume of 300pl of glutathione elution buffer over a period of 45min. Assuming that all the 
Lyn SH3-GST was eluted (i.e. 400pg = 1 1 .6nM) the final concentration o f Lyn SH3-GST 
in this eluate can be estimated to be 38.6pM
Samples of this glutathione eluate containing rpdeb bound to Lyn SH3-GST were 
mixed 1:1 (v/v) witli purified GST-RB3‘‘“ " or GST diluted in 20mM Tris-HCl, pHS.O. 
These mixtures were incubated on ice for Ih. Samples o f these mixtures (50pl) were then 
assayed for PDE activity, begimiing with the addition of 50pl 2pM 8-[^H]-cAMP. The final 
concentration of Lyn SH3-GST in these assays was therefore ~9.6pM. As a control, the 
activity of samples of cytosolic ipde6, diluted in glutathione elution buffer, were 
determined in the presence or absence of GST-RB3^’^ ^^  or GST. The activity of rpde6 ±
Lyn SH3-GST added to the assay was within the linear range (see section 2.15.3) in the 
absence of GST or GST-RB3^'^^^ The final concentration ofGST-RB3^"^^° or GST in the 
assay was 1 pM.
2.17 Pull down/binding assay with GST-fusion proteins
This was performed using a modification of a procedure described previously (O' 
Connell et al., 1996). GST-fusion proteins were purified on glutathione Sepharose beads 
using the batch method (section 2.7.2.1). Volumes of 50% glutathione Sepharose sluny 
containing 200pg of immobilised fusion protein were made up to 200pl with a 50% slurry 
of PBS-washed beads. The beads were then pelleted and the supernatants were discarded. 
The pellets were resuspended in the high-speed supernatant (S) fraction from COS-7 
transiently transfected with rpde6, containing 100 EU of PDE activity. The immobilised 
fusion protein and cytosol were incubated for 30min at 4°C end-over-end. The beads were 
then collected by centrifugation for 5s at 13,000g and the supernatant was retained. The 
beads were held on ice and washed 3 times with 400pl complete KHEM buffer (see Table 
2.11, section 2,11) over a 15min period. The original supernatant and washes were pooled 
to form unbound fraction and aliquots were taken for PDE assay and western blotting. 
Bound PDE was eluted from the beads by incubating 3 times in 1 OOpl elution buffer 
(lOmM glutathione, 50mM Tris-HCl, pH8.0), at 4°C for 15min. The eluted fractions were 
pooled and aliquots were taken for PDE assay and western blotting.
2.17.1 Determination of percentage binding
The percentage binding of PDE4 species to GST fusion proteins was determined 
from both the PDE enzyme activity and immunoreactivity in the bound and unbound 
fractions obtained as described above.
2.17.1.1 Percentage binding determined from PDE enzyme activity
The total PDE activity in the bound (E U bqund) and unbound (E U unbound) fractions 
was determined using the PDE assay. The percentage of the PDE4 species that was ‘pulled 
down’ by the GST-fusions under the experimental conditions described (section 2.17) was 
calculated as follows:
% binding = 100% x [E U bqund /  (E U bqund+  E U unbound)]-
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2.17.1.2 Percentage binding determined from PDE immunoreactivity
A range of sample volumes (e.g. 5, 10, 15, 20 and 25pi) for the bound and unbound 
fractions were separated by SDS-PAGE (section 2.9) and transferred onto nitrocellulose. |
The nitrocellulose membranes were immunoblotted using a primary antibody specific the 
PDE4 species of interest. The membranes were then developed by ECL and exposed to X-
■'Sray film (section 2.10). The net intensities of the bands corresponding to the protein of 
interest were determined by densiometry using the Kodak ID image analysis software. For 
both fractions, the net intensity values were plotted against the Jhaction volume originally 
loaded on the SDS-PAGE gel to yield linear graphs. The gradients of these graphs gave '1
values for the intensity units per pi as a measure of the immunoreactivity in the bound and 
unbound fractions (see Figure 2.2, section 2.12). The total immunoreactivity values for the 
bound and unbound fractions were used to calculate the percentage binding of the PDE4 
species to the GST fusions.
CHAPTER 3
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CHAPTER 3 INTRODUCTION
I
In this chapter I describe my contribution to a collaborative project examining the 
role of PDE4 in the growth hormone (GH) promoted differentiation of 3T3 F442A 
preadipocyte cells to adipocytes. In section 3 .1 1 give the background to this project and I 
describe the initial observations showing that GH activates PDE4 in the 3T3 F442A cells. 
In section 3.2 I present my RT-PCR and sequence analyses of the PDE4 isoenzymes 
expressed by these cells. Dr S. MacKenzie showed that GH caused an increase in the 
activity of PDE4A immunoprecipitated with anti-PDE4A antiserum in a PI3-kinase- and 
p70S6 kinase-dependent mamier (MacKenzie et al., 1998). Having shown that PDE4A5 is 
the sole PDE4A splice variant expressed in these cells (section 3.2.1), I go on to show that 
the level of the PDE4A transcript is not affected by GH treatment (section 3.3). This result 
suggested that GH does not increase PDE4A activity by upregulating PDE4A5 
transcription, but rather via an affect on translation or a post-translational modification. 
Following this result. Dr MacKenzie showed that GH treatment caused an upward band 
shift o f the PDE4A5 isoenzyme on SDS-PAGE that was concomitant with PDE4A 
activation (section 3.4.1). Depletion of PDE4A5 with specific antisense 
oligodeoxynucleotides enhanced the GH-dependent differentiation o f these cells (section 
3.4.1). These results suggested that GH-dependent activation of PDE4A5, via PÏ3-kinase 
and p70S6 kinase, might serve as a brake on the process of differentiation. In section 3.4.3 
I discuss the implications of these findings and fiituie perspectives.
3.1 A model system for studying the role of PDE4 in cell differentiation
As discussed in the Introduction chapter, (section 1.4), there are now at least 17
different PDE4 isoenzymes identified in mammals. These show different characteristics of
targeting and regulation in cells that ar e determined largely by their unique NHz-terminal 
beenregions. It ha^proposed that the diverse responses of cells to signals that act via cAMP 
may partly depend on the specific combination of PDE isoenzymes that different cells 
express. Therefore, a major aim in the study of the PDE4 isoenzyme family is to assign
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specific physiological roles for individual splice variants in cAMP signalling (Houslay and 
Milligan, 1997).
To this end we require model cell systems where we can analyse the role of 
defined, endogenously expressed PDE isoenzymes on measurable cAMP-dependent 
processes in vivo. The differentiation of certain strains of mouse-derived 3T3 fibroblast 
cells to adipocytes is one example of a model system for study. These cell lines permit the 
study of adipocyte differentiation in culture.
For some time it has been known that the non-specific phosphodiesterase inhibitor, 
IB MX, promoted the differentiation of 3T3 preadipocyte cell lines to mature adipocytes 
(Russell and Ho, 1976). In 1985 Elks and Manganiello (Elks and Manganiello, 1985) 
showed that Ro 20-1724, now known to be a PDE4 specific inhibitor (Houslay et al.,
1998), promoted 3T3-L1 adipocyte differentiation as effectively as IBMX. The PDE3 
selective inhibitor, cilostamide, however, had no such effect. These results suggested that 
an increase in the intracellular concentration of cAMP, caused by inliibition of PDE4 
activity (but not by inhibition of PDE3), promoted the differentiation of preadipocytes to 
adipocytes. However, it should be pointed out that the effect of cAMP on preadipocyte 
differentiation is complex and stage-dependent (Yai’wood et al., 1998). Therefore, in the 
past, different groups have reported positive (Elks and Manganiello, 1985), negative 
(Spiegelman and Green, 1981) and neutral (Wang et al., 1992) effects of cAMP on 
differentiation. Currently it is thought that preadipocytes go through a ‘priming’ stage prior 
to a final progression to differentiation. Increased cAMP levels appear to be needed to 
allow the final differentiation stage (see below).
3.1.1 The effect of growth hormone (GH) on the differentiation of 3T3 F442A 
preadipocyte cells to adipocytes
The presence of growth hormone (GH) is essential for the differentiation of 3T3 
cells to adipocytes (Xu et al., 1995; Zezulak and Green, 1986). GH is a major regulator of 
cell growth and metabolism. It is known to have a positive regulatoiy effect on the 
differentiation of a range of cells lines, including myoblasts (Ewton and Florini, 1980), 
liver cells (Norstedt and Palmiter, 1984) and bone cells [osteoblasts (Kassem et al., 1998) 
and osteoclasts (Nishiyama et al., 1996)]. The mechanism of action o f GH has been 
extensively studied in the 3T3 F442A cell line (Smit et al., 1996; Xu et al., 1995; Yarwood 
et al., 1998; Yarwood et al., 1999). A dual effector theory has been proposed for the GH-
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dependent differentiation o f preadipocytes (Yarwood et a l, 1998; Zezulak and Green,
1986). Initially, GH treatment of the preadipocytes, over a two-day period, provokes the 
formation of a pool of cells that are primed for differentiation. When given the appropriate 
signal, e.g. insulin, IGF-1 or EGF, these cells progress to a fully differentiated state where 
they exhibit the biochemical and morphological characteristics of mature adipocytes I
(Bjorntorp et a l, 1980; Yarwood et a l, 1998; Zezulak and Green, 1986). In the absence of 
this second signal the cells fail to differentiate.
GH is larown to activate a number of signalling pathways as shown in Figure 3.1. 
However, the precise GH signalling pathways that regulate 3T3 F442A differentiation 
remain to be determined. A key event following the binding of GH to its plasma 
membrane-associated receptor (GHR) is the dimérisation of this receptor and the I
recruitment, dimérisation and activation of the Janus family cytoplasmic tyrosine kinase,
JAK2. This event leads to the activation of a number o f signalling pathways including the 
phosphoinositide-3 kinase (PI3-kinase) pathway, the PKC pathway and possibly the raf- 
MEK-ERK pathway (see Figure 3.1) (Argetsinger and Carter-Su, 1996). There is evidence 
to suggest that activated JAK2 recruits and activates the SH2- and SH2+SH3 domain-
containing proteins, SHC and Grb2 respectively (Argetsinger and Carter-Su, 1996;
VanderKuur et a l, 1995). This event may lead to the activation o f the raf-MEK-ERK 
pathway via Sos and ras as shown in Figure 3.1, although the GH-dependent activation of 
the ras, raf and MEK components of this pathway has not been shown to date. In this 
regard it should also be noted that in 3T3 F442A cells the GH-dependent activation of 
ERK by requires specific isoforms o f PKC (MacKenzie et a l, 1997) (Anderson, 1992).
Activation of JAK2 GH has also been shown to lead to the activation of the cytoplasmic 
transcription factors STATs (signal transducers and activators o f transcription) (Smit et a l,
1996). Once activated, STATs translocate to the nucleus where they bind to specific 
enhancer elements and activate the transcription of a number of genes including those
Ïencoding the detoxifying hydroxylase cytochrome P450, the transcription factor c-fos and 
the serine protease inhibitor 2.1 (spi 2.1) (Argetsinger and Carter-Su, 1996).
Given that the PDE inhibitors, particularly the PDE4 inhibitors, promoted 
differentiation we wished to ascertain if GH served to acutely regulate the PDE activity in 
these cells. If this should prove to be the case, we wished to determine whether PDE had 
any role in the manner whereby GH regulates differentiation. Intriguing, a post-doctoral 
investigator in our laboratory. Dr S. MacKenzie, showed that GH treatment of 3T3 F442A
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preadipocytes produced a rapid (maximal at -20-3Grain), transient increase in the rolipram- 
inhibited PDE4 activity [see ref. (MacKenzie et ah, 1998)]. It was further shown that 
activation of PDE4 by GH in these cells resulted in a decrease in the intracellular 
concentration of cAMP. The latter was shown to be the case (MacKenzie et al., 1998). 
Furthermore, rolipram inhibition o f PDE4 activity ablated this drop in cAMP levels and 
served to potentiate the differentiation of these preadipocytes (MacKenzie et al., 1998).
Therefore, whilst GH is necessary to prime cells for differentiation, it might also serve as a 
brake on the differentiation process by increasing PDE4 activity.
In order to understand this process more fully, it was necessary to define the PDE4
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Splice variants that are expressed in 3T3 F442A cells. This would allow the identification 
of the precise PDE4 splice variant(s) involved in the GH-stimulated response. 
Unfortunately, splice variant-specific antibodies are not available for the majority of 
individual isoforms that differ at their NHz-termini. However, PDE4 specific antibodies are 
available that allow the detection of members of the four separate subfamilies 4A, 4B, 4C
and 4D (see Introduction, section 1.4). These were raised against the extreme COOH- 
terminal regions that are shared by all the splice variants derived from a single gene. It is 
thus possible to get some idea of the isoforms present by rumiing cell lysate on SDS- 
PAGE, immunoblotting with subfamily specific antisera and determining their size relative 
to recombinant standai'ds. However, no such standards are available for murine enzymes 
and rat and human splice variants can migrate differently. Therefore, in order to identify 
the PDE4 splice variants expressed by 3T3 F442A cells it was imperative to use RT-PCR 
as a diagnostic probe (see section 3.2 below). Dr MacKenzie verified the results o f my RT- 
PCR analyses by using the western blotting strategy described above. This type of strategy 
has been successfully used by our laboratory in a number of studies (Bolger et al., 1997;
Erdogan and Houslay, 1997; Huston et al., 1997; Kostic et al., 1997). An additional 
advantage of the RT-PCR approach is that the PCR fragments amplified using this method j
can be used to obtain sequence information for the 5’ ends of the splice variant mRNAs.
This can be used to design antisense oligodeoxynucleotides to block the expression of 
specific isofbrms and thus determine their function in GH-dependent differentiation of 
adipocytes.
41..
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Figure 3.1 Signalling downstream of the growth hormone receptor
GHR dimerises upon binding GH and this complex recruits, homodimerises and activates 
JAK2 cytoplasmic tyrosyl kinase. JAK2 phosphorylates itself and GHR, which leads to the 
recruitment and phosphorylation o f  the 1RS 1 and She. 1RS 1 in turn recruits and activates 
PI3-kinase, which activates the proteins involved in glucose transport and p70S6 kinase via 
a pathway which may involve PDKl and PKB. Phosphorylated She recruits and activates 
Grb2, which may lead to the activation o f the Raf-MEK-ERK pathway, although in 3T3 
F442A cells the GH-dependent activation ERK requires specific isoforms o f PKC. 
Activated ERKs phosphorylate and regulate a number o f proteins including phospholipase 
A2 (PLA2), protein kinases (e.g. p90rsk) and transcription factors (e.g. c-fos and Elk). 
Activated JAK2 can also phosphorylate and activate the STAT cytoplasmic transcription 
factors and protein kinase C (PKC) via the phospholipase C pathway.
In the above figure proteins given a broken outline have not yet been shown to be activated 
by GH stimulation. A circled P denotes proteins that are tyrosyl phosphorylated by JAK2. 
This figure is based on the one shown in (Argetsinger and Carter-Su, 1996).
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CHAPTER 3 RESULTS AND DISCUSSION
3.2 Screening of 3T3 F442A preadipocyte cells for the expression of PDE4 
splice variants using RT-PCR
Reverse-transcription PCR (RT-PCR) has been used in a number of studies to 
define the PDE mRNA transcripts that are expressed by various cells or tissues (Bolger et 
al., 1997; Engels et al., 1994; Huston et al., 1997; Kostic et al., 1997; Spence et al., 1997; 
Spence et al., 1995). This teclmique requires the extraction of total RNA from the cell. This 
is then reverse-transcribed to make cDNA. PCR reactions are carried out on this cDNA to 
detect the presence of mRNA transcripts for the various isoenzymes using isoenzyme- 
specific primer pairs. The successful amplification of the appropriate part of the cDNA 
encoding a PDE4 splice variant indicates the expression of the mRNA for this isoenzyme 
in 3T3 F442A cells. The advantages of this technique are that it is simple, the components 
of the reaction are easily prepared and the reactions themselves are quick (Scotland et al., 
1998).
As discussed in section 1.4, the process of 5’ alternative RNA splicing in PDE4 
primary transcripts involves the fusion of upstream exons, that encode the unique NH2- 
terminal domains of PDE4 isoenzymes, with downstream exons that encode UCRl, UCR2 
and the catalytic unit. The downstream exons that encode the catalytic unit and portions of 
UCR2 are found in all splice variants. Therefore, RT-PCR primer pairs that anneal to 
sequences within these exons will detect any of the splice variants for a particular gene and 
are thus referred to as generic primers. Detection of specific splice variants requires the use 
of 5’ (sense) primers that anneal to sequences within the regions that encode the unique 
NH2-terminal splice domains. I have used a range of RT-PCR primer pairs to screen 3T3 
F442A cells for the mRNA transcripts for all the known PDE4 splice variants. The results 
for each of the four PDE4 genes (PDE4A-D) are presented separately in the sections below 
(sections 3.2.1 to 3.2.4).
3.2.1 RT-PCR analysis of PDE4A splice variants and detection of the murine 
PDE4A5 transcript
The 3T3 F442A preadipocytes aie a mouse cell line. At the start o f this study no 
sequence information was available on murine PDE4 isoenzymes. Therefore, the primer
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pairs were designed using rat or human sequence data. This is acceptable, as a comparison 
of the nucleotide sequences for rat PDE4 isoenzymes with their human counterparts 
indicates that there is high sequence conservation between species (Houslay et ah, 1998).
RNA was extracted from unstimulated 3T3 F442A preadipocytes and reverse-
transcribed to make cDNA, using reverse transcriptase in combination with a poly (dT)
oligodeoxynucleotide (ODN) primer (see Methods chapter, section 2.6.4). This primer |
initiates reverse transcription from the poly A tail found at the COOH-terminal end of
mature mRNAs. The resultant cDNA was used in a set of PCR reactions to detect either
any PDE4A isoenzyme (generic PDE4A) or one of the thi'ee known rat PDE4A splice
variants: -RNPDE4A1 (RDI), RNPDE4A5 (rpde6), and RNPDE4A6 (rpde39). All PCR
reactions were carried out as described in the Methods chapter, section 2.6.5. The ODN
primer pairs used and the PCR reaction conditions are shown in Table 3.2. As positive
controls, identical PCR reactions were carried out using plasmids encoding the appropriate
PDE4A splice variants (see legend for Figure 3.3). The amiealing positions for the primers
used are shown in Figure 3.2. Samples of the PCR reaction products were separated by
.agarose gel electrophoresis and the DNA bands were then stained with ethidium bromide 
and visualised with UV light.
The results for the RT-PCR screen for PDE4A splice variants are shown in Figure 
3.3. The bands corresponding to the fragments obtained for the positive control reactions 
(using plasmid template) are shown on the left-hand side o f this figure. Note that no bands 
were observed for the no-template negative control reactions (data not shown). The bands 
obtained using 3T3 F442A cDNA are shown on the right-hand side o f the figure. Positive 
results were obtained for the PCR reactions used to detect generic PDE4A and the splice 
variant PDE4A5. No fragment bands of the appropriate size were obtained for the splice 
variants PDE4A1 or PDE4A6. I
The bands obtained must be of the correct molecular weight in order to exclude the 
possibility that the primers have detected pre-mRNA or the wrong splice variant. The 
‘observed’ molecular weights of the PCR fragments were calculated from their distances of 
migration relative to the molecular weight markers (see Methods chapter, section 2.6.5).
There is a close correspondence between the predicted and observed molecular weights 
(MW) in base pairs (bp) for the generic PDE4A band (see Table 3.1, below). However, the 
observed molecular weights of the bands obtained in the PDE4A5 PCR reactions (positive j
control and 3T3 F442A cDNA template) were higher than predicted. In order to verify that
the fragment obtained in 3T3 F442A cDNA reaction did correspond to the mouse 
homologue of PDE4A5, it was sequenced as described in section 3.2.1.1.
Table 3.1 Comparison of the predicted and observed molecular weights (in bp) for 
the bands obtained in the PCR screen for PDE4A splice variants.
PDE4A species Predicted MW (bp) Observed MW  (bp)*
Positive control 3T3 F442A
(plasmid template) cDNA template
PDE4A (generic) 233 244.2 ± 1.4 252.6 + 2.8
PDE4A5 825 872.8 ± 26 924.7 ± 42
* means of at least three separate experiments ± SE
Western blot analyses ((MacKenzie et al., 1998) and Dr MacKenzie-personal 
communication) failed to identify imniunoreactive species that co-mi grated with RDI 
(79kDa) and rpde39 (98kDa). However a band was present that co-migrated with rat rpdeb 
(RNPDE4A5) at 109kDa. Thus, the RT-PCR results would indicate that this species is 
indeed the murine homologue of RNPDE4A5.
The tissue distribution of both RNPDE4A1 and RNPDE4A6 appears to be rather 
restricted. Thus, RNPDE4A1 has only ever been detected in the brain, whereas 
RNPDE4A6 expression appears to be confined to the testes (Bolger et al., 1996) and 
hepatocytes (Houslay lab- unpublished). However, RNPDE4A5 and its human homologue 
HSPDE4A4 appear to have a wider distribution in tissues, being found in both brain 
(McPhee et al., 1995), thymocytes (ElBawab et al., 1997), Jui'kat T-cells (Seybold et al., 
1998), pheochi'omocytoma (PC 12) cells and U937 human monocytes (MacKenzie and 
Houslay, 2000).
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Table 3.2 Table showing PDE4A RT-PCR primers used and conditions
P D E4A
Species
P rim er 
S=Sense, A = A ntisense
Nucleotide
fragment
amplified
F rag .
Size
(bp)
C ycle conditions
D A E
PDE 4A 
(generic) 
M 26715
S
A
GR28"
GR29"
G C G G G A C C T(A /G ) CTGAAGAAAT TCC  
C A G G G T G (A /G )T C  CACATCGTGG
459-651* 233 94°C
Imin
57°C
2min
72®C
3min
PDE4A1
M 26715
S
A
GR37"’’’
G R36“’*’
TTC TTC TG C G  AGACCTGCTC CAAGC 
CAGGCCCCAT TTGCTC AA G T TCTCC
16-387 372 94°C
Im in
52°C
2min
72°C
3min
PDE4A5
L27057
S
A
GR43
GR36
TCCTTCCACG GCACCGGTAC C 
CAGGCCCCAT TTGCTC AA G T TCTCC
265-1089 825 94°C
Im in
62°C
80sec
72°C
Im in
PDE4A6
L36467
S
A
G R20“
G R 2 f
GCCCAGAGAG GCTTGGTGAT TT A TC C  
ATATTCGAGG CAGTGTCAGC CTCTTGC
-178-37 215 94°C
Im in
62°C
80sec
72°C
Im in
In the above table the sequences of the sense (5’) and antisense (3’) RT-PCR 
oligodeoxynucleotide (ODN) primers are shown alongside the PDE4A transcript (splice 
variant or generic transcript) that they detect. The GenBank accession numbers for the 
sequences of the rat PDE4A splice variants used to design the primer sets are given in the 
first column. The temperatures and hold times for the dénaturation (D), amiealing (A) and 
elongation (E) stages of the PCR cycle are shown. All PCR reactions were carried out in a 
total volume of 25pi as described in the Methods chapter, section 2.6.5. The number of 
cycles carried out in each case was 40. The nucleotide fragments amplified and their sizes 
in base pairs (bp) are also given for each primer pair where negative positions refer to 
nucleotides upstream of the translation start codon. The specificity of these primer pairs 
was verified by screening them against a libraiy of PDE4 cDNAs. 
a =(Kostic et al., 1997), b = (Sullivan et al., 1998).  ^= fragment o f cDNA corresponding 
to RNPDE4A1 amplified
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Figure 3.2 Figure showing the annealing positions of RT-PCR primers used to probe 
PDE4A splice variants identified in rat.
This diagram shows the annealing positions for the RT-PCR primers on the cDNA 
obtained by reverse-transcription of the mRNA transcripts for the thi'ee known rat PDE4A 
splice variants» RNPDE4A1. RNPDE4A5 and RNPDE4A6. The positions of the ATG 
initiator methionine codons are marked with white squares, whereas the termination 
codons are marked with black squares. Grey and white bars mark the positions of the 
upstream conserved regions (UCRl and UCR2) and the catalytic unit,respectively. Black 
bars represent the unique NH2-terminal splice domains and grey circles mark the splice 
junctions. The annealing positions for the splice variant-specific ODN primers are 
indicated with grey arrows. Black arrows show the position of primers used for the 
detection of the generic PDE4A mRNA transcript. Note that the sense primer (GR21) for 
the detection of PDE4A6 cDNA anneals to a position on the cDNA that is upstream of the 
start codon of the corresponding mRNA transcript.
I
I
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Plasmid control 3T3 F442A cDNA
M W  standards 
(bp)
;
1 3 5 3 ^  
1 0 7 8 ^
8 7 2 “^
603
310
281/271
234
194
A A1 A5 A6 A A1 A5 A6
Figure 3.3 RT-PCR analysis of PDE4A splice variants expressed in 3T3 F442A mouse 
preadipocyte cells.
RNA was extracted from 3T3 F442A mouse preadipocyte cells and used as a template for 
first strand cDNA synthesis as described in the Methods chapter, section 2.6.1. The cDNA 
that was produced was used as a template in PCR reactions using generic primers for the 
detection o f all PDE4A splice variants (A) or the splice variant specific primers for the 
detection o f PDE4A1 (A l), PDE4A5 (A5) and PDE4A6 (A6). As a positive control, the 
same sets o f primers were used in PCR reactions where plasmids containing the 
appropriate clones were used as a template. The positive control plasmids used were 
pSVL-RDl (for PDE4A and PDE4A1), pSV-SPORT-rpde6 (for PDE4A5) and pcDNA- 
rpde39 (for PDE4A6). The results for the positive control reactions are shown in the left- 
hand four lanes, whereas the results obtained using 3T3 F442A cDNA as a template are 
shown in the right-hand four lanes. The molecular weight standards (in bp) are shown on 
the left. The predicted amplified product sizes are PDE4A (generic) = 233 bp, PDE4A1 = 
372 bp, PDE4A5 = 825 bp and PDE4A6 = 215 bp.
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3.2.1.1 Sequencing of the PDE4A5 amplified fragment
In order to confirm that the fragment amplified in the above RT-PCR screen was 
indeed mouse PDE4A5, this fragment was ‘TA’ cloned and sequenced as described in 
detail in the Methods chapter, 2.6.6. This nucleotide sequence has been deposited in 
GenBank (accession number AF038895).
An alignment of the new nucleotide sequences obtained for mouse PDE4A5 with
'■fthe corresponding sequences from rat PDE4A5 and the human homologue (HSPDE4A4) is 4 
shown in Figure 3.4. The new mouse nucleotide sequence determined as a result of this 
analysis (excluding the primer sequences at each end of the insert) corresponds to
.Ï:nucleotides 286 to 1064 of rat PDE4A5 and nucleotides 286-1106 in human PDE4A4.
Figure 3.5 shows an alignment of the predicted amino acid sequences for this region in the 
mouse, rat and human homologues. As illustrated in Figure 3.5 the region sequenced 
encompasses the COOH-terminal seven amino acid residues of the unique NH2-terminus of 
PDE4A5, the upstream conserved regions UCRl and UCR2 and the first 37 amino acid 
residues of the catalytie unit as defined by Houslay et al (Houslay et al., 1998). Figure 3.4 
and Figuie 3.5 both show the high sequenee conservation between rat and mouse PDE4A5.
The nucleotide sequenees of rat and mouse PDE4A5 are 79% identical. However, 73% of 
these mutations are silent so that the predicted amino acid sequences show 94% identity.
This high conservation suggests that the NH2-terminal non-catalytic region plays an 
essential role in the regulation or function of PDE4A5.
As expected, the mouse sequence shows more similarity to the rat sequence than 
the human sequence (Figure 3.5). The mouse and rat forms of PDE4A5 lack a 5-residue 
insert found at the COOH-terminus of the unique NH2-terminal splice domain o f the 
human homologue HSPDE4A4. Moreover, mouse PDE4A5, like rat PDE4A5, lacks the 
proline-rich insert found in the LR2 region of the human homologue, PDE4A4 (amino 
acids 313-320). This proline-rich insert in HSPDE4A4 is proposed to act as a molecular 
switch that mediates the interconversion of high and low rolipram affinity conformations 
that can be operated with appropriate SH3 domain-containing proteins (Huston et al., 1996; 
McPhee et al., 1999). My sequence analysis suggests that the kinetic properties of mouse 
PDE4A5 (MMPDE4A5) will reflect rat PDE4A5 rather than the human homologue, I
HSPDE4A4. However, it should be noted that apart from the insert regions, the
MMPDE4A5 and HSPDE4A4 sequences show 89.7% identity at the amino aeid level. f|
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Figure 3.4 Alignment of the nucleotide sequences for mouse and rat PDE4A5 
(nucleotides 286 to 1064) and human PDE4A4 (nucleotides 286-1106).
This figure shows the nucleotide sequence o f the fragment amplified with PDE4A5-
specific primers using 3T3 F442A cDNA as a template. The primer sequences at both ends
of the PCR fragments have been excluded. The mouse nucleotide sequence has been
aligned with the corresponding rat and human sequences; nucleotides 286 to 1064 in
RNPDE4A5 and nucleotides 286 to 1106 in human HSPDE4A4. The bases that match the
mouse sequence are boxed. The regions encoding the upstream conserved regions UCRl
and UCR2 and part o f the catalytic unit are shaded. The GenBank accession numbers for
the mouse, human and rat sequences are AF038895, L20956 and L27057, respectively. The
key for the upper diagram in this figure is the same as that described in the legend for
Figure 3.2. This alignment was performed using the Clustal method (Higgins and Sharp,
1988) within the DNA Star programme (Lasergene).
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Figure 3.4 continued
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Figure 3.5 Alignment of the predicted amino acid sequence for mouse and rat 
PDE4A5 (amino acids 96-354) and human PDE4A4 (amino acids 96-368)
In this alignment the residues that match the mouse sequence are boxed. The region of
mouse PDE4A5 cDNA that was amplified and sequenced encompasses the COOH-
terminal seven amino acid residues of the unique NHz-terminus of PDE4A5 (lower case
letters), UCRl and UCR2 (both shaded), and the first 37 amino acids of the catalytic unit
(shaded). The points at which the sequences of PDE4A6 and PDE4A1 diverge from
PDE4A5 are marked as splice junctions 1 and 2,respectively. The GenBank accession
numbers for the mouse, human and rat sequences are AF038895, L20956 and L27057
respectively. The key for the upper diagram in this figure is the same as that described in
the legend for Figure 3.2. This alignment was performed using the Clustal method (Higgins
and Sharp, 1988) within the DNA Star programme (Lasergene).
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3.2.2 RT-PCR analysis of PDE4B splice variants and detection of the murine 
PDE4B2 transcript
The 3T3 F442A cDNA was used in a PCR screen for PDE4B splice variants. There 
are thr ee splice variants that have been cloned from rats and humans, PDE4B1, PDE4B2 
and PDE4B3. The primer pairs and the PCR reaction conditions used for the detection of 
these PDE4B splice variants are shown in Table 3.4. The annealing positions for the ODN 
primers on the cDNA corresponding to the three alternative mRNA transcripts are shown 
in Figure 3.6. As positive controls, identical PCR reactions were carried out using plasmids 
encoding the appropriate PDE4B splice vai'iants. Samples of the PCR reaction products 
were separated by agarose gel electrophoresis and visualised as before. The results from the 
RT-PCR analysis of 3T3 F442A cells are shown on the right of Figure 3.7 next to the 
results for the positive control reactions, shown on the left. Again, no bands were observed 
for the no-template, negative control reactions (data not shown).
This PCR screen detected the presence of transcripts for PDE4B (generic) and the 
splice variant PDE4B2. The bands obtained using 3T3 F442A cDNA as a template co­
migrated with the bands obtained in the corresponding positive control reactions. There is a 
reasonably close correspondence between the predicted and observed molecular weights 
(MW) for these fragments as shown below in Table 3.3.
Table 3.3 Comparison of the predicted and observed molecular weights (in bp) for 
the PDE4B2 amplified PCR fragment.
PDE4B species Predieted MW (bp) Obseiwed M W  (bp)* .7
Positive control 
(plasmid template)
3T3 F442A cDNA 
template 4
PDE4B (generic) 786 787.8 ± 26 826.6 ± 26 3
PDE4B2 679 676.2 ± 5.6 732.9 ± 18 ■3
* means of at least three separate experiments ± SE
No bands were observed using the ODN primers specific for the Tong’ PDE4B 
splice variants PDE4B1 and PDE4B3 (see Figure 3.6). Therefore, the short form PDE4B2 
appears to be the only PDE4B splice variant expressed by mouse 3T3 F442A 
preadipocytes. This result supports western blot analysis done using a PDE4B-specific 
COOH-terminal polyclonal antibody as primaiy reagent (MacKenzie et al., 1998). This 
showed the presence of a single imniunoreactive band that co-migrated with recombinant 
HSPDE4B2 (human).
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:Table 3.4 Table showing PDE4B RT-PCR primers used and conditions
P rim er 
S=Sense, A= A iitisense
N ucleotide
frag m en t
an ip lihed
F rag .
Size
(bp)
Cycle conditions
D A E
PDE4B
(generic)
J04563
S
A
GR30
GR31
CAGCTCATGA CCCAGATAAG TGG 
G T C T G C A C A (A /G ) TGTACCATGT TGCG
907-1692* 786 94°C
Im in
55°C
2min
72°C
3min
PDE 4B 
(long 
form) 
J04563
S
A
GR3
GR4
AAACCTTCAC GGAGCACCGA ACAAGAGG 
GCCACGTTGA AGATGTTAAG GCCCCATT
561-1067* 507 94°C
Imin
58°C
80sec
72°C
70sec
PDE 4B2 
L27059
S
A
GR17
GR4
TTGGTAGATC ACTGACACCT CATCCGG 
GCCACGTTGA AGATGTTAAG GCCCCATT
-116-551 667 94°C
Im in
58°C
80sec
72°C
70sec
PDE 4B3 
U85048
S
A
4123
4122
CTCCACGCAG TTCACCAAGG AAC 
TGTGTCAGCT CCCGGTTCAG C
137-734 598 95°C
1
mill
63°C
2min
72°C
3min
The sequences of the sense (5’) and antisense (3’) RT-PCR ODN primers for the detection 
of PDE4B transcripts are shown. The primer sets for the detection o f PDE4B (generic), 
PDE4B2 or PDE4B (long forms) were designed using sequence information for rat splice 
variants (Kostic et al., 1997). The PDE4B3-specific primers were designed using the 
sequence of the human splice vai’iant HSPDE4B3 (Huston et al., 1997). The GenBank 
accession numbers for the sequences of the rat and human PDE4B splice vai’iants used to 
design the primer sets ai’e given in the first column. The number of cycles carried out in 
each case was again 40.
^Nucleotide fragment amplified in RNPDE4B1
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GR3 GR30 GR4 GR31
B3
Sen se-4123  GR17
Figure 3.6 Figure showing the annealing positions of RT-PCR primers used to probe 
PDE4B splice variants identified in rats and humans
This diagram shows the annealing positions for the RT-PCR primers on the cDNA 
obtained by reverse-transcription of the mRNA transcripts for the tln ee Imown PDE4B 
splice variants, PDE4BL PDE4B2 and PDE4B3. Note that the sense primer (GR17) for the 
detection of PDE4B3 cDNA amieals to a position on the cDNA that is upstream of the start 
codon. The key for this figure is the same as that described in the legend for Figure 3.2.
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Molecular
weight
(bp)
1 0 7 8 ^
872
6 0 3 ^
310
281/271
1 9 4 ^
Plasmid control 
B B B2 B3 
’long’
3T3 F442A cDNA 
B B B2 B3 
’long’
Figure 3.7 RT-PCR analysis of PDE4B splice variants expressed in 3T3 F442A mouse 
preadipocyte cells.
The cDNA produced from total RNA extracted from 3T3 F442A cells was used as a 
template in an RT-PCR screen for PDE4B mRNA transcripts. The primers used were 
either generic primers for the detection o f all PDE4B splice variants (B), long PDE4B 
specific primers (B ‘long’) for the detection o f PDE4B1+PDE4B3 or splice variant specific 
primers for the detection o f PDE4B2 (B2) or PDE4B3 (B3). The positive control templates 
used were pDPD (RNPDE4B1) for PDE4B and long-PDE4B, mouse brain cDNA for 
PDE4B2 and pdeos41 (HSPDE4B3) for PDE4B3. Samples (9ul) o f  the positive control 
reaction products and the 3T3 F442A cDNA template reaction products were separated by 
agarose (2%) gel electrophoresis, stained with ethidium bromide and visualised with a UV 
transilluminator. The results for the positive control reactions are shown in the left-hand 
four lanes, whereas the results obtained using 3T3 F442A cDNA as a template are shown 
in the right-hand four lanes. The molecular weight standards (in bp) are shown on the left. 
The predicted sizes o f the amplified fragments are PDE4B (generic) = 786, PDE4B1 = 507, 
PDE4B2 = 667 and PDE4B3 = 598.
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3.2.2.1 Sequencing of the PDE4B2 amplified fragment
In order to confirm that the hagment amplified in the above RT-PCR screen was 
indeed mouse PDE4B2, this fragment was again ‘TA’ cloned and sequenced as described 
in the Methods chapter, section 2.6.6. Note that the 5’ sense primer used to identify 
PDE4B2 (GR17) amieals to a region on the cDNA template that is upstream of the 
translation start codon. Therefore, a portion of the mouse nucleotide sequence at the 5’ end 
corresponds to a non-coding sequence.
An alignment of the new nucleotide sequences obtained for mouse PDE4B2 
(excluding the primer sequences at each end of the insert) with the corresponding 
sequences from rat and human PDE4B2 is shown in Figure 3.8. The sizes of the nucleotide 
sequence fragments that are encompassed by the PDE4B2-specific primer pair 
(GR17+GR4) differed in mouse, rat and human. In mouse PDE4B2 this region, excluding 
the primer sequences at each end, extended from nucleotides -95  to 524 (total length = 619 
bases). This aligns with nucleotides -89  to 524 (613 bases) o f RNPDE4B2 and nucleotides 
-107 to 524 (631 bases) in HSPDE4B2. The differences in the lengths of the sequence are 
due to insertions and deletions in the non-coding region of the PDE4B2 mRNA (see Figure 
3.8).
An alignment of the predicted amino acid sequence for the coding region of the 
amplified fragment for mouse PDE4B2 with the corresponding sequences from rat and 
human is shown in Figure 3.9. This region covers the first 174 amino acids of PDE4B2 and 
includes the whole o f UCR2 and the first 42 amino acids of the catalytic unit. As shown in 
Figure 3.6, PDE4B2 is a short splice variant and therefore lacks U C R l.
Figure 3.8 and Figure 3.9 both show the high sequence conservation between rat 
human and mouse PDE4B2. Of the 9 nucleotide differences noted between the mouse and 
human PDE4B2, 7 of these mutation were silent, producing no change in the predicted 
amino acid sequence. The predicted amino acid sequence of the mouse PDE4B2 is 98.9% 
identical to the rat sequence and 93.1% identical to the human sequence. All of the amino 
acid differences between the mouse, rat and human sequences occur within the unique 
NH2-terminal splice domain of PDE4B2.
This result confirms that mouse 3T3 F442A cells do express a mouse homologue of
fPDE4B2. This result again demonstrates the high conservation of sequence between f
.equivalent PDE4 isoenzymes from different species.
:
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Figure 3.8 Alignment of the nucleotide sequences for mouse, rat and human PDE4B2
This figui'e shows the nucleotide sequence of the fragment amplified with PDE4B2- 
specific primers using 3T3 F442A cDNA as a template. The primer sequences at both ends 
of the PCR fragments have been excluded. The mouse nucleotide sequence has been 
aligned with the coiTesponding rat (GenBank accession number L27058) and human 
(GenBank accession number L20971) sequences. The bases that match the mouse sequence 
are boxed. The regions corresponding to UCR2 and part of the catalytic unit are shaded. 
The numbers on the left refer to the nucleotide position. This alignment was performed 
using the Clustal method (Higgins and Sharp, 1988) within the DNA Star programme 
(Lasergene).
3 Determination o f the PDE4 splice variants expressed In mouse 3T3-F442A preadipocyte cells using the 108
reverse transcription polymerase chain reaction (RT-PCR) I
’I
G C T G A C A C  A C C  T  C T  C A  G A  G A T  G A G  G A G A  
GXLXLX3.A C_JLXLAJXJiXUlJlLh.A G A G  A
,G  T  G T  C T 'G  A ^ T  A  C  A ^T T  T  C .  
AÜll.£..l..i:,X„,a.ArAl,y,A.£,.A...I..I...i.,£l gi
C A  G G G A  fl C C
A...G.,.£...£,„A..A,.C„.C
C A O  G T  T  C T  T  A  G A  C A  A  G .C A  G A A  C G A  T  . G T  G 
C. A  C G T  .T C T  T  A  G A  C  A  A  G C A  G A  A  C G A  T  G T  G
G A G  Â Â I  A lG  A C A  G G G 
C A G A A G G A C A G G G  
G A G A A G G A G A G G GCatalytic unit
a g a a I a I a a g a a I a I a a g c a g c a g c t c
A G A A G A A G A A G A A G C A G C A G C T G  
A_G_A_A_G  A A G A A G A A G C A G C A G C T C
4 0 4
4 0 4
4 0 4
-A, G A  T  A A G T  # ' G # # T ' G  À ' A ' G "A A ' A x T x  G A  T  X r -C 'lT C :'  
A  G A  T  A A  G I  G .G -A  . G : : t ; g : £ L g ; A  A i A  .0 T lG  A l X
4 3 4 | î l T j T  C a  '^  G Ç C lT jy y À  A  C A a [ £ | a  C A  A  G a T  C X C  A  C
4 3 4  Id C  T  C Â  A  G C C l T  G. A  A  .C A  A G A C A A G G A  î ' t : i ¥ ‘C:'A  t
4 3 4 b  G -T C A. A  G G C  T
4 6 4 1 g '  C T T T b j G  G A G 'x  C A A  C À  c f s !  q'  a X a  A  T  0  A^Bj G *A ‘ï  ' C 
4 6 4 l a  C T  Ÿ ^ G  'G A. G T  'Ç- A  A  C A 'C  G  G A ^ A ';A '-A IT 'G  A G G  A  T  ï :  4 64[„s g X i ^ g g f i Q ï G
human P D E 4B 2  
mouse P D E 4 B 2  
r a t  P D E 4 B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4 B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4B 2
human P D E 4B 2  
m ouse P D E 4B 2  
r a t  P D E 4B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4B 2
human P D E 4B 2  
mouse P D E 4B 2  
r a t  P D E 4B 2
4 9 4
4 9 4
4 9 4
Stdc'fLfiFG C .C  A .A  G - G A G C T G G A A G A C C T S A A C A  
A / % C T  Ac G C C ‘A,  A  G  G A G  G T ' G  G A A  G A  d ' C  T ' G  A  Aii fi ^ # , & r f  T « i .â r ,  h
P D E 4B 2
P D E 4B 2
D E 4B 2
Figure 3.8 continued.
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Figure 3.9 Alignment of the predicted amino acid sequence for mouse, human and rat 
PDE4B2 (amino acids 1-174)
The predicted amino acid sequence of the amplified region of mouse PDE4B2 is shown 
aligned with the corresponding rat (GenBank accession number L27058) and human 
(GenBank accession number L20971) PDE4B2 sequences. Amino acid residues that match 
the mouse sequence are boxed. Upstream conserved region 2 (UCR2) and the first 42 
amino acid residues of the catalytic unit are shaded. This alignment was performed using 
the Clustal method (Higgins and Sharp, 1988) within the DNA Star programme 
(Lasergene).
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3.2.3 RT-PCR analysis of PDE4C
The splicing of the PDE4C mRNA is more complex than that for PDE4A, B and D. 
At the present time, seven human PDE4C clones have been isolated (Bolger et al., 1993; 
Obernolte et a l, 1997; Owens et a l, 1997) although PDE4C5-7 may be cloning artefacts 
(Sullivan et a l, 1999). The mRNAs that have been shown to encode naturally occurring 
HSPDE4C splice variants (HSPDE4C1-HSPDE4C4) are shown in Figure 3.10. At the time 
at which this study was carried out, only one PDE4C splice variant, PDE4C1, had been 
cloned from rat and human. Therefore, the primers used in this study were designed against 
rat PDE4C1 (rpde36) (Bolger et a l, 1994). The sequences and PCR conditions for these 
primers aie shown in Table 3.6. The amiealing positions of these primers on cDNA 
complementary to the rat and human PDE4C mRNA transcripts are shown in Figure 3.10. 
This diagram shows that this primer pair will detect all the known PDE4C splice variants.
This primer pair was used on 3T3 F442A cDNA. As a positive control, an identical 
PCR reaction was carried out using a plasmid encoding rpde36 (RNPDE4C1, (Bolger et 
a l, 1994)). Samples of the PCR reaction products were separated by agarose gel 
electrophoresis and visualised as before. The results from this RT-PCR analysis are shown 
in Figure 3.11. Again, no band was observed for the no-template negative control reaction 
(data not shown).
This PCR screen detected the presence of a DNA sequence complementaiy to a 
PDE4C transcript in 3T3 F442A cDNA. The band obtained co-migrated with the band 
obtained in the corresponding positive control reaction. There is a close correspondence 
between the predicted and observed molecular weight (MW) for this fragment as shown 
below in Table 3.5.
Table 3.5 Comparison of the predicted and observed molecular weights (in bp) for 
the PDE4C amplified PCR fragment.
PDE4C species Predicted MW (bp) Observed MW  (bp)*
Positive control 
(plasmid template)
3T3 F442A cDNA 
template
PDE4C1 390 378.9 ±2.2 379.7 ±2.8
* means of at least three sepamte experiments ± SE
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We can therefore conclude from this result that 3T3 F442A preadipocytes do 
express a PDE4C splice variant. This result was supported and extended by western blot 
analysis using a PDE4C-specific COOH-terminal polyclonal antibody as primary reagent 
(MacKenzie et al., 1998). This showed an immunoreactive band that co-migrated with a 
recombinant HSPDE4C2 standard (Owens et al., 1997). It was therefore concluded that 
3T3 F442A cells express a mouse homologue of PDE4C2.
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1Table 3.6 Table showing PDE4C RT-PCR primers used and conditions
P r im er Nucleotide F rag . Cycle conditions
fragment Size
S=Seiise, A = A ntisense amplified (bp) D A E 4
PDE 4C 
L27061
S
A
GS32
GS31
CCATGGCCCA GATCACTGGG CTG 
RGTCHGTGAA VACAGCVTCC ARDGC
857-1246 390 94°C 
1 min
SS'^C
80sec
72^'C
70sec 1
R = (A  or G); V= (A, C, or G); D = (A, G, or T) and H = (A ,C  or T). The GenBank 
accession number for the sequence of rpde36 (RNPDE4C1) used to design these ODN 
primers is given. The number of cycles carried out was again 40.
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Figure 3.10 Figure showing annealing position of RT-PCR primers used to probe 
PDE4C
3■0
!
GS32 GS31
This diagram shows the annealing positions for the RT-PCR primers on the cDNA 
.obtained by reverse-transcription of the mRNA transcripts for the four known human 
PDE4C splice variants. The key is the same as that described in the legend for Figure 3.2. 
Note that the translated regions of the mRNAs encoding the splice variants PDE4C1 and 
PDE4C4 are identical, because the nucleotide sequences of these mRNAs diverge 
immediately upstream of the initiator methionine codon. Note also that the unique NHg- 
terminal splice domain of HSPDE4C2 contains stop codons in all thi’ee reading frames. 
Therefore, translation of HSPDE4C2 starts at a methionine that is downstream of the splice 
junction.
I
3 Determination o f  the PDE4 splice variants expressed in mouse 3T3-F442A preadipocyte cells using the 114
reverse transcription polymerase chain reaction (RT-PCR) I
Molecular
weight standards 3X3 F442A
(bp)
i
1353
1078
872
603
310
281/271
194
control cDNA
Figure 3.11 RT-PCR analysis of PDE4C expressed in mouse 3T3 F442A preadipocyte 
cells.
3T3 F442A cDNA was used as a template in RT-PCR reaction for PDE4C. The primers 
used detected the presence o f the mRNA transcripts for any o f the four naturally occurring 
PDE4C splice variants (PDE4C1- PDE4C4). The positive control template used was 
pRPDE36 (RNPDE4C1). Samples (9ul) o f the positive control reaction products and the 
3T3 F442A cDNA template reaction products were separated by agarose (2%) gel 
electrophoresis, stained with ethidium bromide and visualised with a UV transilluminator. 
The molecular weight standards (in bp) are shown on the left. The predicted size o f the 
amplified fragment is 390bp.
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3.2.4 RT-PCR analysis of PDE4D splice variants and detection of the 
transcripts for murine PDE4D3, PDE4D4 and PDE4D5
The 3T3 F442A cDNA was again used in a PCR screen for PDE4D splice variants. 
There are five splice variants that have been eloned from rats and humans, PDE4D1-5. The 
primer pairs and the PCR reaction conditions used for the detection of these tliree PDE4D 
splice variants are shown in Table 3.7.
Note that a single pair of primers was used for the detection of both PDE4D1 and 
PDE4D2. As explained in the legend for Figure 3.12, PDE4D2 mRNA is obtained from 
PDE4D1 by deletion of an 86 nucleotide section, downstream of the PDE4D1 start codon 
(ATG). The primers GR8 and GR6 that anneal to either side of this deletion point, can 
detect both PDE4D1 and PDE4D2. The size of the amplified fragment obtained indicates 
whether the PDE4D1 or PDE4D2 transcript is expressed.
3.2.4.1 Design of PDE4D3-specific oligonucleotide primers
At the time when this study was carried out no PDE4D3-specific primer pair was 
available. Only a Tong form’ PDE4D-specific 5’ primer existed, GR5 (Kostic et al., 1997), 
which aimealed to a sequence found between the first and second splice junctions (see 
Figure 3.12). Therefore, I designed a new PDE4D3-specific primer, AP4 (Table 3.7) that 
would anneal to a section of the unique NHi-terminal splice region of PDE4D3. Mouse 
PDE4D3 has not yet been cloned. Therefore, the new primer was designed using sequences 
for rat and human forms of PDE4D3.
A number of factors relevant to the design of ODN primers were taken into 
consideration. Internal complementarity within the primer sequence, which might result in 
the formation of secondaiy structures, was avoided. The overall codon degeneracy of the 
amiealing site for the primer was kept as low as possible in order to minimise the 
possibility of mutations between species. This is because inter-species mutations are more 
likely in regions of high degeneracy, where more silent mutations can occur, which do not 
cause deleterious changes in the amino acid sequence of the protein. The primer was 
designed so that its melting temperature would be in the 60-65°C range o f the potential 3’ 
PDE4D antisense primers GR35, GR6 and SE 13 with which it could be used (see Table 
3.7). The AP4 + GR6 primer pair combination gave the strongest signal in pilot
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experiments using a plasmid control template (HSPDE4D3) and this combination was 
chosen for future studies.
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Table 3.7 Table showing PDE4D RT-PCR primers used and conditions
PD E4A
Species
P rim er 
S=Sense, A = A ntisense
N ucleotide
fragm en t
A m plified
F rag
Size
(bp)
Cycle conditions
D A E
PDE 4D S GR43“ C C (C /T )(C /T )T G A C T G  TTATCATGCA CACC 583-8 4 4 262 94°C 50°C 72°C
(generic) A GR35“ G A T C (C /T )A C A T C  ATGTATTGCA CTGGC 1 min 80sec 70sec
M 25342
PDE 4D1 S GR8 ACGTCAAGCT GGAGCATCTC GGC -85-313 398 94°C 58°C 72^0
M 25342 A GR6 CCTGGTTGCC AGACCGACTC ATTTCA 1 min 80sec 70sec
PDE4D2 S GR8 ACGTCAAGCT GGAGCATCTC GGC -233-79 312 94°C 58°C 72°C
M 25349 A GR6 CCTGGTTGCC AGACCGACTC ATTTCA 1 min 80sec 70sec
PDE 4D3 S AP4 ATTTTCCGTT CAGAAGGCAT TCCTGG 17-577 561 94°C 50°C 72'’C
L20970 A GR6 CCTGGTTGCC AGACCGACTC ATTTCA 1 min 80sec 70sec
PDE 4D4 S SE 10“’*’ AGCGCTACCT GTACTGTC 338-922 585 94^C 52°C 72°C
L20969 A SE 13“’*’ ACTTGTTGGA GGCCATCTCA C 1 min 70sec lOOsec
PDE 4D5 S 2779 CTGTTGCAGC ATGAGAAGTC C 109-793 685 94°C 52°C 72°C
AFO12073 A GR6 CCTGGTTGCC AGACCGACTC ATTTCA 1 min 70sec lOOsec
The ODN primers labelled GR-number were designed by Dr. G. Rena using the sequences 
for the rat homologues of the appropriate splice variants. The primers SE 10, SE 13 and 
2779 were designed by Dr S. Erdogan using the sequences for human homologues of the 
appropriate splice variants. The PCR reaction conditions aie presented as they were in 
Table 3.2 for the PDE4A-specific RT-PCR primers. The GenBank accession numbers for 
the sequences of the rat and human PDE4D splice valiants detected by the primer sets are 
given in the first column. The number of cycles carried out in each case was again 40. 
a = (Kostic et a l, 1997), b = (Bolger et a l, 1997)
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GR34 GR35GR62779D4
D5
SE13D3
AP4 GR8
D2
Figure 3.12 Figure showing the annealing positions of RT-PCR primers used to probe 
FDE4D splice variants
This diagram shows the annealing positions for the RT-PCR primers on the cDNA 
obtained by reverse-transcription of the mRNA transcripts for the five known PDE4D 
splice variants, PDE4D1 (D l) to PDE4D5 (D5). The key used is the same as that 
described in the legend for Figure 3.2. Note that a single primer pair (GR8 + GR6) is used 
for the detection of both PDE4D1 and PDE4D2. PDE4D2 mRNA is obtained from 
PDE4D1 mRNA by deletion of an 86 nucleotide section, downstream of the start codon 
(ATG). This results in a switch to a different reading frame, which prevents the expression 
of a functional PDE. Instead, translation of PDE4D2 is initiated from an ATG in the 
middle of UCR2. GR8 and GR6 anneal to positions on either side of the deletion point. 
The size of the amplified fragment obtained indicates whether the PDE4D1 or PDE4D2 
transcript is present, as shown in Table 3.7.
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3.2.4.2 Results for the RT-PCR analysis of PDE4D splice variants expressed in 
3T3 F442A cells
As positive controls, identical PCR reactions were carried out using plasmids 
encoding the appropriate PDE4D splice variants. Samples of the PCR reaction products 
were separated by agarose gel electrophoresis and visualised as before. The results from the 
RT-PCR analysis of 3T3 F442A cells are shown on the right o f Figure 3.13 next to the 
results for the positive control reactions, shown on the left. Again, no bands were observed 
for the no-template negative control reactions (data not shown).
Fragments of the expected sizes were obtained using 3T3 F442A cDNA for generic 
PDE4D and the splice variants PDE4D3, PDE4D4 and PDE4D5. The bands obtained using 
3T3 F442A cDNA co-migrated with the bands obtained in the corresponding positive 
control reactions. There is a close correspondence between tire predicted and observed 
molecular weights (MW) for these fragments as shown below in Table 3.8.
Table 3.8 Comparison of the predicted and obseiwed molecular weights (in bp) for 
the P0E4D  amplified PCR fragments.
PDE4D species Predicted MW  (bp) Observed MW (bp)*
Positive control 
(plasmid template)
3T3 F442A cDNA 
template
PDE4D (generic) 262 268.0 ± 4.3 274.9 + 6.2
PDE4D3 561 573.4 + 8.9 587.9 + 17
PDE4D4 585 634.0 ± 9.7 611.7 + 3.3
PDE4D5 685 706.8 ± 23 700.8+21
means of at least thr ee separate experiments ± SE.
The above result was supported by western blot analysis using a PDE4D-specific 
COOH-terminal polyclonal antibody as primary reagent (MacKenzie et al., 1998). This 
showed two immunoreactive bands that co-migrated with recombinant HSPDE4D3 and 
HSPDE4D5 (data not shown). From these independent analyses it was concluded that 3T3 
F442A cells express mouse homologues of PDE4D3 and PDE4D5.
No immunoreactive band co-migrating with the PDE4D4 standard (at 119 kDa)
was observed on the immunoblot of the 3T3 F442A cell lysate (MacKenzie et al., 1998),
even though RT-PCR analysis did detect a transcript for this splice variant (see Figure
3.13). It should be noted that western blotting analyses have a window of sensitivity. It may
be that the level of PDE4D4 expression was below the limit of detection of the antibody
used. It is possible that the expression of PDE4D4 is specifically regulated at the level of
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translation. Examples of this phenomenon of translational regulation include the iron (Fe)- 
dependent regulation of the mammalian Fe storage protein, ferritin (Walden et al., 1988; 
Walden and Thach, 1986) and the proteins of the Surf Clam oocyte before and after 
fertilisation (Rosenthal et al., 1980). In the former case, the translation of ferritin is 
inhibited by an Fe-binding protein which binds to the 5’ untranslated region of the feiritin 
mRNA. Upon binding soluble Fe atoms, this protein is released, which allows the 
translation o f ferritin. Translational regulation of protein expression allows rapid control of 
protein concentrations, without turnover of mRNA. In resting 3T3 F442A cells the 
expression of PDE4D4 could be inliibited at the level of translation. Certain signals or 
conditions might release PDE4D4 mRNA from this inhibition, which would allow a 
sudden increase in PDE4D4 activity. The above result for PDE4D4 underlines the need to 
back up the results of RT-PCR screening, which detect the transcripts for specific proteins, 
with western blot analysis, which detects the actual proteins themselves.
In conclusion, western blot analysis suggests PDE4D4 is not expressed in resting 
3T3 F442A eells or that it is expressed at a much lower level than PDE4D3 and PDE4D5. 
Therefore, PDE4D3 and PDE4D5 are the major species present in 3T3 F442A cells.
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standards (bp)
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1353
1078
872
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281/271
Plasmid control 3T3F442A cDNA
D4 D5D3 D4
Figure 3.13 RT-PCR analysis of PDE4D splice variants expressed in 3T3 F442A 
mouse preadipocyte cells.
The cDNA produced from total RNA extracted from 3T3 F44A cells was used as a 
template in an RT-PCR screen for PDE4D mRNA transcripts. The primers used were 
either generic primers for the detection o f all PDE4D splice variants (D), or splice variant 
specific primers for the detection o f PDE4D1 and PDE4D2 (D1/D2), PDE4D3 (D3), 
PDE4D4 (D4) or PDE4D5. The positive control templates used were pPDE79 for PDE4D, 
mouse brain cDNA for PDE4D1 and PDE4D2, pPDE43 for PDE4D3, pPDE39 for 
PDE4D4 and pPDE79 for PDE4D5. Samples (9ul) o f the positive control reaction products 
and the 3T3 F442A cDNA template reaction products were separated by agarose (2%) gel 
electrophoresis, stained with ethidium bromide and visualised with a UV transilluminator. 
The molecular weight standards (in bp) are shown on the left. Amplified product sizes 
were PDE4D (generic) =262bp, PDE4D1= 398bp, PDE4D2 = 312bp, PDE4D3 = 561 bp, 
PDE4D4 = 585bp and PDE4D5 = 681 bp.
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3.2.4.3 Sequencing of the PDE4D5 amplified fragment (nucleotides 109-309)
As further verification o f the above RT-PCR and western blotting results, the 
correct identity of the PDE4D5 PCR fragment was checked by sequencing as described in 
the Methods chapter, section 2.6.7. The nucleotide sequence that was obtained was 
deposited in GenBank (accession number AF038896). In Figure 3.14 this mouse nucleotide 
sequence has been aligned with the equivalent sequence from human PDE4D5 
(HSPDE4D5) and the nucleotide sequence of (rat) RNPDE4D3 (Bolger et a l, 1994) 
downstream of the first splice junction (RNPDE4D5 has not yet been cloned).
The mouse PDE4D5 nucleotide sequence is 93.2% identical to the human sequence 
and 95.8% identical to the rat sequence. All the nucleotide mutations are silent, so the 
predicted amino acid sequence is 100% identical to both the human PDE4D5 sequence and 
the available rat PDE4D sequence downstream of the first splice junction. This region of 
the amino acid sequence is shown in Figure 3.15.
This result confirms that mouse 3T3 F442A cells do express a mouse homologue 
of PDE4D5. The 100 percent conservation of sequence across the mouse, rat and human 
species suggests that this NHi-terminal region of PDE4D5 may perform one or many 
essential functions and any change to its structure cannot be tolerated. We already know 
that amino acids 22-77 of PDE4D5, upstream of the region sequenced here, are essential 
for binding to scaffold protein RACKl (Yarwood et al., 1999) (see Introduction chapter, 
section 1.8.5).
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Figure 3.14 Alignment of the nucleotide sequence for mouse and human FDE4D5 and 
rat PDE4D3
This figure shows the nucleotide sequence of the fragment amplified with PDE4D5- 
specific primers using mouse 3T3 F442A preadipocyte cDNA as a template. The ODN 
primer sequences at both ends of the PCR fragments have been excluded. The mouse 
nucleotide sequence (GenBank accession number AF038896) has been aligned with the 
corresponding human PDE4D5 sequence (nucleotides 130-757, GenBank accession 
number AFO12073) and the rat PDE4D3 sequence downstream of the first splice junction 
(nucleotides 67-554, GenBank accession number L27059). Bases that match the mouse 
sequence are boxed. The sections of nucleotide sequence corresponding to the regions 
encoding UCRl and part o f UCR2 are shaded. The domain structure for the splice variants 
PDE4D3 and PDE4D5 is shown at the top of the diagram. This alignment was performed 
using the Clustal method (Higgins and Sharp, 1988) within the DNA Star programme 
(Lasergene).
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Figure 3.14 continued
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Figure 3.15 Predicted amino acid sequence for mouse PDE4D5 (amino acids 44-255)
The GenBank accession number for this sequence is AF038895. The key for this figure is 
the same as that described in the legend for Figure 3.2. This alignment was performed 
using the Clustal method (Higgins and Sharp, 1988) within the DNA Star programme 
(Lasergene).
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3.2.5 Conclusions from RT-PCR screen of 3T3-F442A cells
From the above studies we ean eonclude that 3T3 F442A cells express the mouse 
homologues of PDE4A5, PDE4B2, PDE4D3, PDE4D5 and a PDE4C splice variant that is 
probably PDE4C2 as deduced from western blotting studies (MacKenzie et al., 1998). 
Therefore, 3T3 F442A cells are unusual in that they express splice variants from all four 
PDE4 genes A, B, C and D (Houslay et al., 1998; Muller et al., 1996). Although generic 
PDE4C has been detected in a few tissues, including brain, lung and kidney (Engels et al., 
1994; Houslay et al., 1998; Muller et al., 1996), the above study provides the first 
description of an endogenous PDE4C species using RT-PCR, western blotting and activity 
analyses [see above and (MacKenzie et al., 1998)],
Sequence analysis showed that the mouse homologue of PDE4A5 is more closely 
related to rat form (RNPDE4A5) than the human form in that it lacks the proline rich-insert 
present in the LR2 region of the latter. The sequence data for the mouse homologues of 
PDE4A5, PDE4B2 and PDE4D5 showed that the PDE4 splice variants are well conserved 
between rats, humans and mice.
3.3 PIMA, GH and wortmannin do not effect the levels of the generic PDE4A 
transcript in 3T3 F442A preadipocytes
As discussed in the introduction to this chapter, one of the initial observations in 
this study, reported by Dr MacKenzie, was a rapid (maximal at ~20-30min), transient 
increase in PDE4 activity caused by GH (MacKenzie et al., 1998). It was then shown that 
GH increased the PDE4A activity immunoprecipitated from the 3T3 F442A cells using 
anti“PDE4A COOH-terminal antisera to immunopurify and analyse PDE4 selectively. 
PDE4A accounted for almost half (47 ± 5%) of the PDE4 activity in these cells. My results 
for the RT-PCR screen for PDE4A splice variants (Figure 3.3) and western blotting results 
(MacKenzie et al., 1998) suggested that PDE4A5 was the sole PDE4A splice variant 
expressed in 3T3 F442A preadipocytes. Therefore, it appeared that GH specifically caused 
an increase in PDE4A5 activity.
Studies were carried out in order to determine the signalling pathway by which GH 
activates PDE4A5 activity. Early on in these investigations it was thought that protein 
kinase C (PKC) might be involved as this is activated downstream of the growth hormone 
receptor (see Figure 3.1, section 3.1.1). Another signalling protein, that is activated as a
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result GH stimulation, is phosphoinositide-3 kinase (PI3-kinase, see Figure 3.1), Dr 
MacKenzie showed that the PI3-kinase inhibitors, wortmannin and LY 294002, blocked 
the activation of PDE4A5 by GH. To corroborate this result. Dr MacKenzie showed that 
transfection of a dominant negative form of PI3-kinase (A p85 PI3-kinase) also ablated GH 
activation of PDE4A5. Therefore, it was concluded that GH activated PDE4A in a PI3- 
kinase dependent manner.
It was originally thought that GH might increase PDE4A activity by upregulating 
gene transcription, in a manner similar to the affect of TSH on PDE4D1 and PDE4D2 
levels in thyroid FRTL-5 cells (see Introduction chapter, section 1.6) (Conti et al., 1995; 
Sette et al., 1994; Swinnen et al., 1991). I used RT-PCR to investigate whether the PI3- 
kinase-dependent increase in PDE4A5 activity in 3T3 F442A cells was due to an increase 
in PDE4A transcription. I used the same technique to investigate whether the PKC 
activator, phorbol 12-myristate 13-acetate (PMA), would affect PDE4A transcription. The 
3T3 F442A cells were stimulated with GH (25nM) or PMA (25nM) in the presence and 
absence of wortmannin (2nM) for 30min before being harvested. These concentrations and 
incubation times were known to be optimal for the desired effects of these biochemical 
agents, described above. Equal amounts of RNA from these stimulated cells and control 
cells were used as templates for first strand eDNA synthesis reactions. In order to compare 
the levels of generic PDE4A transcript in control and treated cells, equal amounts o f the 
resultant cDNA were employed as templates in a PCR reaction using the PDE4A-specific 
primers (GR28 and GR29) used in the experiment presented in Figure 3.3, section 3.2.1. 
The conditions used for this PCR reaction are as shown in Table 3.2, section 3.2,1, As an 
internal control, ODN primers specific for the ubiquitously expressed p-actin (SE 14 +
SE 15) were included in this PCR reaction. Equal volumes of the PCR reaction products 
were separated on a 2% agarose gel and the bands were visualised by ethidium bromide 
staining and UV-transillumination. The levels of the PDE4A transcripts in the differently 
treated cells were assessed on the basis of the intensities of the PDE4A bands relative to 
the p-actin bands. The results are shown in Figure 3.16.
No changes in the level of the PDE4A transcript, relative to the p-actin transcript, 
were observed when 3T3 F442A preadipocytes were treated with GH, PMA or 
wortmannin. This suggests that GH does not cause an increase in PDE4A5 activity by 
increasing the rate of transcription. The results also indicated that the PI3-kinase inhibitor 
wortmamiin and the PKC activator, PMA had no effect on the PDE4A transcript levels.
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Therefore, we can conclude that wortmannin does not ablate GH activation of PDE4A 
through an effect on transcription. It was also later shown that the PKC inhibitor, 
chelerythrine chloride, had no effect on GH stimulation of PDE4A5 activity, suggesting 
that PKC is not involved in this pathway.
In agreement with these results, the transcriptional inliibitor, actinomycin D, failed 
to prevent GH from stimulating PDE4A5 activity (MacKenzie et al., 1998). The rapid 
(maximal at 10-20min) activation of PDE4A5 with GH is not consistent with an effect on 
transcription. In addition, western blotting analysis showed no change in PDE4A5 protein 
levels with GH (MacKenzie et al., 1998). These results suggest that GH activates PDE4A5 
via a post-translational modification. The lack of an effect on transcription suggests that 
STATs (signal transducers and activators of transcription; see section 3.1.1 and Figure 3.1) 
are not directly involved in the activation of PDE4A5.
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Figure 3.16 The intracellular level of the PDE4A transcript in 3T3 F442A cells is 
unaffected by GH, PMA or wortmannin treatment
As described in the Methods chapter, (section 2.1.4.1) confluent, serum starved 3T3 F442A 
preadipocyte cells were incubated for 30min with either GH (25nM) or PMA (25nM) in the 
presence or absence o f 2nM wortmannin, or were left untreated (C = result for untreated 
control cells). Immediately after this treatment, RNA was extracted, purified and used as a 
template for first strand cDNA synthesis as described in section 2.5 o f the Methods. Equal 
amounts o f the resultant cDNA were employed in a PCR reaction that contained a primer 
pair for the detection o f the PDE4A generic transcript and a primer pair specific for the p- 
actin transcript as an internal control. The PDE4A-specific primers were also used on 
mouse testicular cDNA (T) and RDI cDNA (pSVL-RDl) as positive controls. 9ul samples 
o f the PCR reaction products were separated on a 2% agarose gel containing 0.5pg/ml 
ethidium bromide and visualised by UV transillumination. The generic primer pairs used to 
detect PDE4A transcripts amplified a fragment o f 233bp, whereas the P-actin internal 
control primers amplified a fragment o f 466bp. The p-actin internal control primers had the 
following sequences SE 14 (sense) = CATCGTCACC AACTGGGACG AC, SE 15 
(antisense) = CGTGGCCATC TCTTGCTCGA AG. The above result is typical for this 
experiment which was carried out three times.
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CHAPTERS CONCLUSIONS
3.4 Discussion and conclusions
In sections 3.4.1 and 3.4.2 below I describe the final results of this collaborative 
study. In section 3.4.3 I discuss the implications of my results and offer suggestions for 
future work.
3.4.1 GH activation of PDE4A5 serves as a brake on the process of 
differentiation
At the start o f this study it was noted that inhibition of PDE4 activity with rolipram 
potentiated GH-induced differentiation of 3T3 F442A preadipocytes (see section 3.1.1) byly
approximat^two-fold (MacKenzie et al., 1998). Dr MacKenzie went on to show that 
specific ablation of PDE4A5, by antisense treatment, also promoted differentiation. This 
was done using an ODN primer designed to block the translation of PDE4A5 by binding to 
the first 18 nucleotides of the translated region of the PDE4A5 mRNA transcript.
Treatment of 3T3 F442A ceils with this ODN primer potentiated GH-induced 
differentiation, measured using the glycerol-3 -phosphate dehydrogenase (GPDH) assay.
These results suggest that the specific activation of PDE4A5 by GH acts as a brake on 
differentiation. The positive effect o f PDE4A5 inhibition on 3T3 F442A differentiation 
was almost equivalent to the effect of total PDE4 inhibition with rolipram (MacKenzie et 
al., 1998).
As discussed in section 3.1.1, a dual effector theory has been proposed for GH- 
promoted differentiation of 3T3 F442A preadipocytes (Yarwood et al., 1998; Zezulak and 
Green, 1986) in which GH-primed preadipocytes require a secondaiy signal such as insulin 
or IGF-1 to progress to the fully differentiated state. The results o f the above study suggest 
a model where GH holds 3T3 F442A cells in a primed state tlirough the use of PDE4A5 
activation. The secondaiy signals may act by blocking or inhibiting the pathway that 
transduces the GH-dependent activation of PDE4A5 or they may directly inhibit PDE4A5, 
to release the brake and allow full differentiation to progress. Alternatively, they may 
activate other signalling pathways that override the effect o f PDE4A5 activation. :
The 3T3 F442A preadipocytes have been shown to express PDE3 activity at levels 
equal to or greater than PDE4 (MacKenzie et al., 1998). Fuifhermore, the PDE3 specific
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iiiliibitor, cilostamide, partially ablated the GH-dependent drop in intracellular cyclic AMP 
levels (MacKenzie et al., 1998). However, PDE3 inhibition did not potentiate GH- 
dependent preadipocyte differentiation. This result is further evidence that PDEs regulate 
distinct pools of cAMP within cells that control separate processes (see Introduction 
chapter, section 1.2.1).
3.4.2 GH activates PDE4A5 via JAK2, PI3-kinase and p70S6 kinase
As mentioned above, GH-stimulation of 3T3 F442A cells causes a PI3-kinase- 
dependent increase in PDE4A5 activity. My RT-PCR analyses and Dr MacKenzie’s 
western blot analyses showed that this activation was not the result o f an increase in 
PDE4A5 expression. However, Dr MacKenzie showed that GH-stimulation of PDE4A5 
activity was accompanied by an upward band-shifi: for this protein on SDS-PAGE [see ref. 
(MacKenzie et al., 1998)]. This implied that the activation of PDE4A5 by GH might be the 
result o f a post-translational modification, such as a phosphorylation. The PI3-kinase 
inhibitors, wortmannin and LY 294002 and transfection of the dominant negative form of 
P13-kinase (A p85 PI3-kinase) blocked this band-shift. Having established the above. Dr S. 
Mackenzie and Dr S. Yarwood went on to identify the other components of the signalling 
pathway that mediated GH-dependent activation of PDE4A5 (MacKenzie et al., 1998).
A number of groups have shown that PI3-kinase activates p70S6 kinase (see Figure 
3.1, section 3.1.1) (Han et al., 1995; Proud, 1996; Weng et al., 1995). This activation is not 
direct, but is believed to be mediated by a protein called FRAP (FKBP12-rapamycin 
associated protein). The fungal macrolide rapamycin prevents activation by FRAP of 
p70S6 kinase (Brown et al., 1995). Rapamycin blocked both the band-shift and the 
activation of PDE4A5 by GH (MacKenzie et al., 1998). Rapamycin also blocked the GH- 
dependent increase in the intracellular concentration of cAMP. In addition, transfection of 
a constitutively active mutant form of p70S6 kinase into 3T3 F442A cells gave rise to GH- 
independent activation of PDE4A5. These results suggest that activated p70S6 kinase 
activates PDE4A5 in vivo. This activation is not necessarily direct.
It was further shown that JAK2 was an intermediate kinase in the GH-dependent 
activation of PDE4A5. Antisense ODN primers, that specifically blocked the expression of 
JAK2, ablated GH-dependent stimulation of PDE4A5 activity (MacKenzie et al., 1998). 
The conclusions of this study are that GH activates PDE4A5 in 3T3 F442A cells via JAK2,
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PI3-kinase and a p70S6 kinase. This pathway is illustrated in Figure 3.17. Specific 
activation of PDE4A5 in this way inliibits the process of differentiation.
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Figure 3.17 GH stimulates PDE4A5 via JAK2, PI3-kinase and p70S6 kinase.
Activation o f PDE4A5 by growth hormone has a negative effect on 3T3 F442A 
preadipocyte differentiation. The signalling pathway that has been established for the 
activation o f PDE4A5 by GH in 3T3 F442A cells is illustrated. The dotted lines indicate 
that each o f the activation steps in this pathway may occur through unidentified 
intermediary proteins. The points o f action o f the inhibitors used in this study are shown. 
The fungal macrolide rapamycin blocks the activation o f p70S6 kinase by acting on FRAP 
(FKBP 12-rapamycin associated protein). As discussed in chapter 5, section 5.2.2, 
rapamycin associates with the immunophilin protein FKBP 12. Rapamycin-FKBP 12 
complexes associate with FRAP and this prevents activation by FRAP o f p70S6 kinase 
(Brown et al., 1995). It is possible that other signalling pathways may act via FRAP to 
regulate the GH-dependent activation PDE4A5.
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3.4.3 Final conclusion and future work
My RT-PCR analysis showed that 3T3 F442A cells express a number of splice 
variants (PDE4B2, PDE4C, PDE4D3 and PDE4D5) in addition to PDE4A5. Unlike 
PDE4A5, these other splice variants do not appear to be involved in the negative effect of 
GH on 3T3 F442A differentiation. This is because PDE4A5 inhibition with antisense and 
total PDE4 inhibition with rolipram both potentiated GH-dependent differentiation to 
equivalent degrees. These results suggest that different PDE4 splice variants have distinct 
roles in 3T3 F442A preadipocytes as opposed to interchangeable functions that merely 
increase the redundancy of the PDE system. The other splice variants may be tai'geted to 
different locations within the cell where they control different intracellular pools of cAMP 
and different cAMP-dependent processes. An aim for future studies will be to define the 
roles for the other PDE4 splice variants in 3T3 F442A intracellular signalling.
We still need to establish the exact post-translational modification (e.g. 
phosphorylation event) that causes the upward band-shift for PDE4A5 on SDS-PAGE that 
is concomitant with PDE4A5 activation downstream of p70S6 kinase. This may uncover 
other mechanisms for controlling PDE4A5 activity and hence 3T3 F442A differentiation. 
In addition, it would also be interesting to assess whether similar' mechanisms for the 
control of differentiation occur in other cells where PDE4A5 is specifically expressed.
The post-translational modification of PDE4A5 may directly cause activation of 
this enzyme via a change in the conformation of its active site that facilitates the catalytic 
process. Alternatively, the post-translational modification may disrupt the interaction of 
PDE4A5 with an inliibitoi'y protein. Either process may cause a change in the subcellular 
location of PDE4A5. Therefore, it would be interesting to use immunofluorescence 
confocal microscopy to analyse the intracellular distribution of PDE4A5 before and after 
treatment of 3T3 F442A preadipocytes with GH. If GH did cause a change in PDE4A5 
localisation within the cells it would be of further interest to know the effect o f rapamycin 
(which inliibits p70S6 kinase) on this change. It would also be interesting to know whether 
the activation status of PDE4A5 and any change in its subcellular distribution were 
maintained in differentiated adipocytes.
%
:S
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CHAPTER 4
Studies on the association of PDE4 amino-terminal 
regions with the membrane fraction of COS-7 cells
i:
s
i:,-:
4. S tudies on the association of PDE4 amino-terminal regions 
with the m em brane fraction of COS-7 cells
CHAPTER 4 INTRODUCTION
111 this chapter I investigate the intracellular tai'geting of PDE4 splice valiants, via 
their unique NHz-termiiial regions. I have expressed the NHz-terminal regions of the rat 
PDE4A isoenzymes RNPDE4A1 (RDI) and RNPDE4A5 (rpde6) as fusions to the COOH- 
terminus of the soluble enzyme glutathione-^-transferase (GST) and I have tested the 
ability o f these constructs to interact with the P2-membrane fraction of COS-7 cells. In 
section 4.2 I demonstrate that the NHz-terminal 100 amino acids of RDI confer P2- 
membrane association on GST and that this association is disrupted by the non-ionic 
detergent Triton X-100. In section 4.3 .21 use GST constructs to show that just the NH2- 
terminal domain of rpde6 can associate with the membrane fraction and that the region 
between GlylOS and Lys256 is sufficient for this association. In section 4 .4 1 examine the 
association o f these PDE4 NH2-termini-GST fusions with heat-treated P2-niembrane 
fraction. These studies suggest that the NH2-terminal regions o f RDI and rpde6 interact 
with distinct components of the P2-membrane fraction with different thermal stabilities. In 
section 4.5 I discuss the above findings, and the potential use of GST-fusion proteins in 
further studies on PDE4 targeting and protein-proteiii interactions.
4.1 The NH2 -terminal splice domains of rpde6 and RDI isoenzymes 
determine their intracellular targeting
As discussed in the introduction (section 1.8) the NH2-terminal regions of PDE4 
splice variants are involved in intracellular targeting (Houslay et al., 1997; Houslay, 1996; 
Houslay et al., 1998). Studies have shown that the PDE4 splice variants within a particular 
subfamily, which differ only at their unique NH2-termini, show distinct modes of targeting 
in cells (Bolger et al., 1997; Huston et a l, 1997). For instance, immunofluorescence 
analyses showed that the rat PDE4A splice variant, RDI (RNPDE4A1) associated with the 
plasma membrane and intracellular vesicles of transfected COS-7 cells (Shakur et a l,
1995), whereas ipde6 (RNPDE4A5) associated with the cytoskeleton, particularly in the 
perinuclear region (Huston et a l, 2000). An NH2-terminal truncate Met^'^RDl, which 
consisted of just the rat PDE4A core unit, had a diffuse cytosolic distribution in ti’ansfected 
COS-7 cells. This suggested that removal the unique NH2-terminal regions abolished the 
association of PDE4A splice variants with the membrane and cytoskeleton. It has further 
been shown rpde6 can bind to the SH3 domains of Src-family tyrosyl kinases in contrast to 
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the other long PDE4A splice variant rpde39 (RNPDE4A6) (O' Connell et al., 1996). This 
suggests that splice variants ar e targeted to specific proteins by their unique NHi-terminal 
splice domains. The identification o f these targeting proteins is a major research aim.
Differences were also observed between the splice variants in terms of their 
distribution between the PI (low-speed pellet), P2 (high-speed pellet) and S (cytosolic) 
subcellular fractions of transfected COS-7 cells (see Methods chapter, section 2.11 for the 
definition of these fractions). Furthermore, the splice variants that associate with the 
particulate fractions differ in terms of the resistance of these associations to disruption with 
salt and detergent. For example, the association of both rpde6 and rpde39 (RNPDE4A6) 
with the P2-pellet fraction was resistant to high salt concentrations (NaCl) and the non­
ionic detergent Triton X-100 (Bolger et al., 1996; McPhee et al., 1995). This suggested that 
these splice variants associate with components of the cytoskeleton (Jackson et al., 1994; 
Slusarewicz et a l, 1994). RDI, in contrast, was dissociated from the P2-pellet fraction by 
Triton X-100 treatment, which suggested an interaction with a membrane protein or lipid
(McPhee et a l, 1995). The PDE4B and PDE4D splice variants also show marked
w ithdifferences in their ability to interac^the particulate fractions and the susceptibility of these 
interactions to Triton X-100 and high NaCl concentrations. These observations again 
suggest that the different unique NHa-terminal splice domains interact with different 
intracellular components.
One unanswered question is whether the targeting sequences of PDE4 enzymes are 
contained completely within their unique NHz-termini or whether sequences within the 
NH2-termini combine with sequences within the core region to form binding surface for 
interaction with the relevant targeting proteins. The ability o f the unique NHz-termini to 
target PDE4 isoenzymes can be tested by expressing these domains separately as fusions to 
essentially ‘soluble’ proteins that do not associate with the PI or P2 particulate fractions. 
This strategy was used successfully by Scotland and Houslay to show that the NH2- 
terminal 25 amino acid splice domains of RDI conferred membrane (high speed pellet) 
association on the soluble bacterial enzyme CAT (Scotland and Houslay, 1995) (see 
section 1.8.1).
In this chapter an alternative strategy was used where PDE4 NH2-terminal regions 
were expressed as fusions to the soluble protein glutathione-5'-transferase (GST) from 
Schistosoma japonicum  (Smith and Johnson, 1988). This protein has a self-contained 
globular structur e (Lim et a l, 1994). The COOH-terminus of GST is on the outside of the 
structure and peptides fused to this end are likely to be exposed for interaction with their 
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tai'get proteins or lipids. The GST tag also provides a means for the detection of these 
fusion proteins using anti-GST antibodies. GST-fusions have been used by a number of 
groups to define the membrane association domains of various proteins. For instance, 
Wang et al showed that the PH domain (as opposed to the Dbl-homology domain) of the 
metastasis-inducing Tiam-1 protein mediated the binding of this protein to brain 
membranes (Wang et al., 1997). Similarly, Plant et al used GST-fusions to show that the 
C2 domain of the ubiquitin protein ligase Nedd-4 was sufficient to mediate the Ca^”^- 
dependent association of this protein with cellular' membranes (Plant et al., 1997).
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1CHAPTER 4 RESULTS AND DISCUSSION I
vs
4.2 The NHa-terminal region of RNPDE4A1 (RD1) confers P2-membrane 
fraction association on the normally soluble GST
I began by investigating whether the NHi-terminal region of RDI could confer 
membrane (high-speed pellet) fraction association on GST. COS-7 cell membranes were 
used as this was the original cell line used to characterise both rpde6 and RDI (McPhee et 
a l, 1995; Shakur et al., 1993; Shakur et al., 1995). A plasmid (pGS31) was prepared that 
expressed the NHz-terminal 100 amino acids region of RDI as a fusion to the COOH- 
terminus of GST. The structure o f this GST-RDE’^^  ^construct is illustrated in Figure 4.1. 
The first 100 amino acids of RDI includes the unique 25 amino acid splice domain, the 
second half of UCR2 and a segment of the core region up to the first 4 amino acids of the 
catalytic unit.
4.2.1 Purification of GST-RDI^ ’”"
This fusion protein was purified using the column purification method and eluted 
with glutathione buffer as described in the Methods chapter (section 2.7.2). The purified 
preparation was analysed by SDS-PAGE and Coomassie staining (see Figure 4.2). GST 
alone was similarly over-expressed, pui'ified and analysed by SDS-PAGE (see Chapter 5, 
section 5.4, Figure 5.9). The observed molecular weight for GST-RDl^"^^^ (38.1 ± l.OkDa, 
[mean ± SE, n=3]), was close to its actual molecular weight calculated from its sequence 
(39.0kDa). In addition to the bands corresponding to the full-length fusion proteins, there 
were a number of lower molecular weight bands in the ~25-32kDa range. These bands may 
be the result of the proteolytic degradation of the RDI section of this fusion protein. Only a 
few of these bands ran below the obseiwed molecular weight for the GST tag (~27kDa), 
which is relatively resistant to proteolytic degradation (Harris, 1998).
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(PDE4A6ri UCR1 UCR2 Catalytic unitrpde6" gg i_i | -----------------------
(PDE4A5)
fPDE4A1\/
■'amino acids 1-1Ù0
N H 2- ( n S i T ) — C ) ~ M  GST-RD11-100
Figure 4.1 GST-RDl* '"'’ fusion protein
This figure illustrates the NHi-terminal region of RDI expressed as a fusion to the COOH- 
terminus of GST (GST-RDT"^°^). The other rat PDE4A splice variants, rpde6 and rpde39, 
are also shown in this diagram. The unique NHi-terminal splice domains are indicated by 
the thinner black lines. The circles represent the positions of the splice junctions. Grey and 
white rectangles represent the UCR and catalytic regions, respectively.
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Figure 4.2 Over-expression and purification of G ST -R D l‘*‘®®
Samples (<60pg protein) from different stages o f the glutathione Sepharose column 
purification process (see section 2.7.2.2) were separated by SDS-PAGE (10%[w/v] 
acrylamide) and stained with Coomassie blue. C = crude bacterial lysate; P  = pellet and 
S'/A = supernatant after sonication and centrifugation; FT1/FT2 =  Flow through 1 and 2 
after passing the sonicated supernatant through the column twice. W  = complete PBS wash. 
E l-4 =  elutions with glutathione buffer. The observed molecular weight o f full-length GST- 
RDl on SDS-PAGE was 38.1 + 1.0 (mean ± SE, n=3), which corresponds closely with 
its calculated molecular weight o f 39.0kDa.
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4.2.2 Binding of GST-RD1^"^°°to P2-membrane fraction of COS-7 cells.
Purified GST-RDT'^^° and GST (control) were incubated with the P2-pellet 
fraction of untransfected COS-7 ceils. This P2-pellet fraction was obtained by high-speed 
(100,000g) centrifugation of the supernatant obtained from a low speed (lOOOg) 
centrifugation of cell homogenate [as described in the Methods, section 2.11 and in 
(Shakur et al., 1995)]. The P2-pellet fraction contains plasma membrane, Golgi, ER and 
lysosomal membranes and cytoskeletal components (Jung and Moroi, 1988; Scotland et al.,
1998). Therefore, from now on this fraction will be referred to as the P2-memhrane 
fraction.
After incubation with GST-fusion protein, the P2-membrane mixtures were 
subjected to high-speed centrifugation as described above to obtain membrane pellets and 
supernatants (SI), containing unboimd fusion protein. The membrane pellets were then 
washed by resuspension in complete KHEM buffer with or without the non-ionic detergent 
Triton X-100 (1% v/v). The mixtures were then centrifuged again at high-speed to obtain 
membrane pellet (P) and supernatant (S2) fractions. Samples of the pellet and supernatant 
fractions were then separated by SDS-PAGE and immunoblotted with anti-GST antisera as 
the primary reagent.
As shown in Figure 4.3, full-length GST-RDl does indeed become associated 
with the P2-membrane fraction of COS-7 cells: a single immunoreactive band was 
observed in the bound fraction (P, lane 1) after washing with KHEM. This band co­
migrated with an immunoreactive band in the unbound fraction (SI) running at the 
expected molecular weight for GST-RDl*"^^^ (~39kDa). This association was resistant to 
washing with the KHEM buffer as no immunoreactive band was observed in the resultant 
supernatant (S2) from this wash. In contrast, GST did not appear to associate with the 
membrane pellet (P, lane 7) under these conditions, but was present in excess in the 
unbound fraction (SI, lane 8). Therefore, the NHz-terminal 100 amino acids of RDI appear 
to confer membrane association on the normally soluble GST.
My results on the membrane association of GST-RDl agree with the findings 
o f Scotland and Houslay who showed that the NH2-terminal 25 amino acid splice domain 
of RDI conferred membrane association on CAT (Scotland and Houslay, 1995). However, 
in this CAT construct the RDI splice domain was fused to the NHz-terminus of CAT. In 
contrast, in the GST~RDT"^®° construct used in my experiments, the 100 amino acid NH2- 
terminal region of RDI was fused to the COOH-terminus of GST (see Figuie 4.1).
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Therefore, I have shown that the NHz-terminus of the RDI splice domain does not have to 
be free for this region to associate with the membrane fraction. This is significant, as it 
suggests that the RDI splice domain does not interact with the membrane via the direct, 
transmembrane insertion of its extreme NHi-terminus into the lipid bilayer, as the NH2- 
terminal GST tag would prevent this. However, if the NH2-terminal splice domain can 
bend to form a hairpin structur e, hydrophobic sequences within this domain could be 
presented in a way that allows their interaction with the membrane bilayer (discussed 
below).
Figure 4.3 also shows that the association of GST-RDT“^ ^^  with the P2-membrane 
fraction is disrupted by non-ionic detergent. After just one wash with 1% Triton X-100, 
GST-RDl appears in the supernatant (S2, lane 6) in contrast to the supernatant 
obtained after washing with KHEM buffer alone (S2, lane 3). In addition, the amount of 
GST-RDl associated with membrane pellet after washing with Triton X-100 is clearly 
less than that associated with the membrane pellet after washing with complete KHEM. 
These results suggest that the association of RDI with P2-membrane fraction is 
predominantly mediated by hydrophobic (and not electrostatic) interactions. This agrees 
with studies showing the dissociation of both RDI (Shakur et al., 1995) and an RDI (1-100 
amino acid)-CAT construct (Scotland and Houslay, 1995) from the particulate fraction of 
transfected COS cells in the presence of low concentrations of this non-ionic detergent.
This observation did not answer the question of whether RDI interacts with a membrane 
lipid or protein, as both interactions could be mediated by weak hydrophobic forces.
In an attempt to answer the latter question, an analysis o f the structure o f this NH2- 
teiminal splice domain has been carried out by ^H-NMR (Smith et al., 1996) (see 
Introduction, section 1.8.1). Smith et al showed that this splice domain consists o f two 
helical regions separated by a hinge. The first helical region, Leu3-Cysl 1, is amphipathic 
in nature, and contains the polai' residues Asp5, Cys8, Glu9, ThiiO, and Cysl 1. The 
second of these helical regions, Prol4-Lys24 contains a compact unit of hydrophobic 
residues, Prol4-Trp20, shown to be necessary for membrane association (Smith et al.,
1996). The overall structuie of the RDI NFH-terminal splice domain suggests that it could 
form a hairpin conformation that could present the hydr ophobic region for an interaction 
with the membrane bilayer. This agrees with my finding that the membrane association of 
the RDI NH2-terminal region was not prevented by an NH2-terminal GST tag (see above).
As shown in Figure 4.3, the unbound fractions (SI, lanes 2 and 5) contain a number 
o f immunoreactive bands that rim below the band corresponding to full-length GST-RDl 
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(main ones indicated with arrowheads). These bands probably represent the products of
the proteolytic degradation of GST-RDT"'^”. The fact that these bands are immunoreactive
suggests that they represent COOH-terminal truncates of GST-RDl where theNH2- 
.terminal domain of RDI has been partially removed (see schematic diagram of GST-RDl 
in Figure 4.1). The bands at -29kDa (lower arrowhead) are just above the molecular 
weight of GST (SI, lanes 8 and 11), which suggest that the RDI 100 amino acid NH2- 
terminal region has been almost entirely removed. As Figure 4.3 shows, thèse degradation 
products do not associate with the F2-membrane fraction (P, lanes 1 and 4). Therefore, this 
suggests that the disruption of the RDI NH2-terminus prevents the membrane association 
ofGST-RDT"^®®.
GST
62 
4 7 . 5 - ^
GST‘RDP-^00^ 
Observed mw  
=  40.2 kDa
32.5“ ^
25
1 2 3
No Triton
P S1 S2
4 5 6
1 % Triton
P S1 S2
7 8 9 
No Triton
P S1 S2
10 11 12
1 % Triton
P S1 S2
GST
Observed mw  
=  26.5kDa
Figure 4.3 The NHz-terminal 100 amino acids of RDI confer P2-membrane 
association on the normally soluble GST.
Samples (200pg) o f the P2-membrane fraction o f COS-7 cells were completely 
resuspended in 200pl complete KHEM buffer containing either purified GST-RDT'*^^ or 
purified GST (50pg/ml) and incubated on ice for Ih. After incubation these mixtures were 
subjected to centrifugation at 100,000g for 30min. The unbound fractions (SJ)  from this 
first centrifugation step were retained. The pellets were then washed once by resuspension 
in complete KHEM buffer with or without 1% Triton X-100. These mixtures were then 
centrifuged before to yield a second supernatant fraction (S2). All three fractions, S I, P  and 
S2  were resolved by SDS-PAGE [10% (w/v) acrylamide], transferred onto nitrocellulose 
and immunoblotted with anti-GST antisera as primary reagent (see Methods chapter, 
section 2.10, Table 2.10 for the details o f this antibody). Arrowheads indicate the products 
of GST-RDl proteolytic degradation.
The molecular weight standards (in kDa) are shown on the left. The molecular weight o f  
GST-RDl predicted from its amino acid sequence is 39.0 kDa.
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4.3 The NHa-terminal region of rpde6 confers P2-membrane fraction 
association on the normally soluble GST
As discussed above, studies have suggested that the NHi-terminal region of rpde6 
(RNPDE4A5) is responsible for the intracellulai' targeting of rpde6 and its association with 
the particulate fractions of COS-7 cells. This hypothesis had not been tested directly.
Therefore, I expressed the entire 256 amino acid NHi-terminal region of rpde6 as a fusion 
to GST. I then tested this construct for association with the P2-membrane fraction of COS- 
7 cells. The precise location of the membrane-targeting region within the NH2-terminus of 
rpde6 was investigated further by expressing the region Leul03-Lys256 as a fusion to 
GST. This is the region of NH2-terminus of rpde6 that is shared with the other long rat 
PDE4A splice variant, rpde39 (RKPDE4A6).
4.3.1 Purification of GST-rpde6’'^ ®* and GST-rpde6^“ '^ ®®
A schematic diagram of the constructs GST-rpdeô'”^ ^^  and GST-rpde6'° '^^^  ^is
shown in Figure 4.4. These GST-fusions were over-expressed and purified as described in 
the Methods (section 2.7.2). Samples taken at various stages o f the purification process 
were analysed by SDS-PAGE and Coomassie staining (Figure 4.5). The observed 
molecular weights for GST-rpde6 “^^ ^^  (56.2 ± 1.7) and GST-rpde6 ®^^“^ ^^  (46.6 ± 0.5) were 
close to their actual molecular weights calculated from their sequences (55.4kDa and 
44.0kDa,respectively). In the purification of GST-rpde6 '^^ ^^  a number of molecular weight 
bands were observed particularly in the 27-34kDa range which are probably the products of 
the proteolytic degradation of GST-rpde6 '^^ ^^ .
i'
i
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Figure 4.4 GST-rpdeô -^^^*  ^and GST-rpde6^^^ ^^  ^fusion proteins
This figure illustrates the NHi-terminal regions of rpde6 (RNPDE4A5) that were expressed 
as fusions to the COOH-terminus of GST. GST-rpdeô '^^^*" contains the entire NHz-
terminus to the core region. GST-rpde6^^ ’^^ ^^  contains the part of the NHz-terminus of 
rpdeô, from the first to the second splice junction, that is shared with rpde39 
(RNPDE4A6). The key to this diagram is the same as that used in Figure 4.1.
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Figure 4.5 Purification of GST-rpde6‘’^ ^^  and GST-rpdeô'^^^^^
The fusion proteins GST-rpde6''^^^ and GST-rpde6*^^‘^ ^^  were routinely over-expressed 
and purified on glutathione Sepharose using the ‘batch’ methods (see section 2.7.2). 
Samples (<60pg) were separated by SDS-PAGE and visualised by staining with 
Coomassie. C= crude bacteria, P =  sonicated pellet, S/N =  sonicated supernatant, U= 
supernatant containing unbound protein after incubation with glutathione Sepharose beads. 
W= PBS wash , E l-2= elutions with glutathione buffer. Curly brackets indicate possible 
proteolytic degradation products (See discussion on the purification o f [GST-RDl'
(section 4.2.1)].
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4.3.2 Binding of GST-rpde6 and GST-rpde6 to P2-membrane 
fraction of COS-7 cells
These constructs were tested for association with the P2-membrane fraction using 
the same method that was used for GST-RDl in the previous section. Samples of 
purified GST-rpde6 "^^ ^^  and GST-rpde6^^ "^^ ^^  were incubated with samples of the P2- 
membrane fraction o f COS-7 cells. The P2-pellets were washed several times with 
complete KHEM buffer. They were then separated by SDS-PAGE, transferred onto 
nitrocellulose and immunoblotted using anti-GST as primary reagent (Figure 4.6). Samples 
of each of the purified proteins were run alongside the appropriate pellets to confirm that 
the immunoreactive proteins in the bound fraction ran at the correct molecular weight. The 
lanes for the bound fractions (B) in Figure 4.6 show that both GST-rpde6*^ "^^ ^^  and GST- 
rpdeb’"^ ^^  associated with the P2-membrane fraction. The association of these two GST 
fusions was resistant to repeated washing with KHEM. In contrast GST showed no 
association after just one wash with KHEM buffer (see Figure 4.3, P, lane 7). The 
immunoreactive bands for GST-rpde6 ®^^"^ ^^  and GST-rpde6 '^^ ^^  in the bound fractions (B) 
co-migrated with purified protein standards (Sta) at observed molecular weights of 46.6 ±
0.5 and 56.2 ± 1.7 respectively (mean ± SE, n=3).
Therefore, these results indicate that the NHi-terminus of rpde6 can target the
normally cytosolic GST to the high-speed P2-membrane fraction of COS-7 cells.
Furthermore, these results suggest that the region from residues Leu 103 to Lys256 in rpde6
is sufficient for membrane association and that the unique NH2-terminal splice region and
the core region are not necessaiy for this association. Unfortunately, studies on the
membrane association of the unique NH^-terminal splice domain of rpdc6 were prevented
by the susceptibility of the GST-rpdeô’"^"* construct to proteolytic degradation.
.Intriguingly, the 103-256 region of rpde6 contains UCRl, which is shared by all
'long PDE4 splice vai'iants. It should be noted that all the long forms that have been 
analysed so far associate with the particulate fractions, PI and P2, o f transfected COS-7 
cells, to varying degrees (Bolger et al., 1997; Bolger et al., 1996; Huston et al., 1997). In 
addition to the UCRl region, there is a ~25 amino acid region upstream of UCRl, 
extending from GlylOS-Alai 32 in rpde6, that is moderately conserved in a number o f long 
forms (see Figure 4.7) (Houslay et al., 1998). Either or both of these regions may contain 
targeting motifs for association with P2-membrane proteins.
-
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Interestingly, studies have shown that a deletion mutant o f rpdeô (Ap7 rpdeô), 
which lacks the NHz-terminus to the start o f UCR2 (Ser218 in Figure 4.7), associated with 
the P2-membrane fraction of transfected COS-7 cells (Beard and Houslay, unpublished). 
However, Met^^RDl, which was truncated to the RDI splice junction, half way thiough 
UCR2 (see Figure 4.1), was completely soluble. These results suggested that a motif within 
the NH2“terminal half of UCR2 (amino acids 218-256) was sufficient for P2-membrane 
fraction association.
However, this theoiy is not supported by the lack of particulate fraction association 
shown by the short splice variant HSPDE4D1 (Bolger et al., 1997) and human PDE4A 
truncated species HSPDE4A4C (hô.l) which have complete UCR2 regions (McPhee et al.,
1999). The conformations of tliese particular splice domains may hide the proposed 
UCR2 membrane-association domains. Alternatively, other sequences upstream of the 
NHi-terminal half of UCR2 mediate the P2-membrane fraction association.
It has previously been shown that the association of rpdeô with the high-speed P2 
pellet fraction of COS-7 cells is resistant to washing with a combination of high salt 
concentrations and Triton X-100 (McPhee et al., 1995). The Triton X-100-insoluble high­
speed pellet represents the cytoskeletal fraction. (El Benna et al., 1999; Jung and Moroi, 
1988; Perrot-Applanat et al., 1992; Yan et al., 1995). Therefore, these results suggest that 
rpdeô interacts with a component o f the cytoskeletal fraction of transfected COS-7 cells. If 
the region between amino acid residues 103 and 256 in rpdeô is responsible for P2- 
membrane fraction association it is possible that this region associates with a cytoskeletal 
protein. However, BLAST analysis of this region, using the SWÏSPROT database, did not 
reveal any significant sequence similarities with other proteins, except with other PDE4 
splice variants. Therefore, this does not give us any insight into the nature of the interacting
. ::=Vprotein.
4 Studies on the association o f  PDE4 amino-terminal regions with the membrane fraction o f  COS-7 cells 151
103-256 1-256
Sta B Sta B
5 8  — >
m#»— K 0^*0 #  G ST -rpdeÔ '^ '^^^
Observed MW=48.5  ^  56.2kDa
G S T “rp d e 6 ^ o ^ -2 ^ ^ ^
Observed MW=46.6kDa
Figure 4.6 The NHz-terminal 256 amino acids of rpde6 confer P2-membrane 
association on the normally soluble GST.
Samples of the P2-meinbrane fraction of COS-7 cells were resuspended to a concentration 
of Img/ml protein and incubated with purified GST-rpde6 '^^ *^^ , or GST-rpde6 ®^^"^ ^^  
(50pg/ml) as described in the legend for Figure 4.3. After incubation, the P2-membrane 
pellets were recovered by centrifugation and washed three times in complete KHEM buffer 
(see Methods, section 2.13). The pellet fractions (B) were tlien resolved by SDS-PAGE 
[10% (w/v) acrylamide], transferred onto nitrocellulose and immunoblotted with anti-GST 
antisera as primaiy reagent (see Methods chapter, section 2.10, Table 2.10). As a positive 
control, samples of the purified GST-fusion proteins (Sta) were separated alongside the 
bound fractions.
The molecular weight markers (in kDa) are shown on the left. GST-rpde6 '^^ *^' and GST- 
rpdeô^ ^^ '^ ^*^  have calculated molecular weights of 57.3 and 46kDa respectively.
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4.4 The NH2 -terminal regions of rpde6 and RD1 interact with components of 
the P2-membrane fraction that exhibit different thermostabilities.
The thermal-stabiiities o f the components of the P2 fraction that interact with the 
NH2"terminal regions of rpdeô and RDI were investigated. This was does in order to gain 
further insight into the natui'e of these targeting components, which could be lipids or 
proteins. Therefore samples of the P2-membrane fraction were treated at 50°C for varying 
periods of time. This temperature was chosen as a being suitable for the dénaturation of 
proteins as it had previously been shown to completely inactivate RDI catalytic activity 
over a period of 30min (Shakur et al., 1993). The heat-treated P2 samples were incubated 
with the fusions GST-rpde6*'^ ^^  and GST-RDT'^^® as described above (sections 4.2.2 and 
4.3.2). The P2~pellets were then washed several times prior to separation by SDS-PAGE 
and immunoblotting with anti-GST antisera in order to determine the relative amounts of 
fusion protein bound to each of the samples.
As shown in Figm'e 4.8 heat-treatment of the P2 fraction caused a marked decrease 
in the association of GST-rpde6 “^^ ^^ . This suggested that the component(s) of the P2- 
membrane fraction that associated with GST-rpdeô^'^^^ were denatured at 50°C. 
Quantitative analysis of the western blots by densitometry indicated that the half-life of 
dénaturation of these component(s) was ~23min (see Figure 4.9). The above results support 
the hypothesis that the NH2-terminus o f rpdeô associates with the P2-membrane fraction by 
interacting with one or a number o f proteins that are susceptible to thermal dénaturation.
In contrast. Figure 4.8 and Figure 4.9 show that no general decrease was obseiwed 
in the associatioij^GST-RDT"^^^, even after incubation of the P2-membranes at 50°C for 
2h. This suggests that RDI interacts with a relatively thermostable component of the P2- 
membrane fraction, possibly a lipid.
Panel B  in Figure 4.8 provides further evidence that the NHg-terminus of rpdeô is 
essential for membrane association. On this immunoblot, a sample of the purified 
preparation o f GST-rpdeô*'^^^ had been run for comparison (Sta). The 25-33kDa 
immunoreactive bands probably represent truncates of GST-rpde6 ”^^ ^^  where the rpdeô 
section of GST-rpde6 "^^ ^^  has been degraded by bacterial proteases during the purification 
process. It should be noted that in contrast to the full-length GST-rpde6 '^^ ^^  ^which runs at 
~56kDa, the 25-33kDa degradation products do not bind to the P2-membrane fraction. 
Therefore, this further confirms that an intact rpdeô NFIi-terminal region is necessaiy for 
P2-pellet association.
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Figure 4.8 Heat treatment of the P2-membrane fraction reduces the binding of GST- 
rpde6'‘^ “  but not GST-RDl
Equal samples (200pg) of the COS-7 cell P2-membrane fraction were resuspended in 
complete KHEM buffer and incubated at 50°C for the indicated periods o f time (in mins). 
The P2 fractions were then pelleted by centrifugation (100,000g, 30min, 4°C) and 
resuspended in 50pg/ml o f either /t GST-RDl or B GST-rpdeb''^^^ as described in the 
legend for Figure 4.3. After incubation for Ih on ice, the pellets were washed 3 times in 
complete KHEM buffer prior to separation by SDS-PAGE [10% (w/v) acrylamide] and 
transferred onto nitrocellulose. The relative amounts o f GST-fusion protein associated with 
the membrane samples were analysed by immunoblotting with anti-GST antisera as 
primary reagent. In panel B purified GST-rpdeb’’^ ^^  {Sta) was also immunoblotted for 
comparison.
GST-rpde6*‘^ ^^  and GST-RDl have calculated molecular weights o f 55.4 and 39.0kDa 
respectively.
These results are typical o f an experiment repeated three times for GST-rpde6*‘^ ^^  and 
twice for GST-RDl'"'T
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Figure 4.9 Quantitative analysis of the association of GST-rpdeô^ "^ *^’ and GST-RDl*" 
***“ with heat (50°C) treated P2-membrane fraction
Immunoblots as shown in Figure 4.8 were scanned and analysed using Kodak imaging 
software. The net intensities of the immunoreactive bands were used to calculate the 
relative association of A GST-RDl and B  GST-rpde6*"^ ^^  with the 50°C-treated P2- 
membranes. The binding values were expressed as a percentage of the association with 
untreated P2-membranes. The plots shown are of Log (% association) against incubation 
time. The half-life of dénaturation for the targeting component that binds to GST-rpdeb*'^^*  ^
was calculated as the treatment time that gave 50% association (NB. Log [50%] = 1.7). 
These results are typical of an experiment repeated three times for GST-rpdeb*"^ '^^ and 
twice for GST-RDl
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CHAPTER 4 CONCLUSIONS
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4.5 Discussion and conclusions
This study has shown that fusions of the NH2"terminal regions o f PDE4 splice 
variants to GST can be used as tools for analysing potential high speed P2-membrane 
association domains. The advantages of this method are that the GST fusion proteins can 
be prepared and purified easily and these constructs can be readily detected using anti-GST 
antisera. In this way different regions of PDE4 splice variants can be assessed for 
membrane-association in isolation from the rest o f the protein. Using this method, both the 
NHa-terminal 100 amino adds of RDI and amino acids 103-256 within the NHz-terminal 
region of rpde6 were shown to be sufficient for P2-membrane association.
A potential disadvantage of using GST-PDE4 fusion proteins to assess membrane 
binding was the susceptibility of the PDE4 paits of these fusions to degradation by 
bacterial proteases. However, the proteolytic degradation products o f GST-RDl and 
GST-rpdeô '^^^*^ failed to associate with the P2-membrane fraction in contrast to the full- 
length fusion proteins. This provided further evidence that the NHi-terminal domains of 
rpde6 and RDI were necessary for P2-membrane fraction association. Therefore, in this 
case the presence of proteolytic degradation products was an advantage.
The NH2-terminus of RDI was able to associate with the P2-membrane fraction 
even though it was fused to the COOH-terminus of GST. Therefore, this result suggested 
that the RDI NH2-terminus does not have to be free to mediate P2-membrane fraction 
association.
The region Leul03- Lys256 within the NHa-terminal region of rpde6 (RNPDE4A5) 
is shared with the other long rat PDE4 splice variant rpde39 (RNPDE4A6). Both these 
splice variants interact with P2-membrane fraction in a manner resistant to detergent and 
high [NaCl]. The results of my study suggest that the 103-256 region mediates interaction 
with the P2-membrane fraction, rather that the unique NH2-terminal regions of rpde6 and 
rpde39. It should be noted that the unique NH2-terminal splice domain of rpde6 contains 
the putative SH3-domain binding motifs that are believed to mediate the interaction of 
rpde6 with the SH3 domains of Src-family tyrosyl kinases (O' Connell et ah, 1996). 
Therefore, rpde6 may form a complex with both a membrane-fraction targeting protein via 
region 103-256 and an SH3-domain containing protein via its unique NH2-terminal splice 
domain.
This chapter has also shown that the analysis of the binding o f these GST fusion 
proteins with heat-treated P2-membrane fractions could be used to assess the relative 
thermostabilities of the P2-membrane components that interact with the PDE4 isoforms in 
question. This method provides a means for determining the half-life of dénaturation of the 
unknown targeting components. A 50°C treatment of the P2-membrane fraction had no 
effect on the association of GST-RDl but reduced the binding of GST~rpde6*"^ ^^ . This 
implied that the NHa-terminus of RDI interacted with thermostable component(s) of the 
P2-membrane fraction. In contrast the component(s) that interacted with the NHi-terminus 
of rpde6 were denatured at 50°C with a half-life of 23min.
The thermostable natm*e of the targeting component that binds to RDI suggests that 
it might be a lipid. However, rather than having a imiform association with all cellular 
membranes, RDI has a specific subcellular distribution pattern, whieh differs according to 
the cell type. In follicular thyroid carcinoma cells RDI was observed to associate mainly 
with the Golgi apparatus (Pooley et a l, 1997). This was also observed in COS-7 cells, but 
in the latter cell type a major fraction of RDI was found to be associated with punctate 
vesicular structures (Shakur et a l, 1995). If the target for RDI interaction is a lipid, this 
lipid must have a non-uniform distribution within cellular membranes. Evidence has
gaccumulated for the existence of lipid microdomain^in cells (Brown and London, 1998). 
For instance lateral clusters of lipid cholesterol and sphingolipids called rafts have been 
shown to occur. These form specific associations with integral membrane proteins such as 
the IgE receptor in mast cells (Holowka et a l, 2000) and the T-cell receptor in T- 
lymphocytes (Janes et a l, 1999) and they affect downstream signalling from these 
receptors. It is possible that RDI specifically interacts with a similar type of lipid 
micro domain. An alternative explanation for my results is that RDI is interacting with a 
thermostable protein.
The tliermal-denatui ation of the P2-membrane fraction component that interacts 
with GST-ipde6*‘^ ^^  agrees with the subcellular fractionation studies and 
immunofluorescence microscopy studies that suggest that rpde6 is targeted to a 
cytoskeletal protein (Huston et a l, 2000). Components of the cytoskeleton are Icnown to be 
present in the P2-membrane fraction (El Benna et a l, 1999; Jung and Moroi, 1988; Perrot- 
Applanat et a l , 1992; Yan et a l, 1995).
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4.5.1 Suggestions for future work
The next step in this investigation is to identify the precise molecular components
within the P2-membrane fraction that interact with these PDE4 splice variants. In the
search for protein-interaction partners, a major problem that needs to be addressed is the
insoluble nature of the P2-membrane fraction. Note that the interaction of rpde6 with the
P2-membrane fraction is resistant to solubilisation with Triton X-100 detergent and high
o f[NaCl]. Therefore, the affinity purificatioi^interacting proteins in the P2-fraction using 
GST-PDE4 (NHz-termini) fusion proteins bound to a glutathione Sepharose column camiot 
be performed as this method relies on there being a soluble fraction that can be passed 
through the column.
However, these GST-fusions could be used to probe the P2-membrane fraction by 
far-western blotting (Joyal et al., 1997; Tibbs et al,, 1998). In this method, the proteins in 
the P2-membrane fraction could be separated by SDS-PAGE and transferred onto 
nitrocellulose. The nitrocellulose filters could then be incubated with the purified GST- 
PDE4 (NH2-termini) fusion proteins as a primary prohe. The filters could then be probed 
with anti-GST antisera followed by secondaiy antibody, and developed by ECL as usual. 
Alternatively, radiolabelled GST fusions could be used to probe the filters which could 
then be developed by autoradiography (Bregman et al., 1989). The signals obtained would 
then reveal the molecular weights of potential binding partners, as estimated from the 
distance of migration of the bands on the SDS-PAGE gel (Carr and Scott, 1992; Joyal et 
al., 1997; Scott and Gurnett, 1998). Used in conjunction with other techniques such as 
expression library screening and yeast-2-hybrid analysis, this information could be used to 
determine the precise identity o f the interaction partners for these PDE4 splice variants in 
the P2-membrane fraction.
The identification of these binding partners and the interaction domains on the 
PDE4 splice variants may lead the way to drugs that disrupt the targeting and function of 
specific PDE4 isoenzymes that aie only expressed in certain tissues. Such drugs would 
hopefully have veiy specific actions, with minimal side effects.
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CHAPTER 5
The immunophilin-like protein RB3 interacts with and 
inhibits the PDE4 cyclic AMP-specific phosphodiesterase
rpdeh (RNPDE4A5)
6. The immunophilin-like protein RB3 interacts with and inhibits 
the PDE4 cyclic AMP-specific phosphodiesterase rpde6 
(RNPDE4A5)
CHAPTER 5 INTRODUCTION
a
In this chapter I have chai'acterised the interaction between the rat PDE4 isoenzyme 
RNPDE4A5 (rpdeô) and a novel immunophilin-like protein, RB3. RB3 was originally 
identified as a protein binding partner of rpde6 by Prof. Graeme Bolger (University of 
Utah) who used the yeast two-hybrid system to screen a rat brain cDNA library using rpde6 
as a bait. In section 5.11 have briefly described the results of this yeast-2-hybrid analysis 
carried out by Prof G. Bolger. In section 5.2 I have analysed the sequence and domain 
structui'e of RB3 and have reviewed work that has been published on the human and mouse 
homologues of this protein. In sections 5.3 to 5.13 I have described my analysis of the 
interaction between rpde6 and RB3.1 have mapped the sites of contact on both proteins 
and determined the effect of RB3 on the catalytic activity of rpde6, which points towards a 
regulatoiy role for RB3 in vivo. In section 5.13 I have also investigated whether rpdeb 
interacts with FKBP52, a protein that shares homologous domains with RB3.1 end the 
chapter in section 5.15 by discussing the implications of the rpde6:RB3 interaction on the 
regulation and function of rpdeb in vivo. For simplicity, the original name rpde6 is used 
rather than RNPDE4A5 tliroughout this chapter.
5.1 Yeast-2-hybrid analysis of rpde6
The PDE4 cyclic AMP specific phosphodiesterase isoenzyme rpde6 (RNPDE4A5) 
was originally cloned from a rat brain cDNA library (Bolger et ah, 1994). This long form 
PDE4A splice variant is expressed in the cortex, hypothalamus and striatum of the brain 
(McPhee et al., 1995). However, as mentioned in the Introduction, section 1.8.2, the 
expression of rpde6 is not limited to the CNS. Recombinant rpde6 has been extensively 
characterised in transfected COS-7 cells in terms of its subcellular distribution, inhibition 
by rolipram and kinetic properties (McPhee et al., 1995). As discussed in chapter 3, the 
endogenous murine form of this splice vaiiant is specifically activated by growth hormone 
in mouse 3T3 F442A preadipocytes (MacKenzie et al., 1998), The unique extreme NH2-
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terminal splice domain of rpde6 contains three pro line-rich putative SH3 domain binding 
sites and confers on rpdeô the ability to interact with the SH3 domains of Src family tyrosyl 
kinases (O' Connell et ah, 1996). To gain a greater understanding of the intracellular 
targeting and regulation of this splice variant, a search was made for potential protein- 
protein interaction partners using the yeast two-hybrid system.
As rpde6 was originally cloned from brain, it was logical to use a rat brain cDNA 
library in a yeast two-hybrid screen for proteins that interact with rpde6. Prof. Bolger 
cloned the full open reading frame of rpde6 into the Not\ site of pLEXAN to generate a 
plasmid which encodes a fusion between rpde6 and the DNA binding domain of 
Escherichia coli LexA protein (Bolger, 1998; Yai'wood et al., 1999). The rat brain cDNA 
libraiy that was used was cloned into the vector pGADGH that expresses proteins as 
fusions with the activation domain of the Saccharomyces cerevisiae protein GAL4. Screens 
of this library, using the LexA-rpde6 construct, were performed in S. cerevisiae strain L40 
(Bolger, 1998). Positive clones were initially selected for growth in the absence of histidine 
and then transferred to patches and assayed for LacZ activity using a filter p-galactosidase 
assay.
5.1.1 Yeast two-hybrid analysis identified the rat homologue of ARA9/XAP2 
as a protein binding partner for rpdeG
The cDNA clone that was isolated using rpde6 in yeast two-hybrid screen was the 
rat homologue of the human protein ARA9/XAP2 (Carver and Bradfield, 1997;
Kuzhandaiveiu et al., 1996) and the mouse protein AIP (Ma and Whitlock, 1997). The 
function and characteristics of ARA9/XAP2 are discussed below in section 5.2. In this 
thesis, I shall refer to this rat homologue of ARA9/XAP2 by the original name of the clone,
RB3 (rat brain No. 3). The predicted amino acid sequences of rat RB3 and its human and 
murine homologues are shown in Figure 5.1. As shown, this protein is highly conserved 
between species.
Using the yeast two-hybrid system, no interaction was observed between RB3 and a 
large variety of control baits expressed as LexA fusions (Prof. Graeme Bolger, personal 
communication). This panel of control baits included lamin, several kinases (including 
casein kinase II, ras and raf), protein phosphatases and transcription factors. The negative 
results from these controls suggests that the rpde6:RB3 interaction is specific. They also
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demonstrate that RB3 does not exhibit intrinsic transactivation activity, i.e. it does not 
combine directly with the DNA binding domain, LexA, to initiate LacZ  transcription. In 
addition, Prof. Bolger observed no interaction between the rpdeb bait and the above control 
proteins expressed as GAL4 fusions.
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Figure 5.1 Alignment o f ARA9/XAP2, AIP and RB3
This figure shows an alignment o f the predicted amino acid sequences o f human 
ARA9/XAP2 (GenBank accession No. U78521), mouse AIP (GenBank accession No. 
U85489) and rat RB3 cloned by Prof. Graeme Bolger (University o f Utah). These 
homologues are highly conserved between species. The regions o f homology (Asp 11 - 
Cys90 and Leul48-Serl59) with the immunophilin FKBP12, first observed by Carver and 
Bradfield (Carver and Bradfield, 1997), are shaded in dark grey. The TPR domain between 
Val265 and Leu298 is indicated by a lighter shade o f grey. Amino acid numbering is 
shown to the left.
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5.2 Characteristics of ARA9/XAP2
Several studies suggest that the expression of RB3 is not confined to the brain. The 
human form of RB3, ARA9 (aryl hydrocarbon receptor associated protein 9) and the mouse 
form of RB3, AIP (aryl hydrocarbon receptor interacting protein), were both isolated using 
the yeast two-hybrid system to search for proteins that interacted with the aryl hydrocarbon 
receptor (AhR) (Carver and Bradfield, 1997; Ma and Whitlock, 1997). The ARA9 protein 
was isolated from a human B-cell line cDNA library (Carver and Bradfield, 1997), whereas 
AIP was isolated from a mouse hepatoma cell line cDNA libraiy (hepalclc7) (Ma and 
Whitlock, 1997). The aiyl hydrocarbon receptor (AhR) is a ligand-activated transcription 
factor that regulates the transcription of the enzymes of xenobiotic metabolism such as 
cytoclirome P4501A1. The function of the aiyl hydrocarbon receptor is discussed below in 
section 5.2.1
Kuzhandaiveiu et al independently discovered ARA9, using the yeast two-hybrid
system, as a protein that interacts with the hepatitis B vims transcriptional activator protein
X (Kuzhandaiveiu et al., 1996). This group named the isolated protein XAP2 (X-associated 
.protein 2). XAP2 appears to have a negative effect on transcriptional activation mediated 
by X. Another group, Meyer and Perdew, independently discovered ARA9/XAP2 as a 
protein that co-immunoprecipitates with AhR in COSl cells. They subsequently cloned the 
simian (Afiican green monkey) homologue of ARA9/XAP2 from COS-1 cells (Meyer et 
al., 1998).
As in shown in Figure 5.1, the human, mouse and rat forms of ARA9/XAP2 are all 
highly homologous. The human and simian forms of ARA9/XAP2 are identical. The 
human and mouse homologues of ARA9/XAP2 are all cytosolic proteins of around 38kDa 
(Carver and Bradfield, 1997; Kuzhandaiveiu et ah, 1996; Ma and Whitlock, 1997; Meyer 
et al., 1998). Northern blot analysis shows that they are ubiquitously expressed in a wide 
number o f cell lines and tissues (Carver and Bradfield, 1997; Kuzhandaiveiu et al., 1996; 
Meyer et al., 1998). Western blotting analysis by Meyer et al with anti-ARA9/XAP2 
antibodies identified the highest levels of the ARA9/XAP2 in the mouse spleen and thymus 
(Meyer et al., 1998).
1
I
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5.2.1 Interaction of ARA9/XAP2 with the aryl hydrocarbon receptor (AhR) 
and heat shock protein 90
Several independent studies have shown that ARA9/XAP2 forms a complex with 
AliR and the molecular chaperone heat shock protein 90 (hsp90). ARA9/XAP2 and AhR 
can he co-immunoprecipitated with anti-AhR antisera or anti-ARA9/XAP2 antisera 
(Carver and Bradfield, 1997; Ma and Whitlock, 1997; Meyer et ah, 1998). Similarly, 
ARA9/XAP2 and hsp90 can be co-immunoprecipitated with anti-ARA9/XAP2 or anti- 
hsp90 antisera (Carver and Bradfield, 1997; Ma and Whitlock, 1997). There is some 
uncertainty over whether the presence of AhR is required for an interaction between hsp90 
and ARA9/XAP2. Ma and Whitlock showed that hsp90 and AIP (the murine homologue of 
ARA9/XAP2) could be co-immunoprecipitated in the absence of AhR (Ma and Whitlock, 
1997). However, Carver and Bradfield conversely showed that the presence of AhR was 
necessary for a ARA9/XAP2:hsp90 interaction (Carver and Bradfield, 1997).
As mention above, AhR is a cytoplasmic ligand-activated transcription factor, 
expressed in a wide range of cells. The ligands that bind to and activate AhR are polycyclic 
halogenated aromatic hydrocarbons (PAHs) that include the environmental toxin 2,3,7,8- 
tetrachlorodibenzo-j!?-dioxin (TCDD) (Schmidt and Bradfield, 1996). In the liver, ligand 
binding and activation of AhR results in the induction of the gene encoding cytochi'ome 
P4501A1 that oxygenates PAHs (Ma and Whitlock, 1997; Sclimidt and Bradfield, 1996). 
Therefore, AhR appeal's to be a major player in mediating response of the cell to 
environmental pollutants.
The current model for the mode of action of AhR is as follows. In the cytoplasm, 
prior to ligand binding, AhR is found in a complex with a dimer of the heat shock protein 
90 and a ~43kDa protein which is probably ARA9/XAP2 (Carver and Bradfield, 1997). 
Upon ligand binding to AhR a complex of AhR with the hsp90 dimer translocates to the 
nucleus where AliR dissociates from the hsp90 dimer and becomes associated with the 
ARNT (aryl hydrocarbon receptor nuclear translocator) (Carver and Bradfield, 1997;
Meyer et al., 1998). It is not known whether ARA9/XAP2 also translocates to the nucleus.
This AhR: ARNT heterodimer binds dioxin response elements (DREs) within the promoter 
regions of genes such as C YPlA l and regulates their transcription.
This model for signalling via AhR is strikingly similar to the model for signalling 
via steroid hormone receptors such as the glucocorticoid receptor, GR (Barnes, 1997) and 
the progesterone receptor, PR. These receptors mediate the effects of steroid hormones on
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the transcription of specific sets of genes within cells. GR forms associations that are 
similar to those suggested for AhR (Silverstein et al., 1997). In the absence of 
glucocorticoid, cytoplasmic GR is complexed with an hsp90 homodimer and an 
immunophilin protein, such as FKBP52 or Cyp40 (Barnes, 1997; Carver and Bradfield, 
1997). In the presence of glucocorticoid GR translocates to the nucleus and the hsp90 
homodimer dissociates. Within the nucleus the GRs then dimerise. The GR homodimers 
associate with the glucocorticoid response elements (GREs) within the promoter regions of 
specific genes where they can activate or inliibit gene transcription. The models for steroid 
and aiyl hydrocarbon receptor signalling are illustrated in Figure 5.2.
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Figure 5.2 Proposed model for steroid hormone signalling.
The proposed models for glucocorticoid receptor (GR in and aryl hydrocarbon receptor 
(AhR in E) signalling are similar. In both models a ligand (either glucocorticoid or TCCD) 
binds to the receptor which causes the receptor-hsp90 complex to translocate to the 
nucleus. Once inside the nucleus hsp90 dissociates and the activated GR homodimerises or 
the activated AhR heterodimerises with ARNT. These complexes then bind to their 
cognate enhancer elements to regulate the transcription o f specific sets o f genes. hsp90 is 
essential for the function o f GR and AhR (Carver and Bradfield, 1997). In GR signalling, 
hsp90 association increases hormone binding capacity whereas hsp90 dissociation is 
associated with increased DNA binding capacity (McGuire et al., 1994). The role o f the 
immunophilin (FKBP52) component o f the cytosolic GR complex maybe to target the GR 
complex to specific locations within the cell (Owens-Grillo et al., 1996).
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5.2.2 RB3 shows homology to the FKBP-immunophilin family of proteins
The predicted amino acid sequence of RB3 is homologous to the FKBP-family of 
immunophilin proteins. Table 5.1 shows the results of BLAST search of the SWISSPROT 
protein sequence database (National Centre for Biotechnology Information) using the RB3 
sequence. BLAST analysis shows that the proteins most similar to RB3 are mostly 
homologues of the FK506 binding proteins, FKBP52 and FKBP51. An alignment of the 
amino acid sequences o f RB3 and FKBP52 is shown in Figure 5.3.
FKBPs form part of the immunophilin family. This family of proteins bind to the 
immunosuppressant fungal macrolides FK506, rapamycin, and cyclosporin A. The 
immunophilin family is divided into two main sub-families in eulcaiyotes: FK506 binding 
proteins (FKBP) and cyclophilins (Cyp). The cyclophilins bind cyclosporin A and range in 
size from about 20kDa (CypA, CypB, CypC and CypD) to 40kDa (Cyp40). FKBPs bind 
FK506 and rapamycin and are named according to their molecular weights, which range 
from 12 to 52kDa. Members of the FKBP subfamily include FKBP 12, FKBP 12.6,
FKBP13, FKBP25, FKBP51 and FKBP52. Despite having similar functions in cells, 
cyclophilins and FKBPs have different 3 dimensional structures and their sequences do not 
align.
Immunophilins are found to be conserved throughout a wide range of organisms 
including plants and prokaryotes (Kay, 1996; Marks, 1996). Both families exhibit an 
enzyme activity known as peptidyl prolyl cis-trans isomerase activity (otherwise known as 
PPIase or rotamase activity). In FKBP proteins the PPIase active site is located in the 
FKBP homology region. PPIase enzymes catalyse the rotation of the C-N bond on the NH2- 
terminal side of proline residues in proteins (Kay, 1996). This suggests that immunophilins 
might regulate protein folding in the cell (Fruman et al., 1994) although this has not been 
demonstrated in vivo. The PPIase activity of immunophilins is inhibited by the 
immunosuppressant drugs they bind. The amino acid residues in FKBP 12 that interact with 
FK506 are also components o f the PPIase active site (Miclinick et al., 1991; Van Duyne et 
al., 1991). As yet, no physiological function has been defined for the PPIase activity of 
FK506 binding proteins in cells (Fruman et al., 1994; Kay, 1996; Maiks, 1996).
The immunosuppressant compounds FK506, rapamycin and cyclosporin A, that 
bind immunophilins, have been used to prevent tissue rejection following organ 
transplantation (Marks, 1996). One mechanism for immunosuppression has been 1
T
established for FK506 and cyclosporin A. The immunophilin:drug complexes 
FKBP12:FK506, CypA:CsA and CypB:CsA have been shown to bind to and inhibit the 
Ca^”^ and calmodulin-dependent protein phosphatase calcineurin (otherwise known as 
protein phosphatase 2B) (Liu et al., 1991). Inliibition of calcineurin prevents the 
dephosphorylation of the nuclear factor of activated T-cells (NF-AT). This prevents the 
translocation of NF-AT to the nucleus where it activates a number of immune response 
genes including the gene for the cytokine IL-2 (Fruman et al,, 1994). This mechanism is 
illustrated in Figure 5.4. Therefore, immunophilin:drug complexes are directly involved in 
immunosuppression.
As mentioned above (section 5.2.1), immunophilin proteins such as FKBP52 (Czar 
et al., 1994), FKBP51 (Nair et al., 1997) and Cyp40 (Owens-Grillo et al., 1996) form 
complexes with steroid hormone receptors in vivo. A model has been proposed where these 
immunophilins are involved in the targeting and movement of these complexes to specific 
regions within the cell (Owens-Grillo et al., 1996; Pratt et al., 1999). For instance, FKBP52 
is found in the both the cytoplasm (-20%) and the nucleus (-80%). Cytoplasmic FKBP52 
has been localised to microtubules (Czar et al., 1994; Owens-Grillo et al., 1996; Perrot- 
Applanat et al., 1995) which suggests that it may be associated with the trafficking 
machinery of the cell. In addition, the distribution of nucleai* FKBP52 overlaps that of the 
steroid receptor, GR (Czar et al., 1994). These observations provide circumstantial 
evidence that FKBP52 is involved in the cytoplasmic-nuclear trafficking of GR.
The similarity between RB3 and FKBP52 suggests that RB3 may play a role in 
AhR signalling analogous to FKBP52 in GR signalling. Ma and Whitlock suggest that the 
mouse homologue of RB3, AIP, may be involved in the nuclear targeting of AliR although 
their is no evidence that AIP translocates to the nucleus at any stage (Ma and Whitlock,
1997).
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Table 5.1 The first 8 closest homologues of RB3 ranked in order of their similarity to 
the RB3 sequence
Homologue Species” Similarity 
Score (bits)
Expect (E) 
value*’
FKBP52 Rabbit
{Oryctolagus coniculus)
72 1 X 10' ^
FKBP52 Human {Homo sapiens) 71 4 X 10‘‘^
70kDa PPIase Wheat {Triticum aestivum) 68 2 x  10'"
FKBP52 Mouse {Mus musculus) 62 1 X 10 '^
FKBPS 1 Human {Homo sapiens) 62 2 x  lO"'-'
FKBPS 1 Mouse {Mus musculus) 59 9 X 10 '^
Cyp40 Cattle {Bos taurus) 45 4 x  10"
TOM70, mitochondrial 
protein transporter
Yeast {Saccharomyces 
cerevisiae )
44 4 x  10'"
(a) Note that the human, mouse and simian homologues of RB3 have been omitted from 
the list.
(b) The E value is a measure of statistical significance
I.
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Figure 5.3 Sequence alignment of FKBP52 and RB3
This figure shows an alignment of rat RB3 with rat FKBP52 (GenBank accession No. 
P27124). The amino acid residue positions are shown on the left. Amino acid residues in 
FKBP52 that are identical to those in RB3 are boxed. The regions homologous to the 
FKBP-domain consensus are shaded in light grey. Residues shaded in darker grey are 
components of the FK506 binding site (Van Duyne et al., 1991). These residues are also 
components of the PPIase active site (Kay, 1996). The TPR region shared between 
FKBP52 and RB3 (Val265 to Leu298 in RB3) is overlined with a black bai\ The other two 
TPR domains of FKBPS 2 are overlined with grey bars.
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Figure 5.4 One mechanism for the immunosuppressive actions o f FK506 and 
cyclosporin A (CsA)
The immunophilin;drug complexes FKBP12:FK506, CypA:CsA and CypB:CsA bind to 
and inhibit the Ca^’*'/ CaM-dependent protein phosphatase calcineurin, which prevents the 
dephosphorylation of the nuclear factor of activated T-cells (NF-AT). Phosphorylated NF­
AT is unable to enter the nucleus. Inhibition of calcineurin by FKBP 12 or CsA therefore 
prevents the NF-AT-dependent regulation o f a number of immune response genes, 
including the gene for IL-2.
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5.2.3 Analysis of the predicted amino acid sequence of RB3
Figure 5.5 shows a schematic comparison of the domain structure of RB3 with its 
closest relative FKBP52. Note that an amino acid sequence aligmnent of these two proteins 
was shown in Figure 5.3 in the previous section. FKBP52 and RB3 share a number of 
structural features, which ai*e discussed in the sections below. Most notably, both FKBP52 
and RB3 have FKBP homology domains found towards their NH^-termini and TPR repeats 
in their COOH-terminal regions.
5.2.3.1 The FKBP homology domain
FK506 binding proteins contain domains, called FKBP domains. The FKBP 
domain consensus was generated from a comparison of 30 protein sequences from 
eukaryotes and prokaryotes (Kay, 1996). Two or three copies o f this domain are found in 
certain family members. FKBP 12 essentially consists of one FKBP-domain. In Figure 5.5 
black rectangles indicate regions homologous to FKBP 12 in FKBP52 and RB3. RB3 has 
two regions of similarity to FKBP 12, (amino acids 11-90 and 148-159) whereas FKBP52 
appears to contain two complete FKBP domains (amino acids 32-137 and 148-252) (see 
also Figure 5.3). In FKBP proteins these FKBP homology domains contain the PPIase 
active site which binds to FK506. The 14 residues identified as components of the FK506 
binding/PPIase site (Kay, 1996; Van Duyne et al., 1991) in FKBP52 have been highlighted
-,:'3
in grey in Figure 5.3. An alignment of FKBP52 with RB3 suggests that only 3 out of the 14 
component residues are conserved in RB3. A similar alignment of RB3 with FKBP 12 
indicates that only 5 of the 14 FK506 binding residues are conserved in RB3 (Carver et al.,
1998), These results suggest that RB3 may not bind FK506 or have PPIase activity.
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Figure 5.5 Domain structure of RB3 and FKBF52
This figure shows a schematic representation of the domain structures of RB3 and its 
closest homologue, FKBP52. Black blocks indicate regions of homology to the FKBP 
domain consensus (Kay, 1996). The grey blocks indicate the positions of the TPR motifs 
and double-headed arrows maik out the regions that have so far been shown to be 
necessaiy for interaction with hsp90 (and AhR in the case of RB3). A scale indicating the 
number of amino acid residues is shown at the top of the diagram. No attempt has been 
made here to align the schematic structines of these two proteins.
I
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5.2.3.2 The TPR domain and interaction with hsp90
The closest relative of RB3, FKBP52 has been shown to contain tlrree 
tetratricopeptide repeats (TPRs) in its COOH-terminal region. As discussed in the 
Introduction (section 1.11.4) these are 34 amino acid regions that are found in wide range 
of proteins (Goebl and Yanagida, 1991; Hirano et al., 1990; Lamb et al., 1995; Sikorski et 
al., 1990). TPR domains are believed to be involved in protein-protein interactions (Lamb 
et al., 1995). The consensus sequence, generated from a comparison of TPR repeats from 
five different proteins, is shown in Figure 5,6. Note that the consensus sequence is highly 
degenerate (Goebl and Yanagida, 1991).
The groups that cloned the RB3 human form, ARA9/XAP2 (Carver and Bradfield), 
and the RB3 mouse form, AIP (Ma and Whitlock) suggest that RB3 contains 3 TPR repeats 
(Carver and Bradfield, 1997; Ma and Whitlock, 1997). However, only one of these TPR 
motifs between amino acids 265 and 298 closely matches the consensus (see Figure 5.6). 
This is the only TPR identified by Meyer et al who cloned the simian homologue of RB3 
(XAP2) from COS-1 cells (Meyer et al., 1998). An alignment of this region of RB3 with 
the TPR consensus is shown in Figure 5.6.
Note that Ma et al and Carver et al disagree on the location of the other two TPR 
regions. Ma and Whitlock state the positions as amino acids 118-152 (TPRl) and amino 
acids 205-239 (TPR2) (Ma and Whitlock, 1997). Carver and Bradfield state the positions 
as amino acids 182-215 (TPRl) and amino acids 234-268 (TPR2) (Caiver and Bradfield,
1997). However, in all these regions the similarity of these sequences to the TPR 
consensus is only very slight. Therefore, for the remainder of this chapter, I shall work on 
the assumption that RB3 contains only one TPR motif located between amino acids 265 
and 298 (see Figure 5.5). As shown by Meyer et al, this third TPR is very similar to the 
third TPR domain of FKBP52 (see Figure 5.3) (Meyer et a l, 1998).
In addition to FKBP52, TPR domains containing tluee repeats have been identified 
in the FKBP proteins FKBP51 (Young et a l, 1998), FKBP52 (Callebaut et a l, 1992) and 
Cyp40 (Ratajczak and Carrello, 1996). These TPR domains have been shown to mediate 
interaction with the molecular chaperone hsp90 (Carrello et a l, 1999; Nair et a l ,  1997; 
Owens-Grillo et a l, 1996; Peattie et a l, 1992; Perrot-Applanat et a l, 1995; Prodromou et 
a l, 1999). Deletion mapping studies in all three immimophilins have shown that the TPR 
region is required for interaction with the molecular chaperone hsp90 (see Figure 5.5).
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Carver and coworkers showed that the COOH-terminal half o f ARA9/XAP2, from 
amino acids 154 to 330, which contains the TPR motif, interacts with AhR and hsp90 in 
vitro. This result points to a possible role for this single TPR motif in an interaction with 
hsp90. However, more recently, Meyer and Perdew have shown that deletion of the 
COOH-terminus downstream of the TPR motif (amino acids 299-330) abolishes 
association with hsp90. Therefore it appears that the TPR motif may be necessary, but not 
sufficient, for interaction with hsp90. Carver and coworkers also showed that this region of 
ARA9/XAP2 mediates interaction with AhR as well (Carver et al., 1998) (see Figure 5.5).
5.2.3.3 Interaction of RB3 with calcineurin
As discussed earlier, FKBP12-FK506 can bind to and inliibit the protein phosphatase 
calcineurin. A number o f other immunophilin-drug complexes can also associate with 
calcineurin including FKBP51-FK520 (Baughman et al., 1995) and cyclophilin-CsA (Liu 
et al., 1991). The possibility that RB3 interacts with calcinemin is discussed later in this 
chapter (section 5.7,3).
I
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Figure 5.6 Alignment the TPR m otif of RB3 with the consensus
The top line shows the sequence of the TPR domain of RB3 from Val265 to Leu298. The 
bottom line shows the consensus TPR sequence derived from alignments of TPR domains 
from CDC27, CDC23, CDC16, SSN6 and SKI3 (Das et a l, 1998; Lamb et a l, 1995). RB3 
residues that match the consensus residues precisely are shaded in grey. Residues that are 
similar in terms of their hydrophobicity are boxed. 0  = hydrophobic residue
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CHAPTER 5 RESULTS AND DISCUSSION
5.3 Characterisation of the interaction between RB3 and rpde6
It is widely recognised that the yeast two-hybrid system is prone to false positives. 
Even though a number of controls were carried out to test the specificity o f the rpde6:RB3 
interaction in yeast (section 5.1.1 above) it is important use alternative methods to confirm 
and extend results from these yeast two-hybrid analyses.
I used a GST fusion system to analyse the interaction between RB3 and rpdeô 
expressed in COS-7 cells. Initially I examined whether purified full-length RB3, fused to 
GST and immobilised on glutathione Sepharose beads, could ‘pUl down’ rpde6 from the 
cytosolic fraction of rpdeô-transfected COS-7 cells. The approach I have used here is 
similar to the one successfully used to demonstrate an interaction between the SH3 
domains of Src family tyrosyl kinases and rpdeô (O' Connell et a l , 1996; Scotland et a l,
1998).
COS-7 cells were used to express rpdeô as these allow high levels of expression of 
transiently transfected PDE4 isoenzymes and they exhibit veiy low levels of endogenous 
PDE activity (Scotland et a l, 1998). In my hands, the cytosolic fraction from rpdeô 
transfected COS-7 cell typically exhibited a PDE activity of 0.75-1.05nmol 
(cAMP)/min/mg protein. Cytosolic fractions from mock transfected COS-7 cells always 
exhibited an activity <5% of the activity from rpdeô transfected COS-7 cells.
An insert for the coding region of RB3 was cloned into the N otl site of a pGEX- 
5X-3 vector by Prof. Bolger. In E xoli this construct (GST-RB3^'^^^) expresses full length 
RB3 fused to the COOH-terminal end of GST. I over-expressed and purified GST-RB3*'^^^ 
and GST in E. coli as described in the methods (section 2.7). In order to assess the purity of 
these preparations, samples of the purified GST-RB3^'^^° and GST were separated on an 
SDS-PAGE gel (12%[w/v] acrylamide) and visualised by Coomassie blue staining. As 
shown in Figure 5.9 bands of the coiTect predicted molecular weights for GST-RB3^'^^^ 
(65kDa) and GST (27kDa) were observed in the appropriate lanes. Bands corresponding to 
proteolytic degradation products or contaminating bacterial proteins were not observed in 
these lanes.
I then incubated pmified GST-RB3^"^^^ bound to glutathione Sepharose beads with 
cytosol from rpdeô-transfected COS-7 cells diluted in complete KHEM buffer. GST was
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used in the same manner as a control. I then washed the beads with complete KHEM buffer 
and eluted the bound protein with glutathione buffer (see Methods chapter, section 2.17). 
This process was repeated for GST as a control. Samples of the bound fractions (eluted 
protein) and the unbound fractions (washes) were separated by SDS-PAGE, transferred 
onto nitrocellulose and immunoblotted for PDE4A.
As shown in Figure 5.7, rpdc6 becomes associated with GST-RB3^'^^® immobilised 
on glutathione Sepharose beads. An immimoreactive band running at 108 ± 3kDa (mean ± 
S.E., n = 3), which corresponds closely with the published observed moleculai* weight for 
rpdc6 of 1091cDa (McPhee et a l, 1995), was observed in the bound traction for GST-RB3^“ 
This association of GST-RB3^"^^® with rpdeb appeai'cd to be specific; only an 
extremely faint band was observed in the bound fraction for GST. Therefore, the presence 
of RB3 was absolutely necessaiy for binding of rpdeb to occur. This result was the first 
demonstration of an interaction between rpde6 and RB3 in vitro. It strongly suggested that 
the rpdc6:RB3 interaction was not an artefact of the yeast two-hybrid system.
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Figure 5.7 Cytosolic rpdeô from transfected COS-7 cells binds to RB3 in vitro.
A pull down assay was carried out to assess the binding o f rpdc6 to RB3 in v itro  as
described in the Methods chapter (see section 2.17). Samples o f cytosol, containing 100
EU o f PDE activity, from COS-7 cells transiently transfected with a plasmid encoding
rpdc6 (pSV.SPORT-rpde6) were incubated for 30min with 200pg o f GST-RB3*‘^ ®^ or GST
(control) bound to glutathione Sepharose beads. The beads were pelleted by centrifugation |
and washed with 3 x 400pl complete KHEM buffer by resuspension and centrifugation.
The supernatants were retained and pooled to produce an unbound fraction. Bound protein
was eluted with 3 x lOOpl lOmM glutathione, 50mM Tris-HCl pH 8.0. Samples o f  the 
(B) . (U)boun^fraction (20pl) and the unboun(^ffaction (4pl) were then separated on an SDS-
PAGE gel (10% [w/v] acrylamide). The separated proteins were transferred onto
nitrocellulose and probed for rpdeb using anti-PDE4A polyclonal antibody as primary
reagent. The standard molecular weights in kOa are shown on the left. This result is typical
o f an experiment carried out three times.
5.4 Locating the binding region for rpdeG on RB3
As mentioned above in section 5.2.3, RB3 contains regions of similarity to FKBP12 
in its NH2“terminal half and a TPR motif in its COOH-terminal half. Having demonstrated 
that an interaction occurs between RB3 and rpdeô under the conditions of the above pull 
down assay I went on to determine which region of RB3 is responsible for this interaction. f
Constructs encoding GST fusions of the NH2-terminal half o f RB3 (GST-RB3*‘^^ )^ 
or the COOH-terminal half o f RB3 (GST-RB3^^^'^^^ fused to the COOH terminus GST f
were prepared by Prof. Bolger in pGEX-5X-3 (the regions fused to GST are illustrated in 
Figure 5.8). I over-expressed and purified GST-RB3^’*® and GST-RB3^^^'^^^ in E. coli as 
described in the methods (section 2.7). Samples of the GST-RB3*"^^^ and GST-RB3^^^'^^^ 
were separated on an SDS-PAGE gel (10%[w/v] acrylamide) and visualised by Coomassie 
blue staining. As shown in Figure 5.9, bands close to the predicted molecular weights for 
GST-RB3‘' ‘®(47kDa) and GST-RB3'™‘^ ™(46kDa) were observed in the appropriate 
lanes. No proteolytic degradation products or contaminant bacterial proteins were 
observed in these preparations.
A comparison of the binding of rpdeô to the tlnee GST-RB3 fusions, GST-RB3^’^® 
(NH2-terminal half), GST-RB3'™-^^" (COOH-terminal half), GST-RB3'‘“ ® (fhll length) 
and GST was made using the pull down assay method described in the previous section 
(5.3) and the Methods (section 2.17). Samples (200pg) of the GST-fusion proteins or GST 
were immobilised on glutathione Sepharose beads and were incubated with cytosolic rpdeô 
(100 EU) for 30min at 4°C, The beads were then pelleted and washed several times with 
complete KHEM buffer. The supernatant and washes were retained and pooled to produce 
an unbound fraction. Bound protein was eluted with glutathione buffer. To determine the 
percentage binding of rpdeô to the various GST-RB3 fusions, samples o f the bound and 
unbound fractions were assayed for PDE activity.
The results presented in Figure 5.10 again showed that rpdeô specifically associated 
with a GST-fusion of full length RB3 (GST-RB3^”^ ®^) and that essentially no association 
was seen with GST. In addition rpdeô assoeiates with a GST fusion of the COOH-terminal 
half of RB3 (GST-RB3*^^'^^^). In contrast to this, negligible binding was observed between 
rpdeô and the NH2-terminal half of rpdeô fused to GST (GST-RB3^“^ ^^ ). The results 
suggest that regions within the COOH-terminal half of RB3 may mediate association with 
rpdeô.
5 The immunophilin-like protein RB3 interacts with and inhibits the PDE4 cyclic AM P-specific phosphodiesterase 182
rpdeô (RNPDE4A5)
i
The above results for the percentage binding of rpdeô to the tliree GST-RB3 
fusions, presented in Figure 5.10, were determined on the basis o f rpdeô enzyme activity in 
the bound and unbound fractions. To confirm these results the percentage binding was 
detennined on the basis of rpdeô immunoreactivity in these fraetions. Samples o f the 
bound and unbound fractions from the above pull down assay were separated by SDS- 
PAGE, transferred onto nitrocellulose and immunoblotted with anti-PDE4A polyclonal 
antibody. The amount of rpdeô in the bound and unbound fractions was determined from 
the density of the bands obtained. The results obtained for this immunoblot analysis are 
presented in Figure 5.11. These results reflected the results obtained from the analysis of 
PDE activity in the bound and unbound fractions (Figure 5.10). They again showed 
significant association of rpdeô with full length RB3 (GST-RB3^‘^ ^^ ) and the COOH- 
terminal half of RB3 (GST-RB3^™'^^  ^negligible association with GST-RB3*‘^ ^^  and no 
association with GST.
This result is again shown in a representative imnumoblot for the binding o f rpdeô 
to the NH2“ and COOH-terminal halves of RB3 (see Figure 5.12). This again shows the 
COOH-terminal half of RB3 (amino acids 170-330) pulls down cytosolic rpdeô whereas 
the NH2-terminal half (amino acids 1-1 ô9) does not. We can therefore hypothesise that 
RB3 associates with rpdeô via its COOH-terminal half.
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Figure 5.8 GST-fusions of the NH 2- and COOH-terminal halves o f RB3
To assess which region of RB3 interacts with rpdeô, constructs encoding the NH2- or 
COOH-terminal halves of RB3 fused to GST were prepared in pGEX-5X-3. As described 
in section 5.2.3, the NH2-terminal portion (amino acids 1-1Ô9) contains the region 
homologous to the FKBP domain. The COOH-terminal region (amino acids 170-330) 
contains a TPR motif. These GST-fusions were used in pull down experiments to test for 
interaction with rpdeô.
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Figure 5.9 Purification o f GST, GST-RB3' “ ", GST-RB3“ ‘’ and GST-RB3‘™ “ ".
GST fusions of full length RB3 (amino acids 1-330) and the NH2- and COOH-terminal 
halves of RB3 were over-expressed in E. coli and purified as deseribed in the methods (see 
section 2.7). Samples (lOpg) of the GST fusions were separated on an SDS-PAGE gel 
(10% [w/v] acrylamide). The observed molecular weights (in kDa) of these GST-fusion 
proteins (shown on the left) corresponded closely with their actual molecular weights, 
which were as follows: GST, 27.4kDa; GST-RB3‘‘“ ’^, 46.6kDa; GST-RB3‘™'“ “, 45.9kDa 
and GST-RB3''^^“, 65.0kDa.
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Figure 5.10 but not GST-RB3^^^  ^pulls down rpdeG: (PDE activity
data)
This chart shows the relative binding of the rpdeô to the following GST fusions: GST-
RB3 '-‘® (NHî-temiinal half of RB3, amino acids 1-169), GST-RB3 (COOH-terminal 
haifofR B 3, amino acids 170-330), GST-RB3'’^ °^ (full length RB3, amino acids 1-330)
and GST alone. Samples of cytosolic (S fraction) rpdeô from transiently transfected COS-7 
cells, containing lOOEU PDE activity, were incubated with 200|Lig samples of the above 
fusion proteins immobilised on glutathione Sepharose beads for 30min at 4°C as described 
in the Methods chapter, section 2.17. The beads were pelleted and washed with ice-cold 
complete KHEM buffer and the resultant supernatants were combined to form an unbound 
fraction. Bound protein was eluted with lOmM glutathione, 50mM Tris pH 8.0. The total 
PDE activity in the bound (E U b q u n d )  and unbound (E U u n b o u n d )  fractions was determined 
using the PDE assay. The percentage of rpdeô that was 'pi^^ed down’ by the GST-fusions 
under the experimental conditions described was calculated as follows:
% binding = 1 0 0 %  x  [E U b q u n d  /  (E U b o u n d T  E U u n b o u n d )]-
The percentage binding values are shown as the means of three experiments ± S.E.
170-330
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Figure 5.11 but not GST-RB3^^^  ^pulls down rpdeG: (quantitative
western blot analysis)
The % binding of rpdeG to GST-RB3 fusions was re-assessed by measuring rpdeG 
immunoreactivity in the bound and unbound fraction from the pull down assay described in 
the legend for Figure 5.10. Samples of the bound and unbound fractions were run on an 
SDS-PAGE gel, transferred onto nitrocellulose and immunoblotted for RB3. The 
immunoblots were scanned and the net densities of the rpdeG immunoreactive bands were 
plotted against the sample volume run for both the bound and unbound fractions. This was 
used to calculate the % binding of rpdeG to the GST-fusions. This procedure is described in 
detail in the Methods chapter, section 2.17.1. The % binding values are the means of three 
experiments ± S.E.
a
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Figure 5.12 Western blot analysis of the association of GST-RB3*'^^®, GST-RB3^‘*^ ,^ 
GST-RB3‘ “^'^ ®^ and GST with rpdeG
A pull down assay was caiiied out as described in the legend for Figure 5.10. 8pl volumes 
o f the bound fractions (B) and 3.2pl volumes of the unbound (C7) fractions were separated 
by SDS-PAGE and immunoblotted with anti-PDE4A antiserum as primaiy reagent to 
assess the association of rpdeG with either the NH2- or COOH-terminal halves of RB3 
expressed as GST-fusions. The positions of the molecular weight standards (in kDa) are 
shown to the left of the immunoblots. This result is typical of an experiment carried out 
three times.
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5.4.1 The COOH-terminal half of RB3 (amino acids 170-330) binds to rpdeO 
in vitro.
The results shown above suggest that a binding site for rpdeG exists within the 
COOH-terminal half of rpdeG. This is intriguing as the COOH-terminal halves of the 
human and mouse homologues o f RB3 (ARA9/XAP2 and AIP respectively) have been 
shown to mediate association with both hsp90 and AhR (see section 5.2.3.2) (Carver et al., 
1998; Meyer and Perdew, 1999). This region also contains the TPR motif (Figure 5.8) 
between amino acids 2G5 and 298. As mentioned in section 5.2.3.2 the TPR domains 
within the COOH-terminal regions of FKBP52 (Radanyi et al., 1994) and Cyp40 
(Ratajczak and Carrello, 199G) have also been shown to mediate interaction with hsp90. 
Therefore, the TPR domain of RB3 may mediate interaction with both hsp90 and rpdeG.
The NH2-terminal half of RB3, which contains regions of homology to the 
FKBP 12, does not appeal’ to be involved in binding rpdeG, However, this finding does not 
exclude a role for this NH2-teiminal region in regulating the interaction of RB3 with rpdeG. 
Post-translational modifications or protein-protein interactions in either the NH2- or 
COOH-terminal halves of RB3 may increase or decrease the accessibility of the rpdeG 
binding site or its affinity for rpdeG. Indeed, RB3 may adopt two or more interchangeable 
conformations in vivo that have varying affinities for rpdeG. In this way, the factors that 
influence the conformational state of RB3 may regulate the intracellular tai’geting or 
activity of rpdeG.
5.4.2 Time course for the association of rpdeG with GST-RB3^ °^"^ °^.
The time course for the interaction of the COOH-terminal half of RB3 with rpdeG 
was established. This was done to determine the optimal incubation time for studies on the 
interaction between rpdeG and RB3 in vitro. Equal samples of cytosolic rpdeG from 
transfected COS-7 cells were incubated with equal amounts of purified GST-RB3^^^‘^ ^^  
bound to glutathione Sepharose beads. The percentage binding was determined for each 
time point. The results are shown in Figuie 5.13.
Rapid binding of rpdeG to GST-RB3^^®'^^^ was observed. Maximum binding 
appeared to occur within ~8min at 4°C. This is similar to the time course observed for the 
interaction of rpdeG with the SH3 domain of Src kinase in which maximum binding is 
achieved after ~5min (O' Comiell et al., 1996),
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Figure 5.13 Time course for the binding of rpde6 to
Samples of cytosolic rpdc6 (containing lOOEU PDE activity) were incubated at 4°C with 
200pg samples of bound to glutathione Sepharose beads for the times
shown. Incubation was terminated by pelleting the beads at ~13,000g for 5s. The 
supernatants were removed and the beads were washed 3 times with complete KHEM 
buffer. Bound protein was eluted with lOmM glutathione, 50mM Tris-HCl, pH 8.0. 
Percentage binding was determined by comparing the total PDE activity in the bound and 
unbound fractions (see the legend for Figure 5.10, section 5.4) and plotted against time (n 
!)•
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5.5.1 Generation of anti-RB3 antisera
Antisera were raised against purified GST-RB3^'^^^ in two New Zealand White 
rabbits (574 and 575) as described in Methods section 2.13. To test the antisera produced,
5.5 Comparison of the subcellular distributions of RB3 and rpdeG in 
transfected COS-7 cells
An important aspect of the PDE4 isoenzymes is their specific targeting to different 
compartments within the cell (see Introduction chapter, sections 1.8). The various patterns 
o f intracellular targeting are conferred on PDE4 splice variants by their unique NHz- 
terminal splice domains. The subcellular distributions of a number of PDE4 isoenzymes, 
including rpdeô, have been determined in transiently transfected COS-7 cells. (Houslay et 
al., 1998) (see Introduction section 1.4). Immunofluorescence analysis indicated that rpdeô 
was distributed tiuoughout the cytoplasm (Huston et al., 2000). The pattern of 
immunofluorescence was not diffuse, but was localised to specific structmes. The 
immunofluorescence signal intensified near the nucleus and the cell periphery suggesting 
an association with the perinuclear and cortical cytoskeleton. No nuclear staining was 
observed (Huston et al., 2000). The distribution of rpdeô was also analysed by simple 
cellular fractionation in both transfected COS-7 cells and brain. In both cases, rpdeô was 
distributed between the particulate (PI and P2) and the soluble cytosolic (S) fractions 
(McPhee et al., 1995).
PDE4 isoenzymes may form different protein-protein interactions and adopt 
different conformations in different subcellular compartments. The most notable example 
of this is HSPDE4A4B (pde4ô) (McPhee et al., 1999) which appears to switch from a low 
to a high affinity state for rolipram inhibition when it becomes associated with a 
component of the pai'ticulate fraction of COS-7 cells (see Introduction chapter, 1.8.3). 
rpdeô also exhibits slightly different kinetic properties in the particulate and soluble 
fractions of COS-7 cells. The conformational state of rpdeô may affect its interaction with 
RB3. For this reason it is important to define the subcellular compartment(s) where the 
rpdeô :RB3 interaction occurs. 1 therefore analysed the subcellular distribution of RB3 in 
transfected COS-7 cells. A necessary tool for this analysis was a primary antibody specific 
for RB3. Therefore, I generated anti-RB3 antisera in rabbits as described in the section 
below.
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COS-7 cells were transfected with plasmid expressing RB3 (pcDNARB3VSV). Samples of 
whole cell lysate from these cells (or untransfected C0S-7s) were separated by SDS-PAGE 
and transferred onto nitrocellulose. The nitrocellulose filters were then immunoblotted with 
the antisera (574 and 575) as primaiy reagent (see Methods chapter, section 2.10). The 
antisera were diluted 1:1000.
Figure 5.14 shows that the rabbits had raised antibodies to RB3 just 20 days after 
the first injection with GST-RB3*'^^^. The antisera detected a band at 41.2 ± 0.1 (mean ± 
S.E.) which is close the predicted molecular weight for RB3 of 37.7 kDa. The slight 
discrepancy between the observed and expected molecular weights was partly due to the 
fact that the plasmid used in these transfections (pcDNARB3VSV) expressed RB3 with an 
11 residue epitope tag (vsv tag) (Soldati and Perriard, 1991), which would produce a slight 
increase in the molecular weight. Note that this band was only detected in the lanes 
containing lysate from COS-7 cells transfected with plasmid expressing RB3 
(pcDNARB3VSV). No band was detected in lanes containing an equivalent amount of 
protein from untransfected COS-7 cells. This strongly suggests that these two antisera 
specifically detect RB3. The specificity of these antisera appears to be good; few 
background bands were observed on the blots.
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Interestingly, the subcellular distribution of RB3 is similar to that of a human 
truncated PDE4A species HSPDE4A4C (h6.1) (Huston et ah, 1996; McPhee et ah, 1999). 
Like RB3, h6.1 was largely cytosolic, but showed -15-20% association with the low speed 
(PI) pellet and no association with the high speed pellet (P2) in transfected COS-7 cells. 
Intriguingly, immunofluorescence analysis of the subcellular distribution of h6.1 by laser
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5.5.2 Subcellular distribution of RB3 in transfected COS-7 cell
The anti-RB3 antisera generated as described above were used to determine the 
subcellular distribution of RB3 in transfected COS-7 cells. COS-7 cells were transfected 
with a plasmid expressing untagged full length RB3 (pcDNARB3) provided by Prof. 
Bolger. The cells were homogenised and sepai'ated into low speed (PI) and high-speed 
(P2) particulate fractions and a cytosolic (S) fraction as described in the Methods chapter 
(section 2.11). The volumes of these fractions were normalised and samples were 
immunoblotted for RB3 to determine the relative amounts o f immunoreactive protein in 
each fraction. The apparent moleculai’ weight on SDS-PAGE of the untagged RB3 used in 
the above experiments was 39.3 ± 0.6 kDa (mean ± S.E., n=4). This is close to calculated 
molecular weight of RB3, which is 37.7 kDa.
The above method for subcellular distribution analysis has been used routinely to 
assess the subcellular distribution of a number of PDE4 isoenzymes including rpde6 
(Bolger et al., 1997; Huston et al., 1997; Lobban, 1994; McPhee et al., 1995; Shakur et al.,
1995). The results of the analysis for RB3 are shown in Figure 5.15 and Figure 5.16. Data 
for the subcellular distribution of rpde6 in transfected COS-7 cells from (McPhee et al., 
1999) are also presented in Figure 5.15 (b) for comparison.
Although both rpde6 and RB3 have major components in the cytosolic fraction of 
transfected COS-7, their subcellular distributions differ (Figure 5.15 and Figuie 5,16). 
Whereas -28%  of rpde6 immunoreactivity was associated with the P2-particulate fraction 
(McPhee et al., 1999) almost no RB3 was P2-associated. However, portions of both rpde6 
and RB3 are present in the PI low speed pellet fraction of transfected COS-7 cells. The 
rpde6;RB3 interaction differs from the RACKl ;PDE4D5 interaction (described in the 
Inti'oduction, section 1.8.5) where RACKl and PDE4D5 show veiy similar patterns of
distribution between the subfractions of transfected COS-7 cells (Yarwood et al., 1999).ofThe results suggest that endogenous RB3 does not mediate the associatioii^rpde6 with the 
P2 pellet fraction but may be involved in targeting rpde6 to the PI pellet fraction.
scanning confocal microscopy, showed that it had a non-random distribution throughout 
the cytosol, with pronounced labelling of the perinuclear cytoskeleton (Huston et ah,
1996). Therefore, this result shows that although fractionation studies suggest that RB3 is 
largely cytosolic, RB3 may actually localise mainly to specific subcellular structures in 
intact cells. During subcellular fractionation analysis, the interaction of RB3 with these 
structui'es may be disrupted to release soluble RB3 that appears in the cytosolic (S) 
fraction. The advantage of immunofluorescence analysis is that, in this method, the cells 
are not ruptured, but are instead fixed to microscope slides and stained with the appropriate 
primary antibody followed by an appropriate secondaiy antibody, tagged with a fluorescent 
marker. Therefore, this technique is more likely to preserve the protein-protein associations 
that exist in vivo. This indirect immunofluorescence analysis also can be used to analyse 
the co-localisation of two different proteins such as rpde6 and RB3.
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(a) RB3 subcellular distribution in C 0S 7 cells
P2
n
P I = 15.9 + 3.23 
P2 = 1.1 + 0 .43  
S = 82.9 + 3.65
(b) rpdeS subcellular distribution in C 0S 7 cells (Data from McPhee et al, 1999)
□
P I = 21 + 1.73 
P2 = 28 + 2.31 
S = 51 +2.31
Figure 5.15 Calculated distribution of RB3 immunoreactivity in the subcellular 
fractions of transfected COS-7 cells
(a) COS-7 cells were transiently transfected with pcDNARB3 prepared by Prof. Bolger, 
University o f Utah. The transfected cells were homogenised and fractionated to produce a 
low-speed pellet (PI), a high-speed pellet (P2) and a high-speed supernatant (S) as 
described in section 2.11.2. The volumes o f these fractions were normalised and samples 
o f varying volumes were separated on a 12% (w/v) SDS-PAGE gel and immunoblotted for 
RB3 using the anti-RB3 antiserum 574 (see section 2.10) as the primary antibody. The 
relative densities o f  the immunoreactive bands corresponding to RB3 were plotted against 
sample volume. The slopes obtained were used to calculate the distribution o f RB3 
immunoreactivity in the PI, P2 and S fractions. This procedure is described in detail in 
section 2.12.
(b) The subcellular distribution o f rpdeô in transiently transfected COS-7 cells as 
determined by McPhee et al, using the method described above, (McPhee et al., 1999) is 
shown for comparison.
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Figure 5.16 Subcellular distribution o f RB3 in transfected COS-7 cells
This figure shows a representative immunoblot for the subcellular distribution o f RB3 in 
transfected COS-7 cells. Equal volumes o f the fractions PI, P2 and S from RB3 transfected 
COS-7 cells were separated by 12% SDS-PAGE and immunoblotted for RB3. This result 
is typical for this experiment which was repeated three times.
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5.5.3 Subcellular distribution of ARA9/XAP2 in other cells
The above result for the subcellular distribution of RB3 disagrees slightly with the 
,results obtained for the subcellular distributions of the human and mouse homologues of
RB3 in the cells where they are expressed endogenously. Kuzhandaivelu et al showed that
human homologue, ARA9/XAP2, is present in the cytosolic but not the nuclear fraction of
HeLa cells and Ma et al showed the same result for the mouse homologue of AIP in mouse 
7hepatoma (hepalclg; cells (Kuzhandaivelu et ah, 1996; Ma and Whitlock, 1997). Both
I
groups defined the ‘nuclear fraction’ as the pellet obtained by centrifuging cell homogenate 
at a low speed. This fraction is comparable to the low-speed pellet (PI) obtained by our 
fractionation procedure where I observe -15%  of total RB3 immunoreactivity. Leaving 
aside the possibility that RB3 is incorrectly targeted in transiently transfected COS-7 cells 
as opposed to native cells, my result suggests that RB3 may indeed have a role in targeting 
proteins to the nucleus. This role has been suggested for both the mouse homologue AIP 
(Ma and Whitlock, 1997) and FKBP52 (Owens-Grillo et ah, 1996; Pratt et ah, 1999). f
5.6 The anti-RB3 polyclonal antibody detects the presence of RB3 in MOLT3 
monocytes, B-cells, Jurkat T-cells, U937 cells and HEK293 cells
All investigation into the functional significance of the rpde6:RB3 interaction 
would be aided by the availability of a cell line that expresses RB3 endogenously.
Therefore, the anti-RB3 polyclonal antibody generated above was used to screen a number 
of cell lines for the expression of RB3. Given that RB3 is highly conserved between 
species, (see Figure 5.1), we would expect the anti-RJB3 polyclonal antibody used above to 
be able to detect the human and mouse forms of RB3 (ARA9/XAP2 and AIP respectively).
A number o f immune system cell lines were included in this screen, in response to the 
observation by Meyer et al of high levels of AIP expression in mouse thymus and spleen 
(Meyer et ah, 1998). All cells were homogenised in 0.5% Triton X-100 and samples of the 
whole cell lysates, containing equal amounts of protein, were separated by SDS-PAGE 
(12% [w/v] acrylamide), transferred onto nitrocellulose and immunoblotted for RB3.
Whole cell lysate from COS-7 cells transfected with RB3 was used as a positive control.
An immunoreactive band that co-migrates with RB3 is observed in lanes 
corresponding to T-lymphoblastic MOLT-3 cells, U937 human monocytes, B-cells, Jurkat 
T-cells and human embryonic kidney (HEK) 293 cells (see Figme 5.17). These cell lines
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represent potential model systems for the study of RB3 function in vivo, although RB3 
expression appears to be relatively loAv in U937 cells. In addition, U937 monocytes 
(MacKenzie and Houslay, 2000) and Jurkat T-cells (Seybold et al., 1998) have been shown 
to express the human homologue of rpde6 (HSPDE4A4B, pde46). Therefore, an in vivo 
interaction between ARA9/XAP2 and the human homologue of rpde6 may occur in these 
cells. MOLT-3 monocytes (Hayon et al., 1999) and B-cells (Hewitt et al., 1997) have not 
yet been screened for PDE4 isoenzymes.
Intriguingly, my anti-RB3 antibody detected the expression of a slightly larger 
protein in COS-1 and COS-7 cells. This may represent a larger relative of RB3 that is 
preferentially expressed in COS cells, or a post-translationally modified form of RB3. A 
number of other immunoreactive bands are observed in the 55-83kDA range and these may 
represent high molecular weight immunophilins with structural similarities to RB3. A band 
at ~56kDa (marked with an aiTow) is frequently observed. This may correspond to RB3’s 
closest relative, FKBP52, which runs at approximately this molecular weight (Czar et al.,
1994).
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Figure 5.17 Western blot analysis of various cell lines for the presence of RB3
Homogenates from various cell lines were analysed by immunoblotting for the expression 
of endogenous RB3. The homogenates were prepared as described in the Methods chapter 
(section 2.11). Briefly, confluent adherent cells (COS-7 cells, COS-1 cells and HEK293) 
were washed twice with ice cold incomplete KHEM buffer and then scraped into complete 
KHEM buffer (+ ImM DTT and protease inhibitors) containing 0.5% Triton-X-100. 
Suspended cells (M0LT3 monocytes, U937 and B-cells) were centrifuged and washed 
twice with ice cold KHEM buffer before being resuspended in ice cold complete KHEM 
buffer containing 0.5% Triton-X-100. All cell lines were homogenised, Bradford assayed 
for protein and mixed with Laemmli buffer. These mixtures were then boiled for 3min and 
samples containing lOOpg o f protein were separated by SDS-PAGE (12% [w/v] acrylamide 
gel). A sample o f the S fraction from COS-7 cells transfected with RB3 (pcDNA RB3) was 
run on the same gel as a positive control. The separated proteins were transferred onto 
nitrocellulose and probed with anti-GST-RB3 antibody (antibody 574, see Table 2.10). The 
molecular weight standards (in kDa) are shown on the left. The position o f  the RB3 
immunoreactive band is marked with an arrow. The arrow above this, at around 56kDa, 
indicates a band that may correspond to FKBP52.
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5.7.1 Inhibition of rpdeG activity with GST-RB3^^^^
To assess the effect of RB3 on rpdeô activity, cytosol from rpdeô transfected COS- 
7 cells was incubated with increasing concentrations of purified GST-RB3*'^^^. To do this, 
GST-RB3^'^^^ was purified as described in the Methods chapter (section 2.7) and dialysed
5.7 RB3 interaction inhibits the activity of cytosolic rpdeG
An important step towards understanding the functional significance of the 
rpdeô:RB3 interaction is to determine whether RB3 affects the catalytic activity of rpdeô in 
vitro. If an effect was observed this would imply a direct role for RB3 in the regulation of 
PDE4 function and cAMP signalling. No effect would imply that RB3 might have a role in 
tethering rpdeô to other signalling proteins, or in targeting rpdeô to specific locations 
within the cell, without altering its catalytic activity. In this role, RB3 would be analogous 
to an adaptor protein or targeting subunit (Hubbard and Cohen, 1993).
I
into Tris buffer (20mM Tris-HCl, pH 8.0). The fusion protein was then diluted to the 
appropriate molar concentrations with Tris buffer. Equal amounts of cytosolic rpdeô, 
diluted in complete KHEM buffer and containing -1  EU of PDE activity (in the absence of 
GST-fusion protein), were combined with varying concentrations of GST-fusion protein, 
incubated on ice for Ih, and then assayed for PDE activity as described in the Methods I
chapter, section 2.1Ô. The time course presented in Figui'e 5.13 suggests that Ih is a 
sufficient time for the rpdeô:RB3 interaction to reach saturation.
As shown in Figure 5.18, G S T - R B 3 i n h i b i t e d  rpdeô activity in a dose- m
dependent manner. A 1 pM concentration of GST-RB3 achieved a maximum ~ôO% 
inhibition of the activity measured in the absence of GST-RB3 An identical I
concentration of GST had no effect on rpdeô activity. Therefore, the RB3 part of GST- 
was absolutely required for this inhibition. The concentration of GST-RB3^'^^^ 
that produced a half-maximal inhibition of rpdeô (IC50), was 0.22 ± 0.04 pM (mean value 
from three separate dose-response curves ± S.E.). Assuming that this IC50 value reflects the 
dissociation constant (Kj), this result suggests that RB3 associates with rpdeô with a 
submicromolar binding affinity.
RB3 could not completely inhibit rpdeô activity. Concentrations of GST-RB3^"^^^ 
higher than IpM  did not inhibit more than ~ôO% of total rpdeô activity (data not shown).
This suggests that RB3 is a non-competitive inhibitor, i.e. RB3 does not block the access of
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cAMP to the active site on rpdeô, but instead binds to another site, causing a 
conformational change that impairs the catalytic process.
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Figure 5.18 GST-RB3^‘^ ®^ inhibits cytosolic rpdc6 from transfected COS-7 cells
This figure shows the dose-dependent inhibition by GST-RB3^'^^®, o f soluble, cytosolic 
rpde6. This experiment was carried out as described in the Methods chapter, section 2.16. 
Equal samples of the cytosolic (S) fraction of rpde6 transfected COS-7 cells diluted in 
complete KHEM buffer were mixed with increasing concentrations of GST-RB3^'^^^ (□) or 
GST (O) diluted in 20mM Tris-HCl pH 8.0. Molar concentrations of GST-RB3*'^^^ and 
GST were determined on the basis of their calculated molecular weights. After incubating 
on ice for Ih, the mixtures were assayed for PDE activity as described in the Methods 
chapter. The PDE activities are expressed as a percentage o f the control activity in the 
absence of GST-fusion protein and are the means of thiee experiments ± S. E.
5 The immunophilin-lilce protein RB3 interacts with and inhibits the PDE4 cyclic AMP-specific
phosphodiesterase rpded (RNPDE4A5)
203
5.7.2 Inhibition of rpde6 with MBP-RB3’ ” °
To confirm that this inhibitory effect was not peculiar to a GST fusion of RB3,1 
assessed the effect o f a maltose binding protein (MBP) fusion of RB3 on rpdeô activity. A 
pMAL plasmid (pcDNARB3) expressing MBP fused to the amino terminus of full length 
RB3 (MBP-RB3^‘^ ^^ ) was generated by Prof. Bolger. I expressed and purified both MBP- 
RB3*'^^® and MBP (from the plasmid pMALc2) on amylose beads as described in the 
Methods chapter (section 2.7.2). The purified proteins were eluted with maltose buffer and 
dialysed into 20mM Tris pH8.0. Samples were analysed by SDS-PAGE and Coomassie 
blue staining (see Figuie 5.19).
The effect of MBP-RB3^"^^^ on rpdeô activity was determined as described for 
Gs t _r b 3^ -330 • equal samples of cytosolic rpdeô in complete KHEM buffer were mixed 
with a range of concentrations of MBP-RB3^"^^^, diluted in 20mM Tris pH8.0. These 
mixtures were then assayed for PDE activity. The results are shown in Figure 5.20.
The MBP-RB3^"^^^ fusion also inliibited rpdeô activity, the maximum inhibition 
being 40-45%. Note that a small inliibitory effect is also observed for MBP, although only 
at concentrations > 0.5qM. The IC50 (see above) for inhibition with MBP-RB3^'^^^ was 
0.11 ± 0.01 pM which is very similar to the I C 5 0  value obtained for GST-RB3^'^^^ (see 
section 5.7.1). Therefore, RB3 expressed in two different fusion constructs consistently 
causes inhibition of rpdeô in vitro. The submicromolar (-0.l-0.2pM ) I C 5 0  values obtained 
in both experiments may suggest that the rpdeô:RB3 interaction has a submicromolar 
dissociation constant (Kd).
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Figure 5.19 Purification o f M BP-RB3' “ " and MBP
A fusion o f  RB3 to the COOH-terminus o f  MBP (MBP-RB3''^^°) and MBP alone were 
over-expressed in E .co li and purified on amylose beads as described in the Methods 
chapter (section 2.7.2). The purified proteins were eluted with lOmM maltose in PBS and 
dialysed into 20mM Tris, pH8.0. lOpg samples were analysed by SDS-PAGE (12% [w/v] 
acrylamide) and Coomassie blue staining. The molecular weight standards (Biorad) are 
shown on the left o f  the figure. The actual molecular weights (from their sequences) o f  
MBP-RB3*'^^^ (88.5kDa) and MBP (50.8kDa) corresponded closely with their observed 
molecular weights o f  88.7kDa and 53.7kDa respectively.
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Figure 5.20 inhibits cytosolic rpde6 from transfected COS-7 cells
This figure shows the dose-dependent inhibition, by o f soluble, cytosolic
rpdeb from transfected COS-7 cells. The effects of both MBP-RB3^'^^^ (□) and MBP (O) 
on rpdeb activity are shown. This experiment was canied out as described for GST-RB3^’ 
in the legend for Figure 5.18 and the Methods chapter (section 2.16). The PDE activities 
are expressed as a percentage o f the control activity measured in the absence o f MBP- 
fusion protein and are the means o f tluee experiments ± S. E.
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î5.7.3 The presence of FK506 and rapamycin does not affect the inhibition of 
rpde6 by RB3
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As discussed in section 5.2.3.1, RB3 contains regions o f similarity to FKBP- 
homology domain I o f FKBP52 and also FKBP12 which essentially consists o f one FKBP- 
homology domain. The FKBP homology domains o f FK506-binding proteins contain the 
PPIase active site, which catalyses the cis-trans isomérisation o f peptide bonds on the 
amino terminal side o f pro line residues. PPIase activity is also found in the cyclophilins.
The immunosuppressant drugs FK506, rapamycin and cyclosporin A bind to and inhibit the 
PPIase active sites of immunophilins. Several studies have implicated PPIase activity in the 
regulation o f protein function. For example, the cyclophilin Cyp40 inliibits the DNA 
binding capacity o f the oncogenic transcription factor c-Myb. This negative regulation o f c- 
Myb is dependent on the PPIase activity o f Cyp40 (Leverson and Ness, 1998). Another 
example is the prolyl isomerase P in l . The PPIase o f this protein is required for it to restore 
the function o f the protein tau, which binds to microtubules and promotes microtubule 
assembly (Lu et al., 1999).
The presence o f proline rich motifs within the unique NHi-terminus o f rpde6 
suggested that a PPIase active site within RB3 might be responsible for its inhibitory effect 
on rpde6. To test this hypothesis, the inhibitory effect of GST-RB3 on rpdeb was
' "3assessed in the presence o f the PPIase inhibitors FK506 and rapamycin. These inhibitors
were incubated with GST-RB3^"^^“ at 4°C for Ih prior to the addition o f rpde6. The assay 1
was then carried out as described in section 5.7.1 and the Methods chapter, section 2.16.
Samples o f GST-RB3 ^ '^^^/immunosuppressant mixture were mixed with cytosolic rpde6 
from transfected COS-7 cells. These mixtures were then incubated for a further Ih  on ice 
and assayed for PDE activity. The final concentrations o f FK506 and rapamycin used in 
this assay were 1 pM and 1 OnM respectively. These were chosen on the basis o f their 
published affinities (K.s) for various FKBP proteins as shown Table 5.2 below.
Table 5.2 Affinities of FK506 and rapamycin for various FKBP proteins.
FKBP protein Ki FK506 (iiM) Ki Rapamycin 
(nM)
Reference
FKBP 12 0.6 0.25 (Park et al., 1992)
1 - (Bram et al., 1993)
1.7 - (Harrison and Stein,
0.2 1990)
(Bierer et al., 1990)
FKBP 13 55 - (Bram et al., 1993)
FKBP25 160 0.9 (Galat et al., 1992)
180 - (Bram et al., 1993)
FKBP52 10 8 (Peattie et al., 1992)
:
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For E = enzyme, I = inhibitor and EI= enzyme/inhibitor complex Ki= [E][I]/[EI]
The effect o f IpM  GST-RB3^‘^ ^^  (or GST) on rpde6 activity in the presence of 
IpM  FK506 or lOnM rapamycin was determined. Figure 5.21 showed that neither lOnM 
rapamycin nor IpM  FK506 significantly affected the inhibitory effect of RB3 on rpde6 
activity. The presence o f these concentrations o f drugs produced no change the dose- 
response curve for inhibition o f rpde6 by GST-RB3^“^ ^^  (n=l, data not shown). One can 
infer from these results that the interaction between rpde6 and RB3 is unaffected by the 
presence o f FK506 or rapamycin.
These results imply regulation o f PDE activity is not involved^the mechanism of 
immunosuppression o f either FK506 or rapamycin. In addition to these results, Carver and 
coworkers failed to detect the binding o f  ^ H-FK506 to ARA9/XAP2. These results are 
perhaps unsurprising given that an aligmnent between RB3 and FKBP52 shows that only 3 
o f the 14 residues involved in FK506 binding are completely conserved in RB3 (Kay,
1996; Van Duyne et al., 1991) (see Figure 5.3). Therefore it is probable that RB3 lacks 
both FK506/rapamycin binding capacity and PPIase activity. This further suggests that 
RB3, unlike FKBP 12, does not interact with calcineurin, A composite surface including 
components o f both FK506 and the FKBP 12 is believed to be necessary for a strong 
interaction with calcineurin (Aldape et al., 1992; Futer et al., 1995). As RB3 does not 
appear to bind to FK506 this presumably rules out an interaction with calcineurin.
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Figure 5.21 rpde6 is inhibited by RB3 in the presence of IpM FK506 and lOnM 
rapamycin
GST or GST-RB3^'^^° (4pM) were incubated with 4pM  FK506 or 40nM rapamycin on ice 
for Ih  at 4°C. 25 pi samples o f this mixture were incubated with 25 pi samples o f COS-7 
cell expressed rpde6, diluted in complete KHEM buffer, for a fmther Ih  at 4°C and then 
assayed for PDE activity by the addition o f 1 pM 8-[^H]-labelled cAMP. The final 
concentrations in the assay were therefore GST-RB3^"^^® = IpM , FK506 = IpM , rapamycin 
= lOnM. The activities are presented as a percentage o f the control activity determined in 
the absence o f GST-fusion protein.
These results were presented previously in Figure 5.18 and are shown here for 
comparison.
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5.7.4 Cytosolic rpde6 is inhibited by interaction with the COOH-terminal half 
of RB3 (amino acids 170-330)
In section 5.4 I showed that the COOH terminal half o f RB3 (amino acids 170-330) 
is sufficient for interaction with rpde6. However, another region o f RB3 may be required 
for rpde6 inhibition. Therefore, the effects o f the NH2- and COOH- terminal halves o f RB3 
(illustrated in Figure 5.8) on rpdeb activity were determined. Equal samples o f ipde6 from 
transfected COS-7 cells were incubated with increasing concentrations o f GST-RB3^‘^^  ^
and GST-RB3’ ®^'^ ^^  using the method described above for GST-RB3*"^^® (section 5.7.1). 
The PDE activity in these samples was then determined.
As shown in Figure 5.22, the COOH terminal half o f RB3 expressed as a GST 
fusion (GST-RB3^^®’^ ^^ ) inhibited rpde6 with the similar potency to the full length RB3 
(GST-RB3’"^ ^^ ). Absolutely no inhibition was observed with the NH2-terminal half o f RB3
expressed as a GST-fiision (GST-RB3^'^^^). The maximum inliibition o f rpde6 (-50% ) was 
achieved with IpM  GST-RB3^^°"^^^ The concentration o f GST-RB3*^^'^^“ that produced 
an inhibition o f rpde6 that was 50% of the maximum inhibition (IC50) was 0.31 +0.06 pM 
(mean value fiom three separate dose-response curves + S.E.), which is close to the value 
o f 0.22 ± 0.04 pM obtained for GST-RB3^“^ ^^  (see section 5.7.1). Therefore, the COOH- 
terminal half o f RB3 appears to be able to mediate both the binding and inhibition o f 
rpde6. Note that within the COOH-terminal 161 amino acid residues o f RB3, sepaiate 
sequences may mediate binding and inhibition. These results suggest that regions of 
sequence similarity to FKBP 12 within the NH2-terminal half o f RB3 do not appear to be 
involved in either binding or inhibition.
As discussed in section 5.2.3.2, this COOH terminal region (amino acids 170-330) 
interacts with hsp90 and AhR and contains a TPR motif (Carver et al., 1998; Meyer and 
Perdew, 1999). No specific function has yet been assigned to the NH2-terminal half o f f
RB3. As discussed above (section 5.4.1), the NH2-terminus o f RB3 may introduce a 
mechanism of regulation whereby changes to its phosphorylation status or protein-protein 
interactions affect the inhibitory binding o f the COOH-terminal half to rpde6. :
Another example o f enzyme inhibition mediated by a TPR-containing protein is the 
inhibition o f hsp90 ATPase activity by Stil (Prodromou et al., 1999). S til causes 100% 
inhibition o f hsp90 ATPase activity by directly contacting and obstructing the active site.
In contrast the -50%  inhibition observed with GST-RB3*^^'^^^ suggests that RB3 inhibits
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rpdeô allosterically, causing a conformational change that reduces its catalytic efficiency 
without completely abolishing activity or blocking the active site.
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Figure 5.22 GST-RB3^ bu t not GST-RB3‘"“  ^inhibits cytosolic rpde6
This figure shows the dose-dependent inhibition, by GST-RBS^^ '^^^® but not by GST-RB3^” 
o f soluble cytosolic ipde6. Samples of the cytosolic (S) fraction o f ipde6 transfected 
COS-7 cell fractions diluted in complete KHEM buffer were mixed with increasing molar 
concentrations o f GST-RB3^™’^ ®^ (□) or GST-RB3^‘^^  ^ (O) diluted in 20mM Tris-HCl, 
pH8.0 as described in the Methods chapter, section 2.16. After incubating on ice for Ih  the 
mixtures were assayed for PDE activity. The activities are expressed as a percentage o f the 
control activity in the absence o f GST-fusion protein and ar e the means o f three 
experiments ± S.E.
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6.8 Particulate rpdeS is resistant to inhibition by GST-RB3^^^° and GST- 
RB3^ 70-330
Full length RB3 and the COOH-terminal half of RB3 (RB3^70-330^  ^which contains 
the TPR motif and excludes the NHz-terminal FKBP homology region, have both been 
shov^n to inliibit cytosolic rpde6 (section 5.7). However, rpdeb activity is not only found in 
the cytosolic fraction (-51% ), but is also distributed between the PI low-speed pellet 
fraction (-21% ) and P2 high-speed pellet fraction (-28% ) o f both brain and transiently 
transfected COS-7 cells (McPhee et al., 1995; McPhee et al., 1999). Furthermore, the f
association o f rpde6 with a combined particulate/membrane fraction (PI and P2) is 
resistant to disruption with high salt concentrations (2M NaCl) and/or detergent treatment 
(1% Triton X-100) (McPhee et al., 1995). This suggests that ipde6 may bind to cytoskeletal 
structures associated with these fractions that are not disrupted with detergent and/or salt 
(Jackson et ah, 1994) (Slusarewicz et ah, 1994). Any interaction with peripheral or integral 
membrane protein or membrane lipids would be disrupted by such treatments (McPhee et 
ah, 1995). As discussed in section 5.5.2 (Figure 5.15) RB3 is also found In the PI pellet 
fraction (-16% ) and the cytosolic fraction (-83% ) of transfected COS-7 cells whilst being 
absent from the P2 pellet fraction.
An outstanding question was whether P 1 and/or P2 pellet-associated rpde6 were 
susceptible to binding/inhibition by RB3 in a manner similar to cytosolic rpde6. Therefore, 
the activity o f PI and P2 pellet-associated ipde6 was assessed in the presence o f increasing 
concentrations o f purified GST-fusions o f either full length RB3 (GST-RB3^‘^ ^ )^ or the
TPR-containing COOH-terminal half o f RB3 (GST-RB3 " ). I used the assay procedure ::î170-330^  I  t   r r  
described above in section 5.7 and in the Methods chapter, section 2.16. COS-7 cells were 
transfected with rpde6, homogenised and fractionated to obtain the P 1 and P2 pellet 
fractions as described in the Methods chapter, section 2.11. These pellet fractions were 
resuspended in complete KHEM buffer. Equal samples of these resuspended pellet 
fractions, containing -1 EU of PDE activity in the absence o f GST-fusion protein, were 
incubated on ice for Ih  with increasing concentrations o f either GST-RB3^'^^^, GST- 
RB31^ 0-330 (COOH-terminal half), GST-RB3^’^^  ^(NHi-terminal half) or GST. The samples 
were then assayed for PDE activity as described in the Methods chapter, section 2.15.
As shown in Figure 5.23, GST-RB3^‘^ °^ (full length RB3) did not cause inhibition 
o f P I pellet-associated rpde6 at concentrations up to 3pM. In contrast, soluble cytosolic 
rpde6 was dose-dependently inhibited over this range (Figure 5.18, section 5.7.1). The
.3
NH2-terminal half o f RB3 (GST-RB3^‘^^ )^, which has been shown not to inhibit cytosolic 
rpde6, also did not cause inhibition o f PI pellet-associated rpde6. Therefore, association o f 
rpde6 with the PI low speed pellet fraction appeared to block the inliibitoiy effect o f RB3 
that is observed using cytosolic rpdeb.
A similar result was observed with the P2 (high-speed pellet fraction)-associated 
rpde6 shown in Figure 5.24. Thus, neither GST-RB3^'^^® (full length RB3) nor GST-
170-330 (COOH-terminal half o f RB3) caused inliibition o f P2 pellet-associated rpde6 in 
contrast to the inliibition achieved using soluble cytosolic rpde6. Therefore, association of 
rpde6 with both particulate fractions (PI and P2) appears to prevent the inhibitory effect o f 
RB3.
Note that in these assays, the pellet fractions were resuspended in complete KHEM 
buffer in the absence of detergent or high salt concentrations. This treatment would have 
left many o f the multi-protein complexes intact, including those o f the cytoskeleton. These 
data suggest that particulate fraction-associated rpde6 is protected from RB3 inhibition, 
perhaps by interaction with other proteins. Indeed, it has been suggested that SH3 domain 
containing proteins, such as fodrin and cortactin, may anchor rpde6 to the cytoskeleton and 
hence the particulate fraction o f cells (see Introduction, section 1.8.2) (Houslay et al., 1997; 
Houslay, 1996; Houslay et al., 1998). One possibility is that, in the particulate fractions, 
access o f RB3 to rpde6 may be blocked by SH3 domain containing proteins. Alternatively, 
these proteins may block the ability of RB3 to alter the conformation o f rpde6 so as to 
affect its activity.
O f course, given that both RB3 and rpde6 are present in PI pellet fraction it is |
possible that PI pellet-associated rpde6 is actually in a complex with endogenous RB3 (and 
possibly other proteins) in which it is inliibited. If that is so, we would expect the activity 
o f the PI pellet fraction rpdc6 to be less than that of cytosolic rpdc6. Indeed, the activity o f 
the combined particulate fraction (PI + P2) rpde6 was shown to be -67%  (McPhee et al.,
1995) o f that obtained for cytosolic rpde6.
RB3 may be involved in targeting rpde6 to the P 1 fraction. However, the 
submicromolar affinity of the rpde6:RB3 interaction, estimated from inhibition studies 
(section 5.7) may not be high enough for RB3 to mediate the targeting o f rpde6 to the PI 
fraction by itself. Both RB3 and rpde6 may bind with high affinity to other unidentified 
protein binding partners. These interactions need not necessarily exclude the association o f
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rpde6 and RB3 in the PI-pellet. Indeed, these other interaction partners may facilitate the 
binding o f rpdeb to endogenous COS-7 RB3 in the PI pellet.
In conclusion, the above results suggest that PI and P2 pellet-associated rpde6 is 
resistant to inhibition with both GST-RB3^'^^® and GST-RBS^^^-^ao contrast to soluble 
RB3, which is inhibited by both. The unidentified protein(s) that interact with ipde6 in the 
particulate fraction may sterically block the access of exogenous RB3 or force rpde6 to 
adopt a conformation in which it is inhibited. In the PI pellet fraction the interacting 
protein may be endogenous RB3 itself. The possibility that the GST tag prevents the access 
o f RB3 to the particulate fraction rpde6 in this assay cannot be excluded.
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Figure 5.23 PI pellet fraction rpde6 is resistant to inhibition by full length RB3
This graph shows the effect o f increasing concentrations o f GST-RB3^‘^ ®^ (full length) or
GST-RB3^'’^^  (NHa-terminal half o f RB3) on the activity o f low speed pellet (PI) fraction- 
associated rpde6. Samples o f the PI-pellet fraction of rpde6-transfected COS-7 cells, 
diluted in complete KHEM buffer, were mixed with increasing molar concentrations o f 
G ST-R BS''^” (□) or GST-RB3‘‘‘“  (O) diluted in 20mM Tris-HCl pHS.O. After incubating 
for Ih  on ice the mixtures were assayed for PDE activity as described in the Methods 
chapter, section 2.15. The activities are expressed as a percentage o f the control activity in 
the absence o f GST-fusion protein and are the means o f tlii'ee experiments ± S. E.
#
5 The imimmophilin-like protein RB3 interacts with and inhibits the PDE4 cyclic AM P-specific
phosphodiesterase rpde6 (RNPDE4A5)
216
coü
■ >
■'ë<
140
1 2 0
1 0 0
80
60
40
20
0
L o  T* _
S . „ g
0 .01 0.1
Conc. GST/QST-fusion (^M)
O  = GST  
□  =  G S T -R B 3 1 -3 3 0  
(full length)
A  =  G ST -R B 3170-330
(COOH-term.)
Figure 5.24 F2-fraction rpde6 is resistant to inhibition by both full length RB3 and
the COOH-terminal half of RB3 (RB3 1 7 0 -3 3 0
This graph shows the effect o f increasing concentrations o f GST-RB3*“^ ^^  (full length), 
GST-RB3^^°'^^® (COOH-terminal half o f RB3) and GST on the activity o f high-speed pellet 
(P2) fraction associated rpde6. Samples o f the membrane (P2) fraction of rpde6 transfected 
COS-7 cells, diluted in complete KHEM buffer, were mixed with increasing concentrations
o f GST-RB3^-^^^ (□), G S T - R B 3 ( A )  or GST (O) diluted in 20mM Tris-HCl pH 8. 
After incubating for Ih on ice the mixtures were assayed for PDE activity as described in 
the Methods chapter, section 2,15. The activities are expressed as a percentage o f the 
control activity in the absence o f GST or GST-fusion protein and are the means o f tlu ee 
experiments ± S. E.
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5.9 Lyn-SH3 competes with RB3 for interaction with rpdeG
It has been shown previously that the unique NHz-terminal splice domain o f rpde6 
contains tluee proline-rich putative SH3 domain binding motifs each with the minimal 
consensus PxxP (Alexandropoulos, 1995; O' Connell et al., 1996; Pawson, 1995) (see 
Introduction chapter, section 1.8.2). In addition, this 102 amino acid splice domain confers 
on rpde6 the ability to interact with the SH3 domains of a number o f Src family tyrosyl 
kinases, expressed as GST fusions (O' Comiell et al., 1996). Particularly strong interactions 
were observed between rpde6 and the SH3 domains of Src, Lyn and Fyn (O' Comiell et al.,
1996). As discussed in the previous section, SH3 domain-containing proteins may mediate 
the interaction of rpde6 with the particulate fractions. These interactions may protect 
particulate rpde6 from inliibition by soluble RB3.1 investigated whether the interaction of 
soluble cytosolic rpde6 with Lyn SH3 would block the inhibitory binding o f RB3. Note that 
O ’Connell et al showed that interaction with Lyn SH3-GST does not alter rpde6 activity 
(O' Connell et al., 1996).
The effect o f IpM  GST-RB3^'^^^ on rpde6 activity in the presence o f Lyn SH3-GST 
was assessed. The experimental system I used is detailed in the Methods chapter, section 
2.16.1. A GST fusion o f the SH3 domain o f Lyn [see (McPhee et al., 1999; O' Connell et 
ah, 1996)], was expressed in E coli and affinity purified on glutathione Sepharose beads 
(see section 2.7.2). In order to bind rpde6 to Lyn SH3, a sample (400pg) o f the purified Lyn 
SH3-GST bound to glutathione beads was incubated with a sample (240EU) of cytosolic 
rpde6 from transfected COS-7 cells. The beads were washed with complete KHEM buffer 
and complexes o f rpde6 bound to Lyn SH3-GST were eluted with glutathione elution 
buffer.
Samples o f the glutathione eluate containing rpde6 bound to Lyn SH3-GST were 
mixed 1:1 (v/v) with purified GST-RB3‘'^“  or GST diluted in 20mM Tris-HCl, pHS.O.
These mixtures were incubated on ice for Ih  prior to an assay for PDE activity. As a 
control, the activity o f samples o f cytosolic rpde6, diluted in glutathione elution buffer, 
were determined in the presence or absence of GST-RB3*'^^^ or GST. The activity o f rpde6 
± Lyn SH3-GST added to the assay was within the linear range (i.e. the amount of rpde6 
added to the assay would consume no more than 10% of the cAMP substrate in the absence 
o f GST or GST-RB3^"^^^). The final concentration o f GST-RB3*“^ ®^ or GST in the assay 
was IpM .
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The results in Figure 5.25 show that the association o f Lyn-SH3 with rpde6 
severely reduced the inliibitory effect o f RB3 on rpde6 activity. GST-RB3^'^^^ produced 
only ~20% inhibition o f Lyn SH3-associated rpde6 in contrast to the -45%  inhibition 
observed in the absence o f GST-RB3^'^^® (see Figure 5.18). This result suggests that Lyn 
SH3-GST does indeed alter the functional interaction o f RB3 with rpde6.
It may be that Lyn-SH3 and RB3 bind, in a competitive and mutually exclusive 
manner, to overlapping or topologically adjacent sites on rpde6. Alternatively, Lyn SH3 
binding may affect the conformation o f rpde6 such that RB3 binding is now unable to 
cause inhibition. The latter suggestion is feasible as we already know that SH3 binding to 
the LR2 region of HSPDE4 A4B (the human homologue o f rpde6) can cause 
conformational changes in the catalytic unit (McPhee et a l ,  1999). The slight inhibition 
that is observed in the presence o f Lyn SH3-GST suggests that some RB3 can successfully 
compete with Lyn SH3 for interaction with ipde6. It should be noted that some dissociation 
o f the rpde6/Lyn SH3-GST complex may have occurred after it had been eluted with 
glutathione.
On the assumption that all the Lyn SH3-GST was eluted after binding o f ipde6, the 
final concentration o f Lyn SH3-GST in this assay was estimated to be 8-lOpM (see 
Methods chapter, section 2.16.1). Lyn SH3-GST is thus in considerable excess over the 
1 pM GST-RB3^"^^^ in this assay. Therefore, we cannot use these results to draw 
conclusions on the relative affinities o f Lyn SH3 and RB3 for rpde6. However, we can 
conclude that when Lyn SH3-GST is present in excess, it hinders RB3-mediated inhibition 
o f rpde6. This result lends support to the suggestion that P2-p articulate fraction associated 
rpde6 may be protected from RB3-mediated inhibition by interaction with other proteins.
■a
%
5 The immunophilin-like protein RB3 interacts with and inliibits the PDE4 cyclic AM P-specific 219
phosphodiesterase rpde6 (RNPDE4A5)
.
. ......
"11:
120
Ç  80
‘Free’ rpdeG
□  GST(lj iM)
■  GST-RB3i-330(1|uM)
Lyn-SH3 
associated rpdeG
Figure 5.25 Lyn SH3-associated rpde6 is resistant to RB3 inhibition
The cytosolic fraction o f COS-7 cells expressing rpde6  was incubated with a fusion o f  the 
SH3 domain o f Lyn tyrosyl kinase immobilised as a GST fusion protein on glutathione 
Sepharose beads. After washing the beads, complexes of rpde6  bound to Lyn SH3-GST 
were eluted with lOmM glutathione, 50mM Tris pH 8.0. 25 pi samples o f the eluate ('Lyn 
SH3 associated rpdeb’) were added to 25pl samples o f 4pM GST-RB3^'^^^ or 4pM  GST 
diluted in 20mM Tris pH 8.0. After incubating on ice for Ih, PDE activity was measured in 
the presence o f IpM  8 -[^H] cyclic AMP as described in the Methods chapter (section 
2.15). As a control, cytosolic rpde6  (‘fi*ee’ rpde6 ), diluted in glutathione elution buffer, was 
PDE assayed in the presence or absence o f GST-RB3^'^^^ or GST. The concentration of 
both GST and GST-RB3^'^^° in the final reaction mixture was IpM . The activities are 
expressed as percentages of the control activity determined for Lyn SH3-associated rpdeb 
in the absence o f GST-RB3^'^^^ or GST. The values are the means o f 3 experiments ± S.E.
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5.10 Apl rpdeG (A2-10 rpdeG) is inhibited by RB3
For several years it has been appreciated that the unique NHz-terminal splice 
domains o f PDE4 isoenzymes have a profound effect on the kinetic properties o f the 
catalytic unit. Therefore, proteins that regulate PDE activity may act by binding to these 
NHi-terminal splice domains. In order to understand the mechanism for RB3 inliibition of 
rpde6 , NHi-terminal deletions o f rpde6  were prepared (by Dr Grant Scotland, University of 
Glasgow). I tested one o f these, Apl ipde6 , for inliibition by RB3. Apl rpde6  lacks the first 
9 amino acids o f rpde6  after the initiator methionine (see Figure 5.28, section 5.11, below). 
Interestingly this region contains one o f the 3 putative SH3 domain binding motifs (O'
Comiell et al., 1996). In addition, SerS in this region is within a putative phosphorylation 
site for PKC (S^E^R*®) (see Table 5.3, section 5.11.3.2, below).
As shown in Figure 5.26 and Figure 5.27, GST-RB3^'^^^ and GST-RB3^^^'^^^ both 
caused dose-dependent inhibition o f Apl rpde6 . IpM  GST-RB3’'^^  ^caused a maximum 
inhibition o f around 45-50%. Slightly less marked inhibition (-40% ) was effected by an 
equivalent concentration o f GST-RB3^^®‘^ °^. The IC50 for GST-RB3^"^^^ inhibition o f Apl 
rpde6  was 0.18 ± 0.05pM (mean ± S.E., n -  3). The IC50 for GST-RB3^^^"^^® inhibition was 
0 .2 0 pM  (n = l).Both o f these IC50 values correspond well with the equivalent values 
obtained for inliibition full-length rpde6  (see Figure 5.18 and Figure 5.22). Therefore, we 
can conclude Apl retains the structural features that are required for inhibition by RB3.
These results suggest that RB3 interaction occurs at site downstream of ArglO.
Studies by Beard et al have shown that the association Apl rpde6  with Lyn SH3 is 
severely reduced is comparison with full-length rpde6  (Beard and Houslay, unpublished).
As shown in the previous section, the presence of Lyn SH3 paitially blocks the inliibition 
o f flill-length rpde6  by RB3. Therefore, it would be interesting to see whether the presence 
o f Lyn SH3 also affects the inliibition of Apl rpde6  by RB3.
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Figure 5.26 Apl rpde6 is inhibited by GST-RB3*"^^®,
The effect o f GST-RB3*‘^ ^^  (□ )  or GST (O) on the activity o f soluble Apl rpde6 is shown. 
Equal samples o f the cytosolic fraction o f COS-7 cells transfected with the NHa-terminal 
rpdeb deletion mutant Apl rpde6 (A2-10 rpde6), were diluted in complete KHEM buffer 
and incubated for Ih  on ice with increasing concentrations o f either GST-RB3^'^^^ or GST 
diluted in 20mM Tris-HCl pH 8.0. These mixtures were then assayed for PDE activity. The 
activity is expressed a percentage o f the control activity (~1EU), measui ed in the absence 
o f GST-fusion protein or GST. The values for the GST-RB3^'^^^ (□ )  and GST (O) curves 
are the means o f 3 and 2 experiments, respectively ± S.E.
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Figure 5.27 Apl rpde6 is inhibited by
The effect o f GST-RB3^"^^^ (□ )  or GST (O) on the activity o f soluble Apl rpde6 (A2-10 
rpde6) is shown (n = 1). The experiment was earned out as described in the legend for 
Figure 5.26. The activity is expressed as a percentage o f the control activity (~1 EU), 
measured in the absence o f GST-fusion protein or GST.
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5.11 Locating the binding region on rpde6 for RB3
Locating the acceptor site(s) for RB3 on rpde6 will provide us with an insight into 
the mechanism o f RB3 inhibition. An important question is whether the acceptor site is 
within a conserved region (U C R l, UCR2 or catalytic unit) or a region unique to rpde6. 
Answering this question will allow us to predict whether other PDE4 splice variants in 
addition to rpde6 ar e regulated by RB3.
I have screened a series o f NHi-terminal truncations o f rpde6, (prepared by Dr. G. 
Scotland and Dr. M. Beard), for interaction with RB3 (see Figure 5.28). These NH 2- 
terminal truncations were engineered using the expression vector pSV-SP0RT-rpde6 in 
which rpde6 expression is under the control of an SV40 promoter. These deletions were 
truncated at various significant positions within the NHi-terminus o f rpde6. Apl was 
generated by removal o f the sequence containing the first putative SH3 domain binding 
motif. Ap4 was made by truncating to the first splice junction, where rpde6 and rpde39 
diverge (see Figure 5.28, panel A). Ap5 represents rpde6 downstream of the start o f U CRl. 
In Ap6, rpdeb is truncated to the beginning of linker region 2 (LR2), whereas Ap7 was 
generated by truncation to 5 amino acid residues before the start o f UCR2. Met^^RDl 
represents the core region o f rat PDE4A downstream of the splice junction for RDI, in the 
centre o f UCR2 (Figure 5.28, panel A). The deletion mutant Ap6-loop Ap7 is equivalent to 
Ap6 ipde6 with the region from the start o f UCR2 to the second splice junction removed.
GST-RB3 ■ was used in a pull down assay to test the above rpde6 truncates for 
interaction with RB3. The plasmids expressing the above deletion mutants were each 
transiently transfected into COS-7 cells. Samples o f cytosol from these transfected cells, 
containing lOOEU of PDE activity, were incubated with samples of GST-RB3^^®"^^® (or 
GST) on glutathione Sepharose beads at 4°C for 30min. The time course obtained for the 
binding of rpde6 to GST-RB3*^^'^^^ suggested that this was sufficient time for interactions 
to occur to completion (see Figure 5.13, section 5.4.2). The beads were then isolated by 
centrifugation and washed with complete KHEM buffer. Bound protein was eluted with 
glutathione buffer. The percentage binding o f the rpde6 deletion mutants to GST-RB3^^^“^ ®^ 
was determined from the total PDE activity in the bound and unbound fraction, as 
described previously (see section 5.4). The results are shown in Figure 5.29.
The rpde6 truncates Apl to Ap7 showed significant association with GST-RB3^^^'
However, in contrast, very little association was observed between Met^^RDl and
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GST-RB3^^°"^^*^.No association was observed between any o f the deletion mutants and 
GST (Figure 5.29). These results, obtained from following PDE activity, were supported by 
an analysis o f the immunoreactive protein in the bound and unbound fractions (Figure 
5.30). This was monitored as described above in section 5.4. Samples o f the bound and 
unbound fraction were separated by SDS-PAGE, transferred onto nitrocellulose and 
immunoblotted with anti-PDE4A polyclonal antibody as primaiy reagent. The percentage 
binding values of the various NH 2-terminal deletions to GST-RJB3^^°"^^^ were calculated 
from the densities of the immunoreactive bands obtained. Again, the deletion mutants Apl 
to Ap7 showed significant binding in contrast to Met^^RDl which showed veiy little 
binding.
These results led us to conclude that a 42 amino acid residue region from the start o f 
UCR2 (Ser218) to the RDI splice junction (Arg259) in the middle o f UCR2, is necessary 
for interaction with RB3. In support o f this hypothesis, removal o f this region from Ap6 
rpde6, to create the mutant Ap6-loop-Ap7, abolished binding to GST-RB3^^^'^^^.
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Figure 5.28 NH2 -terminal truncates of rpde6 used to determine the RB3 binding 
domain.
Panel A shows a schematic representation o f ipde6 in relation to the other PDE4A splice 
variants, rpde39 (RNPDE4A6) and RDI (RNPDE4A1). The unique NHi-terminal splice 
domains are shown as black lines. The two splice junctions are marked with grey circles. 
Upstream conserved regions are shown as grey bars, the catalytic imit is indicated with a 
white bar. Panel B shows the range o f rpde6 NHi-terminal deletion mutants used to map 
the binding site for RB3. The names o f the NHz-terminal truncates (in parentheses) and the 
amino acid residues deleted, ai’e shown on the left. Plasmids expressing deletion mutants 
Apl-Ap7 were generated by mutagenesis o f the cDNA for full-length rpde6 in pSVL, by Dr 
G. Scotland, University of Glasgow. Ap6 loop Ap7 is equivalent to Ap6 rpde6 with the 
first half o f UCR2 deleted and was generated by Dr M. Beard. Met^^RDl was engineered 
in pSV-SPORT by our group previously (Shakur et al., 1993). For all truncates except 
Met^'^RDl, the initiator methionine for full-length rpde6 was retained. Excluding this 
methionine, the start sites for the various truncation mutants were as follows: Apl= Seri 1, 
Ap4= Leul03, Ap5= Serl35, Ap6= Pro 197, Ap7= Ser218. The start site for Met^^RDl is at 
Met260 in rpde6.
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Figure 5.29 Association of rpde6 NH2 -termiiial deletion mutants with the COOH- 
terminal half of RB3 (GST-RB3” "'^ "^) (PDE activity data)
This chart shows the relative binding o f rpde6 NH2“terminal deletion mutants to the GST- 
RB3i70-“ ° (COOH-terminal half o f RB3, amino acids 170-330) and GST alone. COS-7 
cells were transiently transfected with the NHi-deletions illustrated in Figui’e 5.28. Samples 
o f the cytosolic (S) fractions from these cells were incubated with pur ified GST-RB3^^^"^^^ 
or GST bound to glutathione Sepharose beads. The beads were then washed with complete 
KHEM buffer and bound protein was eluted with 1 OmM glutathione, 50mM Tris pH 8.0, 
The total PDE activity in the bound ( E U b o u n d )  and unbound (E U u n b o u n d )  fractions was 
determined using the PDE assay. The percentage o f rpde6 that was down’ by the
GST-fusions under the experimental conditions described was calculated as follows: % 
binding = 100% x [E U b o u n d  /  ( E U b o u n d +  E U u n b o u n d ) ] -  The percentage binding values are 
shown as mean of thr ee experiments + standard error. The pull down assay protocol is 
described in detail in section 2.17. FL= full-length rpde6.
*No control data was obtained for the association of Ap6 loop Ap7 with GST.
5 The immunophilin-like protein RB3 interacts with and inhibits the PDE4 cyclic AM P-specific
phosphodiesterase rpde6 (RNPDE4A5)
227
c
B FL3Eco
0)0)■a
%T3CL
A4
A5
A6mç
i0 A7
Xz
m et26
60 800 20 40
% binding to GST-RB3^7o-33o
Figure 5.30 Analysis of the binding of rpde6 NHz-terminal deletion mutants to the 
COOH-terminal half of RB3 (GST-RBS'™-^^*) by western blotting
The % binding o f the NHa-terminal ipde6 deletion mutants (illustrated in Figure 5.28) to 
the COOH-terminal half of RB3 (GST-RB3^^^'^^^) was re-assessed by measuring PDE4A 
immunoreactivity in the bound and unbound fraction from the pull down assay described in 
the legend for Figure 5.29, Samples o f the bound and unbound fractions were separated by 
SDS-PAGE and immunoblotted for RB3. The % binding was calculated from the relative 
densities o f the immunoreactive bands for the bound and unbound fractions. This 
procedure is described in detail in the Methods chapter, section 2.17.1. The % binding 
values are the means of three experiments ± S.E. FL= full-length rpde6.
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5.11.1 NH2 “termînal deletions of rpdeG bind to RB3 with greater affinity than 
the full length rpdeG
The percentage binding values obtained above give a rough indication o f the 
relative binding affinities o f the rpde6 NHi-terminal deletion mutants to GST-RB3^^^'^^^. 
Comparison o f the percentage binding values obtained for the deletion mutants, determined 
from PDE activity and immunoreactivity measurements, suggests truncation o f the NH2- 
terminus up to Ser218 increases the affinity o f the interaction o f rpde6 with the COOH- 
terminal half o f RB3. Analysis o f both PDE activity and immunoreactivity suggested that 
the percentage binding was highest for Ap5 rpdeb; -40-50%  binding was observed for Ap5 
in contrast to -10-15%  binding observed for full-length rpdeb (see Figure 5.29 and Figure 
5.30 above). The binding values for Ap6 (-20-35%) and Ap7 (-25-30% ) were also 
significantly higher than that o f the full-length rpdeb. Therefore it appears that sequences 
upstream of the start of Ap5 (start o f U CRl, see Figure 5.28) do not enliance the binding of 
rpde6 to RB3.
It seems that removal o f sequences in rpdc6 that are not involved in binding RB3 
may increase the affinity o f the interaction. Therefore the sequences upstream o f the RB3 
binding site in rpde6 may impede its interaction with RB3, possibly by steric hindrance. 
Post-translational modifications or protein-protein interaction that alter the conformation of 
rpdeô, may change the accessibility o f the binding sites and, in this way, regulate the 
rpde6:RB3 interaction.
It should be noted that a more reliable assessment o f the binding affinities o f rpdeô 
deletion mutants to GST-RB3^^^"^^^ requires an ELISA binding assay or BIAcore procedure 
using purified rpdeô deletion mutants in addition to purified GST-RB3^^^'^^^ at known 
concentrations (Nieba et al., 1996).
5.11.2 Sequence analysis of the RB3 binding domain
The above results suggest that the region from the staif o f UCR2 to the RDI 
(RNPDE4A1) splice junction contains a sequence required for interaction with RB3 (see 
Figure 5.31 below). As mentioned in the Introduction chapter, section 1.4, the RDI splice 
variant is unusual in that its splice junction is located near the middle o f UCR2. The splice 
junction for the laiown short forms of PDE4B and PDE4D are located at the beginning of 
UCR2 (see Introduction, section 1.4). Therefore, the RB3 interaction site is highly 
conserved in nearly all PDE4 isoenzymes including the short forms PDE4B2 and PDE4DI.
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However, the unique NHz-terminal splice domains of these isoenzymes will affect the 
accessibility of this binding site. Therefore, not all o f these isoenzymes may associate with 
RB3.
This region o f UCR2 is necessaiy, but possibly not sufficient for interaction with 
RB3. Regions downstream of the RDI splice junction may also be necessaiy for interaction 
with RB3. In order to define fully the RB3 binding region, a series o f COOH-terminal 
truncations o f ipde6 will have to be tested for association with RB3. These could be 
expressed as GST-fusion proteins for use in pull down assays using cytosolic COS-7 cell 
expressed RB3. The residues in rpdeô involved in binding RB3 may be spread out in the 
amino acid sequence but topologically adjacent in the 3D structure.
Both the putative SH3 domain binding motifs in the rpdeô (O' Coimell et al., 1996) 
and the RACKl binding site in PDE4D5 (Yarwood et al., 1999) are located in the unique 
NHz-termini o f these PDE4 isoenzymes. In contrast, the region defined above as necessaiy 
for RB3 interaction site is relatively close to the catalytic unit. This may explain why RB3 
affected rpdeô activity, whereas RACKl or SH3 domain interactions do not affect PDE 
activity (O' Connell et al., 1996; Yarwood et al., 1999).
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Figure 5.31 A lignm ent o f rat UCR2 sequences.
This figure shows an alignment o f the UCR2 regions from PDE4A, PDE4B, PDE4C and 
PDE4D. The numbers to the left of the sequences refer to the amino acid positions in the 
splice variants RNPDE4A5 (rpdeô; GenBank accession No. L27057), RNPDE4B2 
(GenBank accession No. L27058), RNPDE4C1 (GenBank accession No. L27061) and 
RNPDE4D3 (GenBank accession No. U09497). Residues that match the consensus 
sequence for this region are boxed. The region in rpdeô necessary for interaction with RB3 
is contained between the vertical dashed lines. Note that this region actually starts 5 amino 
acid residues before the NH2-terminal start o f UCR2. The UCR2 regions were analysed for 
the presence o f putative phosphorylation sites using MotifFinder 
(http://www.motif.genome.ad.jp). Shaded boxes indicate the positions o f putative 
phosphorylation sites for protein kinase C and casein kinase 2.
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5.11.3 Key amino acid residues within the RB3 interaction domain
Analysis using yeast two-hybrid and in vitro  binding studies in PDE4D3 has shown 
that UCRl and UCR2 interact with each other (Beard et al., 2000). This interaction was 
blocked by alanine substitution o f the acidic residues Glul46, G lul47 and Asp 149 within 
the NHa-terminal half of UCR2. The positions of the equivalent residues in rpdeô are 
Giu231, Glu232 and Asp234 and these residues are marked in panel B o f Figure 5,31 
above. The UCRl :UCR2 interaction was also abolished by mutation o f two positively 
charged amino acids to alanine, (Arg98 and ArglOl in PDE4D3), found towards the 
COOH-terminal end o f UCRl (Beard et al., 2000). Significantly, mutation o f Ser54 (in 
PDE4D3) to Asp at the NHi-terminal end o f UCRl also disrupted the interaction. This Asp 
substitution mimics phosphorylation o f Ser54 by PKA. A model was thus proposed, where 
UCRl :UCR2 interactions are determined by electrostatic interactions that are disrupted by 
PKA phosphorylation at Ser54.
Clearly, interaction o f RB3 with the amino terminal half o f UCR2 could potentially 
disrupt the U CRl :UCR2 interaction, which may in turn affect the structure and activity o f 
the catalytic region. This may explain the observed inliibitory effect o f RB3 on rpdeô 
activity.
5.11.3.1 Does the first half of UCR2 contain a TPR domain acceptor site?
As discussed in the introduction to this chapter (section 5.2.3.2), the 
immunophilins FKBP52 and Cyp40 and the immunophilin-related protein, ARA9/XAP2 
(human homologue o f RB3), all interact with hsp90 via their COOH-terminal regions. In 
both FKBP52 and Cyp40, the hsp90-interaction region has been mapped to their three- 
repeat TPR domains (Baient et al., 1998; Radanyi et al., 1994; Ratajczak and Carrello,
1996). This suggests that the single TPR repeat o f ARA9/XAP2 may be involved in 
binding hsp90. As TPR domains are believed to mediate a wide range o f protein-protein 
interactions (Lamb et al., 1995) the TPR m otif o f RB3 may also mediate interaction with 
rpdeô.
It would be extremely useful to know the nature of the TPR domain acceptor site on 
hsp90 as this might help identify the precise residues in rpdeô that interact with RB3. Haiti 
and co-workers have shown that the COOH-terminal 104 amino acid region o f hsp90a 
mediates interaction with several TPR domain containing proteins (Young et al., 1998).
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Similarly, Carrello et al have mapped the acceptor site for a number o f TPR proteins to the 
COOH-terminal 124 amino acids o f hsp90p (Carrello et al., 1999). In addition, Carrello et 
al showed that the sequence EEVD, at the COOH-terminus of hsp90p, is absolutely 
necessary for interaction with Cyp40. This EEVD microdomain is also found in the 
COOH-terminus o f heat shock cognate protein 70 (Hsc70) where it has been shown to 
mediate interactions with TPR domain-containing proteins (Liu et al., 1999).
Interestingly, in rpdeô a similar sequence, g23ig232j^233j^234 in the NHz-
terminal half of UCR2, the region shown to be necessaiy for interaction with RB3. These 
residues are conserved in all members of the PDE4 gene family (see Figure 5.31 above). 
Therefore, it is possible that this microdomain may mediate interaction with TPR m otif in 
the COOH-terminal half o f RB3. As discussed in the above section, the glutamate pair and 
the aspartate residue in this m otif are also essential for the intramoleculai' interaction 
between UCRl and UCR2. The TPR domain o f RB3 may compete with U CRl for 
interaction with these residues.
O f further interest is work by Russell et al who showed that the conserved, positively 
charged residues, Lys97 and A rglO l, in the third TPR m otif of protein phosphatase 5 
(PP5), were essential for hsp90 interaction (Russell et al., 1999). These residues are found 
at similar positions in the TPR m otif o f RB3, (Lys2ôô and Arg271) (see Figure 5.6, section 
5.2.3.2). Russell et al conjectured that these residues might interact electrostatically with 
the EEVD motif. In addressing this question, Russell et al also showed that alanine 
substitution the glutamate pair in this microdomain significantly diminished, but did not 
eliminate binding o f PP5, suggesting the existence of additional binding residues in hsp90 
(Russell et al., 1999). By analogy, rpdeô:RB3 complex formation may depend on 
electrostatic interactions between Lys266 and Arg271of the RB3 TPR m otif and a number 
o f acidic residues, including those in the EELD m otif in the NHz-terminal half o f UCR2.
It should be noted that, unlike the EELD motif o f rpdeô, the EEVD motifs o f both 
hsp90 and hsp70 are found at their extreme COOH-termini, which might be a necessity foi- 
interaction with TPR domains. However, the possibility that the EELD m otif o f rpdeô 
forms part of a TPR acceptor site is worthy of further investigation.
5.11.3.2 Putative phosphorylation sites within the RB3 interaction region
Many protein-protein interactions are affected by phosphorylation. For instance, 
SH2 domains only interact with sequences containing a phosphorylated tyrosine.
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Conversely, as discussed below, phosphorylation of FKBP52 by casein kinase 2 disrupts 
interaction with hsp90 (Miyata et a l ,  1997). Therefore, in attempting to understand the 
regulation o f the rpde6;RB3 interaction it is useful to locate the putative phosphorylation 
sites with the RB3 interaction region on rpdeô and the COOH-terminal half of RB3.
Figure 5.31, panel B shows the putative phosphoiylation sites within the entire 
UCR2 region of rat PDE4A (PDE4A UCR2) and their conservation in other PDE4 genes. 
As shown in this figure, in rpdeô (a PDE4A splice variant) the region necessaiy for RB3 
interaction (enclosed by vertical dotted lines) contains tlnee putative phosphorylation sites; 
two for protein kinase C and one for casein kinase 2. In addition, the COOH-terminal half 
o f UCR2 contains another phosphorylation site for casein kinase 2 as shown in Figure 5.31. 
As mentioned in the beginning o f section 5.11.2, the RB3 interaction region may extend 
downstream of Met260. Phosphoiylation o f one or more o f the putative sites within the 
RB3 interaction region may prevent or enliance the interaction between rpdeô and RB3.
The consensus sequences for these phosphorylation sites are shown in Table 5.3, below.
Table 5.3 Consensus phosphorylation sites for protein kinase C and casein kinase 2
Kinase Consensus phosphorylation site
Casein kinase 2 (CK2) rSTl-X-X-fDEl
Protein kinase C (PKC) [ST]-X-[RK1
In the above table the positions the amino acid residues are represented by letters 
separated by dashes (X= any amino acid). Letters contained within square brackets 
represent the amino acid residues that can occupy that position in the phosphorylation 
motif. Note that PKC and CK2 aie serine/tlireonine protein kinases.
As mentioned above, the protein-protein interactions o f RB3's closest relative, 
FKBP52, are regulated by phosphoiylation. CK2-dependent phosphorylation o f FKBP52 
disrupts hsp90 binding (Miyata et al., 1997) which has been mapped to the COOH-terminal 
TPR domain (Radanyi et a l ,  1994). Although the authors identified Thrl43 as being a 
major substrate for CK2, other sites in FKBP52 may be CK2 phosphorylated, preventing 
interaction with hsp90. RB3 contains four putative CK2 sites and two PKC sites. The 
effect o f CK2 or PKC phosphorylation on the interaction between RB3 and rpdeô is worthy 
o f future investigation.
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5.12 Effect of PIVIA and forskolin/fBMX stimulation on the rpde6:RB3 
interaction.
As mention above, the RB3 interaction domain contains two putative PKC sites. 
This suggested that PKC phosphorylation o f this region might affect the interaction of 
rpdeô with RB3. In addition, a number o f PDE4 isoenzymes are activated or inhibited by 
ERK2 (MAP kinase) phosphorylation o f a conserved site near the COOH-terminus o f the 
catalytic unit (Hoffmami et al., 1999; MacKenzie et a l , 2000). ERK2 phosphoiylation of 
rpdeô may also prevent or enhance the inhibitory binding o f RB3. ERK2 is activated in a 
PKC dependent manner (MacKenzie et a l ,  1997). Therefore, to assess the effect o f PKC 
on the rpdeô:RB3 interaction, COS-7 cells transfected with rpdeô were stimulated with 
phorbol 12-myristate 13-acetate (PMA). PM A mimics the second messenger diacylglycerol 
(DAG) which binds to and activates PKC. COS-7 cells transfected with rpdeô were 
stimulated for 5 min with 1 OOiiM PMA. This treatment is known to produce an optimal 
ERK2-dependent inhibition o f PDE4D3 activity (Baillie, MacKenzie and Houslay, 
unpublished). Cytosolic rpdeô from these cells was then tested for inhibition by GST-RB3^"
330
Protein kinase A (PKA) has been shown to activate the PDE4D3 isoenzyme by 
phosphorylation o f Ser54 at the NHz-terminal end of UCRl (Hoffmami et a l ,  1998; Sette 
and Conti, 1996). This serine is conserved in all Tong’ PDE4 isoenzymes. As mentioned 
above, in section 5.11.3, phosphoiylation at Ser54 of UCRl disrupts interaction between 
UCRl and UCR2 (Beard et a l ,  2000). Alteration in the conformation of the U CRl :UCR2 
domain may affect interaction with RB3. To examine this, rpdeô transfected COS-7 cells 
were stimulated with a combination o f lOOpM forskolin and lOOpM IBMX for 20min to 
elevate intracellulai' cAMP levels and activate PKA. Such treatment is known to cause an 
optimal phosphoiylation of HSPDE4D3 (MacKenzie, Baillie and Houslay, unpublished). 
Cytosolic rpdeô from PKA stimulated cells was tested for interaction with RB3, by 
assessing inliibition with GST-RB3^“^ ®^.
The effect o f PMA or IBMX/forskolin treatment on rpdeô inhibition by GST-RB3^’ 
is shown in Figui'e 5.32. As shown in this figure, such treatments have no significant 
effect on the ~40-50% inliibition observed in the presence of IpM  GST-RB3^'^^^. The 
conditions used were known to activate PKA, PKC and ERK2 (downstream of PKC) 
(MacKenzie et a l ,  1997) to a sufficient level for phosphorylation o f PDE4D3 (Baillie et al,
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unpublished work). Either none o f these kinases phosphoiylate rpdeô (PDE4A5) or 
phosphoiylation does not alter the conformation or electrostatic properties o f ipdeô in a 
way that prevents interaction with RB3.
As mentioned in section 5.11.3.2, the region on rpdeô necessaiy for interaction with 
RB3 contains a  putative CK2 phosphorylation site. The signalling pathways that regulate 
CK2 are unknown (Miyata et al., 1997). Therefore, the above experiment does not exclude 
the possibility that CK2 may regulate the rpdeô:RB3 interaction.
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Figure 5.32 GST-RBS''^^** inhibition o f cytosoiic rpdeô from transiently transfected  
COS-7 cells stimulated w ith either PM A or forskolin /IBM X.
COS-7 cells were transfected with rpdeô and stimulated with either lOOnM PMA for 5min 
or lOOpM IBMX for 20min followed by lOOpM forskolin for a further 20min. Samples of 
the cytosolic (S) fraction from these cells were incubated with GST or GST-RB3^‘^ ®^ (final 
assay concentration = IpM ) for Ih  on ice prior to PDE assay with IpM  8-[^H]-cAMP. The 
activity values are expressed as a percentage of the control activity in the absence o f GST- 
fusion protein. The values are the means o f thi'ee experiments ± S.E.
*= these data were shown previously in Figure 5.18, section 5.7.1 and are shown again here 
for comparison.
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a5.13 Interaction of rpde6 with FKBP52
In terms of understanding the regulation and targeting o f ipde6 it is important to 
establish whether the rpdeô:RB3 interaction is specific, or whether rpdeô can interact with 
other proteins that are similar to RB3. It should be noted that RB3 might not be the ‘real’ 
binding pai tner for rpdeô in vivo. Although RB3 was pulled out in a screen o f a rat brain 
cDNA library, rpdeô (PDE4A5) is expressed in a number o f cell lines including rat 
thymocytes (ElBawab et al., 1997) and 3T3 preadipocytes (MacKenzie et al., 1998). The 
‘real’ rpdeô interaction partner may only be expressed in tissues other than the brain and 
may not have been present in the rat brain cDNA library. Therefore, a screen o f brain
■cDNA may have pulled out RB3 because it bore the closest structural similarity to the 
‘real’ interaction partner. In addition, earlier studies showed that the COOH-terminal half 
o f RB3, which contains a TPR motif, appeal's to be responsible for interacting with (section 
5.4.1) and inhibiting (section 5.7.4) rpdeô. No direct role has been found for the NTH- 
terminal half o f RB3 in these functions. Therefore, the yeast two-hybrid analysis may have 
pulled out RB3 because its COOH-terminal half contains regions that are similar in 
sequence or structure to regions o f the native interaction partner. An important feature o f 
the COOH-terminal half o f RB3 is the presence of a TPR m otif in its COOH-terminal 
region. It may be the case that rpdeô does not exclusively bind to RB3, but instead binds to 
one or a number o f other TPR domain-containing proteins.
Although yeast two-hybrid analyses cannot confirm that RB3 is the ‘true’ binding 
partner for rpdeô, this does not lessen the importance o f studying the rpdeô :RB3 
interaction. At a minimum, RB3 may provide a paradigm for one type o f interaction that 
rpdeô undergoes. At a maximum, RB3 may be one of a number o f TPR proteins that 
interact with rpdeô.
We would expect a potential protein-protein interaction partner to have a similar 
subcellular distribution to rpdeô. Therefore, in order to facilitate the search for potential 
binding partners, a list of TPR proteins, whose subcellular distribution patterns have been 
studied, was compiled (Table 5.4). Many o f the TPR domain proteins fisted in Table 5.4 
are involved in cell cycle control (cdclô, cdc23 and cdc27) or transcriptional repression 
(SSN6 or nuc2+) and are therefore localised to nucleus or the mitotic spindle during 
mitosis (Lamb et al., 1995; Sikorski et al., 1990). These proteins are unlikely to interact 
with rpdeô in vivo as immunofluorescence studies using confocal microscopy suggest that 
the rpdeô is excluded from the nucleus (Huston et al., 2000). Other TPR proteins are
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involved in protein import into the mitochondria (Yano et al., 1998) or the peroxisome 
(Terlecky et al., 1995) and are exclusively targeted to these organelles. This makes them 
unlikely candidates as protein-protein interaction partners for rpdeô, which does not 
associate with these organelles.
More likely candidates include cyclophilin 40 (Cyp40) whose TPR domain 
containing COOH-terminus shares sequence similarity with the COOH-terminus o f RB3 
(see Table 5.1, section 5.2.2) This protein has a speckled distribution in the cytoplasm of 
rat pulmonary endothelial cells (see Table 5.4) (Owens-Grillo et al., 1996). However, 
Russell et al has recently suggested that the TPR containing protein phosphatase 5 (PP5), is 
predominately cytosolic in HeLa cells (Russell et al., 1999) (Table 5.4). This protein may 
therefore occupy the appropriate compartments for interaction with rpdeô. Interestingly, 
rapsyn (Ponting and Phillips, 1996) is an interesting example o f a TPR protein that is 
involved in organising the cytoskeleton at the postsynaptic density. A similar protein may 
mediate the observed targeting o f rpdeô to structiues that resemble the cytoskeleton in 
transfected COS-7 cells (Huston et al., 2000),
As shown in section 5.2.2, FKBP52 is homologous to RB3. Like RB3, FKBP52 
contains a TPR domain in its COOH-terminal region and an FKBP homology domain in its 
NH2-terminal region. It is possible that FKBP52 also interacts with rpdeô. Analysis by 
immunofluorescence microscopy shows that FKBP52 is targeted to both the nucleus and 
the cytoplasm (Owens-Grillo et al., 1996). Cytoplasmic FKBP52 is localised to a 
cytoskeletal network and this pattern is reminiscent o f the subcellular distribution o f rpdeô, 
observed in transfected COS-7 cells (Huston et al., 2000). This suggests that FKBP52 and 
rpdeô may occupy the same intracellular compartments. In order to test whether FKBP52 
could bind to and regulate rpdeô, I assessed the effect o f FKBP52 on rpdeô enzyme 
activity.
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Table 5.4 Subcellular distribution of TPR domain containing proteins
Only TPR domains for which subcellular distribution bas been studied are listed in the 
table below.
TPR protein No. Function Subcellular distribution Refs.
TPRs
Cell Subcellular
distribution
C d c lô , cdc23, 9-10 M itosis- part o f S. cerevisiae Localises to (G oebl and
cdc27, A naphase 
prom oting 
com plex (APC)
HeLa spindle/centrosom e 
during m itosis
Y anagida,
1991)
(Lam b et al., 
1995)
(Sikorski et 
al., 1990)
Cut9+ nuc2+ 10 M itosis S. pombe N ucleus
(nuclear scaffold)
(G oebl and 
Y anagida, 
1991) 
(H irano et 
ah, 1990)
■V,
PRPÔ 9 Splicing S. cerevisiae N ucleus (G oebl and
Y anagida,
1991)
SKI3, Ssnô 8 Transcription S. cerevisiae N ucleus (G oebl and
10 Y anagida,
1991)
FK B P52 3 FK50Ô binding 
protein
R at pulm onary 
endothelial 
C 0 S 7  
M D CK  
G T l (mouse 
neuronal cells)
80%  localised to the 
nucleus (not nucleoli) 
20%  cytoplasm  
Cytoplasm ic FK B P52 
is found associated 
with m icrotubules
(Owens- 
G rillo e t al., 
199Ô) 
(Perrot- 
A pplanat et 
al., 1995) 
(C zar et al., 
1994)
A R A 9/
A IP /
X A P2
1 Form  com plex 
w ith the A iyl 
hydrocarbon 
receptor and 
hsp90
M ouse 
hepatom a 
ce lls :h ep a lc lc7  
H eLa cells
Cytoplasm (K uzhandaiv 
elu et al., 
199Ô; M a 
and
W hitlock,
1997) 3
Cyp40 3 Cyclophilin Rat pulm onary 
endothelial
Punctate bodies in
cytoplasm
N ucleoli
(Owens- 
G rillo et al., 
199Ô) 1
PA S8p, 
PAS 1 Op, 
P X R l
7 Protein import- 
peroxisom es
Pichia pastoris
(m ethylotrophic
yeast)
Peroxisom es (Lamb e t ah, 
1995)
(Terlecky et 
ai., 1995)
%1I
M A S70,
Tom 20,
7 Protein im port- 
m itochondrial
R at pulm onary 
endothelial
O uter m itochondrial 
m em brane
(Owens- 
G rillo et al.. 1
H TO M 34p cells,
Transiently 
transfected 
C 0 S 7  cells
199Ô) (Yano 
et al., 1998)
.1
:&:
a
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Table 5.4 continued
TPR protein No.
TPRs
Function Subcellular distribution Refs.
Cell Subcellular
distribu tion
PÔ7 phox 
CNADPH 
oxidase 
subunit)
4 Superoxide (O y) 
generation
Phagocytes Cytoplasm  
(translocates to 
m em brane when 
activated)
(Ponting,
1996)
Rapsyn 8 M olecular linker
betw een
A ChR and
dystrophin-
dystroglycan
Organises
postsynaptic
cytoskeleton
Torpedo
californica
Postsynaptic
m em branes
(Ponting and
Phillips,
1996)
PP5 3 Protein
phosphatase
C O S l cells
H eLa cells
H eLa cells 
L929
M itotic spindle 
apparatus during 
m etaphase
N ucleus
Cytoplasm
Cytoplasm
(Carrello et 
al., 1999; 
O llendorff 
and
Donoghue,
1997)
(Chen et al,, 
1994) 
(Russell et 
ai., 1999)
O -linked
G lcN A c
transferase
13 O -linked 
glycosylation o f  
proteins in the 
cytoplasm  and 
nucleus
C. elegans 
em bryonic cells
CHO cells 
Transfected 
HEK293 cells
N ucleus and 
perinuclear region
N ucleus and 
cytoplasm
(Lubas e t al., 
1997)
(K reppel et 
al., 1997)
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5.13.1 FKBP52 inhibits rpde6
The effect o f soluble recombinant FKBP52 on rpdeô activity was assessed in a 
manner similar to that for RB3 (see section 5.7). I obtained, from Prof. G. Bolger, a 
plasmid encoding a GST-fusion o f full length FKBP52. The effect o f increasing 
concentrations of this purified GST-FKBP52 on the activity of cytosolic rpdeô from 
transfected COS-7 cells was determined as described previously in this chapter (section 
5.7). I thus over-expressed this protein in E. co li and purified it on glutathione Sepharose 
beads. FKBP52 is a relatively large protein o f the kind that often purify poorly when 
expressed as GST fusions (Harris, 1998). Therefore I used the modifications for the over­
expression and purification procedure set out in section 2.7.3. Note that even with these 
modifications I was unable to pui'ify usable amounts o f a GST-fusion o f another high 
molecular weight immunophilin, Cyp40. Therefore, I was unable to test Cyp40 for 
interaction with rpdeô using the pull down assay procedure.
After purifying the GST-FKBP52 on glutathione Sepharose beads, the protein was 
eluted with glutathione buffer and dialysed into 20mM Tris pH 8.0. Samples were analysed 
by SDS-PAGE and Coomassie blue staining. A typical gel is shown in Figure 5.33. A band 
[74.1+ 3.2 kDa, (mean + SE, n=4)] o f approximately the predicted molecular weight 
(79kDa) was obtained for GST-FKBP52. However, a strong lower molecular weight band 
just below the 50.7 kDa marker was obtained that may represent a proteolytic degradation 
product.
The effects o f GST-FKBP52 on COS-7 cell expressed rpdeô activity were 
determined. This fusion protein was then diluted to the appropriate molar concentrations 
with Tris buffer. Equal amounts o f cytosolic rpdeô, diluted in complete KHEM buffer and 
containing ~1 EU of PDE activity (in the absence of GST-fusion protein), were combined 
with vaiying concentrations o f GST-fusion protein, incubated on ice for Ih, and then 
assayed for PDE activity as described in the Methods chapter, section 2.1Ô.
Interestingly, GST-FKBP52 produced a significant inhibition o f rpdeô activity (see 
Figure 5.34). This inliibition was as marked as the inliibition of cytosolic rpdeô with GST- 
RB3^"^^  ^ (see Figure 5.18, section 5.7.1). A maximal inhibition (-55%  of the control 
activity) was achieved at a GST-FKBP52 concentration of 1 p M .  The I C 5 0  for GST- 
FKBP52 inhibition o f rpdeô was O.lô ± 0.07pM (mean value from three separate dose- 
response cui'ves ± S.E.), which is comparable to the I C 5 0  of 0.22 ± 0.04pM obtained for
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GST-RBS^’^ ®^. It should be noted, however, that if  the fraction of the FKBP52 fusion 
protein that was degraded was inactive, then the IC50 would be lower. Further studies are 
needed using fusion protein purified to remove this degradation product in order to define 
the true IC50 value.
Therefore, RB3 may not be unique in its ability to interact with and inliibit rpdeô. 
The above result suggests that a number o f different TPR protein may be capable of 
binding to rpdeô in a way that restricts its catalytic function. The TPR proteins with which 
rpdeô interacts may vary from cell to cell. This may be a means for the tissue-specific 
regulation and targeting of rpdeô. The above result shows that in order to understand the 
regulation, targeting and function o f rpdeô we need investigate other proteins, apart from 
RB3.
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Figure 5.33 Purification o f GST-FKBP52
A GST-fusion of full length FKBP52 was over-expressed in E. co li (BL21 DE3) and 
purified using the modified method detailed in section 2.7.3. A lOpg sample of purified 
GST-FKBP52 was separated on an 8% SDS-PAGE gel. The proteins were visualised by 
Coomassie staining. The positions o f the molecular weight markers (Biorad broad range) 
are shown on the right. The predicted molecular weight for GST-FKBP52 is 78.9kDa.
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Figure 5.34 FKBP52 inhibits rpdeô
This figure shows the inhibition o f soluble cytosolic rpdeô by GST-FKBP52. Samples of 
the cytosolic (S) fraction o f rpdeô transfected COS-7 cell fractions diluted in cKHEM were 
mixed with vaiying concentrations o f purified GST-FKBP52 diluted in 20mM Tris-FICl 
pH 8.0. After incubating on ice for Ih, the mixtures were assayed for PDE activity by the 
addition o f IpM  8-[^H] labelled cAMP. The concentration on the x-axis refers to the final 
concentration o f GST-FKBP52 in the assay (after the addition of 8-[^H] cAMP). Molar 
concentrations of GST-FKBP52 were determined on the basis of calculated molecular 
weights as described in the Methods chapter (section 2.16). The activities are expressed as 
a percentage o f the control activity in the absence of GST-fusion protein (means ± S.E, n =
3).
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5.14 Does hsp90 mediate or Inhibit the rpde6:RB3 interaction?
As discussed in section 5.2.3.2, hsp90 interacts with ARA9/XAP2 (human form of 
rat RB3) in vivo. There is some controversy as to whether the presence o f the aryl 
hydrocarbon receptor (AhR) is required for this interaction. Ma and Whitlock were able to 
co-immunoprecipitate hsp90 and AIP (the mouse homologue o f ARA9/XAP2) in AhR- 
deficient mouse hepatoma cells (Ma and Whitlock, 1997). However, Carver and Bradfield 
were unable to co-immunoprecipitate in vitro  translated ARA9/XAP2 and hsp90 in the 
absence of AhR (Carver and Bradfield, 1997). The latter finding suggests that 
ARA9/XAP2 and hsp90 only interact in a complex that includes AhR.
Regardless o f whether AhR is necessary for complex formation between 
ARA9/XAP2 and hsp90, two groups have independently shown that the COOPI-terminus 
of ARA9/XAP2 is essential for this interaction. Carver and co-workers showed that amino 
acids 154-330 o f ARA9/XAP2 were sufficient for an interaction with hsp90 (Caiwer et al., 
1998), whereas Meyer and Perdew showed that removal o f the COOH-terminal 32 amino 
acid residues o f ARA9/XAP2 prevented association with hsp90 (Meyer and Perdew, 1999).
Interestingly, in this thesis I have localised the binding site for rpdeô to the COOH- 
terminal half of RB3, amino acids 170-330 (sections 5.4.1). The co-localisation o f the 
binding sites for hsp90 and rpdeô gives rise to a number o f possibilities. Firstly, hsp90 may 
be required for the interaction between rpdeô and the COOH-terminal half o f RB3, i.e. 
rpdeô may directly bind to hsp90, which in turn binds to the COOH-terminus o f RB3. The 
work presented so far in this chapter does not exclude this possibility, as I have not proved 
that the interaction between rpdeô and RB3 is direct. In my analysis o f the rpdeô :RB3 
interaction, I incubated purified GST-RB3 fusion proteins with cytosolic rpdeô from 
transfected COS-7 cells (Sections 5,3 and 5.4). Therefore, an indeterminate amount o f 
endogenous COS-7 cell hsp90 would have been present in these pull-down assays. 
Endogenous hsp90 would also have been present in the yeast strain initially used to identify 
RB3 as an interaction partner for rpdeô.
Secondly, hsp90 and rpdeô may both bind directly to the same site on RB3. We 
would therefore expect hsp90 and rpdeô to compete for binding to RB3 in a manner similar 
to the competition between Cyp40 and FKBP52 for association with the hsp90 (Ratajczak 
and Carrello, 199Ô). Finally, rpdeô and hsp90 may bind independently to separate sites
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w ithin the COOH-terminus of RB3 and the association of one may not affect the 
association o f the other.
5.14.1 Interaction of hsp90 and rpde6 with RB3
The three possibilities described above suggest that hsp90 may enhance, inhibit or 
have no effect on the rpdeô:RB3 interaction. A preliminary experiment was carried out to 
investigate these possibilities. The scheme for this experiment is illustrated in Figure 5.35. 
As this diagram shows, an attempt was made to saturate the hsp90 binding sites on GST- 
RB3i70"330ygjj^g ^ tiuman hsp90 (GenBank accession number P08238) with a COOH- 
terminal V5 tag obtained from Prof. Graeme Bolger (the V5 tag is described in Methods, 
section 2.10). To do this, COS-1 cells were transfected with the plasmid encoding V5- 
hsp90. In the first stage (incubation 1) increasing amounts of the cytosolic (S) fraction from 
these cells was incubated with the GST-RB3^70-330 to glutathione Sepharose beads
for 30min at 4°C. The beads were centrifuged and washed several times with complete 
KHEM buffer. The supernatants and washes were retained and pooled to form an unbound 
fraction (unbound fraction 1). In the second stage (incubation 2) the beads were incubated 
with the cytosol from rpdeô transfected COS-7 cells for 30min at 4°C. After incubation, the 
beads were centrifuged and washed as before. The supernatants and washes were retained 
and pooled to form a second unbound fraction (unbound fraction 2). GST-RB3^70'33o 
associated proteins were then eluted from the beads with glutathione.
The extent o f the association between hsp90 and GST-RB3^70-330 assessed by
immunoblotting samples o f the final bound fraction and unbound fraction 1 for V5-hsp90 
using an anti-V5 antibody. The results are shown in Figure 5.3Ô. As this figure shows, the 
percentage binding o f V5-hsp90 to GST-RB3^70-33o low. However, the immunoblots of
the bound fraction show that some binding o f hsp90 to GST-RB3 7^^ "33o place that was 
resistant to washing with cKHEM buffer.
The total PDE activities in the bound and (second) unbound fractions were 
determined and used to calculate the percentage binding of rpdeô as shown in Figure 5.37. 
This figure shows that pre-incubation of GST-RB3^70-33o increasing amounts o f 
cytosolic hsp90 had no effect on the association of GST-RB3^70-330 rpdeô. This 
suggests that hsp90 and rpdeô bind to separate sites within the COOH-terminus o f RB3.
However, there are a number of limitations to this preliminary experiment. The 
analysis o f the binding o f hsp90 to GST-RB3^70-33o in Figure 5.3Ô does not tell us
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the stoichiometry for this interaction, as we do not know the percentage amount o f V5- 
hsp90 in the COS-1 cell cytosol. Therefore, we cannot estimate the proportion o f GST- 
RB3  ^ 70-330 ji-iolecules that have associated with hsp90. In addition, some endogenous hsp90 
will be present in the COS cell cytosol. Therefore, GST-RB3^70-33o been exposed
to both mock-transfected and V5-hsp90-transfected COS-1 cell cytosol may have become 
associated with an unknown amount o f endogenous hsp90, which may affect the results.
A less ambiguous analysis o f the effect of hsp90 on the rpde6:RB3 interaction 
would require purified hsp90 and puiified rpdeô in addition to purified GST-RB3^70-330 
We would then be able to assess the rpdeô:RB3 interaction in the presence or total absence 
o f hsp90. The results shown in Figure 5.3Ô suggest that the binding o f hsp90 to GST- 
RB3  *70-330 rnay be weak. After incubating purified GST-RB3*70"330 varying amounts of 
the cytosolic fraction from V5-hsp90-tranfected COS-1 cells, only a small proportion of 
hsp90 appears to become associated. Therefore, purified AhR may also be necessaiy in this 
study to facilitate the hsp90:RB3 interaction. Unfortunately, an analysis o f the direct 
interaction between purified affinity tagged forms of rpdeô and RB3 in vitro  has been 
precluded by proteolytic degradation of full-length rpdeô when I attempted to express this 
in E. coli.
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Figure 5.35 Scheme for an experiment to determine whether hsp90 competes with 
rpdeô for association with the COOH-terminal half of RB3
In the first stage {incubation 1) GST-RB3*7^'330 to glutathione Sepharose beads is 
exposed to V5-tagged hsp90 (or untransfected COS-1 cell cytosol as a control) and then 
washed. The wash fraction is retained (unbound fraction I). In the second stage {incubation 
2), the beads are then exposed to rpdeô. They are then washed again and this wash fraction 
is again retained (unbound fraction 2). The GST-RB3*7'^-330 associated proteins are then 
eluted with glutathione to form a bound fraction. In order to calculate the percentage 
binding o f rpdeô to GST-RB3*7^'330 exposure to hsp90, the PDE activities in the 
bound fraction and the unbound fraction 2 are determined. The extent o f binding o f V5- 
tagged hsp90 to GST-RB3*7* '^33o determined by immunoblotting samples of the final 
bound fraction and unbound fraction 1 using an anti-V5 antibody.
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Figure 5.36 Association o f hsp90 with GST-RB3
This figure shows the association of hsp90 with GST-RB3*7 '^330 described in the 
legend to Figure 5.37, samples of the cytosolic fraction (600, 800 or lOOOpg) from V5- 
tagged hsp90 transfected COS-1 cells were incubated with GST-RB3*7 '^330 2^qq bound 
to glutathione Sepharose beads at 4°C for 30min. The beads were pelleted by centrifugation 
and washed with 3 x 400pl of cKHEM buffer. The supernatant and washes were retained 
and pooled to form an unbound fraction (unbound fraction 1 ). They were then incubated 
with cytosolic rpdeô from transfected COS-7 cells. After washing the beads again as 
described above, GST-RB3*7 '^330 associated proteins were eluted with 3 x lOOpl of 
lOmM glutathione, 50mM Tris-HCl, pH 8.0. Samples of this bound fraction and unbound 
fraction 1 were separated by SDS-PAGE (10% [w/v] acrylamide), transferred onto 
nitrocellulose and immunoblotted for V5-hsp90 with anti-V5 antibody as primary reagent. 
The numbers above the lanes refer to the volumes (in pi) of the fractions run on the gel.
The immunoblots shown above were processed on one piece of nitrocellulose.
The calculated MW for V5-hsp90 is 85kDa.
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Figure 5.37 Hsp90 does not compete with rpdeô for binding to RB3.
The percentage binding of rpdeô to GST-RB3*7 '^33o previously been exposed to
hsp90 is shown. Samples of GST-RB3*7 '^33o ^200 pg) bound to glutathione Sepharose 
beads were incubated with various amounts of cytosolic hsp90 (hsp90), the cytosolic 
fraction of mock transfected COS-1 cells (M) or cKHEM buffer alone (0). The amounts of 
hsp90-transfected or mock-transfected COS-1 cell cytosol added are indicated in pg. After 
incubation, the beads were washed with 3 x 400pl cKHEM buffer. The beads were then 
incubated with samples of COS-7 cell expressed cytosolic rpdeô (lOOEU). The beads were 
centrifuged and washed with cKHEM as before. The supernatants and washes were 
retained and pooled to form an unbound fraction (unbound fraction 2). Bound protein was 
eluted with lOmM glutathione, 50mM Tris-HCl pH 8.0. The total PDE activities in the 
bound fraction and unbound fraction 2 were determined and used to calculate the 
percentage binding of rpdeô as described in the legend to Figure 5.29, section 5.11.
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CHAPTER 5: CONCLUSIONS 
5.15 Discussion and conclusions
5.15.1 RB3 can interact with rpde6: possible signalling mechanisms
In this chapter I have demonstrated that the PDE4 A isoenzyme rpdeô can interact 
with an immunophilin-related protein, RB3 in vitro. I have thus confirmed an interaction 
that was initially discovered using the yeast two-hybrid system to probe a rat brain cDNA 
library with rpdeô. In addition, I have shown that this RB3 interaction inhibits rpdeô 
catalytic activity. This is the first example o f a protein-protein interaction that significantly 
inhibits the activity o f a PDE4 isoenzyme.
As discussed in section 5.2, RB3 is the rat homologue o f the human protein 
ARA9/XAP2 which is expressed in a broad range o f tissues, including spleen, thymus and 
liver and brain (Carver and Bradfield, 1997; Meyer et al., 1998). In the liver, ARA9/XAP2 
forms a cytoplasmic complex with the ligand-activated transcription factor AhR (the aryl 
hydrocai'bon receptor). The latter binds to environmental toxins, such as polycyclic 
aromatic hydrocarbons (e.g. TCCD), halogenated dioxins and dibenzofurans. As a result o f 
this binding, AhR translocates to the nucleus where it regulates the transcription o f genes 
encoding the enzymes o f xenobiotic metabolism, such as cytochiome P450 1 A l (Schmidt 
and Bradfield, 199Ô).
The results presented in this chapter may implicate rpdeô in AhR signalling. Indeed, 
the rpdeô:RB3 interaction may serve as a monitor for xenobiotic cell stress. For instance, 
the binding of environmental toxins to AhR may cause a conformational change that is 
transmitted to rpdeô via RB3, causing a change in rpdeô activity. This may result in the 
activation or inhibition o f various cAMP-dependent processes that prepare the cell for 
xenobiotic stress. It would be interesting to see whether the presence of AliR and a ligand 
such as TCCD would affect RB3 inliibition o f rpdeô.
An interesting example o f a possible cAMP-dependent response to cell stress has 
recently been put forward by Anandatheerthavarada et al. This group shows that cAMP- 
dependent phosphorylation o f cytochrome P4502B1 targets this enzyme to the 
mitochondria in preference to the ER (Anandatheerthavarada et ah, 1999). The authors 
suggest that this may provide the mitochondria with protection from oxidative or chemical
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damage. Therefore, cross-talk between cAMP-dependent signalling pathways and the 
response to chemical or oxidative stress may occur at a number of points. The rpde6:RB3 
interaction may represent one such mechanism for this cross talk.
6.15.2 RB3 may protect rpde6 from proteolytic degradation
Meyer and Perdew show that over-expression o f ARA9/XAP2 in COS-1 cells 
enhances the levels o f cytosolic, endogenous AhR (Meyer and Perdew, 1999). This 
suggests that ARA9/XAP2 may stabilise AhR by protecting it from proteolytic 
degradation. The ability of ARA9/XAP2 to bind to AhR may be a requirement for this 
effect. A deletion mutant o f ARA9/XAP2, lacking the COOH-terminal 67 amino acids, 
failed to cause an increase in the cytosolic levels o f AhR.
RB3 may have a similar effect on the levels o f ipde6. To test this, cells that express 
endogenous ipde6 could be transfected with RB3 and the levels o f ipde6 in the various 
subcellular fractions could be monitored. It is known that the PDE4 isoenzymes are 
particularly susceptible to proteolytic degradation (Houslay et al., 1998). Therefore, RB3 
protection may be an important mechanism whereby the levels o f rpdeô are regulated.
6.15.3 RB3 inhibits rpdeG activity
I have shown that submicromolar concentrations o f RB3 inhibited rpdeô in vitro 
(IC50 0.2pM). Inhibition was incomplete (-50-60%) suggesting that RB3 is a non­
competitive inliibitor, i.e. it does not block the active site. Signal-induced inhibition of 
rpdeô by RB3 or a similar protein may have important physiological consequences in vivo 
and this may represent a new mechanism for the control of cAMP levels in cells. An 
equally important physiological event might be a signal-induced release and activation of 
rpdeô from an RB3-bound inhibited state.
Interesting, particulate fraction (PI and P2) rpdeô was resistant to inliibition by 
exogenous RB3. Proteins similar to RB3 may be associated with subcellular structures 
represented in the particulate fractions, such as the cytoskeleton. These may sequester 
ipdeô in an inhibited state that is resistant to further inliibition by soluble RB3. In the PI 
pellet fraction, rpdeô may interact with endogenous RB3. Alternatively, a completely 
different protein may interact with rpdeô in the P2 fraction. In agreement with this, the 
presence o f an excess of Lyn-SH3, previously shown to associate with rpdeô (O' Connell et 
al., 199Ô), diminished the inliibitory effect o f rpdeô on RB3 activity.
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5.15.4 rpdeG interacts with the COOH-terminal half of RB3
I have shown that the COOH-terminal half of RB3 (amino acids 170-330) mediates 
binding and inhibition o f rpdeô. It should be noted that the residues and structures that 
mediate binding may be distinct from those that mediate inliibition. No binding o f rpdeô 
was seen with the NH2-terminal half o f RB3, which contains regions o f homology to 
FKBP 12 and the FKBP-domain o f FKBP52. In addition, FK50Ô and rapamycin, which 
bind to the FKBP domains of FKBP 12 and FKBP52, had no effect on the inliibition of 
rpdeô by RB3. An alignment o f RB3 with its closest relative, FKBP52, showed that only 3 
out of 14 component residues of the FK50Ô binding/PPIase site o f FKBP52 aie consei'ved 
in RB3.
Collectively, these results indicated that the NHz-terniinal region was not directly 
involved in binding or inliibiting rpdeô. However, the results did not exclude the possibility 
that the NH2-terminal half o f RB3 may exert an influence on the interaction with rpdeô.
The NH2-terminal region may affect the accessibility of the COOH-terminal rpdeô binding 
region. In this way it may provide a ‘switch’ mechanism for the control o f the rpdeô:RB3 
interaction by phosphoiylation or protein-protein interactions.
6.15.5 RB3 interacts with the NH2 -terminal half of UCR2
By testing a series of NH2-terminal deletions of rpdeô for interaction with the 
COOH-terminal half o f RB3 expressed as a GST-fusion (GST-RJB3*7^"330  ^the region 
Ser218-Arg259 was shown to be necessary for interaction with rpdeô. This region covers 
the NH2"terminal half o f UCR2. Confirmation that this region is required for RB3 binding 
will be obtained from experiments where a GST-fusion or peptide containing this region 
can block the interaction o f rpdeô with RB3. If a peptide was discovered that disrupted the 
interaction o f rpdeô with RB3 this would have enormous potential value in defining the 
functional significance o f the rpdeô:RB3 interaction in vivo. The RJ33 binding site may 
extend downstream of Arg259. Therefore, COOH-terminal deletions o f rpdeô will have to 
be employed in order to define the RB3 binding site from both sides.
This RB3 interaction region (Ser218-Arg259) has been implicated in various other 
fundamental properties o f PDE4 isoenzymes. For instance, in PDE4D3 this region has been 
shown to contain three acidic residues that mediate interaction with U C R l. In rpdeô the 
equivalent residues are Glu231, Glu232 and Glu234. These negatively charged residues
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may form electrostatic intramolecular interactions with two conserved arginine residues 
near the COOH-terminal end o f UCRl.
UCRl and UCR2 are believed to bind to one another within PDE4 isoenzymes 
(Beard et al., 2000). It has been suggested that this UCR1:UCR2 ‘module’ integrates the 
effects o f PKA phosphorylation at the NH2-terminus of the isoenzyme (beginning of 
U C Rl) and ERIC2 -dependent phosphoiylation near the COOH-terminus of the catalytic 
unit (MacKenzie et al., 2000). ERK2 phosphorylates long and short form PDE4B, PDE4C 
and PDE4D splice variants. Whether ERK2 phosphorylation causes activation or inliibition 
o f PDE activity depends on what UCR sequences are present in the splice variant 
concerned. The NH2-terminal half of UCR2 appears to be crucial in this respect. ERK- 
dependent phosphorylation o f PDE4D1, which has intact UCR2, caused activation o f this 
short PDE4 isoenzyme (see Figure 5.38). However, PDE4D2, which lacks the HH2- 
terminal 32 amino acids of UCR2 was mildly inhibited on ERK2 phosphoiylation. Long 
PDE4 isoenzymes, with both UCRl and UCR2, are strongly inliibited upon ERK2- 
dependent phosphorylation (MacKenzie et al., 2000). These results are summarised in 
Figure 5.38.
The interpretation o f these results is as follows. In long PDE4 isoenzymes, UCRl 
and UCR2 combine to amplify an inlierent inhibitoiy effect o f ERK2 phosphorylation on 
the catalytic unit. The presence o f a lone, intact UCR2 in many short PDE4 isoenzymes, 
such as PDE4D1, causes stimulation of PDE activity upon ERK2-dependent 
phosphoiylation. This effect o f UCR2 is abolished by the removal o f the NH2-terminal 32 
amino acids o f this region in PDE4D2. Therefore, in addition to mediating interaction with 
U CRl, the NH2-terminal half o f UCR2 is specifically required to effect ERK2-dependent 
stimulation o f short PDE4 isoenzymes (MacKenzie et al., 2000). Although PDE4A 
isoenzymes do not appear to be phosphoiylated by ERK2, it would seem likely that an 
association o f RB3, with the NH2-terminal half o f UCR2, would have a major effect on the 
mechanisms o f regulation o f rpde6.
Studies o f the subcellular distribution of a series o f NH2-terminal deletions o f rpde6 
(shown in Figure 5.28) suggest that the 218-259 region in ipde6 can target rpde6 to cellular 
structures represented in the P2-particulate fraction o f transfected COS-7 cells (M. B.
Beai'd and M. D. Houslay, unpublished work). The co-localisation o f regions on ipde6 
required for P2-association and RB3 interaction suggests that a protein similar to RB3 may 
target ipde6 to the P2 fraction. Subcellular distribution studies have excluded RB3 itself
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from this role as RB3 is absent from the P2 pellet fraction. However, a proportion o f RB3 
(-16% ) is present in the PI pellet fraction o f transfected COS-7 cells (see Figure 5.15, 
section 5.5.2). One hypothesis proposed above was that endogenous RB3 itself might be 
involved in the association o f rpde6 with the PI pellet fraction o f rpdeb-transfected COS-7 
cells. Therefore, it would be interesting to investigate whether co-transfection and 
expression of RB3 in rpdeb-transfected cells increased the proportion of rpde6 that became 
associated with the PI-pellet fraction, when compared with cells that were singly 
transfected with rpde6. The presence of the PI pellet-associated RB3 might increase the 
proportion o f ipde6 that associates with this fraction. One could also assess the effect of 
mutations or deletions within the RB3 binding site on rpde6 on the subcellular distribution 
o f this isoenzyme in transfected COS-7 cells. The results to these experiments would 
provide evidence for or against an in vivo interaction between RB3 and rpde6 in the F l-  
pellet fraction.
Catalytic unit
Long form
Long form,
Lacking unique NHg terminus
Short form, 
with intact UCR2 
e.g. PDE4D1
Truncate: 
with intact UCR2
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with truncated UCR2
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Figure 5.38 ERK2 mediated modulation of the activity of PDE4 splice variants
This figure summarises the effect o f ERK2 phosphorylation on the activity o f long and 
short PDE4 isoenzymes and NHi-terminal PDE4 truncates. The position of the Serine 
residue phosphoiylated by ERK2 is marked with an encircled P. Based on a diagram shown 
in (MacKenzie et al., 2000).
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5.15.6 Interaction of rpde6 with other TPR domain containing proteins
An important question was whether rpde6 interacted only with RB3, or whether 
RB3 is one o f a range of similar proteins that interact with rpde6. As the COOH-terminal 
half o f RB3 mediates interaction with the rpde6, it was sensible to search for proteins that 
were similar to this half of RB3 rather than the protein as a whole, A striking feature o f the 
COOH-terminal half RB3 was the presence of a TPR motif. Such TPR motifs are known to 
mediate protein-protein interactions (Lamb et ah, 1995).
A plasmid was obtained that encoded a GST-fusion o f a close homologue o f RB3, 
FKBP52. Like GST-RB3, GST-FKBP52 produced a dose-dependent inhibition o f cytosolic 
rpde6 activity. The IC50 for this inhibition (-0 .16pM) was comparable to the value 
obtained for GST-RB3^“^ ^^ . This result suggested that RB3 might not be unique in its 
ability to interact with and inhibit rpde6. A structural feature common to both RB3 and 
FKBP52, such as a TPR motif may mediate inliibitory binding to rpde6.
5.15.7 TPR proteins involved in intracelluiar targeting
As discussed in the introduction, section 1.11.4, TPR proteins may be involved in 
the intracellular targeting of proteins. Pratt and co-workers showed that complexes 
containing a TPR protein in association with hsp90 and a steroid hormone receptor such as 
the glucocorticoid receptor (GR) had distinct patterns of intracellular targeting. These 
different subcellulai' distributions were determined by the TPR protein that they contained 
(Owens-Grillo et al., 1996).
Other experimental observations suggest a specific role for FKBP52 (RB3’s closest 
relative) in protein transport and targeting. FKBP52 is believed to target GR to nucleus by 
facilitating its movement along cytoskeletal tracts. Cytosolic FKBP52 has been found to 
associate with microtubules and nuclear FKBP52 has the same distribution pattern as GR 
(Czar et al., 1994; Pratt et al., 1999). FKBP52 also co-immmioprecipitates with the 
molecular motor dynein (Pratt et al., 1999). Similarly, RB3 or a similar TPR protein may 
combine with hsp90 to direct rpde6 to a specific compartment within the cell. In this regard 
it is important to assess whether rpde6 associates with hsp90.
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5.15.8 Future perspectives
An outstanding question is whether the interaction between rpdeô and RB3 is direct 
or whether it requires an additional component, such as hsp90. In order to answer this 
question, we need to be able to study the association of purified rpde6 with RB3. 
Unfortunately, my attempts to over-express and purify full-length rpdeb as an MBP-fusion 
have been hampered by the susceptibility o f full-length rpde6 to degradation by bacterial 
proteases. However, my studies suggest that the site required for RB3-binding is contained 
within the NH2-terminal region o f rpde6.1 have also shown that is possible to over-express 
and purify the NHi-terminal region o f rpde6 as the fusion GST-rpdeb^'^^'" (see Chapter 4, 
section 1.1). Therefore, it may be possible to study the interaction of purified MBP-RB3*' 
with GST-rpde6*’^ *^^ [note that MBP and GST do not interact, as shown in (Yarwood et 
al., 1999)]
In order to gain a deeper understanding o f rpde6:RB3 interaction the association of 
these proteins needs to be demonstrated and studied in vivo. Such studies would allow us to 
determine whether the inhibitory effect of RB3 on rpde6 is physiologically significant. In 
addition, the idea that rpde6 might be involved in AhR signalling could be pursued by 
examining the inhibitory binding of rpde6 to RB3 in the presence o f AhR (and the AhR 
ligand TCCD). I have shown that a number of cell lines, including MOLT3 monocytes and 
B-cells, express RB3 endogenously (section 5.6). These cell lines may be potential model 
systems for the above in vivo studies. The precise residues that are involved in the binding 
of RB3 to rpde6 need to be defined by the use of NfU- and COOH-terminal truncations and 
site directed mutagenesis. This may allow the design of a peptide to disrupt the interaction 
and thus determine its function in vivo. A similar method was successfully used by 
Rosenmund et al to block the anchoring of PKA by AKAP79 in hippocampal neurones and 
to show that this interaction is essential for the modulation o f AMPA/kainate receptor 
function (Rosenmund et al., 1994), Even if RB3 is not the true interaction partner for rpde6 
in vivo, a peptide designed to mimic the RB3 binding site on ipde6 may disrupt the 
interaction o f rpde6 with its true protein binding partner. Perfusion o f such a peptide into 
the cell o f interest might, for instance, prevent the correct intracellular targeting of RB3. A 
more accurate definition o f the residues on RB3 required for interaction with rpde6 may 
allow other potential rpde6 interaction partners to be found. These proteins can then be 
tested for binding and regulation o f rpde6.
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CHAPTER 6 
General discussion
"-IT
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J
e.General d iscussion
The ubiquitous second messenger cAMP transduces the action o f a wide range of 
hormones and neurotransmitters and is involved in the regulation of nmnerous 
physiological processes. Complex multi-enzyme families o f adenylyl cyclase (which 
generate cAMP) and PDEs (which degrade cAMP) control the intracellular’ levels of this 
second messenger. The elevation o f cAMP above a certain tlneshold results in the 
activation o f PKA, which can phosphoiylate many different target proteins. Many o f the 
components of the cAMP signalling system are targeted to specific regions o f the cell. For 
instance, the PKA isoforms are targeted to a number of distinct intracellular compartments 
by their association with a diverse family o f AKAP anchoring proteins (Colledge and 
Scott, 1999). Evidence has also accumulated for the specific tai’geting o f isoforms of 
adenylyl cyclase and PDE. The spatial organisation o f these cAMP-signalling components
suggests the existence of differentially regulated pools of cAMP within cells. This theory 
provides one explanation for how different stimuli acting via cAMP can produce distinct 
physiological responses in the same cell (Hohl and Li, 1991).
The cAMP-specific PDE4 family is comprised of four genes which each generate 
multiple isoenzymes by 5’ alternative mRNA splicing. This process generates Tong’ and 
‘short’ splice variants that have a shared central to COOH-terminal catalytic region and 
unique NHz-terminal splice domains, which confer distinct modes o f regulation and 
intracellular targeting. The PDE4 isoenzymes show tissue-specific patterns of expression 
and have been implicated in the regulation o f the cAMP response and the 
compartmentalisation of cAMP in a number of cell types. The determination o f the unique 
protein-protein interactions and regulatory properties of the individual PDE4 isoenzymes 
will aid our understanding o f their physiological roles in vivo.
In the course o f this work I have extended our knowledge o f the properties of one 
particular long form, PDE4A5. Using RT-PCR and sequence analyses I have shown that 
PDE4A5 is the sole PDE4A isoenzyme expressed in mouse 3T3 F442A preadipocytes. 
Further studies showed that murine PDE4A5 has an essential role in the regulation o f 3T3 
F442A preadipocyte differentiation by growth hormone (GH) (MacKenzie et al., 1998). 
PDE4A5 is specifically activated by GH, via JAK2, PI3-kinase and p70S6 kinase and this 
has a negative effect on the process o f differentiation. I have shown that GH-stimulation 
does not affect the level o f the PDE4A transcript. However, the GH-dependent activation
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of PDE4A5 is accompanied by its decreased mobility on SDS-PAGE (MacKenzie et al., 
1998), which implies that it is phosphorylated. Further work is required in order to identify 
the site o f phosphorylation and the kinase involved.
I have identified new sites within the NH2"terminal region o f the rat homologue of 
RNPDE4A5 (rpde6) for the intracellular targeting and regulation of this isoenzyme. Using 
a chimeric construct, I have shown that the NH2-terminal region (amino acids 1-256) of 
rpde6 can confer high-speed P2-membrane fraction association on the normal soluble 
protein GST. The binding component in the P2-membrane fraction was susceptible to heat- 
dénaturation, which suggested that it might be an unidentified anchoring protein. The 
region between Leu 103 and Lys256 on rpde6 was sufficient for P2-membrane association. 
This region includes all o f U CRl, LRl and the NHi-terminal half o f UCR2 (see Figure 
6.1) and is shared with the other long rat PDE4A isoenzyme RNPDE4A6 (rpde39) which 
also associates with the P2-membrane fraction. I have also demonstrated that the NH2- 
terminal 100 amino acid region o f the short form RNPDE4A1 (RDI) can confer P2- 
membrane fraction association when expressed as a fusion to the COOH-terminus o f GST. 
In contrast to rpde6, the NH2-terminal region of RDI interacted with a thermostable 
component o f the P2-membrane fraction, which may be a lipid species.
These studies and the recent work o f Huston et al (Huston et al., 2000) suggest that
two domains within the NH2-terminal region o f rpde6 are responsible for two different
o f
aspects o f the intracellular targeting^his isoenzyme. The NH2-terniinal 67 amino acids of 
rpde6 contain thiee proline-rich motifs which are the putative binding sites for the SH3 
domains o f Src-family tyrosyl kinases such as Lyn (O' Connell et al., 1996). In contrast to 
full-length rpde6, an NH2-terminal truncate o f rpde6 (AP3-rpde6) which lacks the first 72 
amino acids is unable to associate with Lyn SH3. Confocal immunofluorescence analysis 
o f transfected COS-7 cells shows that rpde6 is targeted to both the membrane cortical 
region and a distinct perinuclear region where it co-localises with Lyn (Huston et al.,
2000). In contrast, the truncate AP3-rpde6 localises with the membrane cortical regions but 
is absent from the perinuclear region (Huston et al., 2000). Therefore, a sequence 
downstream of Asp72 appears to be responsible for localising rpde6 to the membrane 
cortical region. This targeting sequence may occui' within the P2 membrane-association 
region Leul 03-Lys256 identified above (see Figure 6.1 ). The targeting o f rpde6 may be 
crucial for its role in the compartmentalisation of cAMP in cells or for the specific 
regulation of signalling proteins that co-localise with rpde6. Further investigation is
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necessary for the precise definition o f the targeting sequence and the identification of the 
protein that anchors rpde6 to the membrane cortical region.
In Chapter 5 I have shown that ipde6 can interact with a novel immunophilin-like 
protein called RB3. RB3 is the rat form of the human protein ARA9/XAP2, which was 
originally identified as a protein binding partner for the ligand-activated cytoplasmic 
transcription factor AhR (Aryl hydrocarbon receptor) (Caiwer and Bradfield, 1997; Ma and 
Whitlock, 1997). RB3 is homologous to the high molecular weight FK506 binding 
proteins, notably FKBP52 and FKBP51.1 have shown that a purified GST-fusion o f RB3 
(but not GST) could pull down rpde6 from the cytosolic fraction o f transfected COS-7 
cells. I have mapped the RB3-binding site on rpde6 to the NHz-terminal half o f UCR2 
(Ser218 to Arg259). The interaction o f RB3 with this region causes the inliibition o f rpde6 
activity (IC50 ~0.2pM). This lends further support to the hypothesis that UCRl and UCR2 
form an intramolecular module that is involved in the regulation of the catalytic unit 
(MacKenzie et al., 2000).
The COOH-terminal region o f RB3 (amino acids 170-330) contains a 34 amino 
acid TPR motif (amino acids 265-298). TPR domains have been implicated in a number of 
protein-protein interactions. I have shown that the COOH-terminal half o f RB3 is sufficient 
for the binding and inhibition of rpde6. The NH^-terminal half o f RB3 (amino acid 1-169) 
contains a region o f homology Icnown as the FKBP domain that is found in FK506 binding 
proteins such as FKBP 12 and FKBP52. The NHz-terminal half o f RB3 did not pull down 
rpde6 or inliibit its catalytic activity, which suggests that it has no direct involvement in the 
interaction with rpde6. However, it is possible that protein-protein interactions or post- 
translational modifications in both halves o f RB3 may result in a conformational change 
that affects the ability of the COOH-terminal half o f RB3 to interact with rpde6. Challenge 
o f rpde6-transfected COS-7 cells with PMA or forskolin had no effect on the inliibition of 
rpde6 with RB3. This implies that either rpde6 is not phosphorylated by PKA or PKC, or 
that phosphoiylation has no effect on the interaction between rpde6 and RB3. Further 
studies will be needed in order to determine the factors which regulate the ipde6:RB3 
interaction in vivo,
Subcellular distribution analysis o f RB3-transfected COS-7 cells showed that RB3 
is distributed between the cytosolic (S) and the PI-low speed pellet fraction, but is absent 
from the P2-membrane fraction, in contrast to rpde6 which was present in all tliree 
fractions. This suggests that the rpde6:RB3 interaction is confined to only certain 
subcellular compartments. In contrast to the cytosolic form of rpde6, the particulate (PI 
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and P2) forms of rpdeô from transfected COS-7 cells were resistant to inhibition with
■;GST-RB3. This implies that interacting components in these fractions, such as cytoskeletal 
proteins, may prevent the association of soluble exogenous RB3 with rpdeb. These 
interacting components may be SH3-domain proteins. Alternatively, they may be RB3-like 
TPR proteins, which associate with the 218-256 binding region. These proteins may 
sterically block the association o f exogenous RB3 or retain rpde6 in an inhibited 
conformation that is resistant to fmther inhibition with exogenous RB3. It should be noted 
that in the PI-pellet fraction, rpde6 might actually interact with endogenous RB3.
As shown in Figure 6.1 the RB3 binding site on rpde6 is downstream of the 
pro line-rich SH3 domain binding sites (Huston et al., 2000; O' Connell et al., 1996). Pre­
incubation of cytosolic rpde6 with Lyn SH3 impeded the binding o f RB3. Therefore, the 
binding o f Lyn SH3 to the unique NH^-terminal splice domain of rpde6 may sterically 
interfere with the binding of RB3 to the NH2-terminal half o f UCR2. The competition 
between proteins for interaction with the NH2-terminal region of rpde6 may be an 
important factor in the dynamic regulation and intracellular targeting o f this isoenzyme.
The above studies suggest that the association o f RB3 may represent a new 
mechanism for the regulation and/or intracellular localisation o f rpde6. This interaction 
could implicate rpde6 in the AhR signalling system. The binding o f a ligand, such the 
dioxin TCCD to AhR may cause a conformational change in this receptor that affects its 
interaction with RB3. This may in turn affect the ability of RB3 to bind to or inhibit rpdeô 
in vivo. The RB3:rpde6 interaction may thus provide a means o f cross-talk between the 
AhR signalling system and cAMP-dependent processes. Therefore, it would be interesting 
to determine the effect o f TCCD-treatment on the subcellular distribution or activity of 
rpdeô in cells that express both RB3 and AhR.
I have demonstrated that a close homologue of RB3, FKBP52, which also contains 
a TPR domain in its COOH-terminal region, can also inliibit rpdeô. This supports the 
hypothesis that other TPR domain-containing proteins may interact with rpdeô in vivo in 
addition to RB3. Interestingly, TPR proteins such as FKBP52, FKBP51 and Cyp40 have 
been implicated in the targeted trafficking o f proteins in cells. For instance, FKBP52 
appears to be involved in the rapid movement of the glucocorticoid receptor (GR) towards 
the nucleus along cytoskeletal tracks (Pratt et al., 1999). This then is consistent with the 
notion that RB3 or a similar protein may be involved in the intracellular targeting of rpdeô.
Further work is required to define the precise residues on rpdeô and RB3 that are 
necessaiy for the association o f these two proteins. In addition to binding AhR, the human 
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homologue of RB3, ARA9/XAP2 also associates with the molecular chaperone hsp90. A 
number o f other TPR proteins, including protein phosphatase 5 (PP5) and FKBP52 interact 
with hsp90 (Barent et al., 1998; Carrello et al., 1999; Cai'ver and Bradfield, 1997; Meyer et 
al., 1998; Nair et ah, 1997; Ratajczak and Carrello, 1996). The mutation to alanine o f 
Lys97 or ArglOl in the third TPR motif of PP5 abolishes its association with hsp90 
(Russell et ah, 1999). A recent paper has shown that the Lys266 in the TPR motif of 
ARA9/XAP2, which is analogous to Lys266 in PP5, is also essential for binding hsp90 
(Bell and Poland, 2000). These conserved basic residues have been suggested to interact 
with the acidic EEVD motif at the COOH-terminus of hsp90, which is essential for its 
interaction with TPR proteins. This EEVD m otif is strikingly similar to the EELD motif in 
the Ser218“Arg259 region of rpde6 (first half of UCR2). Therefore, electrostatic 
interactions may occur between conserved basic residues in the TPR motif o f RB3 and 
conserved acidic residues in rpde6. This could be tested by determining the effect o f the 
alanine substitution of the EELD m otif on the association between rpde6 and RB3.
I have shown that a number o f cell lines express endogenous RB3, including U937 
monocytes which also express the human homologue o f rpde6 (MacKenzie et al., 2000).
Cell lines such as these could be used to as a model for studying the ipde6:RB3 interaction 
in vivo. New teclmiques have been devised for generating knock-out cell lines where both 
alleles for a particular gene are inactivated (Chan et al., 1999; Mortensen et al., 1992).
These methods could be employed to replace endogenous wild type rpdc6 with a mutant 
form that lacks the RB3 binding site. A direct comparison could then be made between the 
wild type and mutant cell lines in order to assess the effect o f RB3-association on the 
activity or intracellular localisation of rpde6. This system could be used to investigate 
whether the interaction of RB3 stabilises rpde6 or protects it from proteolytic degradation 
(see section 5.15.2), which has been suggested for the interaction between ARA9/XAP2 
and AhR (Meyer and Perdew, 1999). Alternatively, we could test whether rpde6 is 
involved in signalling downstream of AhR.
In the work presented in this thesis I have localised the binding site for RB3 and the 
P2-membrane association site to relatively short stretches of sequence within the NHi- 
terminal region of rpde6. From this information it may be possible to design peptides or 
peptide-mimetic compounds that specifically block these interactions. These compounds 
would be extremely useful for determining the functional importance o f these properties of 
rpde6. Furthermore, the development of PDE4 isoenzyme-specific compounds that block I
separate aspects o f their hmction in vivo is a major goal in drug resear ch. These 
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compounds may prove to be effective treatments for inflammatory diseases such as astlima 
and atopic dermatitis, with fewer side effects than the currently available PDE4 inhibitors.
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Figure 6.1 Summary of the protein-protein interactions and intracellular targeting of 
rat PDE4A5 (rpde6)
This figure shows the protein-protein interaction sites in the NHi-terminal region of 
RNPDE4A5 (rpdeô). The proline-rich putative SH3-domain binding motifs in the unique 
NHs-terminal splice domain are indicated with grey semi-circles. This interaction site 
occurs upstream of the RB3-binding site, which has been mapped to the NH2-terminal half 
of UCR2. The region sufficient for P2-membrane association occurs between the two 
splice junctions (grey circles) and is shared with the other long form RNPDE4AÔ (ipde39).
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